"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
"1","NCT04395482","Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury","TAC-COVID19","Recruiting","No Results Available","covid19","Other: Lung CT scan analysis in COVID-19 patients","A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes","University of Milano Bicocca","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TAC-COVID19","2020-04-15T00:00:00","2020-06-15T00:00:00","2020-10-15T00:00:00","2020-05-20T00:00:00","","2020-05-26T00:00:00","Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino","","https://ClinicalTrials.gov/show/NCT04395482"
"2","NCT04395924","Maternal-foetal Transmission of SARS-Cov-2","TMF-COVID-19","Recruiting","No Results Available","Maternal Fetal Infection Transmission|COVID-19|SARS-CoV 2","Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta","COVID-19 by positive PCR in cord blood and / or positive serologies|COVID-19 by positive PCR in amniotic fluid and placenta|New born infected by COVID-19","Centre Hospitalier Regional d'Orleans|Centre de Biophysique Moleculaire - Pr Chantal Pichon|Professeur TOUMI Hechmi","Female","18 Years to 48 Years","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRO-2020-10","2020-05-05T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-05-20T00:00:00","","2020-06-04T00:00:00","CHR Orleans, Orleans, France","","https://ClinicalTrials.gov/show/NCT04395924"
"3","NCT04476940","COVID-19 Breastfeeding Guideline for African-Americans","COVID-BF","Not yet recruiting","No Results Available","Covid19|Exclusive Breastfeeding","Behavioral: COVID-19 Breastfeeding Support","COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M","Meharry Medical College","Female","18 Years to 45 Years","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","330875","2020-09-01T00:00:00","2021-10-01T00:00:00","2022-06-01T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","Meharry Medical College, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT04476940"
"4","NCT04412265","Frailty in Elderly Patients With COVID-19","FRA-COVID","Recruiting","No Results Available","Covid19","Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.","Development of a tool to measure frailty|A ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level.","University of Milano Bicocca","All","18 Years and older","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","FRA-COVID","2020-03-01T00:00:00","2020-06-01T00:00:00","2021-03-01T00:00:00","2020-06-02T00:00:00","","2020-06-09T00:00:00","ASST Monza-Ospedale San Gerardo, Monza, Italy","","https://ClinicalTrials.gov/show/NCT04412265"
"5","NCT04427332","Smell and Taste Disorders in COVID-19 Patients","COVID-19 ORL","Recruiting","No Results Available","covid19","Other: Investigation of smell and taste disorders","Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste","University of Milano Bicocca","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 ORL","2020-05-15T00:00:00","2020-06-30T00:00:00","2020-09-30T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","ASST Monza-Ospedale San Gerardo, Monza, Italy","","https://ClinicalTrials.gov/show/NCT04427332"
"6","NCT04416061","The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic","COVID-19","Active, not recruiting","No Results Available","COVID","Diagnostic Test: COVID 19 Diagnostic Test","Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history","Hong Kong Sanatorium & Hospital","All","Child, Adult, Older Adult","","2500","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC-2020-08","2020-05-25T00:00:00","2020-07-31T00:00:00","2020-08-31T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT04416061"
"7","NCT04367805","COVID-19 Infection in Patients With Hepatocellular Carcinoma","COVID19-CHIEF","Recruiting","No Results Available","Hepatocellular Carcinoma|COVID-19","Diagnostic Test: nasopharyngeal Covid 19 RT-PCR","Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France","Centre Hospitalier Universitaire, Amiens|Centre Hospitalier-Universitaire Bondy|University Hospital, Bordeaux|Centre Hospitalier-Universitaire CLICHY|Centre Hospitalier General CORBEIL-ESSONNE|CHU CRETEIL|University Hospital, Grenoble|University Hospital, Lille|CHU LYON|Poitiers University Hospital|Rennes University Hospital|University Hospital, Rouen|University Hospital, Toulouse|CHU VILLEJUIF|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Montpellier","All","18 Years and older","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0042","2020-04-27T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","CHU Amiens, Amiens, France","","https://ClinicalTrials.gov/show/NCT04367805"
"8","NCT04407585","Testing the Accuracy of a Digital Test to Diagnose Covid-19","","Recruiting","No Results Available","Covid-19","Diagnostic Test: Covid-19 swab PCR test","SARS-CoV-2 infection","King's College London|Zoe Global Limited|Department of Health, United Kingdom","All","18 Years and older","","1000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19 Validation Study","2020-06-01T00:00:00","2021-05-10T00:00:00","2021-05-10T00:00:00","2020-05-29T00:00:00","","2020-06-24T00:00:00","King's College London, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04407585/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04407585"
"9","NCT04473170","Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19","SENTAD-COVID","Completed","No Results Available","Coronavirus Disease 2019","Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells |Drug: COVID-19 standard care","Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.","Abu Dhabi Stem Cells Center","All","18 Years and older","Phase 1|Phase 2","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CT.001.1.0.SENTAD-COVID","2020-04-04T00:00:00","2020-05-20T00:00:00","2020-07-14T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT04473170"
"10","NCT04497298","Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine","COVID-19-101","Recruiting","No Results Available","COVID-19","Biological: Two COVID-19 vaccine candidate  administrations - Low dose|Biological: Two COVID-19 vaccine candidate  administrations - High dose|Biological: One COVID-19 vaccine candidate  administration - High dose|Other: Placebo","To assess the safety and tolerability of the COVID-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|To assess induction of SARS-CoV-2 spike protein-binding antibodies upon one or two administrations of the COVID-19 vaccine by means of ELISA up to study day 390|To assess induction of SARS-CoV-2 neutralizing antibodies upon one or two administrations of the COVID-19 vaccine by means of serum neutralization assay up to study day 390|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses induced by one or two doses of vaccine, by means of intracellular staining|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses induced by one or two doses of vaccine, by means of flow cytometry|To assess potential measles virus shedding by means of RT-qPCR of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42","Institut Pasteur|Themis Bioscience GmbH|Coalition for Epidemic Preparedness Innovations","All","18 Years to 55 Years","Phase 1","90","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","2020-016|2020-002973-89","2020-08-10T00:00:00","2020-11-01T00:00:00","2021-10-01T00:00:00","2020-08-04T00:00:00","","2020-08-12T00:00:00","SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium|CIC Cochin - Pasteur, Paris, France","","https://ClinicalTrials.gov/show/NCT04497298"
"11","NCT04427345","Predictive Factors COVID-19 Patients","MI-COVID","Recruiting","No Results Available","covid19","Other: Predictive factors for clinical response in patients with COVID-19.","Identify risk factors for intra-hospital mortality.|Identify risk factors to build a prognostic score.|Predictive factors for the hospitalization duration.|Predictive factors for clinical status patients based on ""Ordinal Scale for Clinical Improvement""|Describe the anti-viral therapies used commonly in this emergency in terms of efficacy|Describe the anti-viral therapies used commonly used in this emergency in terms of safety|Monitor the clinical course of the disease in discharged patients.","University of Milano Bicocca","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MI-COVID","2020-03-01T00:00:00","2020-06-01T00:00:00","2021-05-31T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","ASST Monza-Ospedale San Gerardo, Monza, Italy","","https://ClinicalTrials.gov/show/NCT04427345"
"12","NCT04407494","Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders","COVID-OLFA","Completed","No Results Available","COVID-19","Biological: Reporting of anosmia, ageusia and other clinical symptoms","Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA","University Hospital, Montpellier","All","18 Years and older","","809","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0176","2020-03-01T00:00:00","2020-04-01T00:00:00","2020-04-30T00:00:00","2020-05-29T00:00:00","","2020-06-01T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04407494"
"13","NCT04403672","Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus","","Recruiting","No Results Available","High Sensitivity and Specificity  of RealDetect™ COVID-19 RT-PCR Kit","Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection","Performance evaluation of RealDetect™ COVID-19 RT-PCR kit|Reduce the price of RT-PCR based COVID-19 diagnostic test kits.","Bangladesh Medical Research Council","All","5 Years to 65 Years","","120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","30005052020","2020-05-18T00:00:00","2020-07-24T00:00:00","2020-07-24T00:00:00","2020-05-27T00:00:00","","2020-05-28T00:00:00","Institute of Epidemiology, Disease Control and Research , Mohakhali, Dhaka , Institute for Developing Science & Health Initiatives ; Mohakhali, Dhaka (For sample analysis, data collection, data analys, Dhaka, Bangladesh","","https://ClinicalTrials.gov/show/NCT04403672"
"14","NCT04384588","COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection","FALP-COVID","Recruiting","No Results Available","COVID-19 Infection|Cancer Patients|General Population","Biological: Convalescent Plasma from COVID-19 donors","in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients |Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization","Fundacion Arturo Lopez Perez|Confederación de la Producción y del Comercio |Bolsa de Santiago","All","15 Years and older","Phase 2|Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","FALP 001-2020","2020-04-07T00:00:00","2021-04-06T00:00:00","2021-04-06T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile","","https://ClinicalTrials.gov/show/NCT04384588"
"15","NCT04377425","COVID-19 Prevalence and Cognitive Deficits in Neurological Patients","Neuro-Covid","Not yet recruiting","No Results Available","Neurological Diseases or Conditions|Stroke, Acute|Seizure Disorder","Diagnostic Test: COVID-19 swap test PCR","Prevalence of COVID-19 infection in consecutive patients with neurological symptoms|Three months cognitive function of COVID-19 positive patients|Clinical presentation of neurological symptoms in COVID-19 positive patients|Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients|Anosmia in COVID-19 positive patients|Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection|Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients","Aarhus University Hospital","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Neuro-Covid-19","2020-05-07T00:00:00","2020-11-29T00:00:00","2022-06-30T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","Aalborg University Hospital, Aalborg, DK, Denmark|Aarhus University Hospital, Aarhus, DK, Denmark|Regional Hospital West Jutland, Hostebro, Holstebro, DK, Denmark|Regional Hospital Central Jutland, Viborg, Viborg, DK, Denmark","","https://ClinicalTrials.gov/show/NCT04377425"
"16","NCT04372004","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection","CATCH COVID-19","Recruiting","No Results Available","COVID-19","Diagnostic Test: diagnostic tests for COVID-19 infection","detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 85 Years","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","TCAI_CATCH COVID-19","2020-05-08T00:00:00","2021-05-01T00:00:00","2021-06-01T00:00:00","2020-05-01T00:00:00","","2020-08-11T00:00:00","Texas Cardiac Arrhythmia Institute, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT04372004"
"17","NCT04490837","Rapid Diagnostic Test for COVID-19 Based on Antibody Detection","YCOVID","Active, not recruiting","No Results Available","Covid-19","Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19","IgG anti-COVID-19|IgM anti-COVID-19|IgA anti-COVID-19|Time of onset symptoms|COVID-19 PCR results|Radiological studies","Corporacion Parc Tauli","All","18 Years and older","","3500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020/587","2020-06-22T00:00:00","2020-07-31T00:00:00","2020-09-30T00:00:00","2020-07-29T00:00:00","","2020-07-29T00:00:00","Parc Tauli University Hospital, Sabadell, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04490837"
"18","NCT04412486","COVID-19 Convalescent Plasma  Transfusion","","Recruiting","No Results Available","COVID-19","Biological: COVID Convalescent Plasma","Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment .|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.","Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center","All","18 Years and older","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","2020-0137","2020-06-01T00:00:00","2022-05-31T00:00:00","2022-05-31T00:00:00","2020-06-02T00:00:00","","2020-07-02T00:00:00","University of Mississippi Medical Center, Jackson, Mississippi, United States","","https://ClinicalTrials.gov/show/NCT04412486"
"19","NCT04424004","MURDOCK Cabarrus County COVID-19 Prevalence and Immunity  Study","C3PI","Enrolling by invitation","No Results Available","COVID 19","Other: COVID-19 PCR and serology testing","Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19.","Duke University|North Carolina Department of Health and Human Services","All","18 Years and older","","500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Pro00105703","2020-06-09T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-06-09T00:00:00","","2020-07-08T00:00:00","Duke CTSI Translational Population Health Office, Kannapolis, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04424004"
"20","NCT04386109","Neonatal Complications of Coronavirus Disease","","Recruiting","No Results Available","Neonatal COVID-19 Disease","Other: No intervention - exposure is to COVID-19","Incidence of neonatal COVID-19|Incidence of vertically transmitted COVID-19|Presentation and natural history of neonatal COVID-19|Presentation of neonates with COVID-19 positive mothers|Outcomes for neonates with COVID-19|Clinical treatment of neonatal COVID-19|Neonatal secondary impacts of maternal COVID-19","University of Oxford|Imperial College London|University of Leicester|University of Nottingham|University of Glasgow|University Hospital of Wales|Public Health England|St George's, University of London","All","up to 29 Days","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14905","2020-04-01T00:00:00","2021-03-31T00:00:00","2021-09-30T00:00:00","2020-05-13T00:00:00","","2020-05-13T00:00:00","Imperial College, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04386109"
"21","NCT04437940","Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test","","Recruiting","No Results Available","COVID|Sars-CoV2","Diagnostic Test: Vaginal fluid Covid-19 PCR test","Vaginal fluid Covid-19 PCR test result|becoming negative from positive","Acibadem University","Female","18 Years to 70 Years","","35","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Acibadem Maslak Ob&Gyn","2020-06-15T00:00:00","2020-07-10T00:00:00","2020-07-30T00:00:00","2020-06-18T00:00:00","","2020-06-18T00:00:00","Acibadem Maslak Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04437940"
"22","NCT04508075","Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","COVID-19","Not yet recruiting","No Results Available","SARS-CoV2 Infection","Biological: SARS-CoV-2 vaccine |Biological: Placebo","Incidence of laboratory-confirmed COVID-19 after the second dose|Incidence of suspected COVID-19 cases|Incidence of laboratory-confirmed cases |Seroconversion rate anti-S antibody IgG titer |Seropositive rate of neutralizing antibodies","PT Bio Farma|Faculty of Medicine Universitas Padjadjaran|National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia|Sinovac Life Sciences Co., Ltd.","All","18 Years to 59 Years","Phase 3","1620","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","CoV2-0320","2020-08-10T00:00:00","2021-06-01T00:00:00","2021-09-01T00:00:00","2020-08-11T00:00:00","","2020-08-11T00:00:00","Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung, West Java, Indonesia","","https://ClinicalTrials.gov/show/NCT04508075"
"23","NCT04356560","COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department","","Enrolling by invitation","No Results Available","COVID-19","Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways","Rigshospitalet, Denmark","All","Child, Adult, Older Adult","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DT P-2020-353","2020-03-23T00:00:00","2020-09-30T00:00:00","2020-12-31T00:00:00","2020-04-22T00:00:00","","2020-04-24T00:00:00","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT04356560"
"24","NCT04376398","Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals","COVID","Recruiting","No Results Available","COVID-19","","Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries","Cliniques universitaires Saint-Luc- Universite Catholique de Louvain|Society for Anesthesia and Resuscitation of Belgium","All","up to 100 Years","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID-ANESTHESIO","2020-04-06T00:00:00","2020-06-30T00:00:00","2020-09-30T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","Cliniques Universitaires Saint Luc, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT04376398"
"25","NCT03305341","Discovery Stage  COVID-19 Antigen Presentation Therapeutic Vaccine","COVID-19--AP","Active, not recruiting","No Results Available","Covid19","Biological: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection","Macrophage Migration Inhibitory Factor","Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair|Medicine Invention Design, Inc","All","22 Years to 72 Years","Early Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","NDA215163|FWA00015357|IRB00009424|IORG0007849|IND152006|BLA761200","2020-07-18T00:00:00","2020-10-08T00:00:00","2020-11-08T00:00:00","2017-10-09T00:00:00","","2020-08-18T00:00:00","Medicine Invention Design Incorporation  - IORG0007849, North Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03305341"
"26","NCT04379310","Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia","Covid-19","Completed","No Results Available","Covid-19","Drug: ACE Inhibitors and Calcium Channel Blockers","extend of lung involvement|oxygen saturation on admission","Nisantasi University","All","18 Years to 99 Years","","54","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20200504441","2020-05-01T00:00:00","2020-05-05T00:00:00","2020-05-08T00:00:00","2020-05-07T00:00:00","","2020-06-05T00:00:00","Vital Hospital, Bahcelievler, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04379310"
"27","NCT04390074","COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality","","Not yet recruiting","No Results Available","COVID-19|Critical Illness","Other: COVID-19 and Intensive Care","Chronic medications as risk factor of intensive care for COVID-19|Comorbidities as risk factor of intensive care for COVID-19|Chronic medications as risk factor of death during intensive care for COVID-19|Comorbidities as risk factor of death during intensive care for COVID-19","Uppsala University|Center for Clinical Research Dalarna, Sweden","All","18 Years and older","","10000","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","UTN: U1111-1251-8195","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-05-15T00:00:00","","2020-05-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04390074"
"28","NCT04360811","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","COroFet","Recruiting","No Results Available","Pregnancy","Diagnostic Test: COVID 19 diagnostic test by PCR","number of positive COVID-19 women","University Hospital, Toulouse","Female","18 Years and older","Not Applicable","3600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","RC31/20/0123","2020-04-17T00:00:00","2021-04-01T00:00:00","2022-04-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","University Hospital of Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04360811"
"29","NCT04353206","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","","Recruiting","No Results Available","Covid-19|Sars-CoV2","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.","Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center","All","18 Years and older","Early Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Acute Care CP Consortium Trial","2020-06-27T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-04-20T00:00:00","","2020-07-15T00:00:00","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04353206"
"30","NCT04460274","Forecast Number of Covid-19 Cases Worldwide","Covid19TmeSer","Completed","No Results Available","Covid-19","Other: Model Building|Other: Model validation","Number of Confirmed cases of Covid-19","Turkish Ministry of Health Izmir Teaching Hospital","All","Child, Adult, Older Adult","","7882471","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TurkishMOHITH-TimeSeries","2019-12-31T00:00:00","2020-06-15T00:00:00","2020-06-20T00:00:00","2020-07-07T00:00:00","","2020-07-08T00:00:00","Republic of Turkey, Health Sciences University, Izmir Bozyaka Education and Training Hospital, İzmir, Turkey","","https://ClinicalTrials.gov/show/NCT04460274"
"31","NCT04366271","Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19","MESCEL-COVID19","Recruiting","No Results Available","COVID","Biological: Mesenchymal cells|Drug: Standard of care","Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","40 Years to 80 Years","Phase 2","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","MESCEL-COVID19|2020-001450-22","2020-05-07T00:00:00","2020-07-31T00:00:00","2021-05-31T00:00:00","2020-04-28T00:00:00","","2020-05-11T00:00:00","Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04366271"
"32","NCT04453748","The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications","","Enrolling by invitation","No Results Available","COVID-19|Coronavirus Infection|Sars-CoV2|Complications","Other: Complex diagnostic panel","Prevalence of COVID-19 complications|Assessment of risk factors of COVID-19 complications","Silesian Centre for Heart Diseases|Medical University of Silesia","All","18 Years to 120 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Complications Study","2020-06-08T00:00:00","2021-10-31T00:00:00","2021-11-30T00:00:00","2020-07-01T00:00:00","","2020-07-01T00:00:00","Silesian Centre for Heart Disease, Zabrze, Silesia, Poland","","https://ClinicalTrials.gov/show/NCT04453748"
"33","NCT04339322","Characteristics and Outcome of Coronavirus Disease 2019  in Egypt","COVID-19","Not yet recruiting","No Results Available","Characteristics Diseases|Outcome, Fatal","Other: Follow up","Demographics of Coronavirus Disease 2019  in the cohort group|Clinical manifestations of Coronavirus Disease 2019 |Laboratory data of included Coronavirus Disease 2019  cohort|Radiological features of Coronavirus Disease 2019  cohort|outcomes of Coronavirus Disease 2019  infection in the cohort group","Assiut University","All","Child, Adult, Older Adult","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 in Egypt","2020-05-01T00:00:00","2020-07-30T00:00:00","2020-07-30T00:00:00","2020-04-09T00:00:00","","2020-04-09T00:00:00","","","https://ClinicalTrials.gov/show/NCT04339322"
"34","NCT04323787","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","COVID-19","Recruiting","No Results Available","Coronavirus","Other: observational","ICU and hospital mortality of COVID-19 patients|30 days mortality","Mayo Clinic|Society of Critical Care Medicine|Boston University","All","Child, Adult, Older Adult","","50000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20-002610","2020-03-30T00:00:00","2021-04-30T00:00:00","2021-04-30T00:00:00","2020-03-27T00:00:00","","2020-08-11T00:00:00","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine , Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT04323787"
"35","NCT04510207","A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines  in Healthy Population Aged 18 Years Old and Above","COVID-19","Recruiting","No Results Available","COVID-19","Biological: Inactivated SARS-CoV-2 Vaccine |Biological: Placebo","The incidence of COVID-19 cases after two-doses of vaccination|The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination|The incidence of any adverse reactions/events|The incidence of serious adverse events |The Geometric Mean Titer  of anti-SARS-CoV-2 neutralizing antibody|The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Fold Rise  of anti-SARS-CoV-2 neutralizing antibody|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody","China National Biotec Group Company Limited|G42 Healthcare company|Abu Dhabi Health Services Company|Wuhan Institute of Biological Products Co., Ltd|Beijing Institute of Biological Products Co., Ltd","All","18 Years and older","Phase 3","45000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","CNBG2020003SQ","2020-07-16T00:00:00","2021-03-16T00:00:00","2021-09-16T00:00:00","2020-08-12T00:00:00","","2020-08-18T00:00:00","Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S, Sanabis, Bahrain|Shaikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates|Al Qarain Primary Health Care Centre-MOHAP, Sharjah, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT04510207"
"36","NCT04387929","Detection of Anti-COVID-19 Antibody Levels in an Hospital Population","","Recruiting","No Results Available","COVID-19","Diagnostic Test: Detection of anti-COVID-19 antibody level","SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations","Istituto Clinico Humanitas","All","18 Years to 90 Years","","6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1374 IgG COVID-19 HUMANITAS","2020-05-04T00:00:00","2021-05-30T00:00:00","2021-05-30T00:00:00","2020-05-14T00:00:00","","2020-05-15T00:00:00","Humanitas Rozzano/San Pio X, Rozzano, Lombardia, Italy","","https://ClinicalTrials.gov/show/NCT04387929"
"37","NCT04355897","CoVID-19 Plasma in Treatment of COVID-19 Patients","","Recruiting","No Results Available","COVID 19","Biological: Convalescent COVID 19 Plasma","Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.","The Christ Hospital","All","18 Years to 80 Years","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-23","2020-04-28T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-04-21T00:00:00","","2020-05-20T00:00:00","The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT04355897"
"38","NCT04377685","Prediction of Clinical Course in COVID19 Patients","COVID-CTPRED","Recruiting","No Results Available","COVID 19","Other: CT-Scan","diagnostic of COVID disease composite","Centre Hospitalier Universitaire de Saint Etienne|Institut National des Sciences Appliquees |Institut National de la Sante Et de la Recherche Medicale, France|Centre National pour le Recherche Scientifique |Universite de Lyon|Universite Jean Monnet","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20CH109|IRBN652020/CHUSTE","2020-03-01T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-05-06T00:00:00","","2020-05-18T00:00:00","Chu Saint-Etienne, Saint-Étienne, France","","https://ClinicalTrials.gov/show/NCT04377685"
"39","NCT04392323","Incidence of COVID-19 Test Conversion in Post-surgical Patients","","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 PCR and Serology","COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19","Northwell Health","All","18 Years and older","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","IRB #20-0404","2020-05-13T00:00:00","2020-07-01T00:00:00","2020-07-31T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States","","https://ClinicalTrials.gov/show/NCT04392323"
"40","NCT04330261","Clinical Characteristics and Outcomes of Pediatric COVID-19","PERN-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","Other: Exposure  - SARS-CoV-2 infection","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","University of Calgary","All","up to 18 Years","","12500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB18-0107_MOD9","2020-03-18T00:00:00","2021-03-17T00:00:00","2022-03-17T00:00:00","2020-04-01T00:00:00","","2020-04-01T00:00:00","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT04330261"
"41","NCT04466657","Antioxidant Therapy for COVID-19 Study","GSHSOD-COVID","Not yet recruiting","No Results Available","Covid-19","Dietary Supplement: Antioxidation Therapy|Other: Standard of Care","Time to clinical improvement|Time to SARS-CoV-2 negativity|Clinical status on day 14|Proportion of participants with SARS-CoV-2 PCR negative result at Day 7|Proportion of participants with SARS-CoV-2 PCR negative result at Day 28|28 Day mortality|Duration of hospitalization in survivors|Time from treatment initiation to death","Obafemi Awolowo University|Borno State Ministry of Health|Ogun State Ministry of Health|Abia State Ministry of Health|Sokoto State Ministry of Health|Benue State Minsitry of Health|University of Calabar Teaching Hospital","All","18 Years to 75 Years","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Supportive Care","GSHSOD-COVID2020","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-12-31T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","Abia State Isolation Centre, Amachara, Umuahia, Abia State, Nigeria|Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria|Brigadier Abba Kyari Memorial Hospital, Borno, Borno State, Nigeria|University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria|University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria|Federal Medical Centre Idi-Aba, Abeokuta, Ogun State, Nigeria|Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria|Infectious Disease Hospital, Amanawa, Sokoto State, Nigeria|Murtala Muhammad Speciaist Hospital, Sokoto, Sokoto State, Nigeria|Occupational Therapy Center, Sokoto, Sokoto State, Nigeria|Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria","","https://ClinicalTrials.gov/show/NCT04466657"
"42","NCT04376996","Slovenian National COVID-19 Prevalence Study","SLO-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing","Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples","University of Ljubljana","All","Child, Adult, Older Adult","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ULMF2020-COVID-19","2020-04-20T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-05-06T00:00:00","","2020-05-07T00:00:00","University of Ljubljana, Ljubljana, Slovenia","","https://ClinicalTrials.gov/show/NCT04376996"
"43","NCT04370288","Clinical Application of Methylene Blue for Treatment of Covid-19 Patients","Covid-19","Recruiting","No Results Available","Covid-19","Drug: MCN","Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count","Mashhad University of Medical Sciences","All","18 Years to 90 Years","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","IR.MUMS.REC.1399.122","2020-04-19T00:00:00","2020-09-20T00:00:00","2020-09-21T00:00:00","2020-04-30T00:00:00","","2020-05-04T00:00:00","Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04370288"
"44","NCT04404062","Validation of COVID-19 Tests","","Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: Covid-19 Rapid Test Kit |Diagnostic Test: Quantitative IgG Test","Identification of asymptomatic carriers of SARS-CoV-2|Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2|Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2|Exploration of SARS-CoV-2 epidemiology","Richmond Pharmacology Limited","All","18 Years to 70 Years","","500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20010","2020-03-16T00:00:00","2020-08-01T00:00:00","2020-08-01T00:00:00","2020-05-27T00:00:00","","2020-05-27T00:00:00","Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04404062"
"45","NCT04474496","Impact of COVID-19 on Marshallese Communities in the U.S.","","Not yet recruiting","No Results Available","COVID-19","Other: Assessing impact of COVID19","Effects of COVID-19 on social determinants of health|Effects of COVID-19 on general health status and mental health|Effects of COVID-19 on disease management|Effects of COVID-19 on diet and physical activity behaviors|COVID-19 screening, testing, and prevention|Trusted sources of COVID-19 information|Impacts of COVID-19 on daily life|COVID-19 attitudes, fears, and beliefs","University of Arkansas|Patient-Centered Outcomes Research Institute","All","18 Years and older","","2000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","261131","2020-08-20T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-07-16T00:00:00","","2020-08-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04474496"
"46","NCT04352764","ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings","","Recruiting","No Results Available","Covid19","Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test","prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms","Texas Cardiac Arrhythmia Research Foundation","All","Child, Adult, Older Adult","","5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TCAI_COVID-19","2020-03-27T00:00:00","2020-12-31T00:00:00","2021-01-31T00:00:00","2020-04-20T00:00:00","","2020-04-27T00:00:00","St. David's Medical Center, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT04352764"
"47","NCT04342637","COVID-19 Endoscopy Survey","COVID-19 Endo","Completed","No Results Available","COVID-19","Other: Practice details","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number","Al-Azhar University","All","30 Years to 70 Years","","163","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WES-2","2020-04-10T00:00:00","2020-04-25T00:00:00","2020-05-01T00:00:00","2020-04-13T00:00:00","","2020-05-20T00:00:00","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04342637"
"48","NCT04416373","COVID-19 and Pregnancy Outcomes","COVID&PREG","Recruiting","No Results Available","Coronavirus Infection|Pregnancy Complications|Vertical Transmission of Infectious Disease|Breastfeeding|Neonatal Infection","Diagnostic Test: RT PCR SARS-CoV-2","SARS-CoV-2 Neonatal Infection|Perinatal mortality|ICU maternal admission|5 minute Apgar Score < 7|Preterm labour|PPROM|Miscarriage","Universidade Nova de Lisboa","Female","16 Years to 55 Years","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID&PREG","2020-03-22T00:00:00","2023-12-01T00:00:00","2023-12-01T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Nova Medical School - UNL, Lisbon, Portugal","","https://ClinicalTrials.gov/show/NCT04416373"
"49","NCT04349202","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","BLAST COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2","Diagnostic Test: EUROIMMUN assay","Prevalence COVID antibodies in employees of Beaumont Health","William Beaumont Hospitals","All","18 Years and older","","50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-134","2020-04-10T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-04-16T00:00:00","","2020-04-28T00:00:00","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT04349202"
"50","NCT04516954","Convalescent Plasma for COVID-19 Patients","CPCP","Enrolling by invitation","No Results Available","COVID 19","Biological: Convalescent COVID 19 Plasma","Evaluate the safety","Vinmec Research Institute of Stem Cell and Gene Technology|National Institute of Hygiene and Epidemiology, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|National Institute of Hematology and Blood Transfusion, Vietnam","All","18 Years to 75 Years","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","ISC.20.11","2020-08-01T00:00:00","2020-11-30T00:00:00","2020-12-30T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam","","https://ClinicalTrials.gov/show/NCT04516954"
"51","NCT04361422","Isotretinoin in Treatment of COVID-19","Randomized","Not yet recruiting","No Results Available","COVID-19","Drug: Isotretinoin Only Product in Oral Dose Form","Clinical clearance","Tanta University","All","18 Years to 40 Years","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","9469305c","2020-04-21T00:00:00","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04361422"
"52","NCT04345679","Anti COVID-19 Convalescent Plasma Therapy","","Not yet recruiting","No Results Available","COVID 19","Biological: anti-SARS-CoV-2 convalescent plasma","Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality","Orthosera Kft.|Semmelweis University|University of Pecs|Hungarian National Blood Service|Humán Bioplazma Kft - Kedrion","All","18 Years and older","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","AntiCOVID19ORT","2020-04-14T00:00:00","2020-06-01T00:00:00","2021-04-01T00:00:00","2020-04-14T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04345679"
"53","NCT04379284","Risks of COVID19 in the Pregnant Population","","Recruiting","No Results Available","COVID19","Other: Biospecimen collection","Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages","Mayo Clinic","Female","18 Years to 45 Years","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-003251","2020-05-08T00:00:00","2021-04-30T00:00:00","2021-07-31T00:00:00","2020-05-07T00:00:00","","2020-07-13T00:00:00","Mayo Clinic Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT04379284"
"54","NCT04410471","Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients","","Recruiting","No Results Available","Liver Transplant Infection|Covid19|Mortality|Immune Response","Diagnostic Test: CLIA of IgG and IgM against SARS-Cov-2","Incidence of IgG against SARS-CoV-2|titration and evolution of humoral response  along first 12 months after having Covid-19|Reinfection of Covid-19","Magdalena Salcedo|Hospital General Universitario Gregorio Marañon","All","18 Years to 100 Years","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Sero-Covid19_TH","2020-05-29T00:00:00","2020-05-29T00:00:00","2021-06-30T00:00:00","2020-06-01T00:00:00","","2020-06-02T00:00:00","Victor Fernandez Alonso, Madrid, Spain|Victor Fernández Alonso, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04410471"
"55","NCT04347174","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients","","Recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed  Mycobacterium w|Drug: Standard therapy of COVID-19","Sequential Organ Failure Assessment  scores|7-category ordinal scale that ranges from 1  to 7 |All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal  sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time  from treatment initiation to death","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","CRSC20004","2020-04-30T00:00:00","2020-06-30T00:00:00","2020-07-30T00:00:00","2020-04-15T00:00:00","","2020-06-11T00:00:00","All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04347174"
"56","NCT04365959","The Prone Position in Covid-19 Affected Patients","PRON-COVID","Active, not recruiting","No Results Available","Sars-CoV2","Procedure: Prone position","Number of patients in whom the prone position caused an increase in oxygenation|The feasibility of prone position","University of Milano Bicocca","All","18 Years to 75 Years","","56","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRON-COVID","2020-03-20T00:00:00","2020-04-09T00:00:00","2020-05-31T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","ASST Monza, Monza, MB, Italy","","https://ClinicalTrials.gov/show/NCT04365959"
"57","NCT04363099","Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.","COVID AMBU 60","Recruiting","No Results Available","Covid-19","Other: observational","clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases","Maison de Sante Pluridisciplinaire de Creil","All","up to 99 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-A01059-30","2020-03-01T00:00:00","2020-06-30T00:00:00","2020-12-31T00:00:00","2020-04-27T00:00:00","","2020-04-27T00:00:00","Msp de Creil, Creil, France","","https://ClinicalTrials.gov/show/NCT04363099"
"58","NCT04332380","Convalescent Plasma for Patients With COVID-19: A Pilot Study","CP-COVID-19","Completed","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay |Requirement of mechanical ventilation|Duration  of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud","All","18 Years to 60 Years","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","ABN011-1","2020-05-01T00:00:00","2020-07-28T00:00:00","2020-07-28T00:00:00","2020-04-02T00:00:00","","2020-08-17T00:00:00","Universidad del Rosario, Bogota, Cundinamarca, Colombia","","https://ClinicalTrials.gov/show/NCT04332380"
"59","NCT04363489","The CEDiD Study","CEDiD","Not yet recruiting","No Results Available","Covid19","Device: Wearable Medical Device |Diagnostic Test: COVID-19 PCR Swab|Diagnostic Test: Pulse Oximeter","COVID-19 Infection|Symptoms|Clinical Observations","King's College London|Guy's and St Thomas' NHS Foundation Trust","All","18 Years and older","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEDiD Study","2020-08-01T00:00:00","2020-08-30T00:00:00","2020-09-30T00:00:00","2020-04-27T00:00:00","","2020-08-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04363489"
"60","NCT04420468","Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children","HEART-COVID","Not yet recruiting","No Results Available","COVID-19","","Acute myocarditis|Multi-systemic inflammatory syndrome|Kawasaki disease|Results of SARS-CoV-2","Assistance Publique - Hôpitaux de Paris","All","up to 17 Years","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200632","2020-06-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Armand Trousseau, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Robert Debre, Paris, France","","https://ClinicalTrials.gov/show/NCT04420468"
"61","NCT04382235","Non-invasive Ventilatory Support of Patients Affected by COVID-19","WARd-COVID","Active, not recruiting","No Results Available","Covid-19","Device: Non-invasive ventilatory support","The number of patients treated with non-invasive ventilation devices.|Incidence of patients requiring mechanical ventilation|Incidence of organ failure|Duration of hospitalization|Clinical outcome at hospital discharge","University of Milano Bicocca","All","18 Years and older","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WARd-COVID","2020-03-26T00:00:00","2020-05-31T00:00:00","2020-06-30T00:00:00","2020-05-11T00:00:00","","2020-05-11T00:00:00","Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale ""Treviglio-Caravaggio"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy","","https://ClinicalTrials.gov/show/NCT04382235"
"62","NCT04337996","Dynamic Evaluation of COVID-19 Diagnostic Tests","TRODVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 diagnostic test","Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies|Positive or negative Covid-19 test|Positive or negative character of the antibodies test|Biological parameters|medical-economic comparison","Tourcoing Hospital","All","18 Years and older","Not Applicable","165","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","RIPH_2020_6","2020-06-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-08T00:00:00","","2020-06-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04337996"
"63","NCT04441502","Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic","COVID_OMICS","Recruiting","No Results Available","Covid19|Interstitial Pneumonia","","Circulating markers for COVID-19 signature|COVID-19 signature and adverse cardiovascular events|COVID-19 related coagulation pattern","IRCCS Policlinico S. Donato","All","18 Years and older","","240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID19_OMICS","2020-03-30T00:00:00","2020-09-30T00:00:00","2020-12-31T00:00:00","2020-06-22T00:00:00","","2020-06-22T00:00:00","IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy","","https://ClinicalTrials.gov/show/NCT04441502"
"64","NCT04410549","Pulmonary Optical Coherence Tomography in COVID-19 Patients","","Recruiting","No Results Available","Covid19|Pulmonary Embolism","Diagnostic Test: Optical Coherence Tomography","optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients|Pulmonary artery vessel anatomy characterization|Correlation between TTE pulmonary hypertension and right ventricular disfunction|Correlations with standard inflammatory, coagulation and tissue damage","IRCCS San Raffaele","All","18 Years and older","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","OCT COVID","2020-06-01T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-06-01T00:00:00","","2020-07-16T00:00:00","Incor - Heart Institute - University of Sao Paulo, São Paulo, Brazil|IRCCS San Raffaele, Milano, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04410549/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04410549"
"65","NCT04364828","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","COVID-19 NGS","Not yet recruiting","No Results Available","COVID-19","Genetic: Whole Genome Analysis|Genetic: T-cell receptor  repertoire|Genetic: SARS-CoV-2 viral composition","Viral evolution|Immune response|Disease severity","University Hospital Tuebingen","All","18 Years and older","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Diagnostic","COVID-19 NGS","2020-04-01T00:00:00","2021-04-01T00:00:00","2021-08-01T00:00:00","2020-04-28T00:00:00","","2020-05-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04364828"
"66","NCT04473248","Spartan COVID-19 System: Evaluation of Clinical Sample Collection","","Recruiting","No Results Available","Covid19","Device: Spartan COVID-19 System","Asses the % agreement between predicate results and Spartan COVID-19 results.","Spartan Bioscience Inc.|Humber River Hospital|The Ottawa Hospital","All","18 Years and older","Not Applicable","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single |Primary Purpose: Diagnostic","VNV-00552","2020-06-28T00:00:00","2020-08-01T00:00:00","2020-08-01T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Humber River Hospital, North York, Ontario, Canada|The Univeristy of Ottawa Heart Institute, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04473248"
"67","NCT04431310","Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic","","Recruiting","No Results Available","Covid-19|Health Personnel|Personnel, Hospital","Other: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic","Serology testing for specific COVID-19|SARS-CoV-2 infection","Nordsjaellands Hospital|University of Oxford|Nykøbing Falster County Hospital","All","18 Years and older","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Journal-nr.: H-20022312","2020-03-27T00:00:00","2025-08-01T00:00:00","2025-08-01T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Nordsjællands Hospital, Hillerød, Capital Region, Denmark|Nykøbing Falster County Hospital, Nykøbing Falster, Southern Region, Denmark","","https://ClinicalTrials.gov/show/NCT04431310"
"68","NCT04332835","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","CP-COVID-19","Recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma|Drug: Standard Therapy","Change in Viral Load|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay |Requirement of mechanical ventilation|Duration  of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud","All","18 Years to 100 Years","Phase 2|Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ABN011-2","2020-08-08T00:00:00","2020-10-31T00:00:00","2020-10-31T00:00:00","2020-04-03T00:00:00","","2020-08-17T00:00:00","Universidad del Rosario, Bogota, Cundinamarca, Colombia","","https://ClinicalTrials.gov/show/NCT04332835"
"69","NCT04384887","""Investigation of the Relationship Between New Coronary Virus Disease  and Anxiety and Depressive Symptoms in Pregnant Women""","","Active, not recruiting","No Results Available","COVID|Anxiety|Depression, Postpartum","Behavioral: covid-19 positive pregnant women","Evaluation of depression and anxiety score changes of covid-19 positive pregnants","Kanuni Sultan Suleyman Training and Research Hospital|Ayşegül Bestel|İbrahim Polat|Merve Aldıkaçtıoğlu Talmaç","Female","18 Years to 45 Years","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","beckcovid","2020-04-25T00:00:00","2020-07-25T00:00:00","2020-07-26T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04384887"
"70","NCT04424849","Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Diagnostic Test: CT-Scan","Invasive respiratory support in patients with COVID-19|Mortality in patients with COVID-19","Tepecik Training and Research Hospital","All","18 Years and older","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020/5-4","2020-03-15T00:00:00","2020-06-15T00:00:00","2020-07-15T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Tepecik Training and Research Hospital, Izmir, Izmir, Konak, Turkey","","https://ClinicalTrials.gov/show/NCT04424849"
"71","NCT04463472","Study of COVID-19 DNA Vaccine","","Recruiting","No Results Available","COVID-19","Biological: AG0301-COVID19","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])|Immunogenicity|Change in GMT of anti-SARS-CoV-2 spike  glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike  glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses  of anti-SARS-CoV-2 spike  glycoprotein-specific antibody|Adverse events","AnGes, Inc.|Japan Agency for Medical Research and Development","All","20 Years to 65 Years","Phase 1|Phase 2","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Prevention","AG0301-COVID19-JN-01","2020-06-29T00:00:00","2020-09-26T00:00:00","2021-07-31T00:00:00","2020-07-09T00:00:00","","2020-07-10T00:00:00","Osaka City University Hospital, Osaka, Japan","","https://ClinicalTrials.gov/show/NCT04463472"
"72","NCT04413045","Novel COVID-19, A National Analysis","","Completed","No Results Available","COVID-19","Other: Prevalence of COVID-19","Patient Prognosis Score|Oxygen Saturation|Laboratory Data|Radiological Features|Hospital Stay|Liver Function|Kidney Function","Assiut University","All","Child, Adult, Older Adult","","61","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Novel COVID-19 Prevalence","2020-05-20T00:00:00","2020-07-28T00:00:00","2020-07-28T00:00:00","2020-06-02T00:00:00","","2020-08-04T00:00:00","Assiut University Hospitals, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04413045"
"73","NCT04393402","Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care","LUS-COVID19","Recruiting","No Results Available","COVID","Procedure: lung ultrasound","LUS applicability with COVID 19|Radiographic correlation |LUS Mortality prediction|Prediction of Prone position response","Centre Hospitalier Universitaire de Nice","All","18 Years to 95 Years","","14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid03","2020-03-20T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-05-19T00:00:00","","2020-05-19T00:00:00","CHU de Nice, Nice, France","","https://ClinicalTrials.gov/show/NCT04393402"
"74","NCT04391738","Association Between BMI and COVID-19","BMI-SARS-CoV-2","Active, not recruiting","No Results Available","SARS-CoV 2","Other: Patients admitted to Intensive Care Unit with SARS-CoV2","Relationship between body mass index  and SARS-CoV-2|Associations between BMI and outcomes is independent of the known cardiometabolic risk factors|Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation|Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality","University Hospital, Lille","All","18 Years and older","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DEC20-095","2020-02-01T00:00:00","2020-05-15T00:00:00","2020-09-30T00:00:00","2020-05-18T00:00:00","","2020-08-04T00:00:00","Centre Hospitalier Regional & Universitaire de Lille , Lille, France","","https://ClinicalTrials.gov/show/NCT04391738"
"75","NCT04460690","Rapid, Onsite COVID-19 Detection","","Enrolling by invitation","No Results Available","COVID-19|Sars-CoV2","Device: Rapid Onsite COVID-19 Detection","Number of Samples Tested Consistently and Accurately per Protocol|Safety: COVID-19 rates of Investigators vs Communities tested","University of Wisconsin, Madison|National Institutes of Health |Wisconsin Alumni Research Fund|AIDS Vaccine Research Lab","All","5 Years and older","Not Applicable","5000","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","2020-0855|A536300|SMPH/PATHOL-LAB MED/ANAT PATH|Protocol Version 8/5/2020|5P51OD011106-59","2020-07-13T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-07T00:00:00","","2020-08-11T00:00:00","University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04460690"
"76","NCT04333862","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","Recruiting","No Results Available","SARS-CoV-2","","Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","University Hospital Inselspital, Berne","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00563","2020-03-19T00:00:00","2020-06-30T00:00:00","2021-12-31T00:00:00","2020-04-03T00:00:00","","2020-04-03T00:00:00","Guido Beldi, Bern, Switzerland","","https://ClinicalTrials.gov/show/NCT04333862"
"77","NCT04355715","Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","COVID-Scan","Active, not recruiting","No Results Available","COVID 19|SARS-Cov-2","","Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion","University Hospital, Montpellier","All","18 Years to 99 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0223","2019-04-01T00:00:00","2020-10-01T00:00:00","2020-10-20T00:00:00","2020-04-21T00:00:00","","2020-04-27T00:00:00","Uh Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04355715"
"78","NCT04343781","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","COVID19PUGG2","Completed","No Results Available","SARS-CoV-2|COVID-19","Other: observation","symptoms of COVID-19 in older patients","University Hospital, Angers","All","70 Years and older","","353","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ar20-0031v1","2020-03-22T00:00:00","2020-04-05T00:00:00","2020-04-05T00:00:00","2020-04-13T00:00:00","","2020-06-16T00:00:00","Angers University Hospital, Angers, France","","https://ClinicalTrials.gov/show/NCT04343781"
"79","NCT04424992","The Natural History of Hospitalized COVID-19 Patients","STORM","Active, not recruiting","No Results Available","Sars-CoV2","Other: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.","Covid19 infection clinical evolution|Risk factors for intra-hospital mortality|The impact of a fragility index |Prognostic score|The lung sequelae of SARS-COV-2 pneumonia|The accuracy of IF in elderly patients|Coagulation system anomalies|The impact of the prone position on the oxygenation","University of Milano Bicocca","All","18 Years and older","","1433","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STORM","2020-02-23T00:00:00","2020-04-10T00:00:00","2020-12-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","ASST Monza-Ospedale San Gerardo, Monza, Italy","","https://ClinicalTrials.gov/show/NCT04424992"
"80","NCT04416256","COVID-19 Pandemic and Worldwide Organ Procurement","COVID","Recruiting","No Results Available","COVID-19","","Organ transplantation activity during COVID-19 pandemic|Further analysis on organ transplantation with stratification","Paris Translational Research Center for Organ Transplantation|Agence de La Biomedecine|Eurotransplant|United Network for Organ Sharing|Deutsche Stiftung Organtransplantation|Centro Nazionale Trapianti|Brazilian Organ Transplant Association|The Canadian Association of Transplantation|Scandiatransplant|Nederlandse Transplantatie Vereniging|Austrotransplant|Centro Nacional de Trasplantes|Instituto Nacional de Donación y Trasplante de Celulas, Tejidos y Órganos|Donor Network of Croatia|Instituto Nacional Central Único Coordinador de Ablación e Implante|Corporación Nacional de Trasplantes de Chile|Australian Organ and Tissue Donation and Transplantation Authority|Organización Nacional de Trasplantes|Autoridade Para Services de Sangue e Transplantacáo","All","Child, Adult, Older Adult","","230000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID/W.W.","2020-02-01T00:00:00","2022-02-01T00:00:00","2022-02-01T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Paris Transplant Group, Paris, France","","https://ClinicalTrials.gov/show/NCT04416256"
"81","NCT04331834","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebos","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Plató|Hospital de Granollers","All","18 Years and older","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","PrEP_COVID","2020-04-03T00:00:00","2020-10-03T00:00:00","2020-10-30T00:00:00","2020-04-02T00:00:00","","2020-07-15T00:00:00","ISGlobal, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04331834"
"82","NCT04347278","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","RegCOVID19","Recruiting","No Results Available","SARS-CoV-2","Drug: Patients with the treatment agains COVID19","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection  in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.","Instituto de Investigación Marques de Valdecilla|Hospital Universitario Marques de Valdecilla|Hospital Universitario de Canarias|Hospital San Pedro de Alcántara","All","1 Year to 100 Years","","1000","Other","Observational","Observational Model: Other|Time Perspective: Other","IDI-REM-2020-1","2020-04-22T00:00:00","2020-10-15T00:00:00","2021-01-01T00:00:00","2020-04-15T00:00:00","","2020-06-02T00:00:00","Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain","","https://ClinicalTrials.gov/show/NCT04347278"
"83","NCT04344912","Impact of COVID19 Outbreak in Cardiac Acute Care","CCU-COVID19","Recruiting","No Results Available","Acute Coronary Syndrome|Heart Failure|COVID","Other: Data collection","Incidence of recurrent Major Cardiovascular Events  and urgent rehospitalization","Assistance Publique - Hôpitaux de Paris|Action, France","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200524|0522070420","2020-03-20T00:00:00","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-04-14T00:00:00","","2020-04-28T00:00:00","Unite de Soins Intensifs de Cardiologie, Pitie Salpêtrière Hospital, AP-HP, Paris, France","","https://ClinicalTrials.gov/show/NCT04344912"
"84","NCT04496141","Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19","","Active, not recruiting","No Results Available","Covid19","Diagnostic Test: SARS-CoV-2 antibody immunoassays","The accuracy of the different commercial SARS-CoV-2 antibody immunoassays","Hong Kong Sanatorium & Hospital","All","Child, Adult, Older Adult","","70","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC-2020-12","2020-07-27T00:00:00","2020-11-30T00:00:00","2020-11-30T00:00:00","2020-08-03T00:00:00","","2020-08-03T00:00:00","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT04496141"
"85","NCT04413864","Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19","DEXDO-COVID","Recruiting","No Results Available","SARS-CoV 2","Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration","Change of inflammatory cytokines concentration  in Covid19 + patients from Baseline at 6 months|Change of interrelationship between inflammation  and ICU delirium in Covid19 + patient from Baseline at 6 months|Modification in inflammatory genes expressed  in PBMC between Baseline and M6|Change in quantity of chromatine's openings  in ICU patient recovering from covid19 infection|Change in genes expression in Covid-19 patient with delirium in ICU between Day2 and Month6","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","APHP200413|2020-A00799-30","2020-04-24T00:00:00","2021-02-28T00:00:00","2021-02-28T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6, Paris, France","","https://ClinicalTrials.gov/show/NCT04413864"
"86","NCT04378452","Assessment of the Psycho-social Impact of COVID-19 Outbreak","COM-COVID","Recruiting","No Results Available","SARS-CoV 2|COVID-19|Quality of Life|Mental Health Wellness 1|Social Distance|SARS |Psychological","Behavioral: COM-COVID anonimous survey","Psychological impact of the outbreak, total score|Psychological impact of the outbreak: depression questions score|Psychological impact of the outbreak: anxiety questions score|Psychological impact of the outbreak: stress questions score|Psychological impact of the outbreak: PSTD questions score|Descriptive statistics for the non-psychological questions","Fundació Institut Germans Trias i Pujol|Anaxomics|Fundació Lluita contra la Sida","All","16 Years and older","","65000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COM-COVID","2020-03-31T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-05-07T00:00:00","","2020-05-07T00:00:00","Fundació Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|Fundació Lluita contra la Sida , Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04378452"
"87","NCT04375098","Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection","","Active, not recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Biological: COVID-19 convalescent plasma","Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization|Median duration of fever|Median duration of mechanical ventilation|Median length of ICU stay|Median length of admission|Hospital mortality rate |30-day mortality |Readmission rate |Median length of viral clearance","Pontificia Universidad Catolica de Chile|Fundacion Arturo Lopez Perez","All","18 Years and older","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","200415015","2020-05-04T00:00:00","2020-12-01T00:00:00","2021-12-01T00:00:00","2020-05-05T00:00:00","","2020-08-07T00:00:00","Hospital Clínico Universidad Católica, Santiago, Chile","","https://ClinicalTrials.gov/show/NCT04375098"
"88","NCT04367402","COST  ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients","COST ACTION","Recruiting","No Results Available","COVID-19","Other: BioMedomics COVID-19 IgM-IgG Rapid Test","Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis.|ACE2 expression in patients with COVID-19 infection","Azienda Ospedaliera San Paolo","All","18 Years and older","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2020/ST/057","2020-03-30T00:00:00","2020-04-24T00:00:00","2020-09-01T00:00:00","2020-04-29T00:00:00","","2020-04-30T00:00:00","AO San Paolo, Milan, IT, Italy","","https://ClinicalTrials.gov/show/NCT04367402"
"89","NCT04477889","Methodist Health System COVID-19 Patient Registry","","Not yet recruiting","No Results Available","COVID-19","Other: Treatment for COVID-19","Patient Characteristics|Treatment Measures and Intervention strategies|Clinical and survival outcomes","Methodist Health System","All","18 Years and older","","500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","024.CRI.2020.A","2020-08-01T00:00:00","2025-12-01T00:00:00","2026-12-01T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","Clinical Research Institute Methodist Health System, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT04477889"
"90","NCT04470557","Relation Between Lab Finding and COVID-19 Severity","","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: D-dimer,CBC.ESR,CRP,|Diagnostic Test: Liver function tests ,serum ferritin and PCR for COVID-19 .","Estimation of severity of patients with COVID-19 in relation to Laboratory findings.","Assiut University","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","RLCS","2020-07-15T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-07-14T00:00:00","","2020-07-14T00:00:00","","","https://ClinicalTrials.gov/show/NCT04470557"
"91","NCT04408001","Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff","IMMUNO-COVID","Recruiting","No Results Available","Sars-CoV2","Other: Clinical interview|Biological: Blood collection|Biological: Saliva collection","Induced SARS-CoV2 immunity|Long-term protection of induced SARS-CoV2 immunity at 6 months|Long-term protection of induced SARS-CoV2 immunity at 1 year|Anti-SARS-CoV2 antibodies kinetics in blood throughout the study|Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study|Kinetics of serum neutralization in blood throughout the study|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 0|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 21","Direction Centrale du Service de Sante des Armees","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-04","2020-06-04T00:00:00","2021-06-04T00:00:00","2021-06-04T00:00:00","2020-05-29T00:00:00","","2020-06-09T00:00:00","Hôpital d'Instuction des Armees Percy, Clamart, France","","https://ClinicalTrials.gov/show/NCT04408001"
"92","NCT04404179","Setting up a COVID-19 Care Facility at a Prison in Pakistan","","Completed","No Results Available","COVID-19","Other: COVID-19 FACILITY","Recovery|Mortality|ICU admission","Services Institute of Medical Sciences, Pakistan","All","Child, Adult, Older Adult","","69","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CovJ","2020-03-27T00:00:00","2020-05-02T00:00:00","2020-05-02T00:00:00","2020-05-27T00:00:00","","2020-05-29T00:00:00","Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan","","https://ClinicalTrials.gov/show/NCT04404179"
"93","NCT04303299","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","THDMS-COVID-19","Not yet recruiting","No Results Available","SARS-COV-2 Infections|COVID-19","Drug: Oral","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Rajavithi Hospital","All","16 Years to 100 Years","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","TH-DMS-COVID19 study","2020-07-15T00:00:00","2020-12-31T00:00:00","2021-03-30T00:00:00","2020-03-11T00:00:00","","2020-06-16T00:00:00","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT04303299"
"94","NCT04336956","Covid-19 Pediatric Observatory","PANDOR","Recruiting","No Results Available","COVID-19","Other: hospitalized children with Covid19","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","Centre Hospitalier Intercommunal Creteil|Association Clinique Therapeutique Infantile du val de Marne|GPIP|Societe Française de Pediatrie|GFRUP","All","up to 18 Years","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PANDOR","2020-04-07T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-04-07T00:00:00","","2020-07-17T00:00:00","Chu Felix Guyon, Saint Denis, La Reunion, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoulème, France|Pringy - Ch D'Annecy, Annecy, France|CH Argenteuil, Argenteuil, France|Ch Armentieres, Armentières, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besançon, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Saône, France|CH de CHAMBERY, Chambery, France|Ch Hotel Dieu, Chartres, France|CHU Estaing, Clermont-Ferrand, France|Hopital Louis Pasteur, Colmar, France|Hopital Louis Mourrier, Colombes, France|CH Sud Francilien, Corbeil-Essonnes, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hyères, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHGeneral du HAVRE, Le Havre, France|Hopital Jeanne de Flandre, Lille, France|Hopital Roger Salengro - Lille, Lille, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Lorient - Ch de Bretagne Sud, Lorient, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital de Mantes, Mantes-la-Jolie, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|Ch de Melun, Meulin, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|Hopital Arnaud de Villeneuve, Montpellier, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|CHU Nimes Caremeau, Nîmes, France|Chr Orleans, Orleans, France|Assistance Publique Hôpitaux de Paris, Paris, France|Hopital St Jean Roussillon, Perpignan, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Americain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|CH de ROMANS, Romans-sur-Isère, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Denis, Saint-Denis, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Hautepierre, Strasbourg, France|CH Tarbes, Tarbes, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-hôpital des Enfants, Toulouse, France|Hôpital Gatien De Clocheville, Tours, France|CH de TROYES, Troyes, France|Hôpital Nord Franche-Comte, Trevenans, France|Ch Bretagne Atlantique, Vannes, France|Ch Le Chesnay, Versailles, France|Hopital de Villeneuve Saint Georges, Villeneuve-Saint-Georges, France|CH Jean Monnet, Épinal, France","","https://ClinicalTrials.gov/show/NCT04336956"
"95","NCT04445415","Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers","","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 antibodies testing","diagnostic value of COVID-19 antibodies testing|Role of COVID -19 Antibodies testing in treatment of Patients|Assement of COVID -19 prevalence among healthcare workers","Assiut University","All","Child, Adult, Older Adult","","250","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","COVID-19 antibodies testing","2020-07-01T00:00:00","2021-06-01T00:00:00","2021-09-01T00:00:00","2020-06-24T00:00:00","","2020-06-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04445415"
"96","NCT04483622","Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients","COVID-19","Recruiting","No Results Available","Covid19","","rising titre of IGg antibodies","Sohag University","All","16 Years to 90 Years","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IBR#S20-133","2020-06-12T00:00:00","2021-01-13T00:00:00","2021-02-15T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","Sohag University Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT04483622"
"97","NCT04420260","Primary Prevention of Infection by COVID-19 in Health Providers","PI-Covid-19","Not yet recruiting","No Results Available","COVID","Dietary Supplement: Group A: oropharygeal spray and immunostimulant|Dietary Supplement: Group B: Placebo oropharyngeal spray + Active principle immunostimulant|Dietary Supplement: Group C:Active principle oropharyngeal spray + Placebo taken PO|Dietary Supplement: Group D:Placebo oropharyngeal spray + Placebo taken PO","Seroconversion of IgM for COVID-19.|Seroconversion of IgG for COVID-19.","Unidad de Investigación Genetica Molecular|Universidad de Antioquia","All","18 Years to 60 Years","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","UNIGEM PT-IC-02","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","","","https://ClinicalTrials.gov/show/NCT04420260"
"98","NCT04420312","Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms","COVID-EP","Completed","No Results Available","Pulmonary Embolism|Covid-19","","Impact of PE on COVID-19 patients|Clinical and radiological characteristics","Groupe Hospitalier Paris Saint Joseph","All","18 Years and older","","1024","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","COVID-EP|MR 4516150520","2020-03-01T00:00:00","2020-04-20T00:00:00","2020-04-20T00:00:00","2020-06-09T00:00:00","","2020-06-25T00:00:00","Groupe Hospitalier Paris Saint-Joseph, Paris, France","","https://ClinicalTrials.gov/show/NCT04420312"
"99","NCT04366882","Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients","MIA-COVID-19","Recruiting","No Results Available","COVID-19","Procedure: CT-scan with minimal invasive autopsy","Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|Detailed description of the postmortem radiological changes induced by COVID-19|Detailed description of the postmortem histopathological changes induced by COVID-19|Postmortem quantity of viral RNA|Postmortem disease mechanisms at cellular level","Jessa Hospital|Hasselt University|University Hospital, Antwerp","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Health Services Research","JessaH_COVID-19_MIA","2020-04-14T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","Jessa Hospital, Hasselt, Belgium","","https://ClinicalTrials.gov/show/NCT04366882"
"100","NCT04318301","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","Completed","No Results Available","COVID-19|Hypertension","","Rate of Death|the severity of pneumonia","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years to 100 Years","","275","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HT-COVID19","2020-03-21T00:00:00","2020-03-28T00:00:00","2020-03-30T00:00:00","2020-03-23T00:00:00","","2020-04-29T00:00:00","Hankou Hospital, Hankou, Hubei, China","","https://ClinicalTrials.gov/show/NCT04318301"
"101","NCT04347070","Implementation of Physiotherapy on COVID-19 Patients in ICU","PHYSIO-COVID","Recruiting","No Results Available","Sars-CoV2|COVID-19","Other: Phsyiotherapy","Time of physiotherapy|Type of physiotherapy implemented","University Hospital, Montpellier|Societe espagnole de pneumologie |Societe française de kinesitherapie en reanimation","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0175","2017-04-01T00:00:00","2020-09-01T00:00:00","2022-12-01T00:00:00","2020-04-15T00:00:00","","2020-04-16T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04347070"
"102","NCT04354831","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","","Recruiting","No Results Available","COVID-19","Biological: anti-SARS-CoV-2 convalescent plasma","Overall Mortality within 60 days|Length of ICU stay during current admission for COVID","Medical College of Wisconsin|Froedtert Hospital","All","18 Years and older","Phase 2","131","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","PRO00037712","2020-05-11T00:00:00","2022-05-01T00:00:00","2023-05-01T00:00:00","2020-04-21T00:00:00","","2020-05-13T00:00:00","Froedtert Hospital, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04354831"
"103","NCT04350320","Trial to Study the Benefit of Colchicine in Patients With COVID-19","COL-COVID","Recruiting","No Results Available","COVID19","Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment |Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","All","18 Years and older","Phase 3","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","IMIB-COLVID-2020-03","2020-04-30T00:00:00","2020-10-20T00:00:00","2020-11-20T00:00:00","2020-04-17T00:00:00","","2020-05-05T00:00:00","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain","","https://ClinicalTrials.gov/show/NCT04350320"
"104","NCT04507893","Comparison Between Positive and Negative COVID-19 Pneumonia","","Recruiting","No Results Available","Covid19|Interstitial Pneumonia","Other: Clinical, laboratory and imaging characteristics of pneumonia","Evaluation of the clinical characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".|Evaluation of the laboratory characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".|Evaluation of the imaging characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".|Evaluation of mortality of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".|Evaluation of clinical severity of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".|Evaluation of hospital stay length of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as ""COVID-19 patients"" and ""COVID-19 negative controls"".","University of Palermo","All","18 Years to 95 Years","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ACPM26","2020-03-15T00:00:00","2020-09-30T00:00:00","2020-12-01T00:00:00","2020-08-11T00:00:00","","2020-08-11T00:00:00","Infectious diseases Unit of the ""Cervello-Villa Sofia"" Hospital, Palermo, PA, Italy|Internal Medicine Division of the ""Cervello-Villa Sofia"" Hospital, Palermo, PA, Italy|Pulmonology Unit Dedicated to COVID-19 Patients, Palermo, PA, Italy","","https://ClinicalTrials.gov/show/NCT04507893"
"105","NCT04457726","Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","","Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 Specific T Cells","Dose-Limiting Toxicities|National Early Warning Score |Time to improvement by one category on a WHO ordinal scale|Time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells|Duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood circulation|Time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion|Overall survival  at 3 months after infusion of SARS-CoV-2 specific T cells","KK Women's and Children's Hospital|Duke-NUS Graduate Medical School|National University Hospital, Singapore|Singapore General Hospital|Sengkang General Hospital|Changi General Hospital","All","1 Year to 90 Years","Phase 1|Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID-T 2.0","2020-07-01T00:00:00","2021-03-01T00:00:00","2022-12-01T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Changi General Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Sengkang General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT04457726"
"106","NCT04474483","Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Melatonin|Other: Placebo  capsule","Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality","State University of New York at Buffalo","All","18 Years and older","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","UBMELCOVID19","2020-08-11T00:00:00","2021-08-10T00:00:00","2021-08-10T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","University at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT04474483"
"107","NCT04488081","I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","I-SPY_COVID","Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast","Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality","QuantumLeap Healthcare Collaborative|University of California, San Francisco|University of Pennsylvania|University of Minnesota|Emory University|University of Alabama at Birmingham|University of California, San Diego|University of Colorado, Denver|University of Southern California|Yale University|Columbia University|Wake Forest University Health Sciences|Sanford Health|Montefiore Medical Center","All","18 Years and older","Phase 2","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","I-SPY-COVID","2020-07-31T00:00:00","2022-07-24T00:00:00","2022-11-01T00:00:00","2020-07-27T00:00:00","","2020-08-12T00:00:00","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco , San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania , Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States","","https://ClinicalTrials.gov/show/NCT04488081"
"108","NCT04481633","Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection","PREPCOV","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID 19 serology|Other: COVID 19 Self-Questionnaire","Rate of patients with positive anti-COVID19 serology|Rate of patients with symptomatic or severe  form of infection","University Hospital, Toulouse","All","18 Years and older","Not Applicable","800","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","RC31/20/0186|2020-A01906-33","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-07-22T00:00:00","","2020-07-24T00:00:00","Limoges university Hospital, Limoges, France|Montpellier University Hospital, Montpellier, France|Pitie Salpêtrière Hospital - Hepatologie, Paris, France|Pitie Salpêtrière Hospital - Medecine interne, Paris, France|Haut-Levêque Hospital - Gastro-enterologie, Pessac, France|Haut-Levêque Hospital - Medecine interne, Pessac, France|Joseph Ducuing Hospital - Medecine interne, Toulouse, France|Toulouse university Hospital - Larrey Dermatologie, Toulouse, France|Toulouse University Hospital - Rhumatologie, Toulouse, France|Toulouse University Hospital, Toulouse, France|University Hospital of Toulouse - Rangueil Medecine interne, Toulouse, France|University hospital Toulouse - Purpan Medecine interne, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04481633"
"109","NCT04393428","Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2","COVID-AKI","Completed","No Results Available","COVID-19|Renal Replacement Therapy|Acute Kidney Injury","Other: [TIMP-2]*[IGFBP-7]","Sensibility and specificity of urinary","University Hospital, Montpellier","All","18 Years to 100 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0294","2020-03-01T00:00:00","2020-06-01T00:00:00","2020-06-30T00:00:00","2020-05-19T00:00:00","","2020-07-29T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04393428"
"110","NCT04432103","Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma","","Not yet recruiting","No Results Available","Covid-19","Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients","INCIDENCE OF CRITICAL PNEUMONIA|MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS|INCIDENCE OF MECHANICAL VENTILATION|DAYS OF MECHANICAL VENTILATION","Centro Medico ABC","All","18 Years and older","Phase 3","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ABC-20-14","2020-06-19T00:00:00","2020-07-30T00:00:00","2020-09-30T00:00:00","2020-06-16T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04432103"
"111","NCT04480060","Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic","","Completed","No Results Available","Covid19","Diagnostic Test: COVID-19 diagnostic PCR","Mortality of the COVID-19 patients","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years to 50 Years","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KSSEAH--EDCC","2020-03-10T00:00:00","2020-06-30T00:00:00","2020-07-14T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","Seda Yilmaz Semerci, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04480060"
"112","NCT04453280","Antibody Detection in COVID-19 Cured Patients","SARSCoV2CZImun","Completed","No Results Available","COVID|SARS-CoV-2","Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies|Diagnostic Test: SARS-CoV-2 diagnostic rapid test","Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.|Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the age and to the severity of the disease.|The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies.","Institute of Health Information and Statistics of the Czech Republic|Ministry of Health, Czech Republic|Faculty of Medicine, Masaryk University|Institute for Clinical and Experimental Medicine|Brno University Hospital|St. Anne's University Hospital Brno, Czech Republic|Masaryk Memorial Cancer Institute|Regional Public Health Office of the South Moravian Region based in Brno, Czech Republic|Public Health Office of the Capital City of Prague, Czech Republic|Regional Public Health Office of the Central Bohemian Region based in Prague, Czech Republic","All","8 Years and older","","695","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","UZIS 2020/2","2020-05-18T00:00:00","2020-06-03T00:00:00","2020-06-03T00:00:00","2020-07-01T00:00:00","","2020-07-01T00:00:00","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia","","https://ClinicalTrials.gov/show/NCT04453280"
"113","NCT04376788","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML","improvement of condition|change in organs function with PFS and OS","Ain Shams University","All","18 Years to 65 Years","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","FMASU P22/2020","2020-05-20T00:00:00","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-05-06T00:00:00","","2020-07-09T00:00:00","Ain Shams University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04376788"
"114","NCT04488484","Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.","PERSO-COVID","Active, not recruiting","No Results Available","COVID-19","Other: Serology test follow-up","Immune Response description|Evolution of the SARS-CoV2 overtime|Clinical and Immunological Analysis|Comparison of the occurrence of clinical events with other immunological data","Groupe Hospitalier Paris Saint Joseph","All","18 Years and older","Not Applicable","450","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","PERSO-COVID","2020-07-01T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-07-28T00:00:00","","2020-08-12T00:00:00","Groupe Hospitalier Paris Saint-Joseph, Paris, France","","https://ClinicalTrials.gov/show/NCT04488484"
"115","NCT04514627","Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19","PENFS COVID-19","Recruiting","No Results Available","COVID-19","Device: Auricular percutaneous neurostimulation","Efficacy of PENFS therapy in preventing dyspnea from COVID-19 through worsening hypoxemia|Efficacy of PENFS therapy in preventing dyspnea from COVID-19 through progression to mechanical ventilation, ECLS or death|Oxygen requirements|Days of hospitalization|Time to hospital discharge|Time to resolution of fever|Days of resting respiratory rate|Serious adverse events or patient or worsening condition|Erythrocyte Sedimentation Rate |C-Reactive Protein |Ferritin|D-Dimer|Creatine Phosphokinase, Total |Troponin|Lactate Dehydrogenase |Procalcitonin |B-Type Natriuretic Peptide |N-Terminal Pro B-Type Natriuretic Peptide |Interleukin-6 , High Sensitive ELISA|Complete Blood Count  with Differential|Comprehensive Metabolic Panel |7-Point Ordinal Scale of Clinical Status|Modified Borg Dyspnea Scale","Olive View-UCLA Education & Research Institute","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","1600899","2020-07-13T00:00:00","2021-07-31T00:00:00","2021-07-31T00:00:00","2020-08-17T00:00:00","","2020-08-17T00:00:00","Olive View-UCLA Medical Center, Sylmar, California, United States","","https://ClinicalTrials.gov/show/NCT04514627"
"116","NCT04342156","Safety And Efficacy Of Hydroxychloroquine For At Risk Population  Against COVID-19","SHARP COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection|Hydroxychloroquine Adverse Reaction","Drug: Hydroxychloroquine Sulfate 200 milligram  Tab","positive serology or reverse transcriptase  for COVID-19 up until day 28.|Positive serology at day 28.|Symptoms of COVID-19.","Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports","All","18 Years to 80 Years","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","2020/00402","2020-04-01T00:00:00","2020-08-01T00:00:00","2020-10-01T00:00:00","2020-04-10T00:00:00","","2020-04-20T00:00:00","","","https://ClinicalTrials.gov/show/NCT04342156"
"117","NCT04430049","Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients","HAD-Covid","Not yet recruiting","No Results Available","Covid-19|Family Members|Critical Illness","Procedure: Covid ICU containment measures","Anxiety|Depression|post-traumatic stress disorder","University Hospital, Clermont-Ferrand","All","18 Years and older","","240","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020 HAD-Covid","2020-06-22T00:00:00","2021-10-22T00:00:00","2022-01-22T00:00:00","2020-06-12T00:00:00","","2020-06-19T00:00:00","University hospital, Clermont-Ferrand, Clermont-Ferrand, Auvergne, France|CH Aurillac, Aurillac, France|CH Cannes, Cannes, France|Centre Jean Perrin, Clermont-Ferrand, France|CH Grenoble, Grenoble, France|CH Le Puy-en-Velay, Le Puy-en-Velay, France|University hopistal, Lyon, Lyon, France|CH Moulins, Moulins, France|CH Perigueux, Perigueux, France|CH Rodez, Rodez, France|CH Vichy, Vichy, France","","https://ClinicalTrials.gov/show/NCT04430049"
"118","NCT04355741","Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease","","Recruiting","No Results Available","COVID-19","Other: Exposure","Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.","Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar Universitário São João|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research","All","18 Years and older","","60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID19_Microbiota","2020-04-20T00:00:00","2020-07-01T00:00:00","2020-12-01T00:00:00","2020-04-21T00:00:00","","2020-06-29T00:00:00","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário São João, Oporto, Portugal","","https://ClinicalTrials.gov/show/NCT04355741"
"119","NCT04364698","Observational Cohort of COVID-19 Patients at Raymond-Poincare","COVID-RPC","Recruiting","No Results Available","COVID-19","","clinical, biological and radiological characteristics|patients' journey description|Treatments effects","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20SBS-COVID-RPC","2020-05-07T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-04-28T00:00:00","","2020-05-14T00:00:00","Department of Infectiology, Raymond Poincare Hospital, APHP, Garches, France","","https://ClinicalTrials.gov/show/NCT04364698"
"120","NCT04361981","Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study","TVP-COVID-RIV","Not yet recruiting","No Results Available","COVID-19","Other: Deep Venous Disease Diagnostic","Deep Venous Disease Incidence|30-days mortality|ICU admission|Anticoagulant treatment","Sociedad Espanola de Angiologia y Cirugia Vascular","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-R3","2020-04-01T00:00:00","2020-08-31T00:00:00","2020-12-31T00:00:00","2020-04-24T00:00:00","","2020-04-27T00:00:00","Red de Investigacion Vascular , Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04361981"
"121","NCT04421404","Effects of COVID-19 Convalescent Plasma  on Coronavirus-associated Complications in Hospitalized Patients","CAPRI","Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: COVID-19 Convalescent Plasma |Biological: Placebo","Mechanical Ventilation or Death Endpoint|8-Point Ordinal Scale Endpoint","Priscilla Hsue, MD|Blood Systems Research Institute|San Francisco General Hospital|University of California, San Francisco","All","18 Years and older","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","20-30794","2020-06-09T00:00:00","2021-04-30T00:00:00","2021-04-30T00:00:00","2020-06-09T00:00:00","","2020-08-06T00:00:00","San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center , San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT04421404"
"122","NCT04336384","Impact of Covid-19 in Congenital Heart Disease","COVID-CHD","Recruiting","No Results Available","Congenital Heart Disease|Covid-19","","Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths","University Hospital, Montpellier|Pr. Jean-Benoît THAMBO, Bordeaux |Dr. Celine GRUNENWALD GRONIER, Strasbourg|Dr. Sebastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier","All","Child, Adult, Older Adult","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0155","2020-03-01T00:00:00","2020-12-01T00:00:00","2020-12-30T00:00:00","2020-04-07T00:00:00","","2020-04-14T00:00:00","Uh Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04336384"
"123","NCT04387968","Epidemiological Study of the Covid-19 Presto Test","COVIDOR","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Covid-19 presto test","o study the prevalence of Covid-19 infection, coronavirus  in territorial agents in the 3 structures Department, 45 and CDG Orleans Metropolitan|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolis, the Department, the Loiret Management Center and contamination by covid-19","Raphael Serreau|François Rabelais University|Orleans Metropole Service de Medecine Preventive","All","18 Years to 65 Years","","700","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2020-A01414-35","2020-06-18T00:00:00","2021-06-18T00:00:00","2022-01-18T00:00:00","2020-05-14T00:00:00","","2020-05-14T00:00:00","Unite de Recherche PARADICT-O - Service de Medecine - Orleans Metropole, Orleans, France","","https://ClinicalTrials.gov/show/NCT04387968"
"124","NCT04470583","Evaluating Clinical Parameters of COVID-19 in Pregnancy","COpregVID","Not yet recruiting","No Results Available","COVID-19|2019 Novel Coronavirus Infection|COVID-19 Infection","","Proportions of leukocyte subsets and thrombocytes in pregnant/postnatal and non-pregnant COVID-19 positive women.|Concentrations of other biochemical markers of severity in pregnant and non-pregnant COVID-19 positive women.|Profiling of clinical severity, determined by clinical symptoms and observations in pregnant and non-pregnant COVID-19 positive women.","Chelsea and Westminster NHS Foundation Trust","All","18 Years to 60 Years","","116","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","C&W20/034|283995","2020-07-01T00:00:00","2021-11-01T00:00:00","2021-12-02T00:00:00","2020-07-14T00:00:00","","2020-07-16T00:00:00","Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04470583"
"125","NCT04470258","Elmo Respiratory Support Project - COVID-19","","Not yet recruiting","No Results Available","COVID-19|Respiratory Failure With Hypoxia","Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS|Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY","Usability tests of the Elmo system using Euristic usability principles|Evaluation of the effectiveness of the ELMO system using physiological parameters","Escola de Saúde Pública do Ceará","All","18 Years and older","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Device Feasibility","4.104.233","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-07-14T00:00:00","","2020-07-14T00:00:00","","","https://ClinicalTrials.gov/show/NCT04470258"
"126","NCT03348670","Follow NCT03305341 - Proof-of-Concept - COVID-19 AP TP Vaccine","AP-TP-V","Active, not recruiting","No Results Available","Covid19","Biological: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection","Test Macrophage Migration Inhibitory Factor","Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair|Medicine Invention Design, Inc","All","22 Years to 72 Years","Early Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","BLA761200|FWA00015357|IRB00009424|IORG0007849|IND152006|NDA215163","2020-07-20T00:00:00","2020-10-10T00:00:00","2020-11-10T00:00:00","2017-11-21T00:00:00","","2020-07-23T00:00:00","Medicine Invention Design, Inc.  - c/o - MIDINC Clinical Investigator Working Site, North Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03348670"
"127","NCT04358536","Classification of COVID-19 Infection in Posteroanterior Chest X-rays","","Completed","No Results Available","COVID-19","Device: CovX","Identification of COVID-19","Dascena","All","18 Years and older","","230","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","04202002","2020-04-01T00:00:00","2020-04-17T00:00:00","2020-04-17T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Dascena, Oakland, California, United States","","https://ClinicalTrials.gov/show/NCT04358536"
"128","NCT04465981","Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins","SARS-CoV-2","Recruiting","No Results Available","COVID-19|Corona Virus Infection","Diagnostic Test: Sampling","Detection Test of COVID-19","INanoBio Inc.|TMC HealthCare","All","18 Years and older","","80","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Other","INANO-CV1","2020-07-01T00:00:00","2020-12-01T00:00:00","2021-06-01T00:00:00","2020-07-10T00:00:00","","2020-07-27T00:00:00","TMC HealthCare, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT04465981"
"129","NCT04376879","Predicting the Need for Intubation in Hospitalised COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Other: Data monitoring for 48h within the first 12 hours of admission for COVID-19","the number of intubations in COVID-19 patients initially hospitalised in wards|the number of intubations in COVID-19 patients initially hospitalised in wards.","Central Hospital, Nancy, France","All","18 Years and older","","384","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01076-33","2020-05-16T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-05-06T00:00:00","","2020-05-27T00:00:00","Louis Mourier hospital , Colombes, France|Brabois Hospital , Vandœuvre-lès-Nancy, France","","https://ClinicalTrials.gov/show/NCT04376879"
"130","NCT04355871","Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","COVID19@Spain","Completed","No Results Available","Covid19","","Overall mortality|Mechanical ventilation","Fundacion SEIMC-GESIDA","All","Child, Adult, Older Adult","","4035","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-19/SEIMC-FSG","2020-03-18T00:00:00","2020-04-15T00:00:00","2020-04-17T00:00:00","2020-04-21T00:00:00","","2020-05-11T00:00:00","Comp. Hosp. Univ. A Coruña, A Coruña, Spain|H. Quiron A Coruña, A Coruña, Spain|H. de Alcaniz, Alcañiz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral , Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Breña Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de Denia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ramón Jimenez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Jaen, Jaen, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Leganes, Spain|H. San Pedro, Logroño, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jimenez Díaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorcón, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de Móstoles, Madrid, Spain|H. Univ. Gregorio Marañon, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ramón y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Mataró, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondragón, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, Málaga, Spain|H. Virgen de la Victoria, Málaga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palamós, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebastián De Los Reyes, Spain|H. de Donostia, San Sebastián, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ávila, Spain","","https://ClinicalTrials.gov/show/NCT04355871"
"131","NCT04482673","Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection","VitD-COVID19","Recruiting","No Results Available","COVID-19|Vitamin D Deficiency|Respiratory Viral Infection","Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo","Change in total circulating 25D concentration|Change in total circulating 25D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration -gamma, Interleukin -1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor -alpha|Respiratory symptoms|Signs and symptoms of rhino/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment","Medical University of South Carolina|Grassroots Health Nutrition Institute|ZRT Laboratory","All","50 Years and older","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","00099939","2020-07-31T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-07-22T00:00:00","","2020-08-04T00:00:00","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT04482673"
"132","NCT04341441","Will Hydroxychloroquine Impede or Prevent COVID-19","WHIP COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.","Henry Ford Health System","All","18 Years to 75 Years","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","1410401","2020-04-07T00:00:00","2020-06-30T00:00:00","2021-04-30T00:00:00","2020-04-10T00:00:00","","2020-05-07T00:00:00","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation , Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04341441"
"133","NCT04387838","Study of the SARS-COV-2  Serological Profile of an Army Training Hospital Staff","SEROSARSCOV","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.|Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.|Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.|Anti-SARS-Cov2 seroprevalence at Day 0.|Correlation between seroconversion and socio-demographic factors - sex|Correlation between seroconversion and socio-demographic factors - age|Correlation between seroconversion and professional factors - job type|Correlation between seroconversion and professional factors - personal protective equipment type|Correlation between seroconversion and non-professional factors - contact with infected individuals|Correlation between seroconversion and non-professional factors - wearing of professional equipment|Correlation between seroconversion and non-professional factors - respect of barrier gestures","Direction Centrale du Service de Sante des Armees","All","18 Years to 62 Years","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-10","2020-05-14T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-05-14T00:00:00","","2020-06-09T00:00:00","Hôpital d'Instuction des Armees Sainte-Anne, Toulon, France|Hôpital d'Instruction des Armees Robert Picque, Villenave-d'Ornon, France","","https://ClinicalTrials.gov/show/NCT04387838"
"134","NCT04483908","COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses","SEROBL-COVID19","Recruiting","No Results Available","COVID-19 Infection","Diagnostic Test: blood draw|Diagnostic Test: fingertip tests for POC assays|Diagnostic Test: saliva collection|Diagnostic Test: collection of swabs","Qualitative method validation |Quantitative method validation |Immune cell repertoire sequencing","University Hospital, Basel, Switzerland|ETH Zurich |Department of Health, Canton Basel-Land","All","18 Years and older","","550","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BASEC Project-ID 2020-00816","2020-04-10T00:00:00","2022-05-30T00:00:00","2022-05-30T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","Department of Health, Economics and Health Directorate Canton Basel-Land, Liestal, Switzerland","","https://ClinicalTrials.gov/show/NCT04483908"
"135","NCT04352348","Cohort of Patients Infected With SARS-CoV2  or Suspected of Being","COVIDeF","Recruiting","No Results Available","COVID-19","Other: blood samples","Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Basic Science","APHP200382|2020-A00754-35","2020-03-31T00:00:00","2021-05-31T00:00:00","2022-03-31T00:00:00","2020-04-20T00:00:00","","2020-05-12T00:00:00","GH Pitie-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France","","https://ClinicalTrials.gov/show/NCT04352348"
"136","NCT04406090","Endovascular Thrombectomy in COVID-19 Infected Patients","ET-COVID-19","Completed","No Results Available","Ischemic Stroke|Covid 19","Other: Mechanical Trombectomy","Intrahospital mortality|short-term morbidity|Angiographic success","University Hospital, Montpellier","All","18 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0322","2020-04-01T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-05-28T00:00:00","","2020-07-29T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04406090"
"137","NCT04456595","Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19  Vaccine in Healthcare Professionals","PROFISCOV","Recruiting","No Results Available","COVID-19","Biological: Adsorbed COVID-19  Vaccine|Biological: Placebo","Incidence of COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to seven days after immunization|Incidence of COVID-19 cases after 14-days of first immunization|Incidence of COVID-19 cases after 14-days of last immunization|Combined incidence of SARS-CoV-2 infection|Frequency of adverse events up to 28 days after immunization|Incidence of severe COVID-19 cases|Seroconversion rate|Cell-mediated immune profile","Butantan Institute|Sinovac Life Sciences Co., Ltd.","All","18 Years and older","Phase 3","8870","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","COV-02-IB","2020-07-21T00:00:00","2021-09-01T00:00:00","2021-10-01T00:00:00","2020-07-02T00:00:00","","2020-08-04T00:00:00","Universidade de Brasília, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital das Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brazil|Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil|Hospital das Clínicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirao Preto, SP, Brazil|Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil|Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil|Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, SP, Brazil|Universidade Municipal de São Caetano do Sul, São Caetano do Sul, SP, Brazil|Faculdade de Medicina de São Jose do Rio Preto - FAMERP, São Jose Do Rio Preto, São Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil","","https://ClinicalTrials.gov/show/NCT04456595"
"138","NCT04459390","Association of Comorbidities With COVID19","","Recruiting","No Results Available","COVID19","Diagnostic Test: realtime PCR","Rate of recovery/ ICU admission/ need for mechanical ventilation|Time to improvement","Assiut University","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID19","2020-07-20T00:00:00","2020-10-20T00:00:00","2020-11-20T00:00:00","2020-07-07T00:00:00","","2020-08-06T00:00:00","Faculty of Medicine, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04459390"
"139","NCT04427878","Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?","TA/SARS-Cov2","Not yet recruiting","No Results Available","Covid-19 Patients","Procedure: biopsies of subcutaneous adipose tissue","The presence of SARS-CoV2 in adipose tissue of Covid19 patients|The expression of inflammatory cytokines in adipose tissue of Covid19 patients","Centre Hospitalier Universitaire de Nice","All","18 Years and older","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","20-PP-15","2020-07-01T00:00:00","2020-07-09T00:00:00","2021-07-09T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","CHU de Nice, Nice, France","","https://ClinicalTrials.gov/show/NCT04427878"
"140","NCT04497272","Assesment of the Metabolomic Signature in COVID-19 Patients","SignCov","Not yet recruiting","No Results Available","COVID 19","Other: COVID-19 patients","Identifying the metabolomic signature|Identification of the metabolomic profile according to clinical severity.","Centre Hospitalier Universitaire de Nice","All","18 Years and older","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Supportive Care","20-PP-18","2020-08-07T00:00:00","2021-08-07T00:00:00","2021-10-07T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","CHU de nice, Nice, Alpes-Maritimes, France","","https://ClinicalTrials.gov/show/NCT04497272"
"141","NCT04470648","COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey","","Not yet recruiting","No Results Available","SARS-COV2 Infection","Diagnostic Test: blood test for SARS-COV2 serology","SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress|Morbidity rate|Covid-19 related death rate in the 3 centers from March to May 2020|Ratio of negative serology rate and positive serology rate in the 3 centers|Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region","Institut National de la Sante Et de la Recherche Medicale, France|Samusocial de Paris|Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","220","Other","Observational","Observational Model: Other|Time Perspective: Prospective","C20-50","2020-07-01T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-07-14T00:00:00","","2020-07-21T00:00:00","Haltes pour femmes, Paris, France|LHSS Saint-Michel, Paris, France|LHSS Ridder-Plaisance, Paris, France","","https://ClinicalTrials.gov/show/NCT04470648"
"142","NCT04468256","The Heart Hive COVID-19 Study","","Not yet recruiting","No Results Available","COVID-19|Cardiomyopathies","Other: COVID-19 experience surveys","Qualitative measures of exposure, perception of risk, behaviour, and experience during the COVID-19 pandemic.|Health Outcomes","Imperial College London","All","18 Years and older","","1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20IC6036-","2020-07-01T00:00:00","2022-07-01T00:00:00","2022-07-01T00:00:00","2020-07-13T00:00:00","","2020-07-13T00:00:00","Imperial College London, London, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04468256/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04468256"
"143","NCT04382781","Immunosupressive Treatment in COVID-19 Patients","SAM-COVID","Recruiting","No Results Available","COVID-19 Infection","Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins","Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale","Spanish Network for Research in Infectious Diseases|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FIS-INM-2020-03","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-05-11T00:00:00","","2020-05-12T00:00:00","Hospital Virgen Macarena, Sevilla, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04382781/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04382781"
"144","NCT04397757","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","","Recruiting","No Results Available","COVID-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score  of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms","University of Pennsylvania","All","18 Years and older","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","843003","2020-05-13T00:00:00","2020-09-13T00:00:00","2020-11-13T00:00:00","2020-05-21T00:00:00","","2020-07-10T00:00:00","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04397757"
"145","NCT04428021","Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure","PLACO-COVID","Not yet recruiting","No Results Available","COVID-19","Drug: Standard Therapy Protocol |Other: STP + Standard Plasma |Other: STP + COVID-19 Convalescent Plasma","30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units |Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment  score|Any variation from Standard Therapy Protocol","Azienda Ospedaliera Città della Salute e della Scienza di Torino","All","18 Years and older","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","CS3/33","2020-06-15T00:00:00","2021-06-15T00:00:00","2021-12-15T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04428021"
"146","NCT04425707","Ivermectin In Treatment of COVID 19 Patients","","Recruiting","No Results Available","Covid19","Drug: Ivermectin","to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.","Ministry of Health and Population, Egypt","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","14-2020/3","2020-06-09T00:00:00","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","isolation and referal hospitals for COVID 19 patients, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04425707"
"147","NCT04459962","Covid-19 Breath Test","","Recruiting","No Results Available","Covid-19 Infection","Diagnostic Test: Breath Test & Cheek Swab","To investigate/ examine the effectiveness of Nanotechnology Biomarker Tagging  in detecting COVID-19 infection using breath samples of patients with COVID-19 symptoms|-To profile the unique pattern of Volatile Organic Compounds  found in the expired breath of COVID-19 patients using the NBT system .|To differentiate this unique profile from the patients that are found to be negative for COVID-19","Ancon Technologies Ltd","All","16 Years and older","Not Applicable","250","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","2020ATL01","2020-06-29T00:00:00","2020-08-28T00:00:00","2021-06-14T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT04459962"
"148","NCT04381858","Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia","","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin","Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","2020-A-10","2020-05-06T00:00:00","2020-08-30T00:00:00","2020-09-30T00:00:00","2020-05-11T00:00:00","","2020-05-12T00:00:00","Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico","","https://ClinicalTrials.gov/show/NCT04381858"
"149","NCT04345991","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","CORIPLASM","Recruiting","No Results Available","Covid19","Drug: Transfusion of COVID-19 convalescent plasma","Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs","Assistance Publique - Hôpitaux de Paris|Etablissement Français du Sang","All","18 Years and older","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","APHP200375-10|2020-001246-18","2020-04-15T00:00:00","2020-05-15T00:00:00","2020-06-01T00:00:00","2020-04-15T00:00:00","","2020-05-20T00:00:00","SMIT, Saint Antoine hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT04345991"
"150","NCT04459637","COVID-19 Surveillance Based on Smart Wearable Device","COVID-19SWD","Not yet recruiting","No Results Available","COVID-19","","Deterioration of the condition|Mortality|The information analysis degree, the proportion of signal loss, the proportion of wrong signal,","Peking University First Hospital","All","18 Years to 75 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020055-0615","2020-07-01T00:00:00","2021-03-10T00:00:00","2021-03-10T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Peking University First Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT04459637"
"151","NCT04398264","Characteristics of COVID-19 Infection Among PREGnant Women","CCOVID-PREG","Recruiting","No Results Available","Corona Virus Infection|Pregnancy Related","Other: COVID-19 positive via testing","Asymptomatic COVID-19 positive pregnant women|Asymptomatic Hispanic COVID-19 positive pregnant women|Follow up of asymptomatic COVID-19 positive pregnant women|COVID-19 positive newborns|Severe COVID-19 disease in pregnant women","Inova Health System","Female","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Other","U20-05-4055","2020-07-22T00:00:00","2020-09-30T00:00:00","2021-03-31T00:00:00","2020-05-21T00:00:00","","2020-07-29T00:00:00","INOVA Health System, Falls Church, Virginia, United States","","https://ClinicalTrials.gov/show/NCT04398264"
"152","NCT04422535","Effects on the Qt Interval of COVID-19 Coronavirus Infection","QT-COVID-19","Recruiting","No Results Available","Coronavirus Infection|Intensive Care Patients","","Assessing the QT and QTc interval in patients admitted to intensive care units for COVID-19 infection|incidence of arrhythmias and impact of the COVI-drugs administered on QT interval","Matilde Zaballos|Hospital General Universitario Gregorio Marañon","All","18 Years and older","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","QT-COVID-19","2020-05-29T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","Servicio de Anestesia, Hospital General Universitario Gregorio Marañon, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04422535"
"153","NCT04375761","COVID-19: Human Epidemiology and Response to SARS-CoV-2","HEROS","Active, not recruiting","No Results Available","Coronavirus Disease 2019 |SARS-CoV-2","Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys","Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period|Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period","National Institute of Allergy and Infectious Diseases |Rho Federal Systems Division, Inc.","All","Child, Adult, Older Adult","","5605","NIH|Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","DAIT-COVID-19-001","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-05-05T00:00:00","","2020-08-07T00:00:00","Children's Hospital Colorado: Inner City Asthma Consortium  Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages  Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium  Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences  and Improving Technology-Assisted Recording of Asthma Control in Children  Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome  and Wheezing Index  Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study , Environmental Assessment of Sleep in Youth , Severe Asthma Research Program  and Preventing Asthma in High Risk Kids  Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium  Site, Boston, Massachusetts, United States|Henry Ford Health System: Childhood Allergy Study  Site, Detroit, Michigan, United States|Henry Ford Health System: Inner City Asthma Consortium  Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets  and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study  Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium  Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium  Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository  and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children  Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium  Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages  Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study  Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study  Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium  Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma  Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort  Site, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04375761"
"154","NCT04508777","COVID SAFE: COVID-19 Screening Assessment for Exposure","COVID SAFE","Not yet recruiting","No Results Available","Covid19","Behavioral: Saliva-based testing","Test compliance","University of Pennsylvania","All","18 Years and older","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","843565-OBS","2020-08-01T00:00:00","2020-12-01T00:00:00","2021-03-01T00:00:00","2020-08-11T00:00:00","","2020-08-13T00:00:00","","","https://ClinicalTrials.gov/show/NCT04508777"
"155","NCT04473690","KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","","Not yet recruiting","No Results Available","Covid19","Biological: Low Dose of KBP-COVID-19|Biological: High Dose of KBP-COVID-19|Biological: Placebo","Solicited Administration site reactions|Solicited systemic events|Unsolicited Adverse Events and medically attended adverse events|Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae|Vaccine ELISA and neutralizing antibody titers for each treatment group|Seroconversion rates","Kentucky BioProcessing, Inc.","All","18 Years to 70 Years","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","KBP-201","2020-09-14T00:00:00","2021-01-25T00:00:00","2021-12-23T00:00:00","2020-07-16T00:00:00","","2020-08-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04473690"
"156","NCT04388436","Post Covid-19 Cardiopulmonary and Immunological Changes","covid-19","Active, not recruiting","No Results Available","COVID","","measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of IGM and IGG level and if there is immunological changes","Mansoura University","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20.05.67","2020-05-11T00:00:00","2021-07-10T00:00:00","2021-10-10T00:00:00","2020-05-14T00:00:00","","2020-05-19T00:00:00","Mansoura faculty of medicine, Mansoura, Dakahlia, Egypt","","https://ClinicalTrials.gov/show/NCT04388436"
"157","NCT04411602","Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD","","Recruiting","No Results Available","Severe Acute Respiratory Syndrome|COVID","Drug: SARS-CoV-2 plasma","Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality","Ascension South East Michigan","All","18 Years and older","Phase 1","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","1589349","2020-04-07T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States","","https://ClinicalTrials.gov/show/NCT04411602"
"158","NCT04331574","Renin-Angiotensin System Inhibitors and COVID-19","SARS-RAS","Recruiting","No Results Available","COVID-19|Hypertension|Cardiovascular Diseases","","Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers  as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers  as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Societa Italiana dell'Ipertensione Arteriosa","All","18 Years to 120 Years","","2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","SARS-RAS","2020-03-10T00:00:00","2020-04-10T00:00:00","2020-04-30T00:00:00","2020-04-02T00:00:00","","2020-04-02T00:00:00","Spedali Civili di Brescia, Brescia, Italy","","https://ClinicalTrials.gov/show/NCT04331574"
"159","NCT04333732","CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION","CROWN CORONA","Not yet recruiting","No Results Available","COVID 19","Drug: MR or M-M-R II ® vaccine|Drug: Placebo","Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing/reducing SARS-CoV-2 infection","Washington University School of Medicine|Bill and Melinda Gates Foundation|COVID -19 Therapeutics Accelerator","All","18 Years and older","Phase 3","30000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","202004099|INV-017499","2020-08-01T00:00:00","2021-08-01T00:00:00","2021-08-01T00:00:00","2020-04-03T00:00:00","","2020-08-11T00:00:00","Washington University School of Medicine, Saint Louis, Missouri, United States|Unity Health Toronto, Toronto, Ontario, Canada|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|St James's Hospital, Dublin, Leinster, Ireland|Radboud University Medical Center, Nijmegen, Netherlands|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Infectious Diseases Institute Kampala, Uganda, Kampala, Uganda|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT04333732"
"160","NCT04432948","Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.","","Recruiting","No Results Available","Covid-19|Maternal Psychological Distress|Anesthesia","Other: PHQ-9 Depression Scale|Other: GAD-7 General anxiety disorder scale|Other: 38-questions questionnaire","Association between Covid-19 pandemic and maternal psychological distress|Association between Covid-19 pandemic, maternal psychological distress and anaesthetic practice","General and Maternity Hospital of Athens Elena Venizelou","Female","18 Years and older","","200","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Maternal Covid 19","2020-05-15T00:00:00","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","""Elena Venizelou"" General and Maternity Hospital of Athens, Athens, Attica, Greece","","https://ClinicalTrials.gov/show/NCT04432948"
"161","NCT04380532","Tableted COVID-19 Therapeutic Vaccine","COVID-19","Active, not recruiting","No Results Available","Covid19","Biological: V-SARS","Effect on CBC as per CTCAE v4.0|Effect on biochemistry parameters as per CTCAE v4.0|Lack of adverse events as per CTCAE v4.0","Immunitor LLC|Immunitor Inc.","All","18 Years to 65 Years","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Imm24","2020-05-15T00:00:00","2021-05-15T00:00:00","2021-06-15T00:00:00","2020-05-08T00:00:00","","2020-05-27T00:00:00","Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia","","https://ClinicalTrials.gov/show/NCT04380532"
"162","NCT04337320","Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study","","Completed","No Results Available","Covid19|Maternal-Fetal Relations","Other: newborns from covid 19 positive mothers","Evaluation of apgar status of newborns from covid 19 positive mothers","Kanuni Sultan Suleyman Training and Research Hospital|Seda Yilmaz Semerci","All","up to 15 Minutes","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","covid19pregnancynewborn","2020-03-15T00:00:00","2020-05-25T00:00:00","2020-05-30T00:00:00","2020-04-07T00:00:00","","2020-06-11T00:00:00","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04337320"
"163","NCT04395170","Convalescent Plasma  and Human Intravenous Anti-COVID-19 Immunoglobulin  in Patients Hospitalized for COVID-19.","","Not yet recruiting","No Results Available","Coronavirus Disease 2019","Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard  therapy for COVID-19","Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody  titers against COVID-19|Safety - Adverse events|Death","Lifefactors Zona Franca, SAS","All","18 Years and older","Phase 2|Phase 3","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","LFCOLCOVID-19-001","2020-09-01T00:00:00","2020-12-01T00:00:00","2021-06-01T00:00:00","2020-05-20T00:00:00","","2020-07-10T00:00:00","LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia","","https://ClinicalTrials.gov/show/NCT04395170"
"164","NCT04421625","Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic","PAPESCO-19","Recruiting","No Results Available","COVID-19","Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff","Establishment of a clinical basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Establishment of a biological basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Dosage of IgM and IgG anti SARS-CoV2|Evaluate the diagnostic performance of the minute test for IgM|Evaluate the quantification of IgG in long term  in the Cancer Centres populations|Evaluate the frequency of reinfections among the persons who have developed IgG|Evaluate the threshold of protective IgG among the subjects who have developed IgG|Evaluate the influence of polymorphisms of receptor of IgG Fc-gamma low-affinity  on the humoral immune response|Evaluate the severity of Covid-19 infection  by age group|Evaluate the frequency of reinfection by Covid-19  during follow-up|Evaluate the risk factors  to develop severe forms of Covid-19 infection in patients|Evaluate the changes in health care practice|Evaluate the resources associated with organizational changes|Evaluate the allocated resources|Evaluate the incidence of Covid-19 infections|Evaluate the distribution of risk factors for contamination in patients and in the general population|Evaluate the anxiety state over time|Evaluate the depression over time|Evaluate the post-traumatic developments|Evaluate the change in health care change frequency|Evaluate the number of patients concerned by health care changes|Evaluate the rate of morbidity|Evaluate the rate of mortality","Institut Cancerologie de l'Ouest","All","18 Years and older","Not Applicable","12000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Screening","ICO-2020-16","2020-06-15T00:00:00","2022-06-15T00:00:00","2022-06-15T00:00:00","2020-06-09T00:00:00","","2020-08-07T00:00:00","Institut de Cancerologie de l'Ouest, Angers, France","","https://ClinicalTrials.gov/show/NCT04421625"
"165","NCT04358835","Keto-diet for Intubated Critical Care COVID-19","KICC-COVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Ketogenic diet|Other: standard of care","Change in the partial pressure of carbon dioxide |Change in minute ventilation|Change in respiratory system compliance|Change in driving pressure|Change in ventilator synchrony|Change in mean arterial pressure|Change in the fraction of inspired oxygen percentage of oxygen |Change in the partial pressure of carbon dioxide  to the fraction of inspired oxygen percentage of oxygen  ratio|Change in hydrogen ion activity |Change in Bicarbonate |Change in red blood cell count|Change in white blood cell count|Change in white cell differential|Change in hemoglobin levels|Change in hematocrit|Change in mean cell volume|Change in mean cell hemoglobin|Change in mean cell hemoglobin concentration|Change in platelet count|Change in red cell distribution width|Change in blood albumin level|Change in serum alkaline phosphatase level|Change in serum aspartate transaminase level|Change in serum alanine aminotransferase level|Change in blood urea nitrogen levels|Change in serum calcium level|Change in serum chloride level|Change in serum potassium level|Change in serum creatinine level|Date patient is re-intubated or need mechanical ventilation for a second time|Length of intensive care unit stay|The total hospital stay|Disposition at discharge|Change in heart rate|Change in the dosage of vasopressor medication","Johns Hopkins University","All","18 Years to 80 Years","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","IRB00247383","2020-09-01T00:00:00","2021-09-01T00:00:00","2021-12-31T00:00:00","2020-04-24T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04358835"
"166","NCT04367142","Rapid Detection of COVID-19 by Portable and Connected Biosensor","COR-DIAL-1","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor","Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission","University Hospital, Lille","All","Child, Adult, Older Adult","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020_36|2020-A01147-32","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-04-29T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04367142"
"167","NCT04467047","Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19","COVID19","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Mesenchymal Stromal Cells infusion","Overall survival|Changes on inflammatory C-reactive protein|Hospital stay|Oxygenation index |Improvement in Liao's score |Radiological improvement|Time of COVID19 PCR negativity","Hospital de Clinicas de Porto Alegre","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20200148","2020-07-25T00:00:00","2020-10-30T00:00:00","2020-12-30T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","","","https://ClinicalTrials.gov/show/NCT04467047"
"168","NCT04412382","Covid-19: Possible Role of Neutrophil Extracellular Traps","NETSINCOVID","Recruiting","No Results Available","Covid-19","Diagnostic Test: NETosis markers","NETOSIS AND MORTALITY|NETOSIS AND DCOVID-19 SEVERITY|NETOSIS AND INFLAMMATION|NETOSIS AND VENOUS THROMBOSIS","Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NETS IN COVID-19","2020-06-01T00:00:00","2020-12-31T00:00:00","2021-12-31T00:00:00","2020-06-02T00:00:00","","2020-07-08T00:00:00","Univeristy of Verona, Verona, Italy","","https://ClinicalTrials.gov/show/NCT04412382"
"169","NCT04351802","CORonavirus  Diagnostic Lung UltraSound Study","COR-DLUS","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Lung ultrasound","Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19","University Hospital Plymouth NHS Trust","All","18 Years and older","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282661","2020-04-20T00:00:00","2021-01-20T00:00:00","2021-01-20T00:00:00","2020-04-17T00:00:00","","2020-04-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04351802"
"170","NCT04479319","Decision Support System Algorithm for COVID-19 Diagnosis","","Not yet recruiting","No Results Available","Covid19","Diagnostic Test: Thorax CT","Diagnosing COVID-19","Ankara University|Presidency of Health Institute Turkey","All","18 Years and older","","10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","09081","2020-08-01T00:00:00","2021-02-01T00:00:00","2021-08-01T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04479319"
"171","NCT04453969","Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a","","Recruiting","No Results Available","SARS-CoV2|Breastmilk","Other: COVID-19","SARS-CoV-2 in breastmilk|SARS-CoV-2 antibody in breastmilk","Deborah O'Connor|University of Toronto|Sinai Health System|The Hospital for Sick Children","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","39373-a","2020-05-24T00:00:00","2021-01-01T00:00:00","2021-01-01T00:00:00","2020-07-01T00:00:00","","2020-07-01T00:00:00","Sinai Health System, Toronto, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04453969"
"172","NCT04366960","Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients","X-Covid 19","Recruiting","No Results Available","Covid19","Drug: Enoxaparin","Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin-6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events","Niguarda Hospital","All","18 Years and older","Phase 3","2712","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-001708-41","2020-05-14T00:00:00","2020-08-01T00:00:00","2020-11-01T00:00:00","2020-04-29T00:00:00","","2020-05-15T00:00:00","Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy","","https://ClinicalTrials.gov/show/NCT04366960"
"173","NCT04437693","Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients","HCQ-COVID19","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine","Prevention of SARS-CoV-2 infection|Presence of any adverse effects related to HCQ|Incidence of COVID-19 related symptoms","Hamad Medical Corporation","All","18 Years to 60 Years","Phase 2|Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","MRC-02-20-442","2020-08-31T00:00:00","2021-08-30T00:00:00","2021-12-31T00:00:00","2020-06-18T00:00:00","","2020-08-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04437693"
"174","NCT04377646","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","COVID-Milit","Not yet recruiting","No Results Available","Sars-CoV2|COVID19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine |Drug: Zinc|Drug: Zinc","SARS CoV2 infection|COVID-19 symptoms description|Adverse Events","Military Hospital of Tunis|UR17DN02 : Autoimmune Diseases Research Unit|Dacima Consulting","All","18 Years to 65 Years","Phase 3","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","UR17DN02-001|TN2020-NAT-INS-38","2020-05-04T00:00:00","2020-05-24T00:00:00","2020-07-31T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","Military Hospital of Tunis, Tunis, Tunisia","","https://ClinicalTrials.gov/show/NCT04377646"
"175","NCT04348877","Plasma Rich Antibodies From Recovered Patients From COVID19","PRA-001","Not yet recruiting","No Results Available","Coronavirus Disease","Other: Antibody-Rich Plasma from COVID-19 recovered patients","viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement","Ain Shams University","All","18 Years to 80 Years","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","FMASU P15/ 2020","2020-04-20T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-04-16T00:00:00","","2020-04-20T00:00:00","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","","https://ClinicalTrials.gov/show/NCT04348877"
"176","NCT04436471","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","","Completed","No Results Available","Preventive Immunization COVID-19","Biological: Gam-COVID-Vac","Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 60 Years","Phase 1|Phase 2","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","02-Gam-COVID-Vac-2020","2020-06-17T00:00:00","2020-08-03T00:00:00","2020-08-10T00:00:00","2020-06-18T00:00:00","","2020-08-12T00:00:00","Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04436471"
"177","NCT04376476","Host-pathogen Interactions During SARS-CoV-2 Infection","HPI-COVID-19","Recruiting","No Results Available","Infection, Coronavirus|Severe Acute Respiratory Syndrome Coronavirus 2","Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call","Initial biological profile of children and adults with COVID-19 infection|Initial immunological profile of children and adults with COVID-19 infection|Clinical worsening|Evolution of the immunological profile of children and adults with COVID-19|Nasopharyngeal swabs SARS-CoV-2 viral loads of children and adults with COVID-19|titers in specific Immunoglobulin G  antibodies of children and adults with COVID-19|titers in specific Immunoglobulin M  antibodies of children and adults with COVID-19|titers in specific Immunoglobulin G  antibodies of children and adults with COVID-19|Genetic profile of adults with COVID-19 infection","Hospices Civils de Lyon","All","up to 70 Years","Not Applicable","450","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","69HCL20_0342|2020-A01102-37","2020-05-05T00:00:00","2021-06-05T00:00:00","2021-06-05T00:00:00","2020-05-06T00:00:00","","2020-05-08T00:00:00","Groupement Hospitalier Nord-Daupine, Bourgoin-Jallieu, France|Hôpital femme-mère-enfant, Bron, France|Hôpital Louis Pradel, Bron, France|Hôpital Louis Mourier, Colombes, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Hopital de la Croix-Rousse, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital mère - enfant Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|Hôpital Nord de Saint Etienne, Saint-Priest-en-Jarez, France|Hôpital Nord-Ouest, Villefranche-sur-Saône, France|Centre Hospitalier D'Annecy-Genevois, Épagny, France","","https://ClinicalTrials.gov/show/NCT04376476"
"178","NCT04416139","Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19","COVID-19","Recruiting","No Results Available","Covid 19","Biological: Infusion IV of Mesenchymal Stem cells","Functional Respiratory changes: PaO2 / FiO2 ratio|Clinical cardiac changes: Heart rate per minute|Clinical Respiratory Changes: Respiratory rate per minute|Changes in body temperature|General biochemical changes in Leukocytes|General biochemical changes on lymphocytes|General biochemical changes on platelets|General biochemical changes on fibrinogen|General biochemical changes on pocalcitonin|General biochemical changes on ferritin|General biochemical changes on D-dimer|Changes on inflammatory C-reactive protein|Cahnges on Inflammatory cytokine TNFa|Changes on Inflammatory cytokine IL10|Changes on Inflammatory cytokine IL1|Changes on Inflammatory cytokine IL6|Changes on Inflammatory cytokine IL 17|Changes on VEGF|Radiological Changes|Immunological changes on T cell|Immunological changes on Dendritic cells|Immunological changes on CD4+ T|Immunological changes on CD8+ T|Immunological changes on NK cell|Adverse events|RNA detection by SARS-Cov2 PCR","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","SCI-3354-20-21-1","2020-05-01T00:00:00","2021-04-30T00:00:00","2021-05-01T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico","","https://ClinicalTrials.gov/show/NCT04416139"
"179","NCT04357028","Measles Vaccine in HCW","MV-COVID19","Recruiting","No Results Available","Covid19","Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos","COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2","Kasr El Aini Hospital","All","18 Years to 50 Years","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","N-30-2020","2020-07-13T00:00:00","2020-10-01T00:00:00","2020-11-01T00:00:00","2020-04-22T00:00:00","","2020-07-16T00:00:00","Cairo University Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04357028"
"180","NCT04454307","Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients","","Not yet recruiting","No Results Available","COVID-19","Drug: Tramadol|Other: Standard care delivered in the isolation hospitals.","Number of COVID-19 PCR negative cases","Tanta University","All","18 Years to 65 Years","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","TRAM/COVID19","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-10-01T00:00:00","2020-07-01T00:00:00","","2020-07-02T00:00:00","","","https://ClinicalTrials.gov/show/NCT04454307"
"181","NCT04359927","Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry","CV-COVID-19","Recruiting","No Results Available","Sars-CoV2|Covid19|Cardiovascular Diseases|Cardiovascular Risk Factor","","Cardiovascular mortality|Acute myocardial infarction|Stroke","Hospital Clinic of Barcelona","All","18 Years and older","","10000","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HCB/2020/0457","2020-04-20T00:00:00","2021-08-31T00:00:00","2025-08-31T00:00:00","2020-04-24T00:00:00","","2020-05-07T00:00:00","Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain","","https://ClinicalTrials.gov/show/NCT04359927"
"182","NCT04374513","Community Pharmacists Behaviour During Covid-19","","Recruiting","No Results Available","Covid19","","community pharmacists facing covid-19","Damanhour University","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pharmacists and covid-19","2020-05-02T00:00:00","2020-10-01T00:00:00","2021-04-01T00:00:00","2020-05-05T00:00:00","","2020-05-19T00:00:00","Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt","","https://ClinicalTrials.gov/show/NCT04374513"
"183","NCT04403581","Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic","","Not yet recruiting","No Results Available","Covid-19","Other: Questionnaire","Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic","Ain Shams University","All","23 Years to 55 Years","","384","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Egyptian doctors in COVID-19","2020-05-01T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-05-27T00:00:00","","2020-05-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04403581"
"184","NCT04351659","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","","Recruiting","No Results Available","COVID-19","Other: Blood donation from convalescent donor","Success rate in production of SARS-CoV-2 specific T cells from convalescent donor","KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore","All","21 Years to 65 Years","","8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-T 1.0","2020-04-14T00:00:00","2020-08-01T00:00:00","2020-08-01T00:00:00","2020-04-17T00:00:00","","2020-07-07T00:00:00","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT04351659"
"185","NCT04434261","Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2","ASTANA","Recruiting","No Results Available","SARS-CoV-2|Oncology|Surgery","Diagnostic Test: PT-PCR test for SARS-CoV-2","Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program|Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test;|Postoperative complications|Mortality|Delay in the cancer treatment","Instituto Brasileiro de Controle do Cancer","All","18 Years and older","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","33467320.0.0000.0072","2020-05-11T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Instituto Brasileiro de Controle do Cancer - IBCC, Sao Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT04434261"
"186","NCT04392414","Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","","Recruiting","No Results Available","COVID-19","Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma","The number and proportion of patients with the normal body temperature  at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 75 Years","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CovPlas-Covid19","2020-05-01T00:00:00","2020-08-01T00:00:00","2020-09-15T00:00:00","2020-05-18T00:00:00","","2020-06-04T00:00:00","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04392414"
"187","NCT04354857","Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","Anosmie-COVID","Recruiting","No Results Available","COVID-19","Other: olfactory and gustatory tests","SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older","","454","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB: 20.04.09","2020-03-27T00:00:00","2020-07-01T00:00:00","2020-11-01T00:00:00","2020-04-21T00:00:00","","2020-04-21T00:00:00","CHU de Nimes, Nîmes, France","","https://ClinicalTrials.gov/show/NCT04354857"
"188","NCT04500639","Over-the-counter Medications & COVID-19","OTC℞&COVID19","Recruiting","No Results Available","SARS-CoV-2 Infection|Covid19","","Ibuprofen exposure for symptom management|Exposure to other drugs implicated in COVID-19 severity","University of Alberta","All","Child, Adult, Older Adult","","14000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00100243","2020-07-23T00:00:00","2020-12-31T00:00:00","2023-03-31T00:00:00","2020-08-05T00:00:00","","2020-08-07T00:00:00","University of Alberta, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT04500639"
"189","NCT04418245","CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis","COVID 19-IA","Active, not recruiting","No Results Available","Covid-19","Diagnostic Test: Imaging by thoracic scanner","Vital status|Patient requiring more than 3 liters of oxygen to maintain a saturation >95% |Percentage of lung affected on CT|Percentage of lung affected by ground glass opacity on scan|Percentage of lung affected by condensation on scan|Length of hospitalization|rehospitalization|Duration of intubation|Software operating time|C-reactive protein levels|lactate dehydrogenase|lymphocytemia|D Dimers level|Time until onset of symptoms|Time between RT-PCR positive results and first scan|Age|BMI> 30|Medical history of cardiovascular disease|Diabetes|Medical history of respiratory disease|Medical history of immunosuppressed condition|Current or previous history of smoking|Calculate a prognostic score from clinical, biological and CT parameters|Calculate a prognostic score from clinical and biological parameters only|Compare receiver operating curves of prognostic scores with and without CT parameters","Centre Hospitalier Universitaire de Nīmes","All","Child, Adult, Older Adult","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NIMAO/2020/COVID 19-IA/JF-01","2020-03-01T00:00:00","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-06-05T00:00:00","","2020-06-05T00:00:00","CHU la Timone, Marseille, France|CHU Montpellier, Montpellier, France|CHU de Nimes, Nîmes, France|CHU Poitiers, Poitiers, France|CHU Strasbourg, Strasbourg, France|CHU Martinique, Fort-de-France, Martinique","","https://ClinicalTrials.gov/show/NCT04418245"
"190","NCT04361591","COVID-19 in Liver Transplant Recipients","COVID19-SETH","Recruiting","No Results Available","Liver Transplant; Complications|COVID19|Respiratory Failure","Other: Observational only","Incidence of COVID19 in LT recipients|Clinical characteristics of COVID19 in LT recipients|Survival and Mechanical ventilation / respiratory support|Observed treatments and immunosuppression management","Hospital Clinic of Barcelona|Sociedad Española de Trasplante Hepático","All","Child, Adult, Older Adult","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCB/2020/0384","2020-03-01T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","SETH-affiliated Liver Transplant Programs in Spain, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04361591"
"191","NCT04386759","COVID-19 Infection in Healthcare Workers","HOP-COVID","Not yet recruiting","No Results Available","COVID-19","Other: Cohort","SARS-COV-2 infection|Individual factors|Hospital ward level","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","6000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200483","2020-05-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-05-13T00:00:00","","2020-05-13T00:00:00","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Creteil, France","","https://ClinicalTrials.gov/show/NCT04386759"
"192","NCT04368338","Lung Ultrasound to Diagnose COVID-19","COVILUS","Recruiting","No Results Available","Covid-19|Lung Ultrasound|Respiratory Complication","Diagnostic Test: COVID-19 RT-PCR|Procedure: lung ultrasound","Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease","Centre Hospitalier Universitaire, Amiens","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0030","2020-04-28T00:00:00","2020-09-28T00:00:00","2020-09-28T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","BAR, Amiens, France","","https://ClinicalTrials.gov/show/NCT04368338"
"193","NCT04381871","Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients","GA&COVID19","Not yet recruiting","No Results Available","COVID 19","Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin","Mean change from baseline score of Immune Response to end of the trial |Mortality rate|Determine viral load in each patient","Al-Neelain University|University of Khartoum","All","5 Years to 90 Years","Phase 2|Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","GA& COVID19","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-05-11T00:00:00","","2020-05-12T00:00:00","Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan|Jabra Hospital,, Khartoum, Sudan","","https://ClinicalTrials.gov/show/NCT04381871"
"194","NCT04481477","Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19","WW2COVID-19","Not yet recruiting","No Results Available","Covid19","Other: Nursing care to reduce anxiety, fear and loneliness","The adequacy of nursing care to the needs of the patient|Intervention effectiveness","Corporacion Parc Tauli","All","18 Years and older","","450","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2020664","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-12-31T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","CorporacionPT, Sabadell, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04481477"
"195","NCT04427358","RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population","COVID-19GAOM","Recruiting","No Results Available","Covid-19","","Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection","University Hospital, Strasbourg, France","All","70 Years and older","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7838","2020-05-07T00:00:00","2020-08-01T00:00:00","2020-08-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Service SSR Geriatrique, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04427358"
"196","NCT04347850","A Cohort of Patients With Possible or Confirmed SARS-CoV-2","COVIDothèque","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Other: blood sample","Number of confirmed COVID-19|Number of severe COVID-19|Identification and validation of predictive biomarkers of a poorer respiratory evolution associated with positive testing for SARS-CoV-2 infection|Evaluate the morbidity and mortality and these risk factors linked to Covid-19 in the congenital heart disease population in France|Identify the characteristics of physiotherapy care for patients with COVID-19 in intensive care|To assess the accuracy and prognostic performance of clinical and biological parameters measured on admission to the emergency department to stratify patients suspected of COVID-19|Evaluate diagnostic tests for olfactory function in relation to the RT-PCR procedure|Assessment of Extra Vascular Lung Water and Pulmonary Permeability by transpulmonary thermodilution in critically ill patients with Coronavirus Disease 2019 pneumonia under invasive mechanical ventilation|Description of trans pulmonary motor pressure in COVID 19+ patients in severe stage in intensive care|Immuno-monitoring of COVID-19 positive patients|Characterization in clinical proteomics of the SARS-CoV-2 spike protein|Diagnosis of endocrine dysfunctions in Covid-19|describe the occurrence of Covid19 infection in patients with systemic lupus erythematosus treated with hydroxychloroquine over the long term|Acral cutaneous thrombotic vasculopathy and Covid-19 infection : search for acquired thrombophilia and interferon-alpha signature|Evaluation of a COVID-19 screening strategy combining chest low dose CT and RT-PCR test for patients admitted for surgical or interventional procedures during the COVID 19 outbreak","University Hospital, Montpellier","All","Child, Adult, Older Adult","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0185","2020-02-01T00:00:00","2022-12-01T00:00:00","2022-12-30T00:00:00","2020-04-15T00:00:00","","2020-07-08T00:00:00","Uh Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04347850"
"197","NCT04350073","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19","","Recruiting","No Results Available","COVID-19","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio  as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures  in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue  Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency","Duke University","All","18 Years and older","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105221","2020-04-20T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-04-16T00:00:00","","2020-06-09T00:00:00","Duke University Medial Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04350073"
"198","NCT04358029","Cardiac Arrhythmias In Patients With Coronavirus Disease","","Recruiting","No Results Available","COVID 19 Cardiac|COVID 16 Arrhythmia|COVID 19 Death","","Frequency of cardiac arrhythmias|Mode of death","Vivek Reddy|Icahn School of Medicine at Mount Sinai","All","Child, Adult, Older Adult","","10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","GCO 20-0931","2020-04-09T00:00:00","2021-05-01T00:00:00","2021-12-01T00:00:00","2020-04-22T00:00:00","","2020-05-13T00:00:00","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04358029"
"199","NCT04386252","Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults","","Not yet recruiting","No Results Available","COVID-19","Biological: AV-COVID-19","Confirm safety|Suggestion of efficacy|Optimal dose of SARS-CoV-2 antigen|Advantage of administering vaccine admixed with GM-CSF|Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination","Aivita Biomedical, Inc.","All","18 Years and older","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","CL-COV-P01-US","2020-07-01T00:00:00","2020-12-01T00:00:00","2021-03-01T00:00:00","2020-05-13T00:00:00","","2020-06-24T00:00:00","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","","https://ClinicalTrials.gov/show/NCT04386252"
"200","NCT04347889","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT","","Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine|Other: Vitamin C","COVID-19 Seroconversion rate|Admission for Covid-19","Stony Brook University","All","18 Years and older","Phase 2","1212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","IRB2020-00222","2020-04-20T00:00:00","2020-12-30T00:00:00","2020-12-30T00:00:00","2020-04-15T00:00:00","","2020-04-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04347889"
"201","NCT04474288","The COVID-19 PUI Reality Check  Study","CPRC","Not yet recruiting","No Results Available","Covid19 Immunology","Diagnostic Test: SARS-CoV-2 antibody testing","SARS-CoV-2 IgG|host immune response|pathogen protein expression","Bassett Healthcare|Bioreference, Inc","All","18 Years and older","","400","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","1613182","2020-07-15T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Bassett Medical Center, Cooperstown, New York, United States","","https://ClinicalTrials.gov/show/NCT04474288"
"202","NCT04411576","Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare","","Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Throat swab sample for measuring current infection with SARS-CoV-2|Diagnostic Test: Blood sample for serology to measure past infection with SARS-CoV-2","SARS-CoV-2 infection","Karolinska University Hospital","All","18 Years to 99 Years","","40000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Studien","2020-04-23T00:00:00","2020-07-01T00:00:00","2020-12-31T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","Karolinska University Hospital, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT04411576"
"203","NCT04423640","Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19","","Recruiting","No Results Available","SARS-CoV-2","Other: Active COVID-19 disease","Serum levels of cytokines and chemokines|Viral load|Immunophenotype of myeloid cells|RBD-SARS-CoV Protein S- antibodies|Analysis of cellular immune response|Hematopoietic stem cells and progenitor cells populations in peripheral blood|Questionnaire of Sociodemographic, labor, pathological and personal characteristics|SOFA |Fibrinogen|C-Reactive protein","Coordinación de Investigación en Salud, Mexico|Instituto Mexicano del Seguro Social","All","16 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R-2020, 3601-043","2020-04-15T00:00:00","2020-06-15T00:00:00","2020-08-15T00:00:00","2020-06-09T00:00:00","","2020-08-13T00:00:00","UMAE Hospital de Especialidades del Centro Medico Nacional Siglo XXI, IMSS., Mexico, Ciudad De Mexico, Mexico","","https://ClinicalTrials.gov/show/NCT04423640"
"204","NCT04408157","A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic","SWitCh","Not yet recruiting","No Results Available","COVID","Behavioral: Self-management booklet","Warwick-Edinburgh Mental Wellbeing Scale : Tennant et al., 2007|Self-rated health status: Bombak, 2013|Brief Resilience Scale : Smith et al., 2008|Intolerance of Uncertainty Scale : Carleton et al., 2007|Positive Affect subscale of the Positive and Negative Affect Scale-X : Watson & Clark, 1999|UCLA 3 item loneliness scale: Russell, 1996|Multidimensional Scale of Perceived Social Support : Zimet et al., 1988|Subjective Health Complaint Scale : Eriksen, Ihlebæk, & Ursin, 1999|Leeds Sleep Evaluation Questionnaire : Parrott & Hindmarch, 1980|Self-reported napping: Stone et al., 2018|Work and Social Adjustment Scale : Mundt et al., 2002|International Physical Activity Questionnaire -short form : Craig et al., 2003","King's College London","All","18 Years and older","Not Applicable","548","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","v1.1 06.05.2020","2020-05-20T00:00:00","2021-05-22T00:00:00","2021-06-22T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","","","https://ClinicalTrials.gov/show/NCT04408157"
"205","NCT04374838","Effect of COVID-19 Pandemic on Pediatric Cancer Care","","Recruiting","No Results Available","Covid19","","pediatric cancer care pattern during COVID 19 pandemic","South Egypt Cancer Institute","All","Child, Adult, Older Adult","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COVID-19 and Pediatric Cancer","2020-05-15T00:00:00","2020-08-01T00:00:00","2021-09-01T00:00:00","2020-05-05T00:00:00","","2020-08-12T00:00:00","South Egypt Cancer Institute, Assiut University, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04374838"
"206","NCT04465656","Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic","COVID-EP","Not yet recruiting","No Results Available","Pulmonary Embolism","Diagnostic Test: Serology test for COVID-19","% of patients for each group presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 6 months after PE diagnosis.|% of patients for each group and subgroup presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 12 months after PE diagnosis.|% of patients in each group presenting the occurrence of each of the following events at each follow-up .|% of patients diagnosed COVID - at M0 by RT-PCR on nasopharyngeal swab and diagnosed COVID + by serology 3 months after PE diagnosis|Effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of PE complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: duration of Heparin treatment","Hospital St. Joseph, Marseille, France","All","18 Years and older","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-05-01","2020-07-01T00:00:00","2020-10-31T00:00:00","2021-04-30T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","","","https://ClinicalTrials.gov/show/NCT04465656"
"207","NCT04388618","Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia","","Recruiting","No Results Available","Anosmia|Ageusia|Covid19|Corona Virus Infection","Other: NHANES smell and taste tests","correlation of anosmia and ageusia to covid19 positive patients|objective assessment of severity of smell and taste senses alterations in covid19 patients","Princess Nourah Bint Abdulrahman University","All","12 Years to 65 Years","","250","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","H-01-R-059","2020-06-15T00:00:00","2020-10-31T00:00:00","2020-12-31T00:00:00","2020-05-14T00:00:00","","2020-07-10T00:00:00","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia|prince Mohammed bin Abdulaziz Hospital, Riyadh, Central, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04388618"
"208","NCT04388683","Inhaled Nitric Oxide for Preventing Progression in COVID-19","NO-COVID-19","Recruiting","No Results Available","COVID-19","Drug: Nitric Oxide","Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay |Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level","Tufts Medical Center|Bellerophon","All","18 Years to 85 Years","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","STUDY00000554","2020-05-12T00:00:00","2021-04-30T00:00:00","2021-07-31T00:00:00","2020-05-14T00:00:00","","2020-05-18T00:00:00","Tufts Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04388683"
"209","NCT04399733","EMPOWER - BAME vs COVID","","Not yet recruiting","No Results Available","COVID-19, SARS-CoV 2 Infection|Health Disparities","","Identify COVID-19 specific host-defence  or predisposing  genetic biomarkers|Epidemiological profiles of COVID-19 infections in different UK ethnic populations","Future Genetics Limited","All","6 Years and older","","12800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMPOWER-BAME vs COVID","2021-02-01T00:00:00","2023-02-01T00:00:00","2024-02-01T00:00:00","2020-05-22T00:00:00","","2020-07-22T00:00:00","Future Genetics Limited, Birmingham, West Midlands, United Kingdom","","https://ClinicalTrials.gov/show/NCT04399733"
"210","NCT04422379","COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study","","Not yet recruiting","No Results Available","COVID-19","","COVID-19 Positive Case","Max Healthcare Insititute Limited","All","18 Years to 75 Years","","314","Other","Observational","Observational Model: Cohort|Time Perspective: Other","COVID 19/LI/2020","2020-06-07T00:00:00","2020-07-30T00:00:00","2020-08-30T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","Max Super Speciality Hospital, Saket , New Delhi, Dlelhi, India","","https://ClinicalTrials.gov/show/NCT04422379"
"211","NCT04387890","Serologic Surveillance for SARS-CoV-2  in a Prospective Cohort of Health Care Workers","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Health Personnel","Diagnostic Test: Serologic SARS-CoV-2 screening","Prevalence of anti SARS-CoV-2 antibodies  in health personnel|COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus|Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2","Hospital Italiano de Buenos Aires|Roche Pharma AG","All","18 Years and older","","50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","5566","2020-06-01T00:00:00","2020-08-31T00:00:00","2020-08-31T00:00:00","2020-05-14T00:00:00","","2020-05-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04387890"
"212","NCT04502472","Open-label Treatment of Severe Coronavirus Disease 2019  With Convalescent Plasma","Inova-CCP","Recruiting","No Results Available","Covid-19","Biological: Convalescent plasma transfusion","Change is clinical status|Transfusion related events|SOFA score at days 0, 7, 14, 21, 28|Length of Hospital Stay|Supplemental oxygen|Mechanical Ventilation|Change in mechanical ventilation status|Mortality|Change in inflammatory markers","Inova Health Care Services","All","18 Years and older","Phase 2|Phase 3","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Inova COVID-19 CCP","2020-06-06T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-08-06T00:00:00","","2020-08-06T00:00:00","Inova Fairfax Medical Campus, Falls Church, Virginia, United States","","https://ClinicalTrials.gov/show/NCT04502472"
"213","NCT04470414","COVID-19 IgG Antibodies in the Serum of Recovered Patients","","Not yet recruiting","No Results Available","Covid19","Diagnostic Test: IgG antibodies immunoassay","Levels of IgG in the serum of recovered COVID-19 patients|Factors related to IgG level","Assiut University","All","20 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Cov-PH2020","2020-08-01T00:00:00","2021-07-01T00:00:00","2021-09-01T00:00:00","2020-07-14T00:00:00","","2020-07-16T00:00:00","Faculty of medicine- Assiut university, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04470414"
"214","NCT04357990","Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19","KONS-COVID-19","Recruiting","No Results Available","COVID-19","Device: Kerecis Oral and Nasal Spray|Other: Placebo","Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group","Kerecis Ltd.","All","18 Years and older","Not Applicable","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","KS-0470","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-22T00:00:00","","2020-05-06T00:00:00","National Hospital of Iceland , Reykjavík, Iceland","","https://ClinicalTrials.gov/show/NCT04357990"
"215","NCT04336462","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Device: oxyhydrogen|Device: Oxygen","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire |minimum oxygen|Negative conversion rate|white blood cell|Red blood cells|Hemoglobin|Platelets|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein |Myocardial enzyme|liver function|Renal function|Muscle enzyme","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 85 Years","Not Applicable","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","JT202002LZ","2020-02-15T00:00:00","2020-02-21T00:00:00","2020-08-01T00:00:00","2020-04-07T00:00:00","","2020-04-07T00:00:00","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT04336462"
"216","NCT04506528","The C3I COVID-19 Project","","Recruiting","No Results Available","Covid19|Cancer|Nicotine Dependence|Pulmonary Disease|Cardiovascular Diseases|Immunosuppression Disorders","","Mortality due to COVID-19|COVID-19 Severity","University of Wisconsin, Madison|National Cancer Institute","All","Child, Adult, Older Adult","","170000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Other","2020-069|OISE-20-66590-1|A534253|SMPH/MEDICINE|CTRI","2020-08-10T00:00:00","2021-01-31T00:00:00","2021-12-31T00:00:00","2020-08-10T00:00:00","","2020-08-12T00:00:00","University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04506528"
"217","NCT04359862","Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection","SEVO-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19 Infection","Drug: Sevoflurane|Drug: Propofol","PaO2/FiO2|TNFα|IL-1b|IL-6|IL-8|Mortality","Fundación para la Investigación del Hospital Clínico de Valencia","All","18 Years to 99 Years","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","SEVO-COVID19","2020-04-16T00:00:00","2020-08-16T00:00:00","2020-09-16T00:00:00","2020-04-24T00:00:00","","2020-04-29T00:00:00","Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT04359862"
"218","NCT04389476","The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes","","Not yet recruiting","No Results Available","The Psychological Impact of COVID-19","Other: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019","Psychological impacts by CoronaVirus Disease 2019","Kaohsiung Kai-Suan Psychiatric Hospital","All","20 Years and older","","2500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KSPH-2020-03","2020-06-15T00:00:00","2023-07-31T00:00:00","2023-07-31T00:00:00","2020-05-15T00:00:00","","2020-06-16T00:00:00","","","https://ClinicalTrials.gov/show/NCT04389476"
"219","NCT04334876","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID-Antibody","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","Indiana University","All","18 Years and older","","340","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2003973826","2020-04-01T00:00:00","2020-11-01T00:00:00","2021-01-01T00:00:00","2020-04-06T00:00:00","","2020-04-06T00:00:00","","","https://ClinicalTrials.gov/show/NCT04334876"
"220","NCT04516928","Study of SARS-CoV2 Virus  Seroprevalence Among Lyon-Bron Military Health Schools Personnel","SeroCovEms","Not yet recruiting","No Results Available","SARS-CoV Infection|Covid19","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Proportion of anti-SARS-CoV2 seropositive participants|Proportion of asymptomatic participants |Correlation coefficient between medical risk factors and a positive serology|Correlation coefficient between epidemiological risk factors and a positive serology|Correlation coefficient between social risk factors and a positive serology","Direction Centrale du Service de Sante des Armees","All","18 Years and older","","950","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-29","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","Antenne Medicale des Ecoles Militaires de Sante de Lyon-Bron , Bron, France","","https://ClinicalTrials.gov/show/NCT04516928"
"221","NCT04367740","ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","","Enrolling by invitation","No Results Available","Asymptomatic Condition|Infection Viral|Coronavirus Infections|Severe Acute Respiratory Syndrome Coronavirus 2|Coronaviridae Infections|RNA Virus Infections|Virus Diseases|Communicable Disease","Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2","Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.|Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection.","University of North Carolina, Chapel Hill","All","18 Years to 99 Years","","10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","20-0937","2020-04-28T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-29T00:00:00","","2020-06-17T00:00:00","Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04367740"
"222","NCT04490174","Serological Surveillance for COVID-19 in Central North Carolina","","Recruiting","No Results Available","COVID-19","","Anti-SARS-COV-2 antibodies|Positive SARS-CoV-2 PCR|Clinical questionnaires and ELISA antibody testing resu|Detection of Anti-SARS-CoV-2 antibodies by ELISA Assay Algorithm|Clinical questionnaires and ELISA antibody testing results","National Institute of Environmental Health Sciences |National Institutes of Health Clinical Center","All","18 Years and older","","2500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200143|20-E-0143","2020-08-21T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-07-29T00:00:00","","2020-08-18T00:00:00","NIEHS Clinical Research Unit , Research Triangle Park, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04490174"
"223","NCT04452682","The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice","","Completed","No Results Available","COVID|Critical Limb Ischemia","Other: COVID 19 impact","The ICU admission with associated Pneumonia|Impact of COVID-19 on the different presentation of vascular surgery at the emergency|Mortality rates","Mansoura University","","Child, Adult, Older Adult","","998","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","R.20.06.898 - 2020/06/16","2020-05-25T00:00:00","2020-06-21T00:00:00","2020-06-21T00:00:00","2020-06-30T00:00:00","","2020-06-30T00:00:00","Mansoura university, Mansoura, Egypt","","https://ClinicalTrials.gov/show/NCT04452682"
"224","NCT04404270","Study of SARS-CoV2 Virus  Seroprevalence in the Population of Creil Air Force Base","EpiCovCreil","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Anti-SARS-CoV2 Serology|Behavioral: Questionnaire|Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization","Proportion anti-SARS-CoV2 seropositive|Proportion of asymptomatic anti-SARS-CoV2 seropositive participants|Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques |Proportion of serum neutralization positive|Change of antibody level over time","Direction Centrale du Service de Sante des Armees","All","18 Years and older","","2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-22","2020-05-26T00:00:00","2021-02-01T00:00:00","2021-02-01T00:00:00","2020-05-27T00:00:00","","2020-06-09T00:00:00","24e antenne medicale de Creil, Creil, France","","https://ClinicalTrials.gov/show/NCT04404270"
"225","NCT04453852","Monovalent Recombinant COVID19 Vaccine","COVAX19","Recruiting","No Results Available","Coronavirus Infection|COVID","Biological: COVID19 vaccine|Biological: Saline","Incidence of Adverse Events|COVID19 neutralizing antibody titers|COVID19 T cell immunogenicity|Durability of antibody response","Vaxine Pty Ltd|Central Adelaide Local Health Network Incorporated","All","18 Years to 65 Years","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","13110","2020-06-30T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-01T00:00:00","","2020-07-01T00:00:00","PARC,, Adelaide, South Australia, Australia","","https://ClinicalTrials.gov/show/NCT04453852"
"226","NCT04368234","Duke COVID-19 Shared Data and Specimen Repository","","Recruiting","No Results Available","COVID-19","","Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens","Duke University","All","Child, Adult, Older Adult","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105316","2020-04-18T00:00:00","2025-04-30T00:00:00","2025-04-30T00:00:00","2020-04-29T00:00:00","","2020-07-23T00:00:00","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04368234"
"227","NCT04388527","COVID-19 Convalescent Plasma for Mechanically Ventilated Population","","Recruiting","No Results Available","Covid-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score  of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.","University of Pennsylvania","All","18 Years and older","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","842996","2020-04-30T00:00:00","2020-08-30T00:00:00","2020-09-30T00:00:00","2020-05-14T00:00:00","","2020-05-29T00:00:00","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04388527"
"228","NCT04393961","At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study","","Recruiting","No Results Available","COVID19|COVID-19|Coronavirus","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","Does Participant Accurately Read Result|Acceptability and Usability of Tests|Social Distancing Behavior Change|COVID-19 Related Anxiety","ProofPilot|Radish Health|Sanesco","All","18 Years to 100 Years","Not Applicable","600","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Device Feasibility","2458","2020-04-05T00:00:00","2020-07-29T00:00:00","2020-08-29T00:00:00","2020-05-19T00:00:00","","2020-05-19T00:00:00","ProofPilot Online App , New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04393961"
"229","NCT04482023","Emotional Support and Stress Management in Patients Diagnosed With COVID-19","WWCOVID-19","Not yet recruiting","No Results Available","COVID-19","Behavioral: Training video on anxiety, fear and loneliness in the COVID-19 environment.","Rate of care actions identified by nurses|Rate of care actions taken by nurses","Corporacion Parc Tauli","All","18 Years and older","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2020663","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-12-31T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","Montserrat Montaña, Sabadell, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04482023"
"230","NCT04361916","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units","Mon-Covid","Recruiting","No Results Available","COVID-19","Other: home care monitoring","SpO2|in-hospital mortality|need of intubation|feasibility of active monitoring","Mario Negri Institute for Pharmacological Research","All","18 Years and older","Not Applicable","425","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Health Services Research","Mon-Covid","2020-04-21T00:00:00","2020-10-31T00:00:00","2020-12-31T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Asl Alessandria, Casale Monferrato, Alessandria, Italy","","https://ClinicalTrials.gov/show/NCT04361916"
"231","NCT04416347","COVID19 Clinical Predictors and Outcome","","Recruiting","No Results Available","COVID|SARS-CoV 2","Other: SARS-CoV2 Infection","SARS-CoV-2 hospital mortality|SARS-CoV-2 mortality in critical care unit","St George's University Hospitals NHS Foundation Trust|St George's, University of London","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020.0115","2020-06-15T00:00:00","2022-04-30T00:00:00","2022-04-30T00:00:00","2020-06-04T00:00:00","","2020-06-19T00:00:00","St. George's University Hospitals Foundation Trust., London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04416347"
"232","NCT04368390","Neuroradiolological Analysis of COVID-19 Patients","COVID-19BRAIN","Recruiting","No Results Available","Covid-19","","Neuroradiological analysis of patients brain MRI","University Hospital, Strasbourg, France","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7759","2020-04-03T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","Service d'Imagerie 2 - Neuroradiologie, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04368390"
"233","NCT04423315","Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia","Covid-19","Not yet recruiting","No Results Available","Corona Virus Infection|Thromboembolic Disease","","length of hospital stay","Nisantasi University","All","18 Years to 99 Years","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20200504443","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","Vital Hospital, Bahcelievler, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04423315"
"234","NCT04393155","Longitudinal COVID-19 Cohort Study","","Recruiting","No Results Available","COVID-19|Acute Respiratory Failure","Other: COVID-19+ observational","Six minute walk distance |Hospital Anxiety and Depression Scale |EuroQol Group standardized measure of health status |MoCA-BLIND|Health Care Utilization Survey |Death|Forced vital capacity |Forced expiratory volume in 1 second |4-meter timed walk|Peripheral blood mononuclear cell type: CD4+ T cells |Peripheral blood mononuclear cell type: CD8+ T cells |Peripheral blood mononuclear cell type: B cells |Peripheral blood mononuclear cell type: NK cells |Peripheral blood mononuclear cell type: monocytes |Circulating markers of inflammation: C-Reactive Protein  |Circulating markers of inflammation: Interleukin 6  |Circulating markers of inflammation: Interleukin 8  |Circulating markers of inflammation: Interferon gamma  |Circulating markers of inflammation: Interferon alpha  |Circulating markers of inflammation: Tumor necrosis factor alpha  |Circulating markers of inflammation: Interleukin 1 beta","University of Vermont","All","18 Years and older","","225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRMS 16-540","2020-04-16T00:00:00","2022-09-30T00:00:00","2023-05-31T00:00:00","2020-05-19T00:00:00","","2020-05-20T00:00:00","Johns Hopkins University, Baltimore, Maryland, United States|University of Vermont College of Medicine, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT04393155"
"235","NCT04401436","COVID-19 Associated Lymphopenia Pathogenesis Study in Blood","","Recruiting","No Results Available","Corona Virus Disease 2019","","Evaluation of lymphocyte subsets in patients with COVID-19 at various stages of disease, including recovery.|Evaluation of inflammatory pathways that may contribute to COVID-19 disease pathogenesis.","National Institute of Allergy and Infectious Diseases |National Institutes of Health Clinical Center","All","18 Years and older","","165","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200111|20-I-0111","2020-05-22T00:00:00","2022-06-30T00:00:00","2022-06-30T00:00:00","2020-05-26T00:00:00","","2020-07-27T00:00:00","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04401436"
"236","NCT04390165","Malaysian COVID-19 Anosmia Study  - A Nationwide Multicentre Cross-Sectional Study","","Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Presence or absence of olfactory and taste disturbances in COVID-19 patients|Prevalence of olfactory disturbances in COVID-19 patients|Prevalence of taste disturbances in COVID-19 patients|Clinical manifestations of study participants|Other pre-existing health conditions|Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey","Hospital Sultanah Bahiyah|Hospital Tuanku Fauziah, Kangar, Perlis|Hospital Sultanah Maliha, Langkawi, Kedah|Penang Hospital, Malaysia|Hospital Raja Permaisuri Bainun|Hospital Sungai Buloh, Selangor|Kuala Lumpur General Hospital|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan|Hospital Melaka, Melaka|Hospital Sultan Ismail, Johor Bahru, Johor|Hospital Permai, Johor Bahru, Johor|Hospital Sultanah Aminah Johor Bahru|Hospital Enche Besar Hajjah Khalsom, Kluang, Johor|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu|Hospital Tengku Ampuan Afzan, Kuantan, Pahang|Sarawak General Hospital|Hospital Queen Elizabeth, Malaysia","All","18 Years and older","","760","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MCO-001","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia","","https://ClinicalTrials.gov/show/NCT04390165"
"237","NCT04418557","COVID-19 and Obstetric Transmission","COVIDOB","Recruiting","No Results Available","COVID|Pregnancy Complications","Diagnostic Test: RT-PCR and antibody testing","Presence of COVID-19 virus|Presence of antibodies to COVID-19 virus","University Hospitals Cleveland Medical Center|Cuyahoga County Board of Health|The Cleveland Clinic|MetroHealth Medical Center|Case Western Reserve University","Female","18 Years to 50 Years","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200479","2020-04-28T00:00:00","2021-07-31T00:00:00","2021-07-31T00:00:00","2020-06-05T00:00:00","","2020-06-09T00:00:00","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT04418557"
"238","NCT04510233","Ivermectin Nasal Spray for COVID19 Patients","","Not yet recruiting","No Results Available","Covid19","Drug: Ivermectin nasal|Drug: Ivermectin oral|Other: standard care","PCR of SARS-Cov2 RNA","Tanta University","All","18 Years to 60 Years","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","IvrInh","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04510233"
"239","NCT04463862","COVID - AirPollution","","Recruiting","No Results Available","COVID-19 Confirmed Cases|COVID-19 Mortality","","COVID-19 related-mortality|COVID-19 confirmed cases","University Hospital, Strasbourg, France","All","50 Years and older","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","7922","2020-06-04T00:00:00","2020-09-04T00:00:00","2020-09-04T00:00:00","2020-07-09T00:00:00","","2020-07-22T00:00:00","Unite de neurologie-geriatrie, Hôpital Erasme, Cliniques Universitaires de Bruxelles, Bruxelles, Belgium|Service de Geriatrie, Hôpital Larrey, Hôpitaux Universitaires d'Angers, Angers, France|Unite de soins palliatifs geriatriques, Centre Hospitalier Departemental de Bischwiller, Bischwiller, France|Unite post urgence geriatriques, Hôpital Pellegrin, Hôpitaux Universitaires de Bordeaux, Bordeaux, France|Service de Geriatrie, Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Service de geriatrie-gerontologie, Hôpitaux Universitaires de Lille, Lille, France|Service de medecine aigüe geriatrique, Hôpital Nord Laennec, Hôpitaux Universitaires de Nantes, Nantes, France|Service de Geriatrie, Hôpitaux Bichat et Bretonnaux, Assistance Publique des Hôpitaux de Paris, Paris, France|Service de Medecine Interne et Geriatrie, Hôpitaux Universitaires de Reims, Reims, France|Service de Geriatrie, Hôpital de la Robertsau, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service de medecine geriatrique, Hôpitaux Universitaires de Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT04463862"
"240","NCT04372368","Convalescent Plasma for the Treatment of Patients With COVID-19","","Available","No Results Available","COVID-19|SARS-CoV 2","Biological: COVID-19 Convalescent Plasma","","University of Colorado, Denver","All","18 Years and older","","","Other","Expanded Access:Treatment IND/Protocol","","20-0990","","","","2020-05-04T00:00:00","","2020-07-17T00:00:00","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States","","https://ClinicalTrials.gov/show/NCT04372368"
"241","NCT04437875","An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","","Completed","No Results Available","Preventive Immunization COVID-19","Biological: Gam-COVID-Vac Lyo","The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days|Number of Participants With Adverse Events|The changing of virus neutralizing antibody titer|The changing of antigen-specific cellular immunity level","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 60 Years","Phase 1|Phase 2","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","03-Gam-COVID-Vac Lyo-2020","2020-06-17T00:00:00","2020-08-03T00:00:00","2020-08-10T00:00:00","2020-06-18T00:00:00","","2020-08-12T00:00:00","Sechenov First Moscow State Medical University, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04437875"
"242","NCT04341766","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid  19","","Completed","No Results Available","Pneumonia, Viral|COVID-19","Other: No special intervention","Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients","Centre Hospitalier Intercommunal Creteil","All","18 Years to 105 Years","","106","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ECHO","2020-03-31T00:00:00","2020-05-27T00:00:00","2020-06-30T00:00:00","2020-04-10T00:00:00","","2020-07-17T00:00:00","CHU Amiens, Amiens, France|CH de la Côte Basque, Bayonne, France|CHU Ambroise Pare, Boulogne-Billancourt, France|CHU Caen, Caen, France|CHG de Chambery, Chambery, France|Centre Hospitalier Intercommunal de Creteil, Creteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|CHU Nîmes, Nîmes, France|CHR Orleans, Orleans, France|CHU Cochin, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen, Rouen, France|CH Saint-Quentin, Saint-Quentin, France|CHU Larrey - Toulouse, Toulouse, France|CHU de Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT04341766"
"243","NCT04331899","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-Lambda","Recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Placebo","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Stanford University","All","18 Years to 75 Years","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","55619","2020-04-24T00:00:00","2021-05-31T00:00:00","2022-05-31T00:00:00","2020-04-02T00:00:00","","2020-06-18T00:00:00","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT04331899"
"244","NCT04362176","Passive Immunity Trial of Nashville II for COVID-19","PassItOnII","Recruiting","No Results Available","COVID-19|Coronavirus|SARS-CoV-2","Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo","COVID Ordinal Outcomes Scale:Day 15|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|COVID Ordinal Outcomes Scale Day 3|COVID Ordinal Outcomes Scale Day 8|COVID Ordinal Outcomes Scale Day 29|Composite of death or receipt of ECMO through Day 28|Oxygen-free days through Day 28|Vasopressor-free days through Day 28|Ventilator-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28","Vanderbilt University Medical Center|Dolly Parton","All","18 Years and older","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","200738","2020-04-24T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-24T00:00:00","","2020-05-04T00:00:00","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT04362176"
"245","NCT04348422","Evaluating the Immune Response for COVID-19","COVIDIMMUNE","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Proportion of symptomatic patients with immune response |Proportion of Asymptomatic patients with immune response |Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement","Assaf-Harofeh Medical Center","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","105-20-ASF","2020-04-20T00:00:00","2020-12-01T00:00:00","2020-12-31T00:00:00","2020-04-16T00:00:00","","2020-04-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04348422"
"246","NCT04399681","The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19","","Recruiting","No Results Available","COVID|Pneumonia, Viral","Device: Bedside lung ultrasound","Presence of viral pneumonia caused by COVID 19","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","KSSEAH--","2020-05-10T00:00:00","2020-08-10T00:00:00","2020-09-10T00:00:00","2020-05-22T00:00:00","","2020-05-22T00:00:00","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04399681"
"247","NCT04366739","Repurposing of Chlorpromazine in Covid-19 Treatment","reCoVery","Not yet recruiting","No Results Available","COVID-19","Drug: CHLORPROMAZINE |Combination Product: Standard of Care","Time To Response |Objective Response Rate |All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein |Biochemical response: blood test for lymphocytes |Parenchymal involvement |Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale |Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered","Centre Hospitalier St Anne|Hôpital Cochin","All","18 Years and older","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","D20-P016","2020-04-29T00:00:00","2020-08-30T00:00:00","2020-09-30T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","Centre Hospitalier Sainte-Anne, Paris, France","","https://ClinicalTrials.gov/show/NCT04366739"
"248","NCT04359667","Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","UHID-COVID19","Not yet recruiting","No Results Available","COVID-19|Severe Pneumonia","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]","serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease  pneumonia treated with tocilizumab","University Hospital for Infectious Diseases, Croatia","All","18 Years and older","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UHID-04","2020-06-16T00:00:00","2021-04-16T00:00:00","2021-05-15T00:00:00","2020-04-24T00:00:00","","2020-06-09T00:00:00","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia","","https://ClinicalTrials.gov/show/NCT04359667"
"249","NCT04383548","Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients","","Not yet recruiting","No Results Available","COVID19","Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin","Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events","Assiut University","All","21 Years to 50 Years","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Mini-pooled IVIG in COVID19","2020-06-01T00:00:00","2020-12-01T00:00:00","2021-01-01T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04383548"
"250","NCT04399109","Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community","ReCOVER","Recruiting","No Results Available","COVID","Device: TCC-COVID mHealth solution","Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case|All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case|Rate of hospital admission per diagnosed COVID case|Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case|Average length of stay  for admitted patients per diagnosed COVID case|Rate of admission to Intensive Care Unit  for admitted patients per diagnosed COVID case|Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case|Rate of intubation in admitted patients per diagnosed COVID case|Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case|All-cause mortality at 90 days per diagnosed COVID case|Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period|Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period|Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period|Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period|Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU|Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period|Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period|Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire","Dr Sze-Yuan Ooi|The University of New South Wales|The George Institute|South Eastern Sydney Local Health District|Prince of Wales Hospital, Sydney","All","18 Years and older","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Supportive Care","PID00770","2020-05-20T00:00:00","2021-05-19T00:00:00","2021-05-19T00:00:00","2020-05-22T00:00:00","","2020-05-22T00:00:00","The Sutherland Hospital, Caringbah, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia","","https://ClinicalTrials.gov/show/NCT04399109"
"251","NCT04373460","Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","CSSC-004","Recruiting","No Results Available","SARS-CoV 2","Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor","Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction  negativity","Johns Hopkins University|State of Maryland|Bloomberg Foundation|United States Department of Defense|National Institute of Allergy and Infectious Diseases","All","18 Years and older","Phase 2","600","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","IRB00247590","2020-06-03T00:00:00","2022-12-21T00:00:00","2023-01-31T00:00:00","2020-05-04T00:00:00","","2020-08-17T00:00:00","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic, Phoenix, Phoenix, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States|University of Miami, Coral Gables, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|MedStar Washington Hospital Center, Hyattsville, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity , Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT04373460"
"252","NCT04444687","COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?","LapCoVIDSurg","Not yet recruiting","No Results Available","COVID","Diagnostic Test: Test for SARS-CoV-2","SARS-COV-2 RNA detection|Viral contamination of peritoneal cavity and fluid|Viral contamination of peritoneal cavity and fluid in open cases|Viral infection of members of the surgical team","University Hospital, Basel, Switzerland","All","18 Years and older","","20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","052020","2020-08-01T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-06-23T00:00:00","","2020-06-23T00:00:00","","","https://ClinicalTrials.gov/show/NCT04444687"
"253","NCT04385017","Role of Inflammasomes in COVID-19 Disease","CoVInnate","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: COVID-19 patients","Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19|Genes nucleoside polymorphism analysis","Centre Hospitalier Universitaire de Nice","All","18 Years and older","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","20-PP-07","2020-05-11T00:00:00","2021-06-12T00:00:00","2021-06-12T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Ch Cannes, Reanimation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France","","https://ClinicalTrials.gov/show/NCT04385017"
"254","NCT04362865","Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection","","Recruiting","No Results Available","COVID-19","","Characterize immune response|B- and T-cell arm immune response|Immune response and outcome","National Cancer Institute |National Institutes of Health Clinical Center","All","18 Years and older","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200103|20-C-0103","2020-04-27T00:00:00","2023-12-01T00:00:00","2024-12-01T00:00:00","2020-04-27T00:00:00","","2020-07-10T00:00:00","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04362865"
"255","NCT04367896","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION  : AN INTERNATIONAL WEB-BASED SURVEY","","Completed","No Results Available","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION","Other: Survey Group","Management of Solid Organ Transplant during COVID-19 pandemic|Equity of resource distribution|Equity rank of resource distribution","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","","Child, Adult, Older Adult","","1819","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Covid-19_V1","2020-03-24T00:00:00","2020-04-17T00:00:00","2020-04-17T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","Fondazione Policlinico Universitario ""Agostino Gemelli"", Rome, Italy","","https://ClinicalTrials.gov/show/NCT04367896"
"256","NCT04321811","Behavior, Environment And Treatments for Covid-19","BEAT19","Recruiting","No Results Available","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","All","18 Years and older","","100000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XC-PCOR-COVID19","2020-03-21T00:00:00","2021-03-20T00:00:00","2022-03-20T00:00:00","2020-03-25T00:00:00","","2020-04-02T00:00:00","BEAT19.org, San Francisco, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04321811"
"257","NCT04386239","Study on the Use of Sarilumab in Patients With COVID-19 Infection","","Not yet recruiting","No Results Available","COVID19","Drug: Sarilumab Prefilled Syringe","Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell  fraction","ASST Fatebenefratelli Sacco","All","18 Years to 84 Years","Early Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","COVID-SARI-001","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-05-13T00:00:00","","2020-05-13T00:00:00","","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04386239"
"258","NCT04408378","Change in the Ratio of Mean Platelet Volume  to Platellet in Covid-19 Pneumonia Patients","","Recruiting","No Results Available","Coronavirus Infection","Other: observation of covid 19 pneumonia","estimation of inflammatory changes in Covid 19 pneumonia by using MVP/PLT ratio","Gaziosmanpasa Taksim Research and Education Hospital","All","18 Years to 70 Years","","156","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","69","2020-06-05T00:00:00","2020-07-20T00:00:00","2020-08-20T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","Gaziosmanpaşa TREH, Istanbul, Gaziosmanpaşa, Turkey","","https://ClinicalTrials.gov/show/NCT04408378"
"259","NCT04459286","The Nitazoxanide Plus Atazanavir for COVID-19 Study","NACOVID","Not yet recruiting","No Results Available","Covid-19","Drug: Nitazoxanide and atazanavir/ritonavir|Other: Standard of Care","Time to clinical improvement|Time to SARS-CoV-2 negativity|Difference in SARS-CoV-2 AUC|Time to symptoms resolution|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14|Duration of hospitalization in survivors|Day 28 mortality|Time from treatment initiation to death|Proportion with viral RNA detection over time","Obafemi Awolowo University|University of Liverpool|African Centre of Excellence for Genomics of Infectious Diseases|Oyo State Ministry of Health","All","18 Years to 75 Years","Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","NACOVID2020","2020-08-01T00:00:00","2020-10-31T00:00:00","2020-12-31T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria","","https://ClinicalTrials.gov/show/NCT04459286"
"260","NCT04374123","COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit","","Completed","No Results Available","COVID","Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19","Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days","Instituto Ecuatoriano de Enfermedades Digestivas","All","18 Years to 80 Years","","111","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IECED-04-15-covid","2020-04-20T00:00:00","2020-05-20T00:00:00","2020-06-15T00:00:00","2020-05-05T00:00:00","","2020-07-28T00:00:00","Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador","","https://ClinicalTrials.gov/show/NCT04374123"
"261","NCT04403828","Impact of COVID-19 on Personal Protection Among Dentist in Egypt","","Completed","No Results Available","COVID 19","Other: Survey","Personal protection measures|impact of Covid-19 pandemic on type of face masks used in dental clinic","Fayoum University","All","18 Years to 75 Years","","323","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PPE in COVID-19","2020-05-20T00:00:00","2020-06-01T00:00:00","2020-07-15T00:00:00","2020-05-27T00:00:00","","2020-07-22T00:00:00","Faculty of Dentistry, Fayoum, Egypt","","https://ClinicalTrials.gov/show/NCT04403828"
"262","NCT04374526","Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.","LIFESAVER","Recruiting","No Results Available","Coronavirus Disease 2019 )COVID-19)","Biological: COVID-19 Convalescent Plasma","Rate of COVID-19 progression","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","65 Years and older","Phase 2|Phase 3","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","3205","2020-05-27T00:00:00","2020-09-30T00:00:00","2021-06-30T00:00:00","2020-05-05T00:00:00","","2020-05-29T00:00:00","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Ospedale SS Annunziata, Chieti, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy","","https://ClinicalTrials.gov/show/NCT04374526"
"263","NCT04348864","COVID-19 Diagnostic Self-testing Using Virtual Point-of-care","","Recruiting","No Results Available","Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus","Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine","Clinical accuracy of the antibody and antigen rapid tests compared to LAMP/PCR-based test result|Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure","Neuroganics LLC","All","18 Years to 99 Years","Not Applicable","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","2020/03/18","2020-04-16T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-16T00:00:00","","2020-08-13T00:00:00","Neuroganics, Northglenn, Colorado, United States","","https://ClinicalTrials.gov/show/NCT04348864"
"264","NCT04379063","COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress","COPING","Recruiting","No Results Available","Burnout, Professional|Psychological Distress","Other: COVID-19 pandemic","Burnout|Psychological Distress|Post-traumatic stress symptoms|Post-traumatic growth","Jon Bailey|Nova Scotia Health Authority","All","Child, Adult, Older Adult","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NSHA REB#1025690","2020-05-13T00:00:00","2021-05-01T00:00:00","2022-05-01T00:00:00","2020-05-07T00:00:00","","2020-05-27T00:00:00","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada","","https://ClinicalTrials.gov/show/NCT04379063"
"265","NCT04479137","Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul","","Completed","No Results Available","Covid-19|Risk Factor, Mortality","Diagnostic Test: PCR for COVID-19","mortality based on COVID-19","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years to 50 Years","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KSSEAH--PPC","2020-03-10T00:00:00","2020-06-30T00:00:00","2020-07-14T00:00:00","2020-07-21T00:00:00","","2020-07-22T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04479137"
"266","NCT04480580","Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery","","Completed","No Results Available","Covid19|Surgery|SARS","Diagnostic Test: SARS-CoV-2 Ab","Seroprevalence of SARS-CoV-2","University of Cagliari","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-SURG","2020-03-30T00:00:00","2020-04-30T00:00:00","2020-06-30T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","AOU Cagliari, Cagliari, CA, Italy","","https://ClinicalTrials.gov/show/NCT04480580"
"267","NCT04463706","COVID19 Severity Prediction and Health Services Research Evaluation","","Recruiting","No Results Available","Covid19","Other: Predictors adverse evolution|Other: Predictors of health care provide","Clinical deterioration|Relief of symptoms|Mortality|Complications at follow up|Cost","Hospital Galdakao-Usansolo|Hospital Costa del Sol|Hospital del Mar|University Hospital of the Nuestra Señora de Candelaria|Instituto de Salud Carlos III|Hospital Universitario Araba|Biocruces Bizkaia Health Reseach Institute|Hospital de Basurto|Hospital Donostia","All","Child, Adult, Older Adult","","20000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID19_0459","2020-06-01T00:00:00","2021-06-30T00:00:00","2021-12-31T00:00:00","2020-07-09T00:00:00","","2020-07-15T00:00:00","Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain|Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain","","https://ClinicalTrials.gov/show/NCT04463706"
"268","NCT04515199","Home Management of Adult Egyptian Mild COVID-19 Cases","COVID-19","Recruiting","No Results Available","Covid19|Telemedicine|Quality of Life|Safety Issues|Symptoms","","Percent of adherence to isolation measures|The incidence of symptoms and their duration|Change in Short Form 35  Questionnaire|Cost- effectiveness of Home Isolation vs hospital admission in mild COVID-19 cases|Identifying the duration of post-COVID-19 symptoms|long-term respiratory complications","Cairo University","All","18 Years to 65 Years","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Telemedicine in Mild COVID-19","2020-07-01T00:00:00","2021-01-01T00:00:00","2021-03-01T00:00:00","2020-08-17T00:00:00","","2020-08-17T00:00:00","Faculty of Medicine Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04515199"
"269","NCT04386564","Kidney Injury Severity and COVID-19","","Active, not recruiting","No Results Available","COVID-19|Kidney Injury","Diagnostic Test: mRNA in urine test","The effect of COVID-19 severity on the severity of renal failure|The expression of viral RNA in the urine with the severity of renal failure|The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure|Assessment of the severity of renal impairment in patients who died from COVID-19|Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19|Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19","I.M. Sechenov First Moscow State Medical University","All","18 Years and older","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sechenov-COVID19_AKI","2020-05-15T00:00:00","2020-10-15T00:00:00","2020-11-15T00:00:00","2020-05-13T00:00:00","","2020-07-28T00:00:00","Sechenov University., Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04386564"
"270","NCT04471649","Hydroxy Chloroquine and Covid in RA Patients","Covid-19","Recruiting","No Results Available","COVID","","Number of patients in need for hospitalization|Length of hospitalization and ICU admission|The need for mechanical ventilation|Severity of COVID-19 disease","Tanta University","All","18 Years and older","","80","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","002","2020-06-15T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-07-15T00:00:00","","2020-07-17T00:00:00","Tanta University Hospital, Tanta, Egypt","","https://ClinicalTrials.gov/show/NCT04471649"
"271","NCT04298814","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","","Withdrawn","No Results Available","COVID-19|Endotracheal Intubation","Other: severe covid-19 pneumonia with ET","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Tongji Hospital","All","18 Years to 90 Years","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVEI","2020-08-07T00:00:00","2020-12-30T00:00:00","2020-12-30T00:00:00","2020-03-06T00:00:00","","2020-07-20T00:00:00","Tongji Hospital, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04298814"
"272","NCT04390503","Convalescent Plasma for COVID-19 Close Contacts","","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Biological: Convalescent Plasma |Biological: Control","Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA","Columbia University","All","18 Years and older","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","AAAT0052","2020-05-01T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","Columbia University Irving Medical Center/NYP, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04390503"
"273","NCT04347798","IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","IMPACT","Enrolling by invitation","No Results Available","Covid-19 Infection|Rheumatoid Arthritis|Psoriatic Arthritis|Hydroxychloroquine","Other: Hydroxychloroquine/Chloroquine","Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action","University of Alberta","All","18 Years and older","","500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00100000","2020-09-01T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-15T00:00:00","","2020-06-04T00:00:00","University of Alberta, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT04347798"
"274","NCT04432272","ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM","ABACCuS","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome |Coronavirus Infections","Biological: COVID-19 convalescent plasma","Avoidance of intubation at 28 days |Mortality |Cardio-circulatory arrest|Patient Outcome at 28 days|Renal failure|Liver failure|Cytokine Storm|Respiratory support|Vasopressor medication support|Length of ICU length of stay|Intensive Care Unit  mortality|Hospital length of stay|Ventilator free days|Intubation duration|Readmission|Serum anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality |Time from Transfusion to end of ventilator support","William Beaumont Hospitals","All","18 Years and older","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-198","2020-07-14T00:00:00","2021-06-01T00:00:00","2021-08-01T00:00:00","2020-06-16T00:00:00","","2020-07-10T00:00:00","William Beaumont Hospital, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT04432272"
"275","NCT04437719","Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","OBVIONCO","Recruiting","No Results Available","Oncology|COVID-19","Other: Obvio-19 app","COVID-19 infection's symptoms|Incidence and course of symptoms of COVID-19 infection|Correlation of the COVID-19 infection with the biological and clinical data of patients","Groupe Hospitalier Paris Saint Joseph|ObvioHealth","All","18 Years and older","Not Applicable","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","OBVIONCO","2020-06-29T00:00:00","2021-12-29T00:00:00","2021-12-31T00:00:00","2020-06-18T00:00:00","","2020-08-14T00:00:00","Groupe Hospitalier Paris Saint-Joseph, Paris, France","","https://ClinicalTrials.gov/show/NCT04437719"
"276","NCT04382092","Co-infection Management in COVID-19 Critically Ill","","Completed","No Results Available","COVID-19","Diagnostic Test: FilmArray Pneumonia","% of COVID-19 co-infections|% of antibiotic switches following FA results","Cliniques universitaires Saint-Luc- Universite Catholique de Louvain|BioMerieux","All","18 Years and older","Not Applicable","32","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","2019/14MAR/124","2020-03-23T00:00:00","2020-04-24T00:00:00","2020-04-24T00:00:00","2020-05-11T00:00:00","","2020-05-11T00:00:00","Cliniques Universitaires Saint-Luc, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT04382092"
"277","NCT04316728","Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","","Not yet recruiting","No Results Available","Coronavirus Infections","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","All","18 Years and older","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","VivaDiag-2020","2020-03-01T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-03-20T00:00:00","","2020-03-20T00:00:00","Unità' Complesse di cure primarie , ASP Catanzaro, Catanzaro, Italy","","https://ClinicalTrials.gov/show/NCT04316728"
"278","NCT04384614","Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study","CONNAITRE","Not yet recruiting","No Results Available","Covid 19|BCG Vaccination","Diagnostic Test: Test PCR|Genetic: TDR|Other: Clinical Examination","Differences related to epidemiological demographic characteristics","Direction des Soins de Sante de Base|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years","","400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ECC2020-07","2020-05-15T00:00:00","2020-07-15T00:00:00","2020-07-15T00:00:00","2020-05-12T00:00:00","","2020-05-13T00:00:00","Eshmoun Clinical Research Centre, Tunis, Tunisia","","https://ClinicalTrials.gov/show/NCT04384614"
"279","NCT04370223","Ozone Auto-hemotherapy for COVID-19 Pneumonia","COVID-OZONE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: Ozone auto-hemotherapy","Rate of patients achieving improvement in clinical condition at day 14 after recruitment|Mortality at day 28|Rate of patients achieving improvement in clinical condition at day 28 after recruitment|Rate of patients achieving improvement in clinical condition at day 7 after recruitment|Time to clinical improvement or hospital discharge|Number of ventilator-free days at 28 days|Hospital length of stay|Time to a 2-fold decrease in ferritin|Time to a 2-fold decrease in C-protein reactive|Time to a 2-fold decrease in Dimer-D|Time to a 2-fold decrease in Lactate Dehydrogenase|Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio","Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|Clinica Nuestra Senora del Rosario","All","18 Years to 90 Years","Phase 3","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID-19 Networking group","2020-05-25T00:00:00","2020-10-25T00:00:00","2020-12-25T00:00:00","2020-04-30T00:00:00","","2020-06-09T00:00:00","Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Señora del Rosario, Ibiza, Spain|Hospital Quirón Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain|Fundació Althaia de Manresa, Manresa, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Clinica Claro, Vigo, Spain","","https://ClinicalTrials.gov/show/NCT04370223"
"280","NCT04318418","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Not yet recruiting","No Results Available","COVID-19","","Severe COVID-19|Death","Neuromed IRCCS","All","Child, Adult, Older Adult","","5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DEP_012020","2020-03-23T00:00:00","2020-04-10T00:00:00","2020-04-30T00:00:00","2020-03-24T00:00:00","","2020-03-24T00:00:00","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy","","https://ClinicalTrials.gov/show/NCT04318418"
"281","NCT04380987","Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis","Predi-COVID","Recruiting","No Results Available","Covid19","Biological: Biological sampling","Description of clinical manifestations|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of biological manifestations|Patient-related prognostic factors|Virus-related prognostic factors|Vocal biomarker of Covid-19 related respiratory complications","Luxembourg Institute of Health|Centre Hospitalier du Luxembourg|Hopitaux Robert Schuman |Laboratoire National de Sante |University of Luxembourg","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Predi-Covid","2020-05-04T00:00:00","2021-07-31T00:00:00","2021-12-31T00:00:00","2020-05-08T00:00:00","","2020-05-08T00:00:00","Luxembourg Institute of Health, Luxembourg, Luxembourg","","https://ClinicalTrials.gov/show/NCT04380987"
"282","NCT04474340","COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients","","Recruiting","No Results Available","Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia|Pneumonia, Viral","Drug: COVID-19 Convalscent Plasma","Time to clinical improvement|All cause mortality","Ministry of Health, Kuwait","All","15 Years to 85 Years","Phase 1","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","MOHKuwait","2020-05-21T00:00:00","2020-09-30T00:00:00","2020-12-30T00:00:00","2020-07-16T00:00:00","","2020-07-21T00:00:00","Ministry Of Health, Kuwait, Kuwait","","https://ClinicalTrials.gov/show/NCT04474340"
"283","NCT04492865","MSCT Chest in Suspected COVID-19 Patients","","Not yet recruiting","No Results Available","COVID-19","Device: MSCT","Accuracy of non contrast MSCT chest in COVID-19|MSCT chest can be used as an alternative diagnostic tool for COVID-19 cases.","Assiut University","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTCOV","2020-07-30T00:00:00","2020-08-30T00:00:00","2020-10-30T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Assiut university, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04492865"
"284","NCT04352933","PROLIFIC ChemoprophylaxisTrial","","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine","Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm","Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 70 Years","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","PROLIFIC2020","2020-05-11T00:00:00","2020-10-31T00:00:00","2021-04-01T00:00:00","2020-04-20T00:00:00","","2020-05-13T00:00:00","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","","https://ClinicalTrials.gov/show/NCT04352933"
"285","NCT04405310","Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial","CPC-SARS","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma of patients with COVID-19|Other: placebo","Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA","Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias","All","18 Years to 70 Years","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","DI/20/201/04/19","2020-05-20T00:00:00","2020-06-20T00:00:00","2020-07-20T00:00:00","2020-05-28T00:00:00","","2020-05-28T00:00:00","Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico","","https://ClinicalTrials.gov/show/NCT04405310"
"286","NCT04335136","Recombinant Human Angiotensin-converting Enzyme 2  as a Treatment for Patients With COVID-19","APN01-COVID-19","Recruiting","No Results Available","COVID-19","Drug: RhACE2 APN01|Drug: Physiological saline solution","All Cause-death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Apeiron Biologics","All","18 Years to 80 Years","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","APN01-01-COVID19","2020-04-30T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-04-06T00:00:00","","2020-07-17T00:00:00","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany","","https://ClinicalTrials.gov/show/NCT04335136"
"287","NCT04467151","Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: anti-SARS-CoV-2 plasma|Other: Placebo","Disease progression measured by WHO scale|Comparison of maximum WHO score per group|Comparison of decrease of median and maximum WHO score per group|Comparison of time to clinical improvement per group|Comparison of time to reach score of ""6"" or greater on the WHO scale","Kashif Khan|University of Southern California","All","18 Years and older","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","HS-20-00516","2020-08-01T00:00:00","2021-10-01T00:00:00","2021-12-01T00:00:00","2020-07-10T00:00:00","","2020-07-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04467151"
"288","NCT04420182","COVID-19 Virtual Care at Home","","Not yet recruiting","No Results Available","Covid-19","Other: Virtual Care at Home","28 Day Patient Satisfaction Questionnaire|Emergency Department Visits|28 Day EQ-5D-5L Scores","Lawson Health Research Institute|Cardiac Arrhythmia Network of Canada","All","18 Years and older","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","CTO 3210","2020-06-08T00:00:00","2021-06-30T00:00:00","2021-12-31T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","London Health Sciences Centre, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04420182"
"289","NCT04425837","Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19","","Not yet recruiting","No Results Available","Sars-CoV2|Covid-19","Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care","Mortality|Adverse events|ICU admission|Mechanical ventilation|ICU length|Reduction of D Dimer|LDH reduction|Reduction of Troponin level|Decrease in ferritin level|Decrease in procalcitonin level|Decrease in CRP|Increase in lymphocyte count|Increase in PaO2 / Fio2|Decrease in Sequential Organ failure assessment  score|Extracorporeal membrane oxygenation |Lung infiltration","Fundación Santa Fe de Bogota","All","18 Years and older","Phase 2|Phase 3","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","PLASMA COVID-19","2020-07-01T00:00:00","2021-02-01T00:00:00","2021-02-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Fundación Santa Fe de Bogotá, Bogotá, Cundinamarca, Colombia","","https://ClinicalTrials.gov/show/NCT04425837"
"290","NCT04474457","Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age","","Recruiting","No Results Available","COVID-19","Drug: Favipiravir","Time to recovery |Decrease in viral load|Adverse Event , Serious Adverse Event  and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase  levels from baseline|Changes in aspartate aminotransferase  levels from baseline|Changes in C-reactive protein  levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time  values from baseline|Changes in partial thromboplastin time  values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oximetry from baseline|Changes in fever from baseline","Ministry of Health, Turkey|Hacettepe University, School of Medicine|Prof. Dr. Cemil Tascıoglu City Hospital|Umraniye Training and Research Hospital|Istanbul Training and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital |Derince Training and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital","All","15 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19-PMS-FAV","2020-06-11T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-07-16T00:00:00","","2020-07-20T00:00:00","Hacettepe University, School of Medicine, Ankara, Turkey","","https://ClinicalTrials.gov/show/NCT04474457"
"291","NCT04397523","Efficacy and Safety of COVID-19 Convalescent Plasma","","Recruiting","No Results Available","Convalescent Plasma|COVID-19|SARS-CoV 2","Biological: anti-SARS-CoV-2 convalescent plasma","Duration of oxygenation and ventilation support|Hospital length of stay |ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery","Institute for Transfusion Medicine of RNM|University Clinic for Infectious Diseases, North Macedonia","All","18 Years and older","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","ITM05/2020MKD","2020-04-30T00:00:00","2021-04-29T00:00:00","2021-04-29T00:00:00","2020-05-21T00:00:00","","2020-05-22T00:00:00","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia","","https://ClinicalTrials.gov/show/NCT04397523"
"292","NCT04343755","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 ,3,10,30, 60","Hackensack Meridian Health","All","18 Years and older","Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Pro2020-0375","2020-04-09T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-13T00:00:00","","2020-07-16T00:00:00","Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT04343755"
"293","NCT04329559","COVID-19 in Patients With Pre-existing Cirrhosis : A Multicentre Observational Study","","Recruiting","No Results Available","COVID-19|Liver Cirrhosis","","All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People's Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People's Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","All","18 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHESS2002","2020-03-30T00:00:00","2020-06-29T00:00:00","2021-06-29T00:00:00","2020-04-01T00:00:00","","2020-04-01T00:00:00","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China","","https://ClinicalTrials.gov/show/NCT04329559"
"294","NCT04443881","Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19","ANA-COVID-GEAS","Recruiting","No Results Available","COVID-19 Pnemonia","Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]","Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.","Fundacion Miguel Servet","All","18 Years to 80 Years","Phase 2|Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ANA-COVID-GEAS","2020-05-08T00:00:00","2020-12-01T00:00:00","2021-03-01T00:00:00","2020-06-23T00:00:00","","2020-06-23T00:00:00","Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Cataluña, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain","","https://ClinicalTrials.gov/show/NCT04443881"
"295","NCT04444596","Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19","","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Diagnostic Test: Conjunctival swab and nasopharyngeal swab","SARS-CoV2 positive conjunctival swabs|Conjunctival swab vs nasopharyngeal swab","Medical University Innsbruck","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","1104/2020","2020-06-17T00:00:00","2021-03-31T00:00:00","2021-03-31T00:00:00","2020-06-23T00:00:00","","2020-06-23T00:00:00","Medical University Innsbruck, Innsbruck, Tirol, Austria","","https://ClinicalTrials.gov/show/NCT04444596"
"296","NCT04362930","Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders","CoCo-Neuro","Recruiting","No Results Available","Neurologic Manifestations|Psychiatric Disorders|COVID-19","","Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19|Progression of pre-existing neurological or psychiatric pathologies","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200525","2020-04-27T00:00:00","2022-04-24T00:00:00","2022-04-24T00:00:00","2020-04-27T00:00:00","","2020-05-13T00:00:00","Hôpital Pitie Salpetrière, Paris, France","","https://ClinicalTrials.gov/show/NCT04362930"
"297","NCT04354610","Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection","Nancy-CovH-AKI","Recruiting","No Results Available","COVID 19","Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up","Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation |Elevation of troponin> 99th percentile in hospitalisation |AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure |The occurrence of cardiovascular events  during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital","Central Hospital, Nancy, France","All","18 Years and older","Not Applicable","57","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","2020PI072","2020-04-27T00:00:00","2020-07-18T00:00:00","2020-10-18T00:00:00","2020-04-21T00:00:00","","2020-05-06T00:00:00","CHRU de Nancy, Nancy, France|CHRU de Nancy, Vandœuvre-lès-Nancy, France","","https://ClinicalTrials.gov/show/NCT04354610"
"298","NCT04401241","How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department","MONACOVID","Completed","No Results Available","Covid19","","routine biomarkers and blood cell count are discriminant to diagnose COVID-19|Probability of COVID-19 and CRP|Probability of COVID-19 and PCT|Probability of COVID-19 and Ddimers|Probability of COVID-19 and NTproBNP|Probability of COVID-19 and cTnT-HS|Probability of COVID-19 and blood cell counts|performance of combined routine biomarkers|Assess usual biomarkers and blood cell count","Centre Hospitalier Princesse Grace","All","18 Years and older","","257","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","20-06","2020-02-01T00:00:00","2020-05-01T00:00:00","2020-05-15T00:00:00","2020-05-26T00:00:00","","2020-05-26T00:00:00","Centre Hospitalier Princesse Grace, Monaco, MON, Monaco","","https://ClinicalTrials.gov/show/NCT04401241"
"299","NCT04377789","Effect of Quercetin on Prophylaxis and Treatment of COVID-19","","Recruiting","No Results Available","COVID-19","Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment","Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","KSSEAH--0058","2020-03-20T00:00:00","2020-07-31T00:00:00","2020-08-31T00:00:00","2020-05-06T00:00:00","","2020-05-15T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04377789"
"300","NCT04339634","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","","Active, not recruiting","No Results Available","COVID|Drug Effect|Drug Interaction|Adverse Drug Event","Other: Simulation of Repurposed Drugs for COVID-19","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.","Tabula Rasa HealthCare","All","55 Years and older","","12123","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-PACE-2020-001","2020-04-07T00:00:00","2020-07-07T00:00:00","2021-04-06T00:00:00","2020-04-09T00:00:00","","2020-04-14T00:00:00","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States","","https://ClinicalTrials.gov/show/NCT04339634"
"301","NCT04475562","Can the Electronic Nose Smell COVID-19?","","Completed","No Results Available","SARS-CoV Infection|Covid19","Device: Aeonose","COVID 19 positive vs negative","Maastricht University Medical Center","All","18 Years and older","Not Applicable","219","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","eNoseCOVID","2020-04-06T00:00:00","2020-05-06T00:00:00","2020-07-01T00:00:00","2020-07-17T00:00:00","","2020-07-17T00:00:00","Maastricht University Medical Center, Maastricht, Netherlands","","https://ClinicalTrials.gov/show/NCT04475562"
"302","NCT04364815","The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial","","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures","Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms |Time to COVID-19 infection in patients receiving study drug |Safety and tolerability of study drug","University of the Philippines","All","18 Years to 59 Years","Phase 3","960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","RGAO-2020-0339","2020-05-01T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-04-28T00:00:00","","2020-05-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04364815"
"303","NCT04394884","Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19","","Recruiting","No Results Available","COVID-19","","To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to BTK inhibition therapy in COVID-19 patients","National Institute of Allergy and Infectious Diseases |National Institutes of Health Clinical Center","All","18 Years and older","","160","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999920114|20-I-N114","2020-08-21T00:00:00","2023-04-30T00:00:00","2023-04-30T00:00:00","2020-05-20T00:00:00","","2020-08-18T00:00:00","Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04394884"
"304","NCT04359264","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial","DISTANSE COVID","Active, not recruiting","No Results Available","COVID-19","Other: Cash transfer","Symptoms consisent with COVID-19|Number of close contacts|Number of participants with positive test for COVID-19|Self-reported health based on the single question: ""In general, would you say your health is..""|Ability to make ends meet based on the single question: ""At the end of the month, are you able to make ends meet?""","St. Michael's Hospital, Toronto","All","18 Years and older","Not Applicable","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","20-081","2020-04-20T00:00:00","2020-05-29T00:00:00","2020-12-30T00:00:00","2020-04-24T00:00:00","","2020-07-07T00:00:00","Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada|St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04359264"
"305","NCT04383535","Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia","PLASM-AR","Recruiting","No Results Available","SARS Virus|SARS-CoV-2|COVID-19","Other: Convalescent SARS COVID-19 plasma|Other: Placebo","Clinical status during follow-up at 30th day|Clinical status during follow-up at 7th day|Clinical status during follow-up at 14th day|Time until hospital discharge .|Time until discharge from ICU |Time to death|Time until complete functional recovery|Percentage of participants with adverse events / serious adverse events|Percentage of patients with negative SARS-CoV-3 PCR at Day 14th|D Dimer plasma concentration at Day 14th|Ferritin plasma concentration at Day 13th|Plasma concentration of neutralizing antibodies at Day 2nd|Plasma concentration of neutralizing antibodies at Day 7th|Post-transfusion adverse reactions","Hospital Italiano de Buenos Aires","All","18 Years and older","Not Applicable","333","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","5565","2020-05-15T00:00:00","2020-08-15T00:00:00","2020-09-20T00:00:00","2020-05-12T00:00:00","","2020-06-16T00:00:00","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina","","https://ClinicalTrials.gov/show/NCT04383535"
"306","NCT04374695","Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19","COVHYP","Not yet recruiting","No Results Available","COVID-19","","Prior treatment by ACEi|Prior treatment by ARB|Baseline characteristics and comorbidities|Major Clinical Adverse Events","Versailles Hospital|Bernard LIVAREK, MD, Cardiology department, Versailles Hospital|Jean-Paul BERESSI, MD, Department of diabetology, Versailles Hospital|Mehrsa KOUKABI FRADELIZZI, MD, Emergency department, Versailles Hospital|Floriane GILLES, MD, Cardiology department, Versailles Hospital|Alisson BERTRAND, Cardiology department, Versailles Hospital|Marie DE TOURNEMIRE, Cardiology department, Versailles Hospital|Victorien MONGUILLON, Cardiology department, Versailles Hospital|Maeva PASQUALINI, Cardiology department, Versailles Hospital|Alix PREVOT, Cardiology department, Versailles Hospital|Guillaume ROGER, Cardiology department, Versailles Hospital|Joseph SABA, Cardiology department, Versailles Hospital|Josephine SOLTANI, Cardiology department, Versailles Hospital|Jean-François PROST, Cardiology department, Versailles Hospital|Cecile LAUREANA, Department of medical information, Versailles Hospital","All","18 Years and older","","700","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","P20/11_COVHYP","2020-05-01T00:00:00","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-05-05T00:00:00","","2020-05-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04374695"
"307","NCT04490850","COVID-19 Seroprevalence Study in French Guiana","EPI-COVID-POP","Recruiting","No Results Available","Coronavirus Infection|Severe Acute Respiratory Syndrome|SARS-CoV Infection|Covid19","Procedure: Blood sample","Measure of the COVID-19 immunity of the population|Evaluation of the level of asymptomatic and pauci-symptomatic infections","Institut Pasteur|Institut Pasteur de la Guyane|Laboratoire de biologie medicale, Institut Pasteur de la Guyane|Laboratoire de biologie medicale de Kourou, French Guiana|Laboratoire de biologie medicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana|Laboratoire Eurofins Guyane de Remire-Montjoly, French Guiana|Centres Delocalises de Prevention et de Soins, Centre Hospitalier Andree Rosemon de Cayenne, Frech Guiana","All","Child, Adult, Older Adult","Not Applicable","1500","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","2020-048","2020-07-15T00:00:00","2021-07-15T00:00:00","2021-07-15T00:00:00","2020-07-29T00:00:00","","2020-07-29T00:00:00","Centre Hospitalier Andree Rosemon, Cayenne, French Guiana|Laboratoire de biologie meicale, Institut Pasteur de la Guyane, Cayenne, French Guiana|Laboratoires Eurofins Guyane, Cayenne, French Guiana|Laboratoire de biologie medicale de Kourou, Kourou, French Guiana|Laboratoire de biologie medicale du Centre hospitalier de Saint-Laurent du Maroni, Saint-Laurent du Maroni, French Guiana","","https://ClinicalTrials.gov/show/NCT04490850"
"308","NCT04387799","Determinants of COVID-19 Pneumonia","MC-19","Completed","No Results Available","Pneumonia, Viral|Pneumonia, Bacterial|Coronavirus Infection|Obstructive Lung Disease","Diagnostic Test: Serology for Covid-19","Serology|Efficacy of CT scan and Serology|Efficacy of different pharmaceutical treatments","Catholic University of the Sacred Heart","All","18 Years to 100 Years","","520","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200505","2020-05-13T00:00:00","2020-06-12T00:00:00","2020-06-17T00:00:00","2020-05-14T00:00:00","","2020-06-19T00:00:00","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy","","https://ClinicalTrials.gov/show/NCT04387799"
"309","NCT04465552","Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients","","Not yet recruiting","No Results Available","Coronavirus Infections","Other: Patients received standard of care treatment during hospitalization","To better characterize arrhythmic manifestations, employed treatment strategies and long- term outcomes in hospitalized COVID-19 patients in the US through a multicenter retrospective chart review.","Kansas City Heart Rhythm Research Foundation","All","18 Years and older","","750","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","KCHRF-COVID-19-0001","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-07-10T00:00:00","","2020-07-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04465552"
"310","NCT04466644","COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA","","Recruiting","No Results Available","COVID-19","Diagnostic Test: ELISA|Diagnostic Test: RT-PCR","Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs|Ratio of asymptomatic immunized  population|To validate saliva specimens as a biological sample for COVID-19 testing","Igenomix","All","18 Years and older","","400","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","IGX2-COV-JC-20-04|20201490","2020-06-08T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","Boston IVF Fertility Clinic, Boston, Massachusetts, United States|Utah Fertility Clinic, Pleasant Grove, Utah, United States","","https://ClinicalTrials.gov/show/NCT04466644"
"311","NCT04514874","Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020","Covae","Not yet recruiting","No Results Available","Covid19|SARS-CoV Infection","Other: Questionnaire","Prevalence of COVID-19 infection among French military professional aircrew|Predictive factors of COVID-19 infection|Techniques used for COVID-19 screening|Reasons for COVID-19 screening|Experienced symptoms of COVID-19|Medical care of COVID-19|Social consequences of the COVID-19 pandemic|Factors associated with pejorative consequences of the COVID-19 pandemic","Direction Centrale du Service de Sante des Armees","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-26","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-08-17T00:00:00","","2020-08-17T00:00:00","Centre d'Expertise Medicale du Personnel Navigant  de l'Hôpital d'Instruction des Armees Percy, Clamart, France|Centre d'Expertise Medicale du Personnel Navigant  de l'Hôpital d'Instruction des Armees Sainte-Anne, Toulon, France","","https://ClinicalTrials.gov/show/NCT04514874"
"312","NCT04382794","Sitagliptin Treatment in Diabetic COVID-19 Positive Patients","SIDIACO-RETRO'","Completed","No Results Available","Covid19","Drug: Retrospective case-control analysis","Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease","University of Milan|Papa Giovanni XXIII Hospital|IRCCS Policlinico S. Matteo|Humanitas Hospital, Italy|Ospedale dell'Angelo, Venezia-Mestre|University of Pavia","All","18 Years and older","","338","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","5/2020","2020-05-14T00:00:00","2020-06-15T00:00:00","2020-06-15T00:00:00","2020-05-11T00:00:00","","2020-07-09T00:00:00","ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy","","https://ClinicalTrials.gov/show/NCT04382794"
"313","NCT04420988","Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","","Available","No Results Available","COVID-19|SARS-CoV 2|SARS-CoV Infection","Biological: COVID-19 Convalescent Plasma","","Rutgers, The State University of New Jersey|University Hospital - Newark, NJ","All","18 Years and older","","","Other","Expanded Access:Individual Patients|Intermediate-size Population","","Pro2020000746, Pro2020000911","","","","2020-06-09T00:00:00","","2020-06-09T00:00:00","Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04420988/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04420988"
"314","NCT04437342","Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia","","Recruiting","No Results Available","Postpartum Depression|Psychological Stress|Maternal Distress","Other: PHQ-9  Depression Scale|Other: GAD-7  scale|Other: 38 questions questionnaire|Other: EPDS","Correlation between the Covid-19 pandemic and postpartum depression with EPDS scale |Correlation between the Covid-19 pandemic, postpartum depression and type of anaesthesia |Correlation between the Covid-19 pandemic, postpartum depression and postpartum pain","General and Maternity Hospital of Athens Elena Venizelou|National and Kapodistrian University of Athens|Alexandra Hospital, Athens, Greece|University of Ioannina|Larissa University Hospital","Female","18 Years and older","","300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Covid-19 Postpartum depression","2020-06-30T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-06-18T00:00:00","","2020-08-04T00:00:00","""Elena Venizelou"" General and Maternity Hospital of Athens, Athens, Attica, Greece|Aretaieio University Hospital, Athens, Attica, Greece|Alexandra Genaral Hospital Athens, Athens, Greece|University of Ioannina Health Science, Ioannina, Greece|University of Ioannina, Medical School, Ioannina, Greece|University of Thessaly Medical School, Larisa, Greece","","https://ClinicalTrials.gov/show/NCT04437342"
"315","NCT04344457","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","Perseverance Research Center, LLC|Athena Medical Group","All","18 Years and older","Phase 1|Phase 2","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","HIZ-PRC-COVID-19","2020-04-16T00:00:00","2020-06-20T00:00:00","2020-09-30T00:00:00","2020-04-14T00:00:00","","2020-07-01T00:00:00","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT04344457"
"316","NCT04345523","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","ConPlas-19","Recruiting","No Results Available","COVID-19","Other: Blood and derivatives.|Drug: Standard of Care","Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older","Phase 2","278","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ConPlas-19","2020-04-03T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-14T00:00:00","","2020-04-15T00:00:00","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04345523"
"317","NCT04473131","Immune Profiling of COVID19-patients Admitted to ICU","IMPROVISE","Recruiting","No Results Available","COVID-19","Other: No intervention","To create an immune profile for each COVID19-positive patient during their ICU stay|To correlate patients' immune profile to disease severity and patient's outcome","Hamad Medical Corporation|Qatar University|Weill Cornell Medical College in Qatar","All","18 Years and older","","300","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MRC-05-007","2020-04-27T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Hamad Medical Corporation, Doha, Qatar","","https://ClinicalTrials.gov/show/NCT04473131"
"318","NCT04395794","SARS-CoV-2 Disguise Study","Disguise","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: SARS-CoV-2-test|Other: SARS-CoV-2 questionnaire survey","SARS-CoV-2 positive test|Transformation|Predictors |Predictors |Percentage from different departments","Meshalkin Research Institute of Pathology of Circulation","All","18 Years and older","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CS-COVID-19","2020-05-07T00:00:00","2020-08-31T00:00:00","2020-11-30T00:00:00","2020-05-20T00:00:00","","2020-05-20T00:00:00","Meshalkin National Medical Research Center, Novosibirsk, Russian Federation","","https://ClinicalTrials.gov/show/NCT04395794"
"319","NCT04387656","NCI COVID-19 in Cancer Patients, NCCAPS Study","","Recruiting","No Results Available","Asymptomatic COVID-19 Infection Laboratory-Confirmed|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed","Procedure: Biospecimen Collection|Other: Data Collection","Patient variables  associated with severe acute respiratory syndrome  coronavirus 2  severity|Effects of COVID-19 on cancer therapy and association with clinical outcomes","National Cancer Institute","All","18 Years and older","","2000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCI-2020-02986|NCICOVID","2020-05-21T00:00:00","2023-05-31T00:00:00","2023-05-31T00:00:00","2020-05-14T00:00:00","","2020-08-17T00:00:00","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|PCR Oncology, Arroyo Grande, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Enloe Medical Center, Chico, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Veterans Affairs Loma Linda Healthcare System, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Cancer Center of Colorado at Sloan's Lake, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Florida Cancer Specialists - Bradenton, Bradenton, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|Florida Cancer Specialists - Sarasota Downtown, Sarasota, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists - Venice Island, Venice, Florida, United States|Florida Cancer Specialists - Venice Healthpark, Venice, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northeast Georgia Medical Center Braselton, Braselton, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|IU Health North Hospital, Carmel, Indiana, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Covington, Covington, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Maine Medical Partners - South Portland, South Portland, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|FMH James M Stockman Cancer Institute, Frederick, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Henry Ford Macomb Health Center - Shelby Township, Shelby, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Gulfport Memorial Hospital, Gulfport, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Cancer Care Specialists - Reno, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus, Elizabeth, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Inspira Medical Center Mullica Hill, Mullica Hill, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Newton Medical Center, Newton, New Jersey, United States|Kennedy Health Systems-Cancer Center, Sewell, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|James J Peters VA Medical Center, Bronx, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Nash General Hospital, Rocky Mount, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|University Pointe, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Saint Vincent Hospital, Erie, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Holy Redeemer Hospital and Medical Center, Meadowbrook, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Baptist Hospital, Columbia, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Thompson Oncology Group-Lenoir City, Lenoir City, Tennessee, United States|Thompson Oncology Group-Maryville, Maryville, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Thompson Oncology Group-Oak Ridge, Oak Ridge, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Audie L Murphy VA Hospital, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Farmington Health Center, Farmington, Utah, United States|University of Utah Sugarhouse Health Center, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Augusta Health Center for Cancer and Blood Disorders, Fishersville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|VCU Massey Cancer Center at Stony Point, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Shenandoah Oncology PC, Winchester, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, United States|Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Ascension Calumet Hospital, Chilton, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Ascension Saint Francis - Reiman Cancer Center, Franklin, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital Ozaukee, Mequon, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Ascension Medical Group Southeast Wisconsin - Mayfair Road, Wauwatosa, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT04387656"
"320","NCT04475575","Can the Electronic Nose Smell COVID-19 Antibodies?","","Completed","No Results Available","SARS-CoV Infection|Covid19","Device: Aeonose","COVID-19 antibodies vs COVID-19 negative","Maastricht University Medical Center","All","18 Years and older","Not Applicable","222","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","eNoseCOVIDantibodies","2020-04-06T00:00:00","2020-06-30T00:00:00","2020-07-01T00:00:00","2020-07-17T00:00:00","","2020-07-17T00:00:00","Maastricht University Medical Center, Maastricht, Netherlands","","https://ClinicalTrials.gov/show/NCT04475575"
"321","NCT04353609","Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","covid19 fai2r","Recruiting","No Results Available","Sars-CoV2|Chronic Inflammatory Rheumatism|Autoimmune Diseases","","Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death|Proportion of patients who die from a severe form of covid-19|Proportion of patients who present an history of diabetes according to medical records|Proportion of patients who present obesity |Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records|Proportion of patients who present an history of Asthma according to medical records|Proportion of patients who present an history of Hypertension according to medical records|Proportion of patients who present an history of cardiac disease according to medical records|Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records|Proportion of patients who present an history of stroke according to medical records|Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records|Proportion of patients who present an history of cancer according to medical records","University Hospital, Lille|FAI²R","All","Child, Adult, Older Adult","","13770","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NI_2020_03","2020-04-18T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-20T00:00:00","","2020-04-22T00:00:00","Hôpital Huriez, Lille, France","","https://ClinicalTrials.gov/show/NCT04353609"
"322","NCT04497818","Correlation Fear of COVID-19 & Dental Treatment Anxiety","","Completed","No Results Available","Covid19|Fear|Dental Anxiety","Other: Cross Sectional study using scientifically validated psychometric Scales","Fear of COVID-19 infection|Dental Anxiety|Correlation of Fear of COVID-19 infection & Dental Anxiety|Correlation of the nearest Dental treatment seeking time and Fear of COVID-19 infection.|Correlation of the nearest Dental treatment seeking time and Dental Anxiety|Correlation of the Age and Fear of COVID-19 infection|Correlation of the Age and Dental Anxiety.","Qassim University","All","20 Years and older","","385","Other","Observational","Observational Model: Other|Time Perspective: Prospective","QassimU2","2020-06-16T00:00:00","2020-07-16T00:00:00","2020-07-25T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04497818"
"323","NCT04495933","A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp  Vaccine in Healthy Adults","","Recruiting","No Results Available","SARS-CoV2|Covid19","Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Other: Placebo","Frequency of Solicited local reactogenicity adverse events |Frequency of Solicited systemic reactogenicity adverse events |Grading of Solicited local reactogenicity adverse events |Grading of Solicited systemic reactogenicity adverse events |Unsolicited adverse events |Serious adverse events , Medically attended adverse events  and any Adverse events  leading to study withdrawal at any time during the study|Geometric Mean Titer  of the serum antibody response|Geometric Mean Titer  of the serum neutralizing antibody  response to SARS-CoV-2 virus|Total serum antibody immune responses|proportion of participants with ≥ 4 fold increase in titer above baseline|GMT of the serum neutralizing antibody  titres","The University of Queensland|Syneos Health|Coalition of Epidemic Preparedness Innovations","All","18 Years to 55 Years","Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple |Primary Purpose: Prevention","UQ-1-SARS-CoV-2-Sclamp|ACTRN12620000674932p","2020-07-13T00:00:00","2020-10-01T00:00:00","2021-09-01T00:00:00","2020-08-03T00:00:00","","2020-08-03T00:00:00","Nucleus Network Brisbane , Herston, Queensland, Australia","","https://ClinicalTrials.gov/show/NCT04495933"
"324","NCT04461340","Efficacy and Safety of Sirolimus in COVID-19 Infection","","Not yet recruiting","No Results Available","COVID 19","Drug: Sirolimus","Time to clinical recovery|Viral clearance|radiological lung extension|drug adverse events|28 day mortality|intensive care unit  admission rate|Duration of hospital stay","Alexandria University","All","18 Years and older","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","sirolimus in COVID 19","2020-07-25T00:00:00","2020-09-30T00:00:00","2020-10-30T00:00:00","2020-07-08T00:00:00","","2020-07-10T00:00:00","Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt","","https://ClinicalTrials.gov/show/NCT04461340"
"325","NCT04438629","Evaluation of Immune Response in COVID-19 Patients","IMMUNOVID","Recruiting","No Results Available","Allergy and Immunology|Infection Viral","Drug: COVID-19 treatment","COVID-19 associated immune disorder|COVID-19 associated inflammation|Oxygenation|Diagnostic of COVID disease composite|Changes at the cytokine pattern|Changes at circulating immune cell composition|Intensive Care Unit Admission|Length of hospital stay|Clinical Status|Mortality","Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 90 Years","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMMUNOVID 2590CESC","2020-03-26T00:00:00","2020-06-10T00:00:00","2020-11-26T00:00:00","2020-06-19T00:00:00","","2020-06-22T00:00:00","Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy","","https://ClinicalTrials.gov/show/NCT04438629"
"326","NCT04407559","COVID-SErology in Rheumatoid Arthritis","COVID-SERA","Active, not recruiting","No Results Available","COVID-19|Rheumatoid Arthritis","Other: Serological analyses to be lead on a pre-existing biobank","Evaluate the false positive results rate|Characterize the RF isotype  associated|Determine the influence of RA on the false positivity rate in subjects|Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test|Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test","University Hospital, Montpellier","All","18 Years and older","","216","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0330","2020-05-01T00:00:00","2020-09-01T00:00:00","2020-09-30T00:00:00","2020-05-29T00:00:00","","2020-06-01T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04407559"
"327","NCT04352634","The Covid-19 HEalth caRe wOrkErS  Study","HEROES","Recruiting","No Results Available","Covid-19|Mental Health Disorder|Stress Disorder|Anxiety|Depression|SARS-CoV-2","Other: Exposure to the SARS-CoV-2 and its consequences","Anxiety and depressive symptoms|Experiences, fears and concerns about the Covid-19|Training and resource prioritization|Suicide ideation |Suicide ideation |Acute stress symptoms|Psycho/social support and network|Resilience","University of Chile","All","18 Years and older","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEROES Covid-19","2020-04-26T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-04-20T00:00:00","","2020-07-14T00:00:00","Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|National Institute of Health Named After Academician S. Avdalbekyan, Yerevan, Armenia|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Medicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care , Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental , Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research , Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela","","https://ClinicalTrials.gov/show/NCT04352634"
"328","NCT04345692","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","OAHU-COVID19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Queen's Medical Centre","All","18 Years to 95 Years","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RA-2020-018","2020-03-26T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-04-14T00:00:00","","2020-06-04T00:00:00","Queen's Medical Center, Honolulu, Hawaii, United States","","https://ClinicalTrials.gov/show/NCT04345692"
"329","NCT04482361","SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES","","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Presence of specific anti-SARS-CoV-2 antibodies","Prevalence of IGG for COVID-19|Changes in prevalence of IGG for COVID-19","Ministerio de Salud de Ciudad Autónoma de Buenos Aires","All","18 Years and older","","5400","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","SEROEPIDEMIOLOGY COVID IN CABA","2020-07-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","","","https://ClinicalTrials.gov/show/NCT04482361"
"330","NCT04395391","Home Usability Study of the SARS-CoV-2  Test","","Completed","No Results Available","COVID-19","Diagnostic Test: SARS-CoV-2","Valid SARS-CoV-2 Test","Exact Sciences Corporation","All","18 Years and older","","30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-06","2020-05-18T00:00:00","2020-05-21T00:00:00","2020-06-16T00:00:00","2020-05-20T00:00:00","","2020-08-11T00:00:00","Exact Sciences, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04395391"
"331","NCT04372979","Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","PLASCOSSA","Not yet recruiting","No Results Available","COVID-19","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.","Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics","Direction Centrale du Service de Sante des Armees|University Hospital, Grenoble","All","18 Years to 80 Years","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","2020-A01166-33","2020-05-01T00:00:00","2020-10-01T00:00:00","2021-05-01T00:00:00","2020-05-04T00:00:00","","2020-05-15T00:00:00","HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Begin, Saint-Mande, France|HIA Sainte Anne, Toulon, France","","https://ClinicalTrials.gov/show/NCT04372979"
"332","NCT04370275","Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia","POCUSars-CoV-2","Recruiting","No Results Available","COVID-19|Pneumonia, Viral","","Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Positive Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Sensitivity and Specificity of Lung Ultrasound in the diagnosis of COVID-19","Ospedale di Latisana","All","18 Years and older","","235","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEUR-2020-Os-086","2020-04-23T00:00:00","2020-05-23T00:00:00","2020-05-31T00:00:00","2020-04-30T00:00:00","","2020-04-30T00:00:00","SC Pronto Soccorso e Medicina d'Urgenza, Latisana, Udine, Italy","","https://ClinicalTrials.gov/show/NCT04370275"
"333","NCT04506229","Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function","GenCov","Recruiting","No Results Available","Covid19","Genetic: Whole exome sequencing","Genetic variants with vs without COVID-19|Cognitive function at baseline|Change in cognitive function at 1 month|Genetic analysis","Texas Cardiac Arrhythmia Research Foundation","All","18 Years and older","","60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TCAI_GenCov","2020-08-01T00:00:00","2021-08-01T00:00:00","2021-09-01T00:00:00","2020-08-10T00:00:00","","2020-08-14T00:00:00","Texas Cardiac Arrhythmia Institute, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT04506229"
"334","NCT04325061","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome Caused by COVID-19","Drug: Dexamethasone","60-day mortality|Ventilator-free days","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomedica en Red, M.P.","All","18 Years and older","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-001278-31","2020-04-03T00:00:00","2020-10-30T00:00:00","2020-10-30T00:00:00","2020-03-27T00:00:00","","2020-04-17T00:00:00","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain","","https://ClinicalTrials.gov/show/NCT04325061"
"335","NCT04361903","Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection","RESPIRE","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19|Improvement of respiratory performance - Arterial Blood Gas Analisys - pH|Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2|Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2|Improvement of respiratory performance - ratio values|Evaluation of known adverse events related to the use of the drug - D-Dimer|Evaluation of known adverse events related to the use of the drug - fibrinogen|Evaluation of known adverse events related to the use of the drug - transaminases|Evaluation of known adverse events related to the use of the drug - aPTT|Evaluation of known adverse events related to the use of the drug - INR|Evaluation of known adverse events related to the use of the drug - glycemia|Evaluation of known adverse events related to the use of the drug - creatinine|Evaluation of known adverse events related to the use of the drug - Leucocytes count|Evaluation of known adverse events related to the use of the drug - Leucocytes formula|Evaluation of the epidemiological parameters: Chest CT|Evaluation of the epidemiological parameters: Eco Chest|Evaluation of the epidemiological parameters: CHEST X-ray|Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment|Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy","Azienda USL Toscana Nord Ovest|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|Azienda Ospedaliera Universitaria Senese|Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older","","13","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020.COVID-19.RUXO106","2020-04-25T00:00:00","2020-05-24T00:00:00","2020-05-31T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04361903"
"336","NCT04371926","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk","PREVENT","Withdrawn","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate","Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients","Texas Cardiac Arrhythmia Research Foundation","All","18 Months to 85 Years","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","TCAI_PREVENT","2020-06-01T00:00:00","2021-06-01T00:00:00","2021-07-01T00:00:00","2020-05-01T00:00:00","","2020-06-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04371926"
"337","NCT04427254","Study of the Sars-Cov2 Neuroinvasiveness - COVID19","CORONEVRAXE","Not yet recruiting","No Results Available","COVID19","Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies","Percentage of patients with COVID-19 positive samples/biopsies","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","PBN_2020_16","2020-06-01T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Fondation A de Rothschild, Paris, France","","https://ClinicalTrials.gov/show/NCT04427254"
"338","NCT04347681","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","","Recruiting","No Results Available","Convalescent Plasma for COVID 19","Other: convalescent plasma from recovered COVID 19 donor","ICU length of stay|Safety of convalescent plasma & Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .","King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital","All","18 Years to 85 Years","Phase 2","575","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","HAEM0321","2020-04-18T00:00:00","2020-12-31T00:00:00","2021-04-11T00:00:00","2020-04-15T00:00:00","","2020-08-11T00:00:00","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04347681"
"339","NCT04377737","Incidence of Covid-19 in School Children","COVIDECOLE","Withdrawn","No Results Available","Infection; Viral, Coronavirus","Diagnostic Test: RT-PCR Covid-19","evaluation of the prevalence of positive real-time-polymerase chain reaction  in school children during the pandemic period in Nice|evaluation of the serological prevalence of the Covid-19 infection|evaluation of the COVID-19 reinfection among seropositive children at the inclusion time|evaluation of the prevalence of positive rt-PCR of other respiratory viruses |comparison of inflammatory response level between different coronavirus strains|Estimation of medico-social risk factors associated with COVID-19 infection","Fondation Lenval","All","3 Years to 10 Years","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","20-HPNCL-02","2020-05-15T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-05-06T00:00:00","","2020-05-27T00:00:00","Hôpitaux Pediatrique de Nice CHU Lenval, Nice, France","","https://ClinicalTrials.gov/show/NCT04377737"
"340","NCT04334291","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","Recruiting","No Results Available","COVID 19","Combination Product: Observational","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain","All","Child, Adult, Older Adult","","6000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20/241-E|EUPAS34399","2020-03-23T00:00:00","2020-05-01T00:00:00","2020-05-05T00:00:00","2020-04-06T00:00:00","","2020-04-28T00:00:00","Hospital Lclinico San Carlos, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04334291"
"341","NCT04484597","Predictors of COVID-19 Infection and Disease Progression","Portsaiduni","Recruiting","No Results Available","Positive COVID-19 by PCR","Diagnostic Test: Rt PCR","correlation of COVID-19 antibody to PCR|correlation of ancillaey tests to PCR","Port Said University","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Prof. Refat Sadeq","2020-03-15T00:00:00","2020-08-15T00:00:00","2020-09-15T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","Prof. Refat Sadeq, Port Said, Egypt","","https://ClinicalTrials.gov/show/NCT04484597"
"342","NCT04452630","Cardiovascular Consequences After COVID-19","","Recruiting","No Results Available","Cardiovascular Consequences After an Episode of COVID 19","Other: Infectious Disease and Cardiology Clinical Consultations","Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering","Assistance Publique Hopitaux De Marseille","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-36","2020-06-23T00:00:00","2020-07-23T00:00:00","2021-11-30T00:00:00","2020-06-30T00:00:00","","2020-06-30T00:00:00","Assistance Publique Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT04452630"
"343","NCT04448717","Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children","CiaoCorona","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Diagnostic Test: COVID-19 Antibody testing","Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies|Presence of self-reported symptoms|Proportion of seropositive children reporting COVID-19 related symptoms from January 2020|Incidence of symptoms in initially seropositive participants|Proportion of participants, seronegative at inclusion, with symptoms in the follow-up|Presence of risk factors for infection at inclusion |Presence of risk factors for infection during follow-up |Self-reported lifestyle changes of participants at inclusion|Self-reported lifestyle changes of participants during follow-up|Self-reported mental well-being |Self-reported mental well-being |Self-reported quality of life |Prevalence of seropositive SARS-Cov-2 clusters in schools at inclusion|Incidence of seropositive SARS-Cov-2 clusters in schools during the follow-up|Change in seropositive participants within school or class, depending on the initial proportion of seropositive participants|Effect of risk factors and preventive measures on SARS-CoV-2 infection incidence within schools","University of Zurich|Swiss School of Public Health","All","5 Years and older","","8000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-01336","2020-06-16T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-06-26T00:00:00","","2020-07-21T00:00:00","Epidemiology, Biostatistics and Prevention Institute , University of Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT04448717"
"344","NCT04401085","COVID-19: Herd Immunity Study in the Czech Republic","SARSCoV2CZPrev","Completed","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies","Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.|Estimation of the proportion of people with a subclinical course of the disease|Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.|Estimation of the proportion of persons suitable for the donation of convalescent plasma","Institute of Health Information and Statistics of the Czech Republic|Ministry of Health, Czech Republic|Faculty of Medicine, Palacky University|Faculty of Medicine, Masaryk University|Faculty of medicine, University of Ostrava|Faculty of Military Health Sciences, University of Defence in Brno|Faculty of Health Studies, J. E. Purkyně University in Ústí nad Labem|First Faculty of Medicine, Charles University, Czech Republic|Institute for Clinical and Experimental Medicine|General University Hospital, Prague|University Hospital Olomouc|Brno University Hospital|Krajská zdravotní, a.s., Ústí nad Labem Region Hospitals|Military University Hospital, Prague|Masaryk Memorial Cancer Institute|Institute Of Sociology, Czech Academy of Sciences|Czech Statistical Office|Faculty of Medicine in Hradec Králove, Charles University","All","8 Years to 89 Years","","27000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","UZIS 2020/1","2020-04-23T00:00:00","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-05-26T00:00:00","","2020-06-01T00:00:00","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia","","https://ClinicalTrials.gov/show/NCT04401085"
"345","NCT04373161","Home Pulse Oximeter Use in Patients With COVID-19","","Completed","No Results Available","Sars-CoV2|COVID-19|COVID","Device: Home Pulse Oximetry Monitoring","Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay","Swedish Hospital","All","18 Years and older","Not Applicable","209","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","2020032301","2020-03-20T00:00:00","2020-04-22T00:00:00","2020-04-22T00:00:00","2020-05-04T00:00:00","","2020-05-06T00:00:00","Swedish Hospital, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04373161"
"346","NCT04359212","Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19","VTE-COVID","Not yet recruiting","No Results Available","COVID-19 Disease|Thromboembolism, Venous","Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux","the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism","Quovadis Associazione|Azienda Ospedaliera di Padova","All","18 Years and older","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VTE-COVID","2020-05-01T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-04-24T00:00:00","","2020-05-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04359212"
"347","NCT04361318","Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care","Number of patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","HCQ/NTZ","2020-05-01T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04361318"
"348","NCT04408066","COVID-19: A POC Test Under Research & Evaluation","CAPTURE","Recruiting","No Results Available","COVID-19","Diagnostic Test: Sample Collection/Performance Evaluation |Diagnostic Test: Sample Collection/Performance Evaluation","Performance of the LumiraDx Assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the SARS-COV-2 IgG/IgM and viral antigen in patient samples.","LumiraDx UK Limited","All","18 Years and older","Not Applicable","2000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","S-CLIN-PROT-00028","2020-04-30T00:00:00","2022-04-30T00:00:00","2022-04-30T00:00:00","2020-05-29T00:00:00","","2020-06-04T00:00:00","Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04408066"
"349","NCT04386369","Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS","APRV-COVID19","Completed","No Results Available","ARDS|COVID19","Other: Airway pressure release ventilation","Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV|Number of interventions on ventilator settings|Change in mean blood pressure|Change in heart rate|Changes in catecholamine doses|Changes in static compliance at the end of 6 hours of APRV|Variations of minute ventilation|Changes in static compliance 4 hours after stopping APRV|Proportion of patients with a decrease of the PaO2/FiO2 ratio","Central Hospital, Nancy, France","All","18 Years and older","","17","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020PI076","2020-04-15T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-05-13T00:00:00","","2020-06-11T00:00:00","Centre Hospitalier Regional Universitaire de Nancy, Nancy, France","","https://ClinicalTrials.gov/show/NCT04386369"
"350","NCT04355702","Covid-19 in Lupus Patients","","Recruiting","No Results Available","Systemic Lupus Erythematosus|Covid-19","","prevalence and severity of Covid-19 infection in patients with SLE|prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine","University Hospital, Montpellier","All","18 Years to 90 Years","","130","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0219","2020-03-01T00:00:00","2020-12-01T00:00:00","2020-12-30T00:00:00","2020-04-21T00:00:00","","2020-06-05T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04355702"
"351","NCT04513964","Impact of COVID-19 on the Benefit of Cardiac Rehabilitation","REACARDIOCOVID","Not yet recruiting","No Results Available","Heart Failure|Covid19","","Impact of COVID-19 on exercise capacity gain after cardiovascular rehabilitation","Groupe Hospitalier Paris Saint Joseph","All","18 Years and older","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","READCARDIOCOVID","2020-09-01T00:00:00","2020-12-31T00:00:00","2021-06-30T00:00:00","2020-08-14T00:00:00","","2020-08-14T00:00:00","Hôpital Corentin Celton, Issy-les-Moulineaux, France","","https://ClinicalTrials.gov/show/NCT04513964"
"352","NCT04379154","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2","VOC-COVID","Recruiting","No Results Available","COVID-19","Device: Volatile Organic Compounds analysis","Profiles of volatile organic compounds  in exhaled air between 2 health conditions|Profiles of volatile organic compounds  in exhaled air on 1 health condition|Profiles of volatile organic compounds  in exhaled air between 2 periods","Hopital Foch","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","2020_0060","2020-04-14T00:00:00","2020-10-01T00:00:00","2020-11-16T00:00:00","2020-05-07T00:00:00","","2020-07-14T00:00:00","Hôpital Foch, Suresnes, France","","https://ClinicalTrials.gov/show/NCT04379154"
"353","NCT04384497","Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","","Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska University Hospital|Karolinska Institutet","All","18 Years and older","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","CP2","2020-05-07T00:00:00","2020-06-01T00:00:00","2020-12-01T00:00:00","2020-05-12T00:00:00","","2020-05-27T00:00:00","Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT04384497"
"354","NCT04357496","COVID-19 Epidemic Response Study","COVeR","Not yet recruiting","No Results Available","Fever|Pneumonia|Cough","","Identification of prognostic parameters for SARS-CoV-2 infected participants.|Investigation of the kinetics of immune activation and antibody production against SARS-CoV-2 and correlation with clinical course","Centogene AG Rostock","All","60 Years and older","","400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVER-2020","2020-04-20T00:00:00","2020-10-30T00:00:00","2020-10-30T00:00:00","2020-04-22T00:00:00","","2020-04-22T00:00:00","","","https://ClinicalTrials.gov/show/NCT04357496"
"355","NCT04374903","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients","COVID19-HOPE","Not yet recruiting","No Results Available","COVID-19 Patients","Drug: HCQ & AZ vs HCQ+SIR","Time to Clinical improvement |Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance","King Hussein Cancer Center","All","18 Years and older","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","20 KHCC 74","2020-05-01T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-05-05T00:00:00","","2020-05-05T00:00:00","King Hussein Cancer Center, Amman, Jordan","","https://ClinicalTrials.gov/show/NCT04374903"
"356","NCT04382417","Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden","","Recruiting","No Results Available","Covid-19|Critical Illness","Other: Observational study","Demographic characteristics of patients with Covid-19 receiving intensive care|Survival rate in patients with Covid-19 receiving intensive care|Clinical course characteristics of patients with Covid-19 receiving intensive care|Number of days on mechanical ventilation","Region Västmanland","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RegionVastmanland","2020-03-26T00:00:00","2020-12-31T00:00:00","2021-05-31T00:00:00","2020-05-11T00:00:00","","2020-05-27T00:00:00","Intensive Care Unit, Västerås Hospital, Västerås, Västmanland, Sweden","","https://ClinicalTrials.gov/show/NCT04382417"
"357","NCT04371679","Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients","COVID-HO","Recruiting","No Results Available","Covid-19","Other: No interventions planned","Death  or discharge from ICU","Hasselt University","All","Child, Adult, Older Adult","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Covid-HO","2020-04-01T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","Jessa Hospital, Hasselt, Belgium","","https://ClinicalTrials.gov/show/NCT04371679"
"358","NCT04409899","The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department","UroCovid","Active, not recruiting","No Results Available","COVID-19|Urologic Diseases|Surgery--Complications|Epidemic Disease","Diagnostic Test: Blood tests","Rate of SARS-CoV-2/COVID-19 in a selected cohort of urological patients undergoing surgery|Post-operative COVID-19 related complication rates|Association between post-surgery inflammatory indexes and COVID-19 diagnosis during hospitalization","Fundacio Puigvert","All","Child, Adult, Older Adult","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FundacióPuigvert","2020-03-20T00:00:00","2020-06-30T00:00:00","2020-12-31T00:00:00","2020-06-01T00:00:00","","2020-07-21T00:00:00","Fundacio Puigvert, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04409899"
"359","NCT04363840","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations","LEAD COVID-19","Not yet recruiting","No Results Available","COVID|Vitamin D Deficiency|Coagulopathy|Disseminated Intravascular Coagulation","Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D","Hospitalization","Louisiana State University Health Sciences Center in New Orleans","All","18 Years and older","Phase 2","1080","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","20-063","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-27T00:00:00","","2020-04-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04363840"
"360","NCT04432779","Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children","ELIKYA COVID","Not yet recruiting","No Results Available","Pregnancy|Covid-19","Other: no intervention","Outcome of pregnancy|Prevalence of positive serology to SARS-CoV-2 at delivery|Transplacental transfer of antibodies to SARS-CoV-2|To characterize placental alterations related to SARS-CoV-2 infection|Presence of maternal antibodies to SARS-CoV-2 in breast milk in breastfeeding mothers|To characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life|Clinical evolution of the children","Centre Hospitalier Universitaire Saint Pierre|Institute for Medical Immunology |Laboratoire Hospitalier Universitaire de Bruxelles","All","Child, Adult, Older Adult","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Elikya Covid","2020-06-25T00:00:00","2024-06-01T00:00:00","2024-06-01T00:00:00","2020-06-16T00:00:00","","2020-06-22T00:00:00","CHU SAINT Pierre, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT04432779"
"361","NCT04491240","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.","COVID-19EXO","Enrolling by invitation","No Results Available","Covid19|SARS-CoV-2 PNEUMONIA|COVID-19","Procedure: EXO 1 inhalation|Procedure: EXO 2 inhalation|Procedure: Placebo inhalation","Number of participants with non-serious and serious adverse events during trial|Number of participants with non-serious and serious adverse during inhalation procedure|Time to clinical recovery |Blood gases changes|SpO2 concentration changes|Chest Imaging Changes","State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin","All","18 Years to 65 Years","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Other","COVID-19 EXO","2020-07-20T00:00:00","2020-12-01T00:00:00","2021-01-30T00:00:00","2020-07-29T00:00:00","","2020-08-04T00:00:00","Medical Centre Dinasty, Samara, Russian Federation","","https://ClinicalTrials.gov/show/NCT04491240"
"362","NCT04344002","LunG canceR pAtients coVId19 Disease","GRAVID","Recruiting","No Results Available","Covid-19|Lung Cancer","","Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors","Spanish Lung Cancer Group","All","Child, Adult, Older Adult","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Other","GECP 20/02_GRAVID","2020-04-21T00:00:00","2020-09-15T00:00:00","2020-12-15T00:00:00","2020-04-14T00:00:00","","2020-05-14T00:00:00","Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|H. Clínica Benidorm, Benidorm, Alicante, Spain|Hospital de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Cetir Centre Mèdic, Esplugues De Llobregat, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|H. Insular de Gran Canarias, Las Palmas De Gran Canaria, Gran Canarias, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Severo Ochoa, Leganes, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital de Manacor, Manacor, Mallorca, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Instituto Onkologikoa, San Sebastián, País Vasco, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|Hospital Universitario de La Ribera, Alzira, Valencia, Spain|Hospital de Manises, Manises, Valencia, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|H. Gen. Universitario Alicante, Alicante, Spain|H. Universitario Quirón Dexeus, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Mancha Centro, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitario de Puerto Real, Cádiz, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Santa María Naí, Ourense, Spain|Hospital Son Espases, Palma de Mallorca, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital universitario Nuestra Señora Candelaria, Tenerife, Spain|H. General U. de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Politècnic i Universitari La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|H. Miguel Servet, Zaragoza, Spain|Hospital Ntra. Sra. Sónsoles, Ávila, Spain|Hospital Universitario de Áraba, Vitoria, Áraba, Spain","","https://ClinicalTrials.gov/show/NCT04344002"
"363","NCT04333693","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Covid-VAS","Not yet recruiting","No Results Available","Vascular Surgical Procedures|COVID-19|Postoperative Complications","Procedure: Vascular surgery","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome |Postoperative sepsis","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","All","18 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-2020-1","2020-04-01T00:00:00","2020-10-01T00:00:00","2020-11-01T00:00:00","2020-04-03T00:00:00","","2020-04-03T00:00:00","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04333693"
"364","NCT04449965","Povidone-Iodine Rinses in the Management of COVID-19","","Not yet recruiting","No Results Available","Covid19","Drug: Povidone-iodine|Drug: Placebo","Change in SARS-CoV-2 positivity in the saliva|Change in the SAR-CoV-2 viral load in the saliva|Change in Wisconsin Upper Respiratory Symptom Survey |Change Sino nasal Outcome Test |Change in clinical condition","St. Paul's Hospital, Canada","All","19 Years and older","Early Phase 1","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","Betadine COVID-19","2020-07-01T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-06-29T00:00:00","","2020-06-29T00:00:00","","","https://ClinicalTrials.gov/show/NCT04449965"
"365","NCT04339608","Max COVID19- Study","","Recruiting","No Results Available","COVID-19","","COVID-19 positive case","Max Healthcare Insititute Limited","All","18 Years and older","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC/2020","2020-04-02T00:00:00","2020-05-30T00:00:00","2020-06-30T00:00:00","2020-04-09T00:00:00","","2020-04-09T00:00:00","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04339608"
"366","NCT04406324","COVID-19: Respiratory and Sleep Follow-up","Co-SURVIVORS","Recruiting","No Results Available","COVID-19","Other: No intervention","Diffusion Capacity for Carbon Monoxide  3 months after COVID diagnosis|Prevalence of Sleep Disordered Breathing  3 months after COVID diagnosis|Prevalence of sleep disorders 3 months after COVID diagnosis|Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis|Prevalence of cardiac impairments 3 months after COVID diagnosis|Follow-up of pulmonary diffusion capacity of carbon monoxide|Follow-up of sleep disorders treatment compliance|Follow-up of sleep disorders treatments efficacy|HLA alleles aspect of COVID clinical presentation|KIR loci aspect of COVID clinical presentation|metabolomic aspect of COVID clinical presentation","University Hospital, Grenoble","All","18 Years and older","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.157","2020-06-01T00:00:00","2021-03-05T00:00:00","2026-03-05T00:00:00","2020-05-28T00:00:00","","2020-06-30T00:00:00","Hôpital Avicenne, Bobigny, France|Centre Hospitalier Henri Mondor, APHP, Creteil, France|CHU Grenoble Alpes, Grenoble, France|CHRU Nancy, Nancy, France","","https://ClinicalTrials.gov/show/NCT04406324"
"367","NCT04420741","Infusion of Prostacyclin  vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","COMBAT-COVID","Recruiting","No Results Available","COVID-19|Respiratory Failure","Drug: Iloprost|Drug: Isotonic saline","Mechanical ventilation free days|28 and 90-day mortality|Modified Sequential Organ Failure Assessment |Vasopressor free days|Renal replacement free days|Serious adverse reactions |Serious adverse events","Pär Johansson|Rigshospitalet, Denmark","All","18 Years and older","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","COMBAT-COVID-19|2020-001296-33","2020-06-15T00:00:00","2021-05-31T00:00:00","2021-05-31T00:00:00","2020-06-09T00:00:00","","2020-07-13T00:00:00","Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark","","https://ClinicalTrials.gov/show/NCT04420741"
"368","NCT04341506","Non-contact ECG Sensor System for COVID19","","Not yet recruiting","No Results Available","COVID-19","Device: Non-contact ECG","ECG changes associated with COVID-19","Northwestern Medicine","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0407","2020-04-15T00:00:00","2020-07-15T00:00:00","2020-09-15T00:00:00","2020-04-10T00:00:00","","2020-04-10T00:00:00","","","https://ClinicalTrials.gov/show/NCT04341506"
"369","NCT04383444","Surveillance of Individuals Following SARS-CoV-2 Exposure","","Recruiting","No Results Available","COVID-19","","Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture|SARS-CoV-2 culture and RT-PCR results|Symptom checklist","National Institute of Allergy and Infectious Diseases |National Institutes of Health Clinical Center","All","18 Years and older","","1050","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200117|20-I-0117","2020-07-07T00:00:00","2023-08-01T00:00:00","2023-08-01T00:00:00","2020-05-12T00:00:00","","2020-08-04T00:00:00","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04383444"
"370","NCT04313946","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","AI-COVID-Xr","Recruiting","No Results Available","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Professor Adrian Covic|Falcon Trading Iasi|Romanian Academy of Medical Sciences|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult","","200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","0110","2020-03-18T00:00:00","2020-08-16T00:00:00","2020-08-18T00:00:00","2020-03-18T00:00:00","","2020-04-27T00:00:00","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04313946"
"371","NCT04390178","Convalescent Plasma as Treatment for Acute Coronavirus Disease","","Active, not recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Disease progression|Adverse events |Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska Institutet|Karolinska University Hospital","All","18 Years to 80 Years","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","CP1","2020-04-10T00:00:00","2020-06-01T00:00:00","2020-12-01T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","Danderyd Hospital, Danderyd, Sweden","","https://ClinicalTrials.gov/show/NCT04390178"
"372","NCT04425915","Efficacy of Convalescent Plasma Therapy in Patients With COVID-19","","Recruiting","No Results Available","COVID","Biological: Convalescent Plasma|Other: Standard of Care","Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement |Proportion of patients in each category according to the ordinal scale|Duration of oxygen therapy in both groups|Duration of hospital stay in both groups|Proportion of patients on mechanical ventilation at day 7 in both groups|Mortality in both groups|Duration of Intensive Care Unit stay|Incidence of adverse effects in both groups|Presence of antibodies against SARS-CoV-2 in serum after plasma administration|Change in Cytokines in both groups|Change in acute phase reactants in both groups|Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.","Institute of Liver and Biliary Sciences, India","All","18 Years and older","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ILBS-COVID-04","2020-06-09T00:00:00","2021-05-30T00:00:00","2021-05-30T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Maulana Azad Medical College, New Delhi, Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, Delhi, India|Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04425915"
"373","NCT04506268","COVID-19 SAFE Enrollment","COVID SAFE","Not yet recruiting","No Results Available","Covid19","Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email","Proportion Enrolled|Participant Age|Participant Sex|Participant Race/Ethnicity|Participant Income|Participant Education|Test Completion","University of Pennsylvania","All","18 Years and older","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Screening","843565","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-08-10T00:00:00","","2020-08-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04506268"
"374","NCT04361604","Clinical Characterisation Protocol for COVID-19 in People Living With HIV","COVIDHIV","Not yet recruiting","No Results Available","Adult Patients Living With HIV  With Confirmed Infection With SARS-CoV-2 Since 1st January 2020","Biological: Biological collection |Other: Auto-questionnaires |Other: Qualitative interviews","Describe the course of COVID-19 disease in patients infected with HIV,","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","270","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-A00984-35","2020-04-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Department of Internal Medicine and Clinical Immunology of Professor Cecile Goujard, Le Kremlin-Bicêtre, France","","https://ClinicalTrials.gov/show/NCT04361604"
"375","NCT04395599","Risk of Air Contamination During Visceral Surgery in COVID19 Patients","COELIOCOVID","Not yet recruiting","No Results Available","Sars-CoV2|Surgery|COVID","Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.","Air contamination|Environment contamination|Surgical approach|Opening of the digestive tract|Biological fluids|Pneumoperitoneum","University Hospital, Lille","All","18 Years and older","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","2020_44|2020-A01461-38","2020-05-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-05-20T00:00:00","","2020-05-20T00:00:00","","","https://ClinicalTrials.gov/show/NCT04395599"
"376","NCT04340050","COVID-19 Convalescent Plasma","","Active, not recruiting","No Results Available","Coronavirus","Biological: anti-SARS-CoV-2 convalescent plasma","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival","University of Chicago","All","18 Years and older","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","IRB20-0523","2020-04-10T00:00:00","2020-12-31T00:00:00","2021-12-31T00:00:00","2020-04-09T00:00:00","","2020-05-14T00:00:00","University of Chicago Medicine, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04340050"
"377","NCT04359303","Indirect Endovenous Systemic Ozone for New Coronavirus Disease  in Non-intubated Patients","OzonoCOVID19","Not yet recruiting","No Results Available","COVID","Other: Systemic indirect endovenous ozone therapy","COVID19 clinical scale|Number of died patients|Oro/nasopharynx virus|Thorax imaging |Days in hospital|Venous gas blood analysis","Javier Hidalgo Tallón|Sociedad Española de Ozonoterapia|Universidad Católica San Antonio de Murcia","All","18 Years and older","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double |Primary Purpose: Treatment","P.Inv. Ozono-COVID19 Ver.1.2","2020-07-01T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-04-24T00:00:00","","2020-06-23T00:00:00","SEOT, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT04359303"
"378","NCT04337762","Beat COVID-19 - Observational Trial","JUPITER","Recruiting","No Results Available","COVID-19","","Health Outcomes","Beat COVID LLC","All","18 Years to 110 Years","","100000","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200835","2020-04-06T00:00:00","2020-12-01T00:00:00","2021-07-01T00:00:00","2020-04-08T00:00:00","","2020-04-09T00:00:00","Beat COIVD, LLC, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04337762"
"379","NCT04422574","COVID 19 Serology in Pulmonologists","Pneumoserocov","Completed","No Results Available","Covid 19","","covid 19 serology|risk factors for positive serology testing","University Hospital, Montpellier","All","18 Years and older","","97","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","RECHMPL20_0343","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-05-30T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","Uh Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04422574"
"380","NCT04435587","Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs  Among Asymptomatic COVID-19 Infection","IDRA-COVID19","Not yet recruiting","No Results Available","Asymptomatic Infections|SARS-CoV2 Infection","Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine","Adverse event rates|Efficacy for shortening duration of SAR-CoV2 detection by PCR|Antibody detection rates","Mahidol University","All","18 Years and older","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","323/2563","2020-07-01T00:00:00","2021-06-01T00:00:00","2021-11-01T00:00:00","2020-06-17T00:00:00","","2020-06-23T00:00:00","Siriraj Hospital, Bangkok Noi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT04435587"
"381","NCT04335747","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","","Recruiting","No Results Available","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","Other: COVID-19 infection","Disease activity|Immune modulating treatments|Biomarkers","Salome Kristensen|Aalborg University Hospital","All","18 Years and older","","333","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200401","2020-04-23T00:00:00","2021-08-01T00:00:00","2021-09-01T00:00:00","2020-04-06T00:00:00","","2020-05-29T00:00:00","Aalborg University Hospital, Aalborg, Denmark","","https://ClinicalTrials.gov/show/NCT04335747"
"382","NCT04402892","COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells","MEMO-COV2","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time |Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time","Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Basic Science","APHP200551","2020-06-01T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-05-27T00:00:00","","2020-05-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04402892"
"383","NCT04501458","Western Kenya Integrated COVID-19 Response","","Recruiting","No Results Available","Covid19","Other: Training of youth, community health assistants and community health workers.|Other: Training clinicians in basic critical care and the management of severe COVID-19 cases","Mortality","Surgical Systems Research Group|Wellcome Trust|Tropical Institute of Community Health","All","18 Years to 100 Years","Not Applicable","200000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Prevention","001","2020-05-18T00:00:00","2020-08-19T00:00:00","2020-08-19T00:00:00","2020-08-06T00:00:00","","2020-08-11T00:00:00","Surgical Systems Research Group/Tropical Institute of Community Health, Kisumu, Kenya","","https://ClinicalTrials.gov/show/NCT04501458"
"384","NCT04448119","Control of COVID-19 Outbreaks in Long Term Care","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Favipiravir|Drug: Favipiravir Placebo","Control of Outbreak|Mortality |COVID-19 Infection |COVID-19 Infection |Hospitalization |Medication Discontinuation |Medication Discontinuation |COVID-19 in new LTCH Units |COVID-19 in new LTCH Units |COVID-19 in new LTCH Units","Appili Therapeutics Inc.|MOUNT SINAI HOSPITAL|Applied Health Research Centre|Sunnybrook Health Sciences Centre|University Health Network, Toronto|University of Toronto","All","65 Years and older","Phase 2","760","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","CONTROL-COVID-Favipiravir-1","2020-06-01T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-06-25T00:00:00","","2020-06-25T00:00:00","","","https://ClinicalTrials.gov/show/NCT04448119"
"385","NCT04369820","C5a Receptor Expression - COVID-19","C5-COV","Recruiting","No Results Available","COVID-19","Other: draw blood","Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients .","Assistance Publique Hopitaux De Marseille|Innate Pharma","All","18 Years and older","Not Applicable","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","2020-14|IDRCB","2020-03-31T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-04-30T00:00:00","","2020-05-04T00:00:00","Assistance Publique Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT04369820"
"386","NCT04380896","COVID-19 Staff Testing of Antibody Responses Study","Co-Stars","Recruiting","No Results Available","SARS-CoV-2 Infection","Other: Blood test|Other: Standardised questionnaires","Change in serial monthly log-transformed antibody titre levels as measured|Proportion of completely asymptomatic healthcare workers with evidence of SARS-CoV-2 antibodies|The attack rate of SARS-CoV-2 in healthcare workers who have antibodies compared to those who do not|The immune correlates of protection against future exposure to SARS-CoV-2","Great Ormond Street Hospital for Children NHS Foundation Trust","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20CB17","2020-04-27T00:00:00","2026-07-27T00:00:00","2026-07-27T00:00:00","2020-05-08T00:00:00","","2020-05-15T00:00:00","Great Ormond Street Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04380896"
"387","NCT04365985","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","SINK COVID-19","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome |Coronavirus Infections","Drug: Naltrexone|Drug: Ketamine|Other: Placebo","Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit  admission|Intensive Care Unit  duration|Intubation|Intubation duration|Time until recovery","William Beaumont Hospitals","All","18 Years and older","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple |Primary Purpose: Treatment","2020-097","2020-04-29T00:00:00","2021-05-01T00:00:00","2021-08-01T00:00:00","2020-04-28T00:00:00","","2020-07-02T00:00:00","William Beaumont Hospital, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT04365985"
"388","NCT04383626","Fear Among Dentists During COVID-19 Pandemic","","Completed","No Results Available","COVID","","fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic","Cairo University","All","20 Years and older","","216","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19 pandemic","2020-03-02T00:00:00","2020-04-05T00:00:00","2020-05-05T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04383626"
"389","NCT04369859","Obstetric and Perinatal Outcomes of Women With COVID-19","GROCO","Recruiting","No Results Available","Pregnant Women","Behavioral: Examine the impact of COVID-19 during pregnancy","Compare the complications rates|Clinical presentation","Assistance Publique Hopitaux De Marseille","Female","18 Years and older","","1300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-18|ID RCB","2020-04-23T00:00:00","2021-04-22T00:00:00","2021-04-22T00:00:00","2020-04-30T00:00:00","","2020-05-04T00:00:00","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France","","https://ClinicalTrials.gov/show/NCT04369859"
"390","NCT04412746","Covid-19 and Diabetes in West of Algeria","COVIDIAB-13","Recruiting","No Results Available","Coronavirus Infections|Diabetes Mellitus|Prevalence|Risk Factors|Patient Outcome Assessment|Severe Acute Respiratory Syndrome","Drug: MANAGEMENT OF COVID-19","Prevalence of diabetes among all hospitalized COVID-19|Diabetes-related factors risk","Laboratoire De Recherche Sur Le Diabete, Universite de Tlemcen|ATRSS, DGRST, Algeria","All","16 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDIAB-13","2020-04-01T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","Department of Internal Medicine, Acedemic Hospital of Tlemcen, Tlemcen, Algeria","","https://ClinicalTrials.gov/show/NCT04412746"
"391","NCT04434118","Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients","","Enrolling by invitation","No Results Available","Rheumatoid Arthritis|COVID","Drug: Traditional antirheumatic drugs","The risk of COVID-19 infection among RA patients|The incidence of hospitalization for Covid-19 patients.","Sadat City University","All","18 Years to 60 Years","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","IRB: RC-5-2020","2020-03-20T00:00:00","2020-06-30T00:00:00","2020-07-30T00:00:00","2020-06-16T00:00:00","","2020-07-15T00:00:00","Faculty of Medicine, Shibīn Al Kawm, Egypt","","https://ClinicalTrials.gov/show/NCT04434118"
"392","NCT04425889","COVID-19 Antibodies Among Healthcare Workers","","Completed","No Results Available","COVID-19|SARS-CoV 2","Diagnostic Test: COVID-19 IgG/IgM Rapid Test Cassette test","Presence of antibody","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years to 99 Years","","156","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IF20-00008","2020-05-05T00:00:00","2020-05-30T00:00:00","2020-06-01T00:00:00","2020-06-11T00:00:00","","2020-06-12T00:00:00","Hospital Universitario Jose E. Gonzalez, Monterrey, Nuevo Leon, Mexico","","https://ClinicalTrials.gov/show/NCT04425889"
"393","NCT04497441","Netizens' Perception of COVID-19 Information & Information Sources.","","Recruiting","No Results Available","Covid19|Information Seeking Behavior|Social Media|Perception, Self","Other: Electronic Survey questionnaire","Netizens' perception of the Sources of COVID-19 information|Netizens' perception on COVID-19 information|Correlation of Age and the Frequency of checking COVID-19 information updates|Correlation of Gender and the Frequency of checking COVID-19 information updates|Correlation of Age and the perception of newly infected COVID-19 cases information update|Correlation of Age and the perception of COVID-19 deaths information update|Correlation of Age and the perception of COVID-19 Vaccine information update|Correlation of Age and the perception of COVID-19 treatment medicines/drugs information update","Qassim University","All","19 Years and older","","385","Other","Observational","Observational Model: Other|Time Perspective: Prospective","QassimU3","2020-06-10T00:00:00","2020-08-10T00:00:00","2020-08-15T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04497441"
"394","NCT04395872","Psychiatric Consultation for COVID-19 Patients","","Not yet recruiting","No Results Available","Covid19|Psychiatric Problem|Isolation, Social","Behavioral: Psychiatric counseling","Change of PHQ-9 |Change of GAD-7 |Change of PC-PTSD-5 |Change of AIS |Change of P4 |Change of SF-36 |Change of SCL-90-R","Daegu Catholic University Medical Center","All","Child, Adult, Older Adult","","54","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CR-20-062","2020-05-28T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-05-20T00:00:00","","2020-05-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04395872"
"395","NCT04389294","HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists","","Recruiting","No Results Available","COVID","Diagnostic Test: SARS-CoV2 serum antibody testing","Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation","Hospital for Special Surgery, New York","All","21 Years and older","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Health Services Research","2020-0850","2020-05-05T00:00:00","2020-09-30T00:00:00","2020-10-30T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","Hospital for Special Surgery, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04389294"
"396","NCT04364802","COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","PIIPPI","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Povidone-Iodine Nasal Spray and Gargle","Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort","Alexandra Kejner|University of Kentucky","All","18 Years to 99 Years","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","58748","2020-04-29T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-04-28T00:00:00","","2020-05-14T00:00:00","University of Kentucky, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT04364802"
"397","NCT04372056","The COVID-ICU Healthcare Professional Study","","Recruiting","No Results Available","COVID-19|Critical Care|Intensive Care Units|Health Personnel","Behavioral: Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic","Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic","Oslo University Hospital","All","20 Years and older","","2200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","136144","2020-05-06T00:00:00","2021-05-06T00:00:00","2021-05-06T00:00:00","2020-05-01T00:00:00","","2020-05-08T00:00:00","Oslo university hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT04372056"
"398","NCT04389515","Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19","","Recruiting","No Results Available","COVID-19|Prenatal Care|Postoperative Care","","Evaluation of pregnant women diagnosed with COVID-19 with ""Post-operative Recovery Index"" and ""Prenatal Care Satisfaction and Patient Expectations Scale""","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years","","75","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","MTalmac3","2020-05-14T00:00:00","2020-08-01T00:00:00","2020-08-03T00:00:00","2020-05-15T00:00:00","","2020-06-11T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey","","https://ClinicalTrials.gov/show/NCT04389515"
"399","NCT04491994","Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","COVID-19","Completed","No Results Available","Covid19|Progression","Drug: HCQ","Progression|Viral clearance","UNICEF|Pak Emirates Military Hospital Rawalpindi","All","18 Years to 80 Years","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Sultan Mehmood Kamran 2","2020-04-10T00:00:00","2020-05-31T00:00:00","2020-05-31T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan","","https://ClinicalTrials.gov/show/NCT04491994"
"400","NCT04501822","One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia","","Recruiting","No Results Available","Covid19|Cardiac Complication","Diagnostic Test: Evaluation of clinical, instrumental and laboratory diagnostics tests","Echocardiographic assessment of cardiac function|МАССЕ|Quantitative analysis of parenchymal lung damage|Functional exercises capacity assessment|Evaluation of renal function|Evaluation of inflammation|Evaluation of coagulation abnormality|Evaluation of quality of life in first year after discharge","Tomsk National Research Medical Center of the Russian Academy of Sciences","All","18 Years and older","","380","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TCRC-COVID","2020-07-19T00:00:00","2021-07-19T00:00:00","2021-12-31T00:00:00","2020-08-06T00:00:00","","2020-08-06T00:00:00","Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04501822/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04501822"
"401","NCT04405271","TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers","","Not yet recruiting","No Results Available","Healthcare Workers|COVID-19|SARS-CoV 2","Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo","COVID-19 incident cases|Number of asymptomatic SARS-CoV-2  infections confirmed by serology|Severity of symptomatic COVID-19|Respiratory symptom duration in days|Relation between treatments and symptoms duration|Time course of specific IgM/IgG seroconversion","Hospital Italiano de Buenos Aires|Sociedad Argentina de Infectología","All","18 Years and older","Phase 3","1378","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","5616","2020-07-31T00:00:00","2020-11-15T00:00:00","2020-11-15T00:00:00","2020-05-28T00:00:00","","2020-07-28T00:00:00","Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina","","https://ClinicalTrials.gov/show/NCT04405271"
"402","NCT04460638","SARS-CoV2  Diagnosis in Human Saliva by MALDI-TOF MS Profiling","CoviDiagMS","Recruiting","No Results Available","SARS-CoV 2","Biological: Saliva collection|Other: Clinical assessment","Development of a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.|Rate of correct classification by the test  from saliva sample|Rate of correct classification by RT-PCR from saliva sample|Identification of proteins specific to the SARS-CoV2 infection|Presence of a positive anti-SARS-CoV2 antibody response by RT-PCR|Correlation between the identified protein markers and the clinical course of the participants.","Direction Centrale du Service de Sante des Armees","All","18 Years and older","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-15","2020-07-23T00:00:00","2022-07-01T00:00:00","2022-07-01T00:00:00","2020-07-07T00:00:00","","2020-08-17T00:00:00","Hôpital d'Instruction des Armees Laveran, Marseille, France","","https://ClinicalTrials.gov/show/NCT04460638"
"403","NCT04338360","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","","Available","No Results Available","COVID19","Biological: COVID-19 convalescent plasma","","Mayo Clinic","All","18 Years and older","","","Other","Expanded Access:Intermediate-size Population","","20-003312","","","","2020-04-08T00:00:00","","2020-04-08T00:00:00","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04338360"
"404","NCT04418206","Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19","EliSpot","Not yet recruiting","No Results Available","Covid 19","Other: patients COVID 19","IgA specific cells of SARS|OMS progression scale","Centre Hospitalier Universitaire de Nice","All","18 Years and older","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","20-PP-10","2020-06-01T00:00:00","2020-12-01T00:00:00","2021-06-01T00:00:00","2020-06-05T00:00:00","","2020-06-05T00:00:00","CH Antibes, Antibes, Alpes Maritimes, France|Ch Cannes, Pneumologie, Cannes, Alpes Maritimes, France|Ch Grasse, Grasse, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France","","https://ClinicalTrials.gov/show/NCT04418206"
"405","NCT04323800","Convalescent Plasma to Stem Coronavirus","CSSC-001","Recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Efficacy of treatment at Day 28|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2|Cumulative incidence of disease severity","Johns Hopkins University","All","18 Years and older","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","IRB00245634","2020-06-10T00:00:00","2022-12-31T00:00:00","2023-01-01T00:00:00","2020-03-27T00:00:00","","2020-08-17T00:00:00","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|JHSPH Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity , Providence, Rhode Island, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT04323800"
"406","NCT04463849","Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients","COBETOX","Recruiting","No Results Available","COVID19|BETA-CELL FUNCTION","Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection","Serum β - cellular function index insulin levels|Serum β - cellular function index C-peptide levels|Serum β - cellular function HOMA-β index|Serum β - cellular function pro-insulin/insulin ratio|Evaluation of the secretory response of insulin to the arginine stimulation test|Viral SARS-CoV-2 particles in β cells|Percentage of patients with preserved β cells function|Glucose values|Values of continuous glucose monitoring|Changes in the inflammatory marker interleukin 1-β|Changes in the inflammatory marker interleukin IL-2|Changes in the inflammatory marker interleukin IL-6|Changes in the inflammatory marker interleukin IL-7|Changes in the inflammatory marker interleukin IL-10|Changes in the inflammatory marker tumor necrosis factor-α|Changes in the inflammatory marker interferon gamma|Changes in the inflammatory marker macrophage inflammatory protein-1β|Changes in the inflammatory marker monocyte chemoattractant protein-1|Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor|Changes in the inflammatory marker granulocyte colony-stimulating factor","University of Milan|Luigi Sacco University Hospital","All","18 Years to 80 Years","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","6/2020","2020-06-30T00:00:00","2020-12-30T00:00:00","2021-06-30T00:00:00","2020-07-09T00:00:00","","2020-07-09T00:00:00","Sacco University Hospital, Milan, MI, Italy","","https://ClinicalTrials.gov/show/NCT04463849"
"407","NCT04416893","Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE2","Not yet recruiting","No Results Available","COVID19","Diagnostic Test: RT-PCR SARS-Cov2|Diagnostic Test: Sars-Cov2 serology","Proportion of asymptomatic children or children with mild respiratory symptoms|Cov2-SARS cases by age|Cov2-SARS cases by symptoms|Viral load|Presence of anti-SARS-CoV-2 antibodies  by the rapid serological test","Centre Hospitalier Intercommunal Creteil|Association Clinique Therapeutique Infantile du val de Marne|GPIP|GFRUP","All","up to 15 Years","","630","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVILLE2","2020-06-07T00:00:00","2020-09-15T00:00:00","2020-11-15T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04416893"
"408","NCT04384055","Predicting Outcomes for Covid-19 Using Sonography","POCUS","Enrolling by invitation","No Results Available","COVID-19|Pneumonia, Viral","Diagnostic Test: Lung Ultrasound","Number of Patients Experiencing Death, ICU Admission, Mechanical Ventilation, or Use of High-Flow Nasal Cannula|Number of Patients Requiring Mechanical Ventilation|Number of Patients Requiring Supplemental Oxygen Usage|Duration of Supplemental Oxygen Usage|Length of Stay|Characterization of Ultrasound Findings","Stanford University","All","18 Years and older","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB-55621","2020-03-21T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-05-12T00:00:00","","2020-06-26T00:00:00","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT04384055"
"409","NCT04389658","Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population","CONDITION","Recruiting","No Results Available","COVID-19","","Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized  population|Description of demographic characteristics","Igenomix","All","Child, Adult, Older Adult","","1000","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","IGX1-COV-XS-20-01","2020-05-07T00:00:00","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-05-15T00:00:00","","2020-05-18T00:00:00","Igenomix, Paterna, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT04389658"
"410","NCT04389944","Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19","","Completed","No Results Available","Coronavirus Disease 2019 Infectious Disease","Other: convalescent plasma application to SARS-CoV-2 infected patients","Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response","University Hospital, Basel, Switzerland","All","18 Years and older","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","Req-2020-00508; me20khanna2","2020-03-31T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-05-15T00:00:00","","2020-08-04T00:00:00","Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT04389944"
"411","NCT04364022","Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland","COPEP","Recruiting","No Results Available","Prevention of COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Lopinavir/ritonavir","21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline  analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline |21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline |Severity of clinical COVID-19 on a 7-point ordinal scale","Calmy Alexandra|University Hospital, Geneva","All","18 Years and older","Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","CCER 2020-00864","2020-04-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-04-27T00:00:00","","2020-04-27T00:00:00","Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland","","https://ClinicalTrials.gov/show/NCT04364022"
"412","NCT04362943","Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults","COVID-AGE","Recruiting","No Results Available","COVID-19","Drug: Baricitinib or Anakinra","Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes","Complejo Hospitalario Universitario de Albacete","All","70 Years and older","","576","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","PAS-BAR-2020-04","2020-04-20T00:00:00","2020-05-15T00:00:00","2020-07-31T00:00:00","2020-04-27T00:00:00","","2020-04-27T00:00:00","Complejo Hospitalario Universitario de Albacete, Albacete, Spain","","https://ClinicalTrials.gov/show/NCT04362943"
"413","NCT04438239","Rehabilitation Needs After COVID-19 Hospital Treatment","REACT","Recruiting","No Results Available","Covid-19","Other: none, this study is observational","number of participants with considerable dyspnea: Medical Research Council |number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in B-ADL|level of participation in social|description of qualitative data about patients' experience","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","428/2020/OSS/AUSLRE","2020-06-30T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-06-18T00:00:00","","2020-07-13T00:00:00","Azienda USL-IRCCS S.Maria Nuova Hospital, Reggio Emilia, Italy","","https://ClinicalTrials.gov/show/NCT04438239"
"414","NCT04355338","Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil","AVISA","Not yet recruiting","No Results Available","COVID-19","","Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies|Previous SARS-CoV-2 infection","Butantan Institute","All","Child, Adult, Older Adult","","4100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV-01-IB","2020-05-15T00:00:00","2020-11-30T00:00:00","2022-05-15T00:00:00","2020-04-21T00:00:00","","2020-04-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04355338"
"415","NCT04471766","Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention","","Enrolling by invitation","No Results Available","COVID-19|Respiratory Illness","Other: Certified cloth face mask plus preventive information|Behavioral: Preventive information","Reported COVID-like illness|Consultation|Severe illness|Mortality","Bandim Health Project|University of Southern Denmark|Engineers without Borders, Denmark","All","10 Years and older","Not Applicable","66000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","BHP MASK01","2020-07-20T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-07-15T00:00:00","","2020-07-22T00:00:00","Bandim Health Project, Bissau, Bissau Codex, Guinea-Bissau","","https://ClinicalTrials.gov/show/NCT04471766"
"416","NCT04368871","Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study","","Recruiting","No Results Available","COVID","","Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study","Max Healthcare Insititute Limited","All","18 Years to 75 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/RFTC/MHC/2020","2020-04-28T00:00:00","2020-06-30T00:00:00","2021-05-30T00:00:00","2020-04-30T00:00:00","","2020-06-09T00:00:00","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, India","","https://ClinicalTrials.gov/show/NCT04368871"
"417","NCT04370808","VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection","VITACOV","Not yet recruiting","No Results Available","COVID-19","Other: Exposure","Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.","University of Lisbon|Cardiovascular Centre of Universidade de Lisboa |Faculty of Medicine of Universidade de Lisboa |Centro Hospitalar Universitário Lisboa Norte |Centro Hospitalar Universitário São João |CINTESIS - Center for Health Technology and Services Research|NOVA Medical School of Universidade NOVA de Lisboa|HeartGenetics, Genetics and Biotechnology SA|Instituto Gulbenkian de Ciência","All","18 Years and older","","500","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VITACOV","2020-06-01T00:00:00","2020-10-01T00:00:00","2021-03-01T00:00:00","2020-05-01T00:00:00","","2020-05-19T00:00:00","Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de São João, Oporto, Portugal","","https://ClinicalTrials.gov/show/NCT04370808"
"418","NCT04424446","Saliva as Source of Detection for SARS-CoV-2","","Recruiting","No Results Available","COVID-19","","Saliva SARS-CoV-2 RT-PCR test results|Saliva and midturbinate swab SARS-CoV-2 RT-PCR test results","National Institutes of Health Clinical Center","All","18 Years and older","","5000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200128|20-CC-0128","2020-07-13T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-06-11T00:00:00","","2020-08-12T00:00:00","Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04424446"
"419","NCT04394026","Imaging Feature of SARS-CoV2 Infection","COVID19IF","Recruiting","No Results Available","Viral Pneumonia|COVID","","Describe qualitative and quantitative variables|Ability of imaging to predict disease progression|Ability of imaging to predict disease evolution|Imaging findings and demographic data|Imaging findings and laboratory exams","Francesco De Cobelli|IRCCS San Raffaele","All","Child, Adult, Older Adult","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","COVID-19 IF","2020-04-16T00:00:00","2020-08-31T00:00:00","2020-10-01T00:00:00","2020-05-19T00:00:00","","2020-05-19T00:00:00","Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy","","https://ClinicalTrials.gov/show/NCT04394026"
"420","NCT04322682","Colchicine Coronavirus SARS-CoV2 Trial","COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Colchicine|Drug: Placebo oral tablet","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Montreal Heart Institute|National Heart, Lung, and Blood Institute |Bill and Melinda Gates Foundation|The Government of Quebec|DACIMA Software","All","40 Years and older","Phase 3","6000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","MHIPS-2020-001|3R01HL146206-02S1","2020-03-23T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-03-26T00:00:00","","2020-08-03T00:00:00","University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04322682"
"421","NCT04405934","COG-UK Project Hospital-Onset COVID-19 Infections Study","COG-UK HOCI","Not yet recruiting","No Results Available","Covid-19|Nosocomial Infection|Coronavirus|Coronavirus Infection|SARS-CoV 2","Other: Use of virus  genome sequence report to inform infection prevention control procedures","Incidence rates of IPC-defined hospital-onset COVID-19 infection |Change in incidence rates of IPC-defined HOCIs with rapid vs standard sequencing|Incidence rates of IPC-defined hospital outbreaks|Incidence rates of IPC+sequencing-defined hospital outbreaks|Changes to IPC actions following viral sequence reports|Recommended changes to IPC actions following viral sequence report - not implemented|Health economic benefit to IPC of standard vs rapid sequencing reports|Impact of both standard and rapid sequencing reports on number of HCW days off work","University College, London|Public Health England","All","Child, Adult, Older Adult","Not Applicable","2000","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Health Services Research","CTU/2020/353|283014|20/EE/0118","2020-07-01T00:00:00","2020-10-01T00:00:00","2021-04-01T00:00:00","2020-05-28T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04405934"
"422","NCT04402853","SARS Cov-2 in Conjunctival Secretion","","Completed","No Results Available","Sars-CoV2|Tear","Diagnostic Test: Tears swab","Virus presence in COVID 19 patients tears|Concordance to Naso-Pharingeal Swab","Università degli Studi dell'Insubria","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","72/2020","2020-02-01T00:00:00","2020-03-01T00:00:00","2020-05-20T00:00:00","2020-05-27T00:00:00","","2020-05-27T00:00:00","ASST Sette Laghi, Varese, Italy","","https://ClinicalTrials.gov/show/NCT04402853"
"423","NCT04387760","Favipiravir vs Hydroxychloroquine in COVID -19","","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients","Primary outcome measure will be time to viral clearance|Requirement of Escalation of Respiratory Support|Adverse effects)|Requirement of ICU Admission|Mortality rate|Serum lactate measurement|Serum Ferritin measurement|Serum D Dimer measurement|Ratio of Lymphocyte to Neutrophil, measurement|Discharge and Length of Hospital Stay|Readmission Rate|Daily Sequential Organ Failure Assessment  score|Daily National Early Warning Score  2 score|Clinical improvement|QT prolongation|Cardiac arrythmia","Royal College of Surgeons in Ireland - Medical University of Bahrain|Ebrahim Khalil Kanoo Community Medical Center|Hereditary blood Disorder Centre - Salmaniya Medical Complex|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali|Jidhafs COVID-19 Centre|Sitra FICU","All","21 Years and older","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","40 / 07-May-2020","2020-08-11T00:00:00","2021-04-14T00:00:00","2021-05-14T00:00:00","2020-05-14T00:00:00","","2020-08-18T00:00:00","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain","","https://ClinicalTrials.gov/show/NCT04387760"
"424","NCT04513158","Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2  Infection","","Not yet recruiting","No Results Available","Covid19","Biological: Convalescent Plasma","Determine the therapeutic efficacy  of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 .|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count |reatinine kinase |C-reactive protein |D-Dimer |Interleukin-6 |Ferritin","Joseph M. Flynn, D.O., MPH|Norton Healthcare","All","18 Years to 99 Years","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-N0124","2020-08-20T00:00:00","2021-08-01T00:00:00","2021-12-31T00:00:00","2020-08-14T00:00:00","","2020-08-14T00:00:00","Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT04513158"
"425","NCT04357639","Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19","","Recruiting","No Results Available","HIV Patients","Other: No intervention","Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor|Determination of the seroprevalence of COVID-19 infection in both groups of the study|Comparison of the severity of COVID-19 infection symptoms in both groups of the study.|Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor","Centre Hospitalier Intercommunal Creteil|Centre Hospitalier Intercommunal Villeneuve St Georges","All","18 Years and older","","1040","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIP","2020-05-28T00:00:00","2021-01-31T00:00:00","2021-07-31T00:00:00","2020-04-22T00:00:00","","2020-07-21T00:00:00","CHI Creteil, Creteil, France|CHU Henri Mondor, Creteil, France|Centre hospitalier de Melun , Melun, France|CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France","","https://ClinicalTrials.gov/show/NCT04357639"
"426","NCT04388670","Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19","2019nCoV_ICU","Recruiting","No Results Available","COVID-19|Critical Illness","","Overall number and characteristics of patients with COVID-19 in ICU","Policlinico Hospital","All","18 Years and older","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PoliclinicoH","2020-02-22T00:00:00","2020-08-22T00:00:00","2020-08-31T00:00:00","2020-05-14T00:00:00","","2020-05-14T00:00:00","Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico, Milan, Italy","","https://ClinicalTrials.gov/show/NCT04388670"
"427","NCT04503447","COVID-19 Seroprevalence Study in ITM Staff","CovAb","Recruiting","No Results Available","Covid19","","SARS-CoV-2 seroprevalence ITM staff|SARS-CoV-2 seroprevalence in ITM staff, stratified by variables","Institute of Tropical Medicine, Belgium","All","Child, Adult, Older Adult","","430","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","SARSCOV2SEROPREVALENCEITMSTAFF","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-08-07T00:00:00","","2020-08-07T00:00:00","Institute of Tropical Medicine, Antwerp, Belgium","","https://ClinicalTrials.gov/show/NCT04503447"
"428","NCT04367792","Cardiac Injury in COVID-19: a Pathology Study","","Active, not recruiting","No Results Available","COVID-19","","Cardiac pathological findings from series of 60 patients dying from COVID-19 disease|viral load in cardiac tissues and the extent of damage|Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart|Multi-organ involvement obtained from hystological analyses of paraffine blocks from different organs","A.O. Ospedale Papa Giovanni XXIII|CVPath Institute Inc. Renu Virmani, Aloke Finn|A.O. Ospedale Papa Giovanni XXIII, Anatomia Patologica, Dr Andrea Gianatti, co-PI","All","18 Years and older","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","56/20","2020-04-23T00:00:00","2020-10-01T00:00:00","2021-03-01T00:00:00","2020-04-29T00:00:00","","2020-08-10T00:00:00","ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy","","https://ClinicalTrials.gov/show/NCT04367792"
"429","NCT04476589","Prognostication of Recovery in Early Disorders of Consciousness After COVID-19","PREDICT-COVID","Recruiting","No Results Available","Covid19|Coma|Consciousness Disorder","Diagnostic Test: Functional MRI","Disability Rating Scale score","Massachusetts General Hospital","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020P001616","2020-07-01T00:00:00","2022-06-30T00:00:00","2023-03-30T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04476589"
"430","NCT04327505","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","COVID-19-HBO","Recruiting","No Results Available","SARS |Cytokine Storm|ARDS, Human|COVID-19|Sars-CoV2|Acute Respiratory Failure","Drug: Hyperbaric oxygen","ICU admission|30-day mortality|Time-to-intubation|Time-to-ICU|Inflammatory response|Overall survival","Karolinska Institutet|Karolinska Trial Alliance|University of California, San Diego|Blekinge County Council Hospital|JK Biostatistics AB|The Swedish Research Council","All","18 Years to 90 Years","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID-19-HBO|2020-001349-37|K-1199/2020","2020-06-03T00:00:00","2021-12-31T00:00:00","2022-12-31T00:00:00","2020-03-31T00:00:00","","2020-06-05T00:00:00","Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Blekingesjukhuset, Karlskrona, Blekinge, Sweden","","https://ClinicalTrials.gov/show/NCT04327505"
"431","NCT04473352","COVID-19 Detection Tests in Different Body Fluids","","Not yet recruiting","No Results Available","Covid19","","Accuracy of Covid19 Detection","Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara|Universidade Federal do Ceará","Male","18 Years and older","","80","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID Fluids","2020-09-01T00:00:00","2021-09-01T00:00:00","2021-11-01T00:00:00","2020-07-16T00:00:00","","2020-08-13T00:00:00","","","https://ClinicalTrials.gov/show/NCT04473352"
"432","NCT04405232","Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK","COVID19","Recruiting","No Results Available","COVID|Thrombosis|Bleeding|Anticoagulation","Other: Non-interventional","Prevalence and characteristics of coagulation abnormalities and their predictive value for respiratory failure requiring ventilation, multiorgan failure and death in patients presenting with COVID 19 infection|Incidence of respiratory failure requiring CPAP or mechanical ventilation|Incidence of thrombosis  including thrombosis within 90 days after hospital admission  4. Incidence of minor bleeding 5. Heparin induced thrombocytopenia 6. Acute coronary syndrome|Incidence of major bleeding 8. Multiorgan failure 9. Development of DIC 10. Duration of hospital stay  11. Hospital mortality|Incidence of clinically relevant non-major bleeding|Incidence of Heparin induced thrombocytopenia|Incidence of Acute coronary syndrome|Incidence of renal failure requiring renal replacement therapy|Incidence of Multiorgan failure|Incidence of Development of DIC|Duration of hospital stay |Hospital mortality","Imperial College London","All","18 Years and older","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20SM5934","2020-05-25T00:00:00","2021-04-25T00:00:00","2021-06-25T00:00:00","2020-05-28T00:00:00","","2020-07-31T00:00:00","Imperial College Healthcare NHS Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04405232"
"433","NCT04464395","Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Drug: CPI-006","Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19|Immunoglobulin Anti-SARS CoV-2 Levels|Negative Nasal Swab Polymerase Chain Reaction  SARS CoV-2 Viral Tests|Duration of symptoms|Time to discharge|Rate of medical procedures","Corvus Pharmaceuticals, Inc.","All","18 Years and older","Phase 1","30","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","CPI-006-002","2020-07-01T00:00:00","2021-03-31T00:00:00","2021-08-31T00:00:00","2020-07-09T00:00:00","","2020-07-20T00:00:00","Icahn School of Medicine at Mount Sinai, New York, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04464395"
"434","NCT04438070","COVID Screening Strategies in Homeless Shelters","","Recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 Swab","COVID-19 Detection Rate|Number of outbreaks|Enrollment over time","St. Joseph's Healthcare Hamilton|Timothy O'Shea|Marek Smieja|Lawrence Mbuagbaw","All","18 Years and older","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Screening","2020-10864-T","2020-04-10T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-06-18T00:00:00","","2020-06-18T00:00:00","Various Homeless Shelters, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04438070"
"435","NCT04358211","Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19","","Available","No Results Available","COVID-19","Biological: Biological: COVID-19 convalescent plasma","","Nakhle Saba, MD|Tulane University","All","18 Years and older","","","Other","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","","2020-595","","","","2020-04-24T00:00:00","","2020-04-24T00:00:00","Tulane Medical Center, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT04358211"
"436","NCT04375176","Monocytes and NK Cells Activity in Covid-19 Patients","","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Immunomodulation","Diagnostic Test: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2","Immune cells activity|Protective factors and new therapeutic strategies","Università degli Studi dell'Insubria","All","18 Years and older","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","67/2020","2020-04-27T00:00:00","2020-06-30T00:00:00","2020-10-31T00:00:00","2020-05-05T00:00:00","","2020-05-05T00:00:00","ATS Insubria, Varese, Italy","","https://ClinicalTrials.gov/show/NCT04375176"
"437","NCT04438941","Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic","COVID-PRONE","Recruiting","No Results Available","Sars-CoV2","","Analysis of the effect of prone position in patients with covid-19 in intensive care","University Hospital, Strasbourg, France","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7911","2020-03-25T00:00:00","2020-06-20T00:00:00","2020-06-20T00:00:00","2020-06-19T00:00:00","","2020-06-23T00:00:00","Service d'Anesthesie-Reanimation - Nouvel Hôpital Civil, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04438941"
"438","NCT04449731","Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population","COVIDiet_Int","Recruiting","No Results Available","COVID-19","","Adherence to the Mediterranean diet before and during the COVID-19 confinement|Eating behaviours|Level of physical activity during the COVID-19 confinement|Weight gain during the COVID-19 confinement","Universidad de Granada|Agricultural University of Athens|University of Zagreb|University of Belgrade|Institute of Technology, Sligo|University of Sarajevo|Lithuanian University of Health Sciences|Jozef Stefan Institute|University of Southern Denmark|Institut Za Javno Zdeavlje|University of Skopje|Poznan University of Life Sciences|Bezmialem Vakif University|Centro Hospitalar e Universitário de Coimbra, E.P.E.|Kuwait University|Universidad Nacional de Colombia|Manav Rachna International University","All","18 Years and older","","30000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","1526/CEIH/2020","2020-03-20T00:00:00","2020-08-30T00:00:00","2021-06-30T00:00:00","2020-06-29T00:00:00","","2020-08-03T00:00:00","Universidad de Granada, Granada, Spain","","https://ClinicalTrials.gov/show/NCT04449731"
"439","NCT04434248","An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","","Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Standard of Care","Rate of viral elimination by Day 10 [pilot stage, dose selection]|Time to viral elimination [pivotal stage]|Time to clinical improvement [pivotal stage]|Rate of viral elimination|Time to normalization of clinical symptoms|Duration of oxygen therapy|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality|Peak plasma concentration |Time to peak plasma concentration |Area under the plasma concentration versus time curve |Trough plasma concentration","Chromis LLC|Chemical Diversity Research Institute","All","18 Years and older","Phase 2|Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","COVID-FPR-01","2020-04-23T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Republican Clinical Hospital, Makhachkala, Russian Federation|""K+31"" Clinic, Moscow, Russian Federation|""Khaven"" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation","","https://ClinicalTrials.gov/show/NCT04434248"
"440","NCT04429815","Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19","MAGIC","Not yet recruiting","No Results Available","Smoking Behaviors","Diagnostic Test: Serological test for COVID-19.","Percentage of patients with a positive serological test for COVID-19.","Central Hospital, Nancy, France","All","18 Years and older","","489","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01681-38","2020-07-01T00:00:00","2021-03-01T00:00:00","2021-04-01T00:00:00","2020-06-12T00:00:00","","2020-06-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04429815"
"441","NCT04343794","Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","","Recruiting","No Results Available","COVID19","Device: BIOVITALS","Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals® Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality","The University of Hong Kong","All","18 Years and older","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","COVID19_Biovitals_Protocol_1","2020-04-01T00:00:00","2021-12-31T00:00:00","2022-01-31T00:00:00","2020-04-13T00:00:00","","2020-04-15T00:00:00","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT04343794"
"442","NCT04493359","Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19","SWITCH-COVID","Recruiting","No Results Available","Covid19|Angiotensin II Receptor Antagonist Adverse Reaction","Drug: Renin-angiotensin system inhibitors","Need for ICU or mortality|High sensitivity troponin levels and covid-19 severity|ACE-2 activity and disease severity|ACE-2 activity with different Renin-angiotensin system inhibitors|Blood control and acute renal failure","University of Sao Paulo","All","18 Years to 80 Years","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","33575220.9.0000.0068","2020-07-25T00:00:00","2022-02-14T00:00:00","2022-02-14T00:00:00","2020-07-30T00:00:00","","2020-07-31T00:00:00","Instituto do Coração - Incor HCFMUSP, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT04493359"
"443","NCT04420286","Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France","FRENCH ICU","Recruiting","No Results Available","Coronavirus Infections|COVID19 Outbreak in France","","origin of the ICU beds created during the COVID-19 outbreak in France.|Human Resources","Centre Hospitalier Universitaire de Nīmes","All","Child, Adult, Older Adult","","9000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","30RC20_0117","2020-05-06T00:00:00","2020-06-05T00:00:00","2020-06-05T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","CHU de Nîmes, Hôpital Universitaire Caremeau, Nimes, France","","https://ClinicalTrials.gov/show/NCT04420286"
"444","NCT04427098","Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","INHIXACOV19","Recruiting","No Results Available","COVID-19","Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin","To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","All","18 Years to 90 Years","Phase 2","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-001308-40","2020-05-22T00:00:00","2020-10-30T00:00:00","2020-10-30T00:00:00","2020-06-11T00:00:00","","2020-06-17T00:00:00","Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. ""Casa Sollievo della Sofferenza"", San Giovanni Rotondo  UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo , San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria ""Policlinico - V. Emanuele"", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unità Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale ""Malattie Infettive"", Matera, Italy|Ospedale San Raffaele Unità Funzionale dell'Unità Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Università di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04427098/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04427098"
"445","NCT04385043","Hyperimmune Plasma in Patients With COVID-19 Severe Infection","COV2-CP","Recruiting","No Results Available","COVID-19","Other: plasma hyperimmune|Drug: standard therapy","decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment","University of Catanzaro|Azienda Ospedaliera Policlinico ""Mater Domini""|Azienda Sanitaria Provinciale Di Catanzaro|Annunziata Hospital, Cosenza, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli","All","18 Years to 60 Years","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Covid-19 convalescent plasma","2020-05-01T00:00:00","2020-10-15T00:00:00","2021-05-15T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy","","https://ClinicalTrials.gov/show/NCT04385043"
"446","NCT04358809","Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill","","Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed  Mycobacterium w|Other: Placebo","Number of patients with increased disease severity|Incidence of adverse events and serious adverse events |Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older","Phase 3","480","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","CRSC20006","2020-04-30T00:00:00","2021-02-28T00:00:00","2021-04-30T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04358809"
"447","NCT04384042","Malaysian COVID-19 Anosmia Study  - A Nationwide Multicentre Case-Control Study","","Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Presence or absence of olfactory and taste disturbances in study participants|Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection|Clinical manifestations of study participants|Other pre-existing health conditions|Positive predictive value  of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection|Negative predictive value  of olfactory and taste disturbances in predicting absence of COVID-19 infection|Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection|Specificity of olfactory and taste disturbances in predicting COVID-19 infection","Hospital Sultanah Bahiyah|Hospital Tuanku Fauziah, Kangar, Perlis|Hospital Sultanah Maliha, Langkawi, Kedah|Penang Hospital, Malaysia|Hospital Raja Permaisuri Bainun|Hospital Sungai Buloh, Selangor|Kuala Lumpur General Hospital|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan|Hospital Melaka, Melaka|Hospital Sultan Ismail, Johor Bahru, Johor|Hospital Permai, Johor Bahru, Johor|Hospital Sultanah Aminah Johor Bahru|Hospital Enche Besar Hajjah Khalsom, Kluang, Johor|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu|Hospital Tengku Ampuan Afzan, Kuantan, Pahang|Sarawak General Hospital|Hospital Queen Elizabeth, Malaysia","All","18 Years and older","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MCO-002","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-05-12T00:00:00","","2020-05-14T00:00:00","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia","","https://ClinicalTrials.gov/show/NCT04384042"
"448","NCT04333355","Safety in Convalescent Plasma Transfusion to COVID-19","","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","All","18 Years and older","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","PC-TecSalud Fase I","2020-05-08T00:00:00","2020-12-20T00:00:00","2021-04-30T00:00:00","2020-04-03T00:00:00","","2020-07-28T00:00:00","Hospital San Jose, Monterrey, Nuevo Leon, Mexico","","https://ClinicalTrials.gov/show/NCT04333355"
"449","NCT04418375","Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals","COVID-HOP","Not yet recruiting","No Results Available","COVID-19","","Identification of markers associated with asymptomatic COVID + status  versus symptomatic COVID + status through a questionnaire  and a biological collection|Identification of markers associated with a positive or a negative serology through a questionnaire  and a biological collection|Description of the serological status according to the professional risk of exposure to the virus|Description of the clinical manifestations of COVID-19 infection in hospital professionals|Identification of risk factors associated with the loss of anti SARS-CoV-2 immunity through a questionnaire  and a biological collection|Identification of markers associated with symptomatic COVID-19 infection during follow-up despite the presence of anti SARS-CoV-2 antibodies through a questionnaire  and a biological collection|Correlation between the serology result and the PCR result  for people who have been tested as part of routine care.|Identification of potential therapeutic targets to avoid developing a symptomatic form|Identification of potential therapeutic targets to promote the maintenance of an anti SARS-CoV2 protective immunity|Creation of COVIDneg and COVID + asymptomatic control groups for other COVID-19 biological collections.","Assistance Publique - Hôpitaux de Paris|Fondation Universite de Paris|Fondation Hôpitaux de Paris-Hôpitaux de France","All","18 Years and older","","4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200609|2020-A01364-35","2020-06-01T00:00:00","2021-02-01T00:00:00","2022-03-01T00:00:00","2020-06-05T00:00:00","","2020-06-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04418375"
"450","NCT04441684","Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France","SeroCoV-HUS","Recruiting","No Results Available","SARS-CoV-2 Serological Status|SARS-CoV-2 Seroprevalence","Diagnostic Test: Blood sample for serological test","Presence of specific SARS-CoV2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit .|Detection and titration of neutralizing antibodies anti-SARS-CoV-2|Kinetics of antibodies and their persistence over a period of 1 year|Number of asymptomatic subjects in the PCR - and -PCR groups|Number of people with positive Sars-CoV-2 serology|Questionnaire","University Hospital, Strasbourg, France","All","18 Years and older","Not Applicable","1800","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Screening","7782","2020-04-17T00:00:00","2020-05-07T00:00:00","2021-08-01T00:00:00","2020-06-22T00:00:00","","2020-06-22T00:00:00","Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04441684"
"451","NCT04344249","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","IBD-COVID-19","Recruiting","No Results Available","IBD|COVID","","IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection","Nantes University Hospital","All","18 Years to 100 Years","","850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0150","2020-04-10T00:00:00","2020-09-30T00:00:00","2021-09-01T00:00:00","2020-04-14T00:00:00","","2020-04-30T00:00:00","Chu Nantes, Nantes, France","","https://ClinicalTrials.gov/show/NCT04344249"
"452","NCT04342689","The Role of Resistant Starch in COVID-19 Infection","","Recruiting","No Results Available","COVID-19","Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery |Symptom Severity Score","Yale University|University of Michigan|University of Minnesota","All","19 Years and older","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","2000027887","2020-06-03T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-04-13T00:00:00","","2020-06-17T00:00:00","Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT04342689"
"453","NCT04401228","Predictive Models for Intensive Care Admission and Death of COVID-19","","Active, not recruiting","No Results Available","COVID19|Pneumonia, Viral|Inflammatory Response","Other: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?","admission to ICU|death","Clinique Saint Pierre Ottignies","All","18 Years and older","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0410508057","2020-03-01T00:00:00","2020-05-01T00:00:00","2021-01-01T00:00:00","2020-05-26T00:00:00","","2020-05-26T00:00:00","Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium","","https://ClinicalTrials.gov/show/NCT04401228"
"454","NCT04424017","Sero-prevalence of Coronavirus Disease 2019  in Healthcare Workers","","Recruiting","No Results Available","COVID|Corona Virus Infection","Biological: Specific anti-SARS-CoV-2 antibodies","Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies","Egyptian Center for Research and Regenerative Medicine|Cairo University|National Research Center, Egypt|Academy of Scientific Research and Technology, Egypt","All","18 Years to 60 Years","","726","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19\004","2020-06-07T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-06-09T00:00:00","","2020-08-11T00:00:00","ECRRM, Cairo, Egypt|Faculty of Medicine, Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04424017"
"455","NCT04380662","Risk Factors Worsening COVID19 for Out-patient With Home Monitoring","COVIDADOMEVA","Not yet recruiting","No Results Available","Covid19","Other: Risk factors","Identify the factors associated with the worsening of the COVID19|Describe the clinical care pathway of patients from Day 0 to Day 14|Describe the health status at Day 30|Describe the quality of life during the disease","University Hospital, Grenoble","All","Child, Adult, Older Adult","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.135|2020-A01040-39","2020-06-30T00:00:00","2020-09-30T00:00:00","2020-12-30T00:00:00","2020-05-08T00:00:00","","2020-06-22T00:00:00","Grenoble University Hospital, Grenoble, France","","https://ClinicalTrials.gov/show/NCT04380662"
"456","NCT04391946","Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19","COVID19_LLC-MW","Recruiting","No Results Available","Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease","Behavioral: Data registry","Prognostic factors for healing of COVID-19 infection|Medical care of Coronavirus infection|national epidemiological monitoring","French Innovative Leukemia Organisation|Institut de Cancerologie Strasbourg Europe","All","18 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FILO-COVID19_LLC-MW","2020-03-14T00:00:00","2022-05-01T00:00:00","2022-12-31T00:00:00","2020-05-18T00:00:00","","2020-08-12T00:00:00","Chu Angers, Angers, France|CHU Jean Minjoz - Hematologie, Besançon, France|Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France|CHU Estaing - Hematologie Clinique Adulte, Clermont-Ferrand, France|Chu Creteil, Creteil, France|CHU Grenoble - Hematologie, Grenoble, France|Chd Vendee, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Hôpital Saint Vicent de Paul, Lille, France|Centre Leon Berard - Hematologie, Lyon, France|Institut Paoli Calmette, Marseille, France|Hopital E.Muller, Mulhouse, France|CHU DE NANTES - Hematologie clinique, Nantes, France|Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|Hôpital de la Miletrie - Hematologie et Therapie Cellulaire, Poitiers, France|Hôpital Robert Debre - Hematologie Clinique, Reims, France|Centre Henri Becquerel - Service Hematologie Clinique, Rouen, France|Hôpital Hautepierre - Hematologie, Strasbourg, France|IUCT ONCOPOLE - Hematologie, Toulouse, France|Hôpital Bretonneau - Hematologie et Therapie Cellulaire, Tours, France|CHU Nancy Brabois, Vandœuvre-lès-Nancy, France","","https://ClinicalTrials.gov/show/NCT04391946"
"457","NCT04483830","Suloexide in the Treatment of Early Stages of COVID-19","SulES-COVID","Recruiting","No Results Available","Covid19","Drug: Sulodexide|Drug: Placebo","hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation","Clinedem|Alfasigma S.p.A.","All","40 Years to 80 Years","Phase 2|Phase 3","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","Clidm/Vas/2020-05-01","2020-06-05T00:00:00","2020-08-05T00:00:00","2020-08-10T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","Clinedem, San Luis Rio Colorado, Sonora, Mexico","","https://ClinicalTrials.gov/show/NCT04483830"
"458","NCT04299724","Safety and Immunity of Covid-19 aAPC Vaccine","","Recruiting","No Results Available","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","GIMI-IRB-20002","2020-02-15T00:00:00","2023-07-31T00:00:00","2024-12-31T00:00:00","2020-03-09T00:00:00","","2020-03-09T00:00:00","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT04299724"
"459","NCT04358783","Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia","COP-COVID-19","Recruiting","No Results Available","Coronavirus Infection","Biological: Plasma|Other: Best Available Therapy","Early all-cause mortality|Time in days for SARS-CoV-2 RT-PCR negatives|The serum anti-SARS-CoV-2 antibody titres|Detection of serum antibodies","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","IF20-00002","2020-04-27T00:00:00","2021-02-01T00:00:00","2021-05-30T00:00:00","2020-04-24T00:00:00","","2020-05-19T00:00:00","Hospital Universitario Jose E. Gonzalez, Monterrey, Nuevo Leon, Mexico","","https://ClinicalTrials.gov/show/NCT04358783"
"460","NCT04381312","Direct and Indirect Impact of COVID-19 In Older Populations","COVID-OLD","Recruiting","No Results Available","Risk Factors for COVID-19 Outcomes in Elderly Populations","","mortality|Risk factors for death|Describe clinical symptoms specific to old population|describe specific and non-specific treatments used for COVID 19|describe all acute complications|functional decline|Rehospitalisation|medical complications|Admission in nursing home|risk factors for 3-month functional decline, acute complication and admission to nursing home","University Hospital, Grenoble","All","70 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.118|2020-A00846-33","2020-04-09T00:00:00","2021-07-09T00:00:00","2021-10-09T00:00:00","2020-05-08T00:00:00","","2020-05-08T00:00:00","Chu Grenoble Alpes, Grenoble Cedex 9, Grenoble, France","","https://ClinicalTrials.gov/show/NCT04381312"
"461","NCT04384549","Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers","COVID-BCG","Recruiting","No Results Available","Infection|Viral, Agent as Cause of Disease Classified Elsewhere","Biological: BCG GROUP|Other: PLACEBO GROUP","Incidence of documented COVID-19 among health care workers exposed to SARS CoV2 and vaccinated with BCG compared to placebo.|Numbers of COVID-19 patients requiring hospitalization in ICU and O2, artificial ventilation or extracorporal membrane oxygenation, or deaths in BCG-vaccinated health care workers compared to placebo|Incidence of asymptomatic SARS CoV2 seropositive subjects among BCG-vaccinated health care workers compared to placebo.|Incidence of subjects with any respiratory infection among BCG-vaccinated health care workers compared to placebo.|Numbers of sick days and numbers of sick leaves among BCG-vaccinated health care workers compared to placebo.|Numbers of subjects with BCG-related advers events among BCG-vaccinated health care workers compared to placebo.|Numbers and intensity of changes in innate immune markers after SARS CoV2 infection among BCG-vaccinated health care workers compared to placebo.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Phase 3","1120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","APHP200462|2020-001678-31","2020-05-20T00:00:00","2021-02-20T00:00:00","2021-02-20T00:00:00","2020-05-12T00:00:00","","2020-08-18T00:00:00","I-REIVAC/CIC 1417 Cochin Hospital, APHP, Paris, France","","https://ClinicalTrials.gov/show/NCT04384549"
"462","NCT04359953","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","COVID-Aging","Recruiting","No Results Available","COVID-19 Infection","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan","Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI |Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living  Activity of Daily Living)|Changes in Activity of Daily Living IADL |The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France","All","60 Years and older","Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","7747","2020-04-25T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-04-24T00:00:00","","2020-07-27T00:00:00","CHU de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04359953"
"463","NCT04381273","Oral Health and Psychosocial Factors During the Covid-19 Pandemic","","Recruiting","No Results Available","Covid-19|Periodontal Diseases","Other: No intervention","How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?|Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?|Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life?|Have people changed their oral hygiene practices in times of the Covid-19 pandemic?","Heidelberg University","All","18 Years and older","","1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","S-303/2020","2020-05-08T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-05-08T00:00:00","","2020-05-08T00:00:00","University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT04381273"
"464","NCT04317040","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","SAC-COVID","Recruiting","No Results Available","Severe Coronavirus Disease","Drug: CD24Fc|Drug: Placebo","Improvement of COVID-19 disease status|Proportion of patients who died or had respiratory failure.|Disease progression of COVID-19|All cause of death|Proportion of clinical relapse|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of high flow oxygen therapy|Absolute lymphocyte count|Change of D-dimers","OncoImmune, Inc.","All","18 Years and older","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","CD24Fc-007|20200674","2020-04-08T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-03-20T00:00:00","","2020-05-29T00:00:00","Baptist Health Research Institute, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04317040"
"465","NCT04487977","Survey on COVID-19 Airway Management","ISAM-COVID","Recruiting","No Results Available","Airway Management","Other: Survey","Preferred device","Spanish Society of Anesthesia and Critical Care |Confederation of Latin American Societies of Anaesthesiology","All","Child, Adult, Older Adult","","5000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ISAM-COVID","2020-04-22T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-07-27T00:00:00","","2020-07-27T00:00:00","Consorcio Hospital General Universitario de Valencia, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT04487977"
"466","NCT04363749","COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities","CRC-COVID","Not yet recruiting","No Results Available","Covid19|Neurological Complication","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Intensity of the emotional response to hypoxic exposure |Perception of a hypoxic stimulus induced dyspnea |Perception of a hypercapnic stimulus induced dyspnea |Perception of a inspiratory mechanical constraint induced dyspnea|brain MRI","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Basic Science","APHP200476","2020-04-27T00:00:00","2021-04-27T00:00:00","2021-11-27T00:00:00","2020-04-27T00:00:00","","2020-04-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04363749"
"467","NCT04367662","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","COVID'HEMOS","Completed","No Results Available","COVID-19","Procedure: blood sampling","Clinical worsening  of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood","University Hospital, Rouen","All","18 Years and older","Not Applicable","99","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","2020/0104/OB","2020-04-09T00:00:00","2020-05-14T00:00:00","2020-05-14T00:00:00","2020-04-29T00:00:00","","2020-06-09T00:00:00","Rouen University Hospital, Rouen, France","","https://ClinicalTrials.gov/show/NCT04367662"
"468","NCT04458519","Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection","","Not yet recruiting","No Results Available","COVID-19 Infection","Other: Probiorinse|Other: Saline solution","Change in severity of COVID-19 infection|Number of days with any symptom of anosmia|Maximal intensity attained in overall assessment of symptoms of COVID-19 infection as measured on Visual Analogue Scale .|Number of days where rescue medication is required","Centre hospitalier de l'Universite de Montreal","All","18 Years to 59 Years","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","PROBCO|249512","2020-07-07T00:00:00","2020-10-15T00:00:00","2020-12-31T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Centre Hospitalier de l'Universite de Montreal , Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT04458519"
"469","NCT04389359","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion","PROTECT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG","Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years and older","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","A095590","2020-09-01T00:00:00","2021-08-01T00:00:00","2025-08-01T00:00:00","2020-05-15T00:00:00","","2020-07-13T00:00:00","","","https://ClinicalTrials.gov/show/NCT04389359"
"470","NCT04347915","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Clevudine|Drug: Placebo","The rate of subjects tested as negative SARS-Coronavirus-2 |The rate of subjects tested as negative SARS-Coronavirus-2  in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load","Bukwang Pharmaceutical","All","19 Years and older","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","BK-CLV-201","2020-05-06T00:00:00","2020-09-30T00:00:00","2020-12-31T00:00:00","2020-04-15T00:00:00","","2020-06-30T00:00:00","Korea University Guro Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT04347915"
"471","NCT04467008","Covid-19 Rapid Diagnostic Tests on Blood Drop","COVID-TEST","Not yet recruiting","No Results Available","Covid19","","Positivity of the rapid diagnostic test","CMC Ambroise Pare","All","Child, Adult, Older Adult","","113","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020/05","2020-07-15T00:00:00","2020-08-15T00:00:00","2020-08-15T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","","","https://ClinicalTrials.gov/show/NCT04467008"
"472","NCT04459819","Respiratory Physiotherapy in Severe COVID-19 Patients","FTR-COVID","Recruiting","No Results Available","COVID-19","Other: Respiratory physiotherapy","Number of physiotherapy treatments|Type of physiotherapy treatments|Time of the first physiotherapy treatment|First time standing|First time walking|First time sitting out of bed|6 minutes walking test |1 minute sit-to-stand test |Upper extremity muscles strength|Lower extremity muscles strength|Functional independence in ADL|ICU stay length|Length of hospitalization|Duration of invasive mechanical ventilation |Patients returned home|Patients discharged to in-patient rehabilitation|Patients transferred to other hospitals|Exitus","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years to 80 Years","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","FTR-COVID","2020-03-01T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-07-07T00:00:00","","2020-08-11T00:00:00","Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy","","https://ClinicalTrials.gov/show/NCT04459819"
"473","NCT04385160","Myeloproliferative Neoplasms  and COVID-19","MPN-COVID","Recruiting","No Results Available","Myeloproliferative Neoplasm|COVID","","pulmonary embolism |fatal or non fatal thrombotic event|Continuous Positive Airway Pressure |invasive ventilation|admission in Intensive Care Unit |death|treatments and interventions applied for MPN|treatments and interventions applied for COVID-19|thrombotic events association to patients characteristic and treatments","Fondazione per la Ricerca Ospedale Maggiore|European Leukemia Net","All","18 Years and older","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Other","FROM - O-MPN-COVID-2020","2020-05-13T00:00:00","2020-07-15T00:00:00","2020-09-01T00:00:00","2020-05-12T00:00:00","","2020-07-23T00:00:00","New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico ""G.B. Rossi"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Sobas Wroclaw Medical University ·, Wrocław, Poland|Hospital Clínic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Català d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital General de La Palma, Breña Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematología Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematología Hospital Universitario de Móstoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04385160"
"474","NCT04364984","ARB, ACEi, DRi in COVID-19","BIRCOV","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Angiotensin converting enzyme inhibitor","BP |COVID-19 course","Medical Practice Prof D. Ivanov","All","18 Years to 90 Years","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID20","2020-04-01T00:00:00","2021-04-01T00:00:00","2021-08-01T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine","","https://ClinicalTrials.gov/show/NCT04364984"
"475","NCT04369300","Anxiety And Depression During COVID-19 IN INDIA","","Recruiting","No Results Available","COVID-19","Behavioral: Registery Data Collection","Prevalence  of anxiety of general adult population during COVID-19|prevalence  of depression and anxiety of general adult population during COVID 19","Max Healthcare Insititute Limited","All","18 Years to 90 Years","","1000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Covid-19/MHC/PSYCH/20-10","2020-04-24T00:00:00","2020-11-24T00:00:00","2021-02-24T00:00:00","2020-04-30T00:00:00","","2020-07-15T00:00:00","Max Super Speciality hospital, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04369300"
"476","NCT04485130","DISulfiram for COvid-19  Trial","DISCO","Not yet recruiting","No Results Available","Covid19","Drug: Disulfiram|Drug: Placebo","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score |Virologic impact of 3 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Immunologic impact of 3 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines .","University of California, San Francisco","All","18 Years and older","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","DSF151837","2020-09-01T00:00:00","2021-06-01T00:00:00","2021-09-01T00:00:00","2020-07-24T00:00:00","","2020-07-24T00:00:00","San Francisco General Hospital, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT04485130"
"477","NCT04370171","Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic","TeleCoviDiab","Not yet recruiting","No Results Available","Diabetes|Covid-19","Other: care modalities|Other: Teleconsultation either by phone or by computer consultation","Comparison of metabolic control  between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.|HbA1C measured at 6 months post-telemedicine consultation for the TC group / post-cancellation of the face-to-face consultation for the P group.|Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.|Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.|Results of patient satisfaction questionnaire.|Results of doctor satisfaction questionnaire.|Number of patients infected with Covid-19 .|Number of conventional hospitalizations, in intensive care and deaths.","University Hospital, Strasbourg, France","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7775","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-30T00:00:00","","2020-05-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04370171"
"478","NCT04405726","Prognostic Factors of COVID19","Covid-HUS","Recruiting","No Results Available","SARS-CoV-2","","Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital","University Hospital, Strasbourg, France","All","1 Year and older","","500","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7760","2020-03-27T00:00:00","2022-03-01T00:00:00","2022-03-01T00:00:00","2020-05-28T00:00:00","","2020-06-25T00:00:00","Service de Virologie - Hôpital Civil, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04405726"
"479","NCT04312464","Myocardial Damage in COVID-19","","Enrolling by invitation","No Results Available","COVID-19|Cardiovascular Diseases","Other: non","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Wuhan Union Hospital, China","All","18 Years and older","","500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MD-COVID-19","2020-01-01T00:00:00","2020-03-15T00:00:00","2020-03-18T00:00:00","2020-03-18T00:00:00","","2020-03-18T00:00:00","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04312464"
"480","NCT04497402","Sex-Informed Data in the COVID-19 Pandemic.","G-COV","Not yet recruiting","No Results Available","Covid19","","Sex differences in platelet and immune function and COVID19 severity|Gut microbiome and COVID19 severity","University of Roma La Sapienza","All","18 Years to 100 Years","","88","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SAPIENZAGENDERCOVID","2020-09-01T00:00:00","2021-09-01T00:00:00","2022-06-01T00:00:00","2020-08-04T00:00:00","","2020-08-13T00:00:00","Sapienza University of Rome - Policlinico Umberto I Roma, Rome, Italy","","https://ClinicalTrials.gov/show/NCT04497402"
"481","NCT04381884","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19","","Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN  arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2","Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes","All","18 Years to 69 Years","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","IVM-AR-1","2020-05-18T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-05-11T00:00:00","","2020-07-14T00:00:00","Centro de Educación Medica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aires, Argentina","","https://ClinicalTrials.gov/show/NCT04381884"
"482","NCT04351139","Impact of the COVID-19 Pandemic in Gynecological Oncology","COVID-GYN","Recruiting","No Results Available","Gynecologic Cancer|Breast Neoplasm Female|Uterine Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms","Other: modification of the planned therapeutic management","percentage of patients with a change in the planned therapeutic management","Hospices Civils de Lyon","Female","18 Years and older","","400","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","69HCL20_0346|2020-A01036-33","2020-05-06T00:00:00","2020-11-06T00:00:00","2020-11-06T00:00:00","2020-04-17T00:00:00","","2020-06-09T00:00:00","Service de Gynecologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gynecologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gynecologie, CHLS, Hospices Civils de Lyon, Pierre-Benite, France","","https://ClinicalTrials.gov/show/NCT04351139"
"483","NCT04492202","Knowledge, Attitudes, and Practices Towards COVID-19 Among Health Care Professionals Among Healthcare Professionals","","Not yet recruiting","No Results Available","COVID|Knowledge, Attitudes, Practice","Other: Survey","Questionnaire for the Evaluation of Knowledge, Attitude and Practise Levels of Healthcare Professionals for COVID-19|Support Approach Survey for Patients in Recovery Stage after COVID-19 Diagnosis","Istinye University","All","22 Years to 75 Years","","200","Other","Observational","Observational Model: Other|Time Perspective: Other","00010","2020-08-01T00:00:00","2020-11-20T00:00:00","2020-12-10T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","","","https://ClinicalTrials.gov/show/NCT04492202"
"484","NCT04341168","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: this study is non- interventional","Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections","University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne  Cologne, Germany","All","Child, Adult, Older Adult","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KICC19","2020-04-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-04-10T00:00:00","","2020-04-14T00:00:00","University Hospital Cologne, Cologne, NRW, Germany","","https://ClinicalTrials.gov/show/NCT04341168"
"485","NCT04407195","COVID-19 and Mental Health","","Not yet recruiting","No Results Available","COVID-19|Mental Health Disorder","Other: Exposure to the SARS-CoV-2","Emotional Impact|Depression|Anxiety|Insomnia|Resilience|Crisis Support Scale","Northeastern University","All","18 Years and older","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-05-22","2020-06-01T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-05-29T00:00:00","","2020-06-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04407195"
"486","NCT04479293","Post COVID-19 Functional Status in Egypt","","Recruiting","No Results Available","COVID-19|Coronavirus Disease|SARS-CoV-2","Other: Post COVID-19 Functional Satus Scale","Degree of functional limitation post COVID-19|Degree of psychologic changes|Sleep Disturbance and quality|Radiologic changes|Laboratory changes","Assiut University","All","Child, Adult, Older Adult","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AssiutU16","2020-07-01T00:00:00","2020-10-30T00:00:00","2020-11-30T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","Aliaa Hussein, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04479293"
"487","NCT04371406","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients","MG-COVID","Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc","Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy  at day 14|The rate of use of secondary antibiotic therapy  at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years","Phase 3","2770","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","APHP200447|2020-001702-35","2020-05-02T00:00:00","2020-08-02T00:00:00","2020-09-02T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04371406"
"488","NCT04475302","BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots","","Recruiting","No Results Available","COVID","Biological: BCG vaccine","Mortality due to COVID-19 disease|Hospital admission and ICU admission due to Covid-19, Severity of Covid-19 , Hospital admission due to other respiratory febrile illness, immunological outcomes in the sub study","Tuberculosis Research Centre, India|ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu|All India Institute of Medical Sciences, New Delhi|National Institute for Research in Environmental Health, Bhopal, Madhya Pradesh|National Institute of Occupational Health, Ahmedabad, Gujarat|King Edward Memorial Hospital|National Institute for Implementation Research on Non-Communicable Disease","All","60 Years to 80 Years","Phase 3","2175","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","2020010","2020-07-01T00:00:00","2021-01-01T00:00:00","2021-05-01T00:00:00","2020-07-17T00:00:00","","2020-07-23T00:00:00","Tuberculosis Research Centre, Chennai, Tamilnadu, India","","https://ClinicalTrials.gov/show/NCT04475302"
"489","NCT04347460","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","COVIDHLH","Recruiting","No Results Available","COVID","","Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria  in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye","Technische Universität München","All","18 Years and older","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","161/20 S","2020-03-27T00:00:00","2020-07-01T00:00:00","2020-08-31T00:00:00","2020-04-15T00:00:00","","2020-04-15T00:00:00","Department of nephrology, Klinikum rechts der Isar, München, Bavaria, Germany","","https://ClinicalTrials.gov/show/NCT04347460"
"490","NCT04343976","Pegylated Interferon Lambda Treatment for COVID-19","","Enrolling by invitation","No Results Available","COVID-19|COVID","Drug: Pegylated interferon lambda","Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs placebo with symptomatic improvement|Percentage of subjects on Lambda vs placebo with improved clinical outcomes","Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital","All","18 Years and older","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","2020P001083","2020-06-22T00:00:00","2021-03-01T00:00:00","2021-08-31T00:00:00","2020-04-14T00:00:00","","2020-06-24T00:00:00","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04343976"
"491","NCT04389385","COVID-19 Specific T Cell Derived Exosomes","","Active, not recruiting","No Results Available","Corona Virus Infection|Pneumonia","Biological: COVID-19 Specific T Cell derived exosomes","Adverse reaction  and severe AE |Efficacy Assessment|The Rate of Recovery Without Mechanical Ventilator","TC Erciyes University","All","18 Years to 75 Years","Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Supportive Care","EruCovid2020","2020-05-01T00:00:00","2020-09-30T00:00:00","2021-05-31T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","GENKOK, Kayseri, Melikgazi, Turkey","","https://ClinicalTrials.gov/show/NCT04389385"
"492","NCT04360356","Ivermectin and Nitazoxanide Combination Therapy for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IVR/NTZ","2020-05-01T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04360356"
"493","NCT04401072","Attitude of Egyptian Population Toward COVID 19 in Ramadan","","Recruiting","No Results Available","Covid 19","","Attitude of the Egyptian population during the COVID 19 pandemic in Ramadan","Damanhour University","All","Child, Adult, Older Adult","","500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","covid 19 in ramadan","2020-04-24T00:00:00","2020-05-22T00:00:00","2020-10-01T00:00:00","2020-05-26T00:00:00","","2020-05-26T00:00:00","Damanhour University, Damanhūr, Beheira, Egypt","","https://ClinicalTrials.gov/show/NCT04401072"
"494","NCT04348435","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy  to Provide Protection Against COVID-19","","Enrolling by invitation","No Results Available","COVID-19","Drug: HB-adMSCs|Drug: Placebos","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Hope Biosciences|Hope Biosciences Stem Cell Research Foundation","All","Child, Adult, Older Adult","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","Allogeneic COVID-19 Protection","2020-05-14T00:00:00","2020-12-31T00:00:00","2021-04-30T00:00:00","2020-04-16T00:00:00","","2020-07-14T00:00:00","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States","","https://ClinicalTrials.gov/show/NCT04348435"
"495","NCT04318366","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","COVID-BioB","Recruiting","No Results Available","Coronavirus Infections","Other: Observational Study","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Università Vita-Salute San Raffaele","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-BioB/OSR","2020-03-19T00:00:00","2022-03-19T00:00:00","2022-03-19T00:00:00","2020-03-24T00:00:00","","2020-06-19T00:00:00","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy","","https://ClinicalTrials.gov/show/NCT04318366"
"496","NCT04404244","Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic","PedCan-COVID","Recruiting","No Results Available","Coronavirus COVID-19","","Incidence of COVID-19 among children with cancer|Families training","Fatma Soliman Elsayed Ebeid|Ain Shams University","All","up to 18 Years","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FMASU P25a/ 2020","2020-01-01T00:00:00","2021-01-01T00:00:00","2021-06-01T00:00:00","2020-05-27T00:00:00","","2020-05-27T00:00:00","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","","https://ClinicalTrials.gov/show/NCT04404244"
"497","NCT04371432","Genetics of COVID-19 Susceptibility and Manifestations","","Recruiting","No Results Available","COVID-19|Coronavirus 2019","","Molecular etiology of host susceptibility to severe COVID-19|Mechanisms of disease","National Human Genome Research Institute |National Institutes of Health Clinical Center","All","3 Years and older","","2500","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","200090|20-HG-0090","2020-08-21T00:00:00","2025-06-01T00:00:00","2025-06-01T00:00:00","2020-05-01T00:00:00","","2020-08-18T00:00:00","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04371432"
"498","NCT04346147","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Covid-19HUF","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet","time to clinical improvement|Safety of treatments|Tolerability of treatments","Hospital Universitario de Fuenlabrada|Centro Nacional de Investigaciones Oncologicas CARLOS III","All","18 Years and older","Phase 2","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","24032020","2020-04-13T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-04-15T00:00:00","","2020-05-08T00:00:00","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04346147"
"499","NCT04353518","Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed  Mycobacterium w|Other: Placebo","Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event |Number of subject developing Upper Respiratory Tract Infection  symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older","Phase 3","4000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","CRSC20005","2020-04-30T00:00:00","2021-03-30T00:00:00","2021-05-30T00:00:00","2020-04-20T00:00:00","","2020-04-22T00:00:00","","","https://ClinicalTrials.gov/show/NCT04353518"
"500","NCT04448769","Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus","COVAL-NANCY","Recruiting","No Results Available","Coronavirus Infection|Prevalence","Biological: Anti-SARS-CoV-2 IgT seropositivity","Anti-SARS-CoV-2 IgT  seropositivity|Proportion of asymptomatic, symptomatic cases among seropositive people|Proportion of asymptomatic cases among seropositive people|Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status.|Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score|Proportion of infected households|Anti-SARS-CoV-2 IgT seropositivity in the household|Clinical expression patterns of infection by symptom/antibody association|Serological Response to Infection|Anti-SARS-CoV-2 IgT seropositivity|• Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum.","Central Hospital, Nancy, France|University of Lorraine|Metropole du Grand Nancy","All","5 Years and older","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Screening","2020PI128","2020-06-26T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-06-26T00:00:00","","2020-07-09T00:00:00","Chru Nancy, Vandœuvre-lès-Nancy, France","","https://ClinicalTrials.gov/show/NCT04448769"
"501","NCT04413838","Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19 Infection","NIVISCO","Not yet recruiting","No Results Available","Obesity, COVID-19 Infection","Drug: NIVOLUMAB|Other: Routine standard of care","Patient's clinical state|Readmission|Mortality|Oxygen flow needs|Requirement of oxygen|Discharge from hospital|Adverse events|Presence of nasopharyngeal SARS-CoV-2|nasopharyngeal SARS-CoV-2 viral charge|Number of total Lymphocytes T|Number of CD3+ Lymphocytes T|Number of CD4+ Lymphocytes T|Number of CD8+ Lymphocytes T|Interleukin 6 |Interleukin 10 |Tumor Necrosis Factor alpha |Interferon gamma |Type I Interferon |Tim3 expression|PD1 expression|PD-L1 expression|Human Leukocyte Antigen - DR isotype gene expression |Production of IFNγ by lymphocytes T|Production of granzyme B by lymphocytesT|Lipopolysaccharides |LBP|sCD14|High Density Lipoproteins|Apolipoprotein","Hospices Civils de Lyon","All","18 Years to 70 Years","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","69HCL20_0478","2020-06-15T00:00:00","2021-06-15T00:00:00","2021-09-15T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Hôpital Lyon Sud Service Endocrinologie, Diabète et Nutrition, Pierre-Benite, France","","https://ClinicalTrials.gov/show/NCT04413838"
"502","NCT04340921","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","","Recruiting","No Results Available","Cardiovascular Disease Acute|Cardiomyopathies|COVID","Biological: COVID-19 exposure","T-cell immunophenotype|Mortality|ITU admission|Myocardial injury","Barts & The London NHS Trust|Queen Mary University of London","All","18 Years and older","","140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282289","2020-05-14T00:00:00","2021-11-10T00:00:00","2021-11-10T00:00:00","2020-04-10T00:00:00","","2020-05-18T00:00:00","Barts Health Nhs Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04340921"
"503","NCT04408170","Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19","FALCON-C19","Recruiting","No Results Available","Coronavirus Infection|COVID-19","Diagnostic Test: Point-of-care test for SARS-CoV-2","If the participant has an active SARS-CoV-2 infection during admission|The participant has had a past SARS-CoV-2 infection","Manchester University NHS Foundation Trust","All","18 Years to 100 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B00944","2020-06-19T00:00:00","2021-02-28T00:00:00","2021-05-31T00:00:00","2020-05-29T00:00:00","","2020-07-07T00:00:00","Manchester University NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT04408170"
"504","NCT04516850","HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients","","Not yet recruiting","No Results Available","Covid19","Genetic: Expression of receptors and activating proteases|Genetic: Polymorphism of the HSD3B1","Expression of receptors and activating proteases|Prevalencen of olymorphisms of the HSD3B1|Association of polymorphisms of the HSD3B1","Ricardo Pereira Mestre|Institute of Oncology Research |Istituto Cantonale di Patologia|Oncology Institute of Southern Switzerland","All","18 Years and older","","500","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","COVID19-GeneExp","2020-09-01T00:00:00","2021-08-31T00:00:00","2021-08-31T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","Oncology Institute of Southern Switzerland , Bellinzona, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland","","https://ClinicalTrials.gov/show/NCT04516850"
"505","NCT04490824","Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals","","Recruiting","No Results Available","Covid19","Device: KELEA Excellerated Water","Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals","Institute of Progressive Medicine","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","KELEA-1","2020-08-10T00:00:00","2020-10-31T00:00:00","2020-11-30T00:00:00","2020-07-29T00:00:00","","2020-08-11T00:00:00","Institute of Progressive Medicine, South Pasadena, California, United States","","https://ClinicalTrials.gov/show/NCT04490824"
"506","NCT04338945","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","","Completed","No Results Available","COVID","Behavioral: COVID-surgRES questionaire","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ItaliansurgRES-SPIGC","2020-03-15T00:00:00","2020-04-15T00:00:00","2020-05-01T00:00:00","2020-04-08T00:00:00","","2020-07-27T00:00:00","U.O.C. Chirurgia Generale Universitaria ""V. Bonomo"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy","","https://ClinicalTrials.gov/show/NCT04338945"
"507","NCT04475107","The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Drug: Pyronaridine-Artesunate|Drug: Placebo","Proportion  of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*|Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline|Proportion  of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*|Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Time to achieve normalization of body temperature, post-dose|Time to achieve normalization of respiratory rate, post-dose|Time to achieve normalization of oxygen saturation, post-dose","Shin Poong Pharmaceutical Co. Ltd.","All","19 Years and older","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","SP-PA-COV-201","2020-07-01T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-07-17T00:00:00","","2020-07-29T00:00:00","Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyungpook national university hospital, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT04475107"
"508","NCT04416048","Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19","COVID-PREVENT","Not yet recruiting","No Results Available","COVID-19","Drug: Rivaroxaban|Other: Standard Of Care","Composite endpoint of venous thromboembolism , arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|Development of disseminated intravascular coagulation  according to the ISTH criteria|Number of days requiring invasive ventilation|Number of days requiring non-invasive ventilation|Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections","Charite University, Berlin, Germany|Deutsches Zentrum für Herz-Kreislauf-Forschung |Bayer","All","18 Years and older","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","COVID-PREVENT|2020-002282-33","2020-08-01T00:00:00","2021-04-30T00:00:00","2021-05-30T00:00:00","2020-06-04T00:00:00","","2020-07-16T00:00:00","Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg, Baden-Württemberg, Germany|Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Bayern, Germany|Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich, Bayern, Germany|Cardiology, Pneumology and Intensive Care Clinic, München Klinik Neuperlach, München, Bayern, Germany|Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf, Brandenburg, Germany|Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Hessen, Germany|Clinic and Polyclinic Internal Medicine Universitätsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|Cardiology and Pneumology Clinic Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany|Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne, Herne, Nordrhein-Westfalen, Germany|Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal, Wuppertal, Nordrhein-Westfalen, Germany|Center for Cardiology, University Medicine Mainz, Mainz, Rheinland-Pfalz, Germany|Clinic for Vascular Medicine, Städtisches Krankenhaus Dresden, Dresden, Sachsen, Germany|Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden, Dresden, Sachsen, Germany|Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden, Pirna, Sachsen, Germany|Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein, Germany|Department of Pneumology and Infectology Charite University Medicine Berlin, Campus Mitte, Berlin, Germany|Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin, Berlin, Germany|Medical Clinic II. St. Joseph Hospital Berlin, Berlin, Germany|Department of Cardiology Charite University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany|Internal Medicine, Hospital Bethel Berlin in Lichterfelde, Berlin, Germany|Internal Medicine/Cardiology department Unfallkrankenhaus Berlin, Berlin, Germany|Department of Cardiology Charite University Medicine Berlin, Campus Virchow, Berlin, Germany|Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin, Germany|Intensive Care and Cardiology, Hospital Havelhöhe, Berlin, Germany|Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT04416048"
"509","NCT04384029","The Geneva Covid-19 CVD Study","","Active, not recruiting","No Results Available","COVID|CVD","Other: Covid-19 + patients","mobidity discharge|mobidity at 30 days|mobidity 1 year after hospitalization|mortality discharge|mortality 30 days after hospitalization|mortality 1 year after hospitalization|Clinical outcomes according to medication at admission|Clinical outcomes related to preexisting cardiovascular risk factors at admission|New onset of CVD induced by COVID-19 disease|Cost of hospital stay|Clinical follow up at 30 days .|Clinical follow up at 1 year .","François MACH|University Hospital, Geneva","All","18 Years and older","","7000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CCER-2020-00610","2020-03-24T00:00:00","2021-03-31T00:00:00","2022-03-31T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Geneva University Hospital , Geneva, Switzerland","","https://ClinicalTrials.gov/show/NCT04384029"
"510","NCT04349540","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation  Affected by Severe COVID19","","Active, not recruiting","No Results Available","COVID19","Other: no intervention","Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH","Great Ormond Street Hospital for Children NHS Foundation Trust","All","3 Months and older","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20BO08","2020-04-15T00:00:00","2020-10-15T00:00:00","2021-01-15T00:00:00","2020-04-16T00:00:00","","2020-04-16T00:00:00","Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04349540"
"511","NCT04458363","Convalescent Plasma in Pediatric COVID-19","","Recruiting","No Results Available","COVID","Biological: Convalescent Plasma |Drug: Standard COVID-19 therapies","Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma  infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay |Mean length of hospital stay |Mean length of ventilation |Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer","Emory University","All","up to 22 Years","Early Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","STUDY00000789","2020-07-01T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT04458363"
"512","NCT04411147","A Longitudinal Study of COVID-19 Sequelae and Immunity","","Recruiting","No Results Available","COVID-19","","Medical Sequelae in COVID- 19 Survivors|Risk Factors for Medical Sequelae in COVID-19 Survivors|Antibody and cell-mediated immune responses to SARSCoV-2|Antibody and cell-mediated immune responses to SARSCoV-2 over time|Incidence of reinfection with COVID-19|Incidence of clinical silent infection|Mental health status in COVID-19 survivors and contacts","National Institute of Allergy and Infectious Diseases |National Institutes of Health Clinical Center","All","18 Years and older","","900","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200123|20-I-0123","2020-06-17T00:00:00","2025-12-31T00:00:00","2027-12-31T00:00:00","2020-06-02T00:00:00","","2020-07-07T00:00:00","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04411147"
"513","NCT04466839","Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients","ERCO-Park","Not yet recruiting","No Results Available","Parkinson Disease|COVID","Other: Questionnaire and interview","Impact of containment related to the Covid-19 pandemic.|Conditions of containment during the Covid-19 pandemic.|The number of patients infected or possibly infected with Covid-19|Symptoms modifications","University Hospital, Toulouse","All","Child, Adult, Older Adult","","400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RC31/20/0193","2020-07-02T00:00:00","2020-12-18T00:00:00","2020-12-18T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","Centre Hospitalier Regionale Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire Lille, Lille, France|Centre Hospitalier Universitaire de Marseille, Marseille, France|Centre Hospitalier Universitaire de Nîmes - Caremeau, Nimes, France|Centre Hospitalier Universitaire de la Pitie-Salpêtrière, Paris, France|Centre Hospitalier Universitaire de Reims, Reims, France|Centre Hospitalier Universitaire de Rouen, Rouen, France|CHU Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04466839"
"514","NCT04387279","The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease","","Recruiting","No Results Available","COVID-19|Perception, Self|Facilities and Services Utilization","Other: Interview","Patient's perception of COVID-19 and medical use patterns|Exacerbation of symptoms","Keimyung University Dongsan Medical Center|Yeungnam University College of Medicine","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020-04-070","2020-04-24T00:00:00","2021-03-30T00:00:00","2021-03-30T00:00:00","2020-05-13T00:00:00","","2020-05-13T00:00:00","KeimyungUniversity, Daegu, Jung-gu, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT04387279"
"515","NCT04360538","Long Term Outcomes of Patients With COVID-19","COVID19 LTFU","Recruiting","No Results Available","Critical Illness|Corona Virus Infection|Respiratory Failure|Covid-19","Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale","Quality of Life score|cognitive dysfunction|Functional Status Score|Physical Disability|Psychological Sequelae","University of Chicago","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0538","2020-04-08T00:00:00","2021-07-01T00:00:00","2021-12-30T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","University of Chicago Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04360538"
"516","NCT04368884","Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients","","Recruiting","No Results Available","Covid-19","","Development of antibodies","Max Healthcare Insititute Limited","All","18 Years to 80 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC-2/2020","2020-04-22T00:00:00","2021-06-30T00:00:00","2021-07-30T00:00:00","2020-04-30T00:00:00","","2020-07-22T00:00:00","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04368884"
"517","NCT04388631","Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.","COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019","Other: Coronavirus Disease 2019","Sperm density|Sperm activity|Erection hardness and duration|IIEF-5/QEQ questionnaire score|Detection rate of SARS-CoV-2 in male genitourinary system|Semen volume|Sperm survival rate|Serum testosterone/luteinizing hormone /follicle stimulating hormone  level|SCL-90 questionnaire score","Tongji Hospital","Male","18 Years to 60 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-S073","2020-05-10T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-05-14T00:00:00","","2020-05-18T00:00:00","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04388631"
"518","NCT04370197","Covid-19 Epidemic on Acute Stroke Management","Stroke-Covid19","Recruiting","No Results Available","Stroke, Acute","","Study of the effect of pandemic covid-19 on the management of stroke patients","University Hospital, Strasbourg, France","All","18 Years and older","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7826","2020-03-03T00:00:00","2020-04-30T00:00:00","2020-04-30T00:00:00","2020-04-30T00:00:00","","2020-04-30T00:00:00","Service de Neuroradiologie Interventionnelle, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04370197"
"519","NCT04428073","Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2  Infection","","Not yet recruiting","No Results Available","COVID","Biological: Covax-19™","To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response|Virologic response after vaccination|Clinical outcome and progression after vaccinations","GeneCure Biotechnologies","All","18 Years to 60 Years","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","GC004","2020-07-01T00:00:00","2021-07-01T00:00:00","2021-12-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04428073"
"520","NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells","COVID_MSV","Recruiting","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","TerCel_007|2020-001682-36","2020-04-01T00:00:00","2020-11-30T00:00:00","2020-12-31T00:00:00","2020-04-24T00:00:00","","2020-04-29T00:00:00","Hospital Universitario Rio Hortega, Valladolid, Spain","","https://ClinicalTrials.gov/show/NCT04361942"
"521","NCT04451889","Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Device: miniprobe Alveoflex","Number of COVID-19 Participants With Notable Differences in the pCLE images in comparison with the pCLE images of non-COVID-19 Participants|Number of Participants With the Correspondence of pCLE Images to High Resolution Computer Tomography and Morphologic Data as a Measure of Specificity and Sensitivity of the Method","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 90 Years","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","COVID-pCLE","2020-08-01T00:00:00","2021-07-01T00:00:00","2021-09-01T00:00:00","2020-06-30T00:00:00","","2020-07-24T00:00:00","Federal Research Clinical Center FMBA Russia, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04451889"
"522","NCT04480593","The Use of Brazilian Green Propolis Extract  in Patients Affected by COVID-19.","Bee-Covid","Recruiting","No Results Available","Covid19","Drug: Brazilian Green Propolis Extract |Other: Standard care","Composite clinical outcome with oxygen therapy dependency time or hospitalization time|Percentage of participants with adverse events during the use of propolis|Rate and severity of acute kidney injury during the study|Renal replacement therapy.|Rate of need for vasopressor use|Need for intensive care unit |Intensive care unit  readmission|Invasive oxygenation time|Variation of plasma c-reactive protein","D'Or Institute for Research and Education|Hospital Sao Rafael","All","18 Years and older","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","31099320.6.0000.0048","2020-06-02T00:00:00","2020-08-15T00:00:00","2020-08-30T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","Hospital Sao Rafael, Salvador, BA, Brazil","","https://ClinicalTrials.gov/show/NCT04480593"
"523","NCT04487951","N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia","","Recruiting","No Results Available","COVID19 Pneumonia","Other: Pro BNP , Vitamin D","NT-pro-BNP and Vitamin D|Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection","Cairo University|Kasr El Aini Hospital","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2020-7-1","2020-07-01T00:00:00","2020-11-01T00:00:00","2021-01-01T00:00:00","2020-07-27T00:00:00","","2020-07-27T00:00:00","Kasr Alainy Cairo University, Cairo, Giza, Egypt","","https://ClinicalTrials.gov/show/NCT04487951"
"524","NCT04346602","A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019","","Recruiting","No Results Available","COVID-2019","Other: all treatment about COVID-2019","fever|cough|diarrhea|anxiety|insomnia|depression","Jilin University","All","1 Year to 80 Years","","132","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130004","2020-02-01T00:00:00","2020-06-01T00:00:00","2020-12-01T00:00:00","2020-04-15T00:00:00","","2020-04-15T00:00:00","the First Hospital of Jilin University, Chang chun, Jilin, China","","https://ClinicalTrials.gov/show/NCT04346602"
"525","NCT04433026","BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: N terminal pro B type natriuretic peptide , D-Dimer, and serum Tropinin - I","Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients|Cardiac complications in COVID-19 patients associated with more adverse effects","Assiut University","All","Child, Adult, Older Adult","","90","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Cardiac markers in COVID-19","2020-07-01T00:00:00","2021-07-01T00:00:00","2021-09-01T00:00:00","2020-06-16T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04433026"
"526","NCT04459520","Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance","","Not yet recruiting","No Results Available","COVID-19","Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario","Behavioral Intentions|Personal Decisions Subscale|Social Expectations Subscale|Voting Behavior Question|Protest Question|Transportation","University of California, Los Angeles","All","18 Years to 110 Years","Not Applicable","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Screening","IRB#20-000980","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-07-07T00:00:00","","2020-07-24T00:00:00","UCLA Health Department of Medicine, Quality Office, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT04459520"
"527","NCT04493242","Extracellular Vesicle Infusion Therapy for Severe COVID-19","EXIT COVID-19","Not yet recruiting","No Results Available","Covid19|ARDS|Pneumonia, Viral","Biological: DB-001","all-cause mortality|median days to recovery","Direct Biologics, LLC","All","18 Years to 85 Years","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","DB-001","2020-09-01T00:00:00","2020-11-30T00:00:00","2020-12-31T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","","","https://ClinicalTrials.gov/show/NCT04493242"
"528","NCT04447235","Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection","TITAN","Recruiting","No Results Available","Cancer|COVID|Coronavirus Infection","Drug: Placebo|Drug: Ivermectin|Drug: Losartan","Incidence of severe complications due COVID-19 infection|Incidence of Severe Acute Respiratory Syndrome|Adverse events|Overall survival","Instituto do Cancer do Estado de São Paulo","All","18 Years and older","Phase 2","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","NP 1677/20","2020-07-23T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-06-25T00:00:00","","2020-07-29T00:00:00","Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT04447235"
"529","NCT04514003","The Corona and COVID-19 Study in Telemark and Agder","COVITA","Recruiting","No Results Available","Covid19","","SARS-CoV-2 IgG antibody level|Risk factors for COVID-19","Sykehuset Telemark|Sorlandet Hospital HF|Norwegian Institute of Public Health|London School of Hygiene and Tropical Medicine, UK|Leiden University|Aalborg University","All","18 Years to 85 Years","","5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVITA","2020-07-01T00:00:00","2023-12-31T00:00:00","2035-12-31T00:00:00","2020-08-14T00:00:00","","2020-08-18T00:00:00","Telemark Hospital, Skien, Vestfold And Telemark, Norway","","https://ClinicalTrials.gov/show/NCT04514003"
"530","NCT04516746","Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Biological: AZD1222|Biological: Placebo","To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age|To assess the safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age|To assess the reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age |To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of SARS-CoV-2 asymptomatic infection|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of symptomatic COVID-19 using CDC criteria|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of University of Oxford defined symptomatic COVID-19|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of severe or critical symptomatic COVID-19|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19-related Emergency Department visits|To assess antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or placebo |To determine anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or placebo","AstraZeneca|Iqvia Pty Ltd","All","18 Years and older","Phase 3","30000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","D8110C00001","2020-08-17T00:00:00","2020-12-02T00:00:00","2022-10-05T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Atlantis, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bloomington, Minnesota, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04516746"
"531","NCT04513470","Allocetra-OTS in COVID-19","","Recruiting","No Results Available","COVID-19","Biological: Allocetra-OTS","Assessment of safety by determining the number of participants with any Adverse Events  and Serious Adverse Events |Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levels","Hadassah Medical Organization","All","18 Years to 80 Years","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","DM003","2020-08-01T00:00:00","2021-01-01T00:00:00","2021-02-01T00:00:00","2020-08-14T00:00:00","","2020-08-14T00:00:00","Hadassah Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT04513470"
"532","NCT04465058","Characteristics of Critically Ill COVID 19 Patients","","Recruiting","No Results Available","COVID19","Other: COVID19","clinical characteristics","Assiut University","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","yte","2020-07-08T00:00:00","2020-08-08T00:00:00","2020-08-10T00:00:00","2020-07-09T00:00:00","","2020-07-09T00:00:00","Assiut university, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04465058"
"533","NCT04343404","Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19","ECMO-COVID-19","Completed","No Results Available","Respiratory Distress Syndrome","","Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","University Hospital, Strasbourg, France","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7772","2020-04-01T00:00:00","2020-04-15T00:00:00","2020-04-15T00:00:00","2020-04-13T00:00:00","","2020-06-29T00:00:00","Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04343404"
"534","NCT04451577","Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection","UNICODE","Recruiting","No Results Available","COVID","Other: No intervention","Clinical response to COVID-19|Immunological response to COVID-19|Genetic predisposition to COVID-19|Microbiome-related response to COVID-19","Istituto Clinico Humanitas","All","18 Years and older","","5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","UNICODE","2020-06-01T00:00:00","2021-06-01T00:00:00","2023-06-01T00:00:00","2020-06-30T00:00:00","","2020-06-30T00:00:00","Humanitas reseach hospital , Rozzano, Milan, Italy","","https://ClinicalTrials.gov/show/NCT04451577"
"535","NCT04391829","Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males","COVIDSPERM","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2|Corona Virus Infection|Semen","Diagnostic Test: Ejaculated semen sample","detection of SARS-CoV-2 in the semen|duration of SARS-CoV-2 presence in semen|semen viscosity|semen volume|semen pH|Sperm motility|Sperm morphology|Sperm density","Universitair Ziekenhuis Brussel","Male","18 Years to 50 Years","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","COVIDSPERM","2020-05-12T00:00:00","2020-07-15T00:00:00","2020-08-31T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","","","https://ClinicalTrials.gov/show/NCT04391829"
"536","NCT04345445","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","","Not yet recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Methylprednisolone","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization  Coronavirus Disease 2019  ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","University of Malaya","All","18 Years and older","Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Treatment","TVCS-COVID19","2020-04-15T00:00:00","2020-10-31T00:00:00","2020-10-31T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","University Malaya Medical Centre, Kuala Lumpur, Malaysia","","https://ClinicalTrials.gov/show/NCT04345445"
"537","NCT04422977","Serological Study of the Exposure of Personnel to Sars-cov-2","SEROPHUGAC","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Sars-Cov-2 serology","Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff","Centre Hospitalier Saint Joseph Saint Luc de Lyon","All","18 Years to 70 Years","Not Applicable","900","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","SEROPHUGAC","2020-06-08T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","","","https://ClinicalTrials.gov/show/NCT04422977"
"538","NCT04405492","Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19","ERap-COV","Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Device: Taking blood samples , saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary sampling","Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection|Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated|Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence|Sensitivity and specificity of immunodiagnostic tests according to the sample used  and according to the duration of the symptoms|Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used  and according to the duration of the symptoms|Suitability of rapid tests in view of its intended purpose for self-testing","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Not Applicable","1210","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","APHP200556","2020-05-25T00:00:00","2021-03-25T00:00:00","2021-03-25T00:00:00","2020-05-28T00:00:00","","2020-05-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04405492"
"539","NCT04359459","Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study","CIPOLLINI","Not yet recruiting","No Results Available","COVID-19","","Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII system","University Medical Center Groningen","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIPOLLINI","2020-06-01T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-04-24T00:00:00","","2020-04-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04359459"
"540","NCT04376580","Use of the Nasal Cannula During COVID-19","","Enrolling by invitation","No Results Available","COVID 19","","Number of physician using los flow nasal cannula during COVID 19 pandemia|Number of physician getting sick during Covid 19 pandemic","Tiva Group","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Nasal cannulas flow rate","2020-04-30T00:00:00","2020-07-31T00:00:00","2020-09-30T00:00:00","2020-05-06T00:00:00","","2020-05-21T00:00:00","Carolina Frederico, Buenos Aires, Caba, Argentina","","https://ClinicalTrials.gov/show/NCT04376580"
"541","NCT04352751","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","","Recruiting","No Results Available","Covid-19","Other: convalescent plasma","Change in COVID-19 severity status","Hilton Pharma","All","18 Years to 55 Years","Not Applicable","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","PIPK- 0000 /NIBD-0000/2020","2020-05-01T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-20T00:00:00","","2020-05-15T00:00:00","National Institute of Blood Diseases and Bone Marrow Transplantation , Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT04352751"
"542","NCT04471051","An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients","","Recruiting","No Results Available","Covid19","","Inpatient Mortality|Requirement for mechanical ventilation|Transfer to ICU|ICU Mortality|ICU Length of Stay |Hospital Mortality|Hospital Length of Stay","University of Colorado, Denver","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0986","2020-04-30T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-07-14T00:00:00","","2020-07-14T00:00:00","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States","","https://ClinicalTrials.gov/show/NCT04471051"
"543","NCT04362813","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","CAN-COVID","Recruiting","No Results Available","Pneumonia and Cytokine Release Syndrome","Drug: Canakinumab|Drug: Placebo","Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein |Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event , serious adverse events , clinically significant changes in laboratory measures, and vital signs","Novartis Pharmaceuticals|Novartis","All","12 Years and older","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CACZ885D2310|2020-001370-30","2020-04-30T00:00:00","2020-09-22T00:00:00","2020-12-22T00:00:00","2020-04-27T00:00:00","","2020-08-11T00:00:00","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Lyon cedex 04, Rhone, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Prien A Chiemsee, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Reggio Emilia, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04362813"
"544","NCT04401254","Recovery of Patients From COVID-19 After Critical Illness","COVID-Recovery","Not yet recruiting","No Results Available","COVID-19|Critical Illness","","Physiotherapy intervention|Disability-free survival|Proportion of patients with COVID-19 who received physiotherapy in ICU|The reported barriers to delivering physiotherapy interventions|Adverse events during physiotherapy interventions|Health status|Global function|Cognitive function|Anxiety and depression|Screening for post-traumatic distress|Work Status|Phenomenological data of the patient and family experience","Australian and New Zealand Intensive Care Research Centre|The Alfred","All","18 Years and older","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-Recovery V1.0 01May2020","2020-07-01T00:00:00","2021-12-01T00:00:00","2022-04-01T00:00:00","2020-05-26T00:00:00","","2020-07-10T00:00:00","Canberra Hospital, Canberra, Australian Capital Territory, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Australian New Zealand Intensive Care Reseearch Centre, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Alfred Hospital, Prahran, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT04401254"
"545","NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years","Phase 2","228","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","020-132","2020-04-03T00:00:00","2020-07-30T00:00:00","2020-07-30T00:00:00","2020-04-03T00:00:00","","2020-05-05T00:00:00","Baylor University Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT04333225"
"546","NCT04367207","African Covid-19 Critical Care Outcomes Study","","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","","In-hospital mortality|Risk factors  associated with mortality","University of Cape Town|University of KwaZulu","All","18 Years and older","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACCCOS","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-31T00:00:00","2020-04-29T00:00:00","","2020-05-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04367207"
"547","NCT04351529","Austrian COVID-19 Registry","","Recruiting","No Results Available","Infectious Disease|COVID-19","","Documentation of natural course and the therapeutic landscape of patients with COVID-19.","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years and older","","1000","Other","Observational","Observational Model: Other|Time Perspective: Other","AGMT_COVID-19","2020-04-01T00:00:00","2021-12-01T00:00:00","2021-12-01T00:00:00","2020-04-17T00:00:00","","2020-04-20T00:00:00","IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria","","https://ClinicalTrials.gov/show/NCT04351529"
"548","NCT04516512","Assessment of SARS-CoV-2 Seroprevalence in Detention","COVIDET","Not yet recruiting","No Results Available","COVID-19","Biological: Blood draw","Determination of the immunological parameters  of the SARS-CoV-2 infection|Symptoms suggestive of COVID-19|Factors assumed to be related to infection with SARS-CoV-2 and the occurrence of moderate to severe forms of COVID-19","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years","Not Applicable","2500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Screening","APHP200667","2020-09-01T00:00:00","2021-01-01T00:00:00","2021-01-01T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","","","https://ClinicalTrials.gov/show/NCT04516512"
"549","NCT04510623","Host Response Mediators in Coronavirus  Infection","ARBS CORONA I","Recruiting","No Results Available","COVID-19|SARS-CoV2","Other: ARBs and/or ACE inhibitors|Other: Usual Care","COVID-19 WHO ordinal scale|Organ Dysfunction|28-day mortality|Hospital/ICU length of stay|ICU admission","University of British Columbia|Canadian Institutes of Health Research |British Columbia Centre for Disease Control|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Toronto|University of Ottawa|University of Calgary|University of Alberta|University of Victoria|Wuhan University|Peking Union Medical College|University of Pennsylvania","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","H20-00600","2020-03-17T00:00:00","2021-06-30T00:00:00","2022-06-30T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","University of Calgary - Foothills, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Pauls Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|William Osler Health System, Brampton, Ontario, Canada|Queens University, Kingston, Ontario, Canada|Humber River Hospital, North York, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Universite de Sherbrooke, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT04510623"
"550","NCT04450017","Clinical Features of Severe Patients With COVID-19","","Recruiting","No Results Available","SARS-CoV2","Diagnostic Test: The demographic, clinical, laboratory, and instrumental data","Mechanical ventilation duration|Non-invasive Mechanical ventilation duration|Mortality|Сomplete blood count|Biochemistry analysis|Сomplete blood count dynamics|Biochemistry analysis dynamics|Computer tomography|High-sensitive troponin Т|High-sensitive troponin Т dynamics|Vitamin D level|Vitamin D level dynamics|Immunogram|Immunogram dynamics","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 90 Years","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","COVID-ICU","2020-04-06T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-06-29T00:00:00","","2020-06-29T00:00:00","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT04450017"
"551","NCT04371315","Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019  In Children","","Recruiting","No Results Available","Corona Virus Infection|Pediatric Cancer|Adult Children|Cancer","","Characteristics and outcomes of acute respiratory infections due to COVID-19 in children.|Clinical risk factors of acute respiratory infection due to COVID-19 in children.|Immunologic response to acute respiratory infection due to COVID-19 in children.|Duration of viral shedding and evolution in children longitudinally.","St. Jude Children's Research Hospital","All","up to 24 Years","","400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19","2020-04-27T00:00:00","2021-06-01T00:00:00","2022-06-30T00:00:00","2020-05-01T00:00:00","","2020-06-29T00:00:00","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT04371315"
"552","NCT04431908","Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects","","Recruiting","No Results Available","COVID-19","Device: olfactory device","sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy","Yale University","All","18 Years and older","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2000028259","2020-06-15T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-06-16T00:00:00","","2020-08-04T00:00:00","Yale New Haven Hospital, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT04431908"
"553","NCT04508556","Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study","COVID","Not yet recruiting","No Results Available","Covid19","Device: Breath Biopsy face masks with removable filters and fitted PVA strip|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: oropharyngeal swabs","Positive control for technical validation|Evaluation of test performance","Owlstone Ltd|OLVG|Maastricht University","All","18 Years and older","","500","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SARS-CoV-2 study","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-08-11T00:00:00","","2020-08-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04508556"
"554","NCT04363450","Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers","HCQPreP","Recruiting","No Results Available","COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection","Louisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at Lafayette","All","18 Years and older","Phase 3","1700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","LSU NO HSC IRB 20-050","2020-04-27T00:00:00","2020-07-06T00:00:00","2020-08-03T00:00:00","2020-04-27T00:00:00","","2020-04-29T00:00:00","Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT04363450"
"555","NCT04323228","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: oral nutrition supplement  enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002  at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1  at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","King Saud University","All","18 Years to 65 Years","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Supportive Care","ONS_COVID-19","2020-07-01T00:00:00","2020-10-01T00:00:00","2020-10-30T00:00:00","2020-03-26T00:00:00","","2020-06-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04323228"
"556","NCT04378829","Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19","","Not yet recruiting","No Results Available","Covid-19|Mean Platelet Volume|Platelet Destruction","Diagnostic Test: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19","Change in PDW and MPV parameters","Konya Training and Research Hospital","All","Child, Adult, Older Adult","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","COVID-19","2020-05-04T00:00:00","2020-05-11T00:00:00","2020-05-13T00:00:00","2020-05-07T00:00:00","","2020-05-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04378829"
"557","NCT04313023","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","","Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","PUL-042-501","2020-06-09T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-03-18T00:00:00","","2020-06-19T00:00:00","University of California Irvine, Orange, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04313023"
"558","NCT04479982","Microbial Infection and AMR in Hospitalized Patients With Covid 19","","Not yet recruiting","No Results Available","Covid19","","Microbial infections and antimicrobial resistance  patterns associated with hospitalized patients with 2019 novel coronavirus disease","Assiut University","All","Child, Adult, Older Adult","","70","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Microbial infection with covid","2020-08-24T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-07-21T00:00:00","","2020-08-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04479982"
"559","NCT04373486","Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels","COVID-APE","Recruiting","No Results Available","Covid-19 With Positive RT-PCR","","Rate of positivity for Acute Pulmonary Embolism","University Hospital, Strasbourg, France","All","18 Years and older","","160","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7840","2020-03-03T00:00:00","2020-04-30T00:00:00","2020-05-01T00:00:00","2020-05-04T00:00:00","","2020-05-04T00:00:00","Service de Radiologie B - NHC, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04373486"
"560","NCT04370249","Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19","VIRUS","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Other: pulmonary ultrasound","Construction of a composite clinical-echo score  predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department|Evaluate the prognostic performance of the VIRUScore on the risk of pulmonary aggravation|Evaluate the prognostic performance of the VIRUScore on the risk of severe pulmonary aggravation defined by resuscitation admission and/or death at D14 .|Construction of a decisional algorithm for triage and management of COVID-19 patients.|Search for ""ultrasound signature""  associated with mild  vs. moderate  vs. severe  clinical forms.|Evaluate the analytical concordance between the pulmonary ultrasound  and the Gold-standard CT-scan |Construction of a score predictive of aggravation in the sub-population of patients returned home","Nantes University Hospital|WINFOCUS-France","All","18 Years and older","","400","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RC20_0164","2020-04-09T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-04-30T00:00:00","","2020-04-30T00:00:00","Chu de Nantes, Nantes, France","","https://ClinicalTrials.gov/show/NCT04370249"
"561","NCT04379089","Neurologic Manifestations of COVID 19 in Children","","Recruiting","No Results Available","COVID|Neurologic Manifestations","Other: Observational study only","Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19|Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19","University of Pittsburgh|University of Utah|Johns Hopkins University","All","up to 17 Years","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY20040154","2020-04-29T00:00:00","2021-12-31T00:00:00","2022-12-31T00:00:00","2020-05-07T00:00:00","","2020-05-07T00:00:00","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04379089"
"562","NCT04412395","Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease","COVID-19_LF","Not yet recruiting","No Results Available","Corona Virus Infection|Middle East Respiratory Syndrome |Acute Respiratory Distress Syndrome|Coronavirus Infection|COVID-19|SARS-CoV 2","Dietary Supplement: Lactoferrin |Drug: Placebo of excipient will be administered","Survival rate.|Rate of disease remission.|The number of patients with PCR negative results.|Mean change in the disease severity .|Mean change in blood pressure.|Mean change in heart beats.|Mean change in body temperature.|Mean change in body respiratory rate.|Mean change in oxygen saturation.|Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen .|Mean change in complete blood picture .|Mean change in C reactive protein .|Mean change in erythrocyte sedimentation rate .|Mean change in D-dimer.|Mean change in ferritin.|Mean change in liver Albumin.|Mean change in total and direct Bilirubin.|Mean change in prothrombin time  and partial thromboplastin time .|Mean change in aspartate aminotransferase .|Mean change in Alanine Aminotransferase .|Mean change in Blood Urea Nitrogen .|Mean change in Serum Creatinine.|Mean change in Serum Creatinine clearance.|Mean change in Glomerular filtration rate .|The mean change in serum interleukin-1 .|The mean change in serum interleukin-6 .|The mean change in serum interleukin-10 .|The mean change in serum tumor necrosis factor-alpha .|Mean changes in immunoglobulin G .|Mean changes in immunoglobulin M .|The mean change in PCR viral load.|Mean change in lung CT manifestation.|Nature and severity of Adverse Events.|Time for lung recovery.|The number of missed drug doses among each treatment group.","National Research Center, Egypt|Egyptian Military Medical Services","All","18 Years to 80 Years","Phase 2","516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","COVID-19_LF","2020-06-01T00:00:00","2020-08-31T00:00:00","2020-09-30T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","National Research Center, Egypt , Cairo, Giza, Egypt|Clinmax CRO , Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services , Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04412395"
"563","NCT04505709","Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19","","Enrolling by invitation","No Results Available","Covid19","","Identification of host genetic markers associated with the evolution of COVID-19|Analysis of bioethical aspects related to in-hospital management of the health crisis|Analysis of the spectrum of mutants of SARS-CoV-2 and its possible association with the clinical evolution of COVID-19","Instituto de Investigación Sanitaria de la Fundación Jimenez Díaz|Hospital Universitario 12 de Octubre|Fundacion Investigacion Biomedica Hospital 12 de Octubre|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario Infanta Elena|Hospital Universitario Virgen de la Arrixaca|Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca","All","18 Months and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STOP-Coronavirus|COV20/00181","2020-08-01T00:00:00","2021-08-01T00:00:00","2021-08-01T00:00:00","2020-08-10T00:00:00","","2020-08-10T00:00:00","Fundacion Jimenez Diaz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04505709"
"564","NCT04492371","COVID-19 Infection and Multiple Myeloma","EMN-COVID","Recruiting","No Results Available","Multiple Myeloma|Covid19|Corona Virus Infection","","Nature of COVID19|Costs related to COVID-19|Systemic anti-cancer therapy subgroup|Laboratory values collected at hospitalization|COVID-19 infection in myeloma patient subgroups|Incidence of COVID-19 infection in frail patients|Infection outcome in different countries","European Myeloma Network|Fondazione EMN Italy Onlus","All","18 Years to 99 Years","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","EMN-COVID","2020-07-01T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","General Hopspital Vienna/Medical University, Vienna, Austria|UCL Saint-Luc, Brussels, Belgium|University Hospital Ostrava, Ostrava, Czechia|University Hospital Würzburg, Würzburg, Germany|Alexandra Clinical Terapeutics, Athens, Greece|AOU Consorziale Policlinico di Bari, Bari, Italy|Amsterdam UMC, Amsterdam, Netherlands|St James's University Hospital, Leeds, United Kingdom","","https://ClinicalTrials.gov/show/NCT04492371"
"565","NCT04428008","Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients","Ta1","Not yet recruiting","No Results Available","COVID-19","Drug: Thymalfasin","Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets |Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters","Inova Health System|Nephrology Associates of Northern Virginia, Inc.|Davita Clinical Research","All","60 Years and older","Phase 2","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","ACW-1221958-1","2020-06-01T00:00:00","2021-01-01T00:00:00","2021-06-01T00:00:00","2020-06-11T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04428008"
"566","NCT04482699","RAPA-501-Allo Off-the-Shelf Therapy of COVID-19","","Not yet recruiting","No Results Available","Severe COVID-19 Disease","Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo","Dose-Limiting Toxicity |Mortality Rate|Ventilation Support|Days of Hospitalization|Number of Deaths|Incidence of Infection|GVHD Incidence","Rapa Therapeutics LLC|Hackensack Meridian Health","All","18 Years and older","Phase 1|Phase 2","88","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double |Primary Purpose: Treatment","RAPA-501-ALLO-COVID-19","2020-09-30T00:00:00","2021-09-30T00:00:00","2021-12-31T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT04482699"
"567","NCT04342663","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","STOP COVID","Active, not recruiting","No Results Available","COVID 19|Coronavirus","Drug: Fluvoxamine|Drug: Placebo","Time to clinical worsening|clinical deterioration on a Likert-type scale |clinical deterioration measured by number of days|Symptomatic severity on a likert scale","Washington University School of Medicine","All","18 Years and older","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","202004023","2020-04-10T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-04-13T00:00:00","","2020-08-12T00:00:00","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT04342663"
"568","NCT04329611","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","","Terminated","No Results Available","COVID-19","Drug: Hydroxychloroquine","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased","Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta","All","18 Years and older","Phase 3","148","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple |Primary Purpose: Treatment","ABCOV-01 version 1.5","2020-04-13T00:00:00","2020-07-20T00:00:00","2020-07-20T00:00:00","2020-04-01T00:00:00","","2020-07-31T00:00:00","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT04329611"
"569","NCT04514302","Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments  for Hospitalized Patients With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments","Proportion of patients with improvement in clinical status|Time to clinical improvement|Proportion of patients that reach a score of 6, 7 or 8 in the NIAID 8-point ordinal scale|Duration of hospitalization|SARS-CoV-2 PCR negativization rate|Proportion of patients with clinical improvement at day 7|Proportion of patients with immediate adverse events |Proportion of patients with late adverse events","Hospital San Jose Tec de Monterrey","All","18 Years and older","Phase 1|Phase 2","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","INOSARS-CoV-2 TecSalud","2020-10-20T00:00:00","2021-02-20T00:00:00","2021-06-20T00:00:00","2020-08-14T00:00:00","","2020-08-14T00:00:00","Hospital San Jose, Monterrey, Nuevo Leon, Mexico","","https://ClinicalTrials.gov/show/NCT04514302"
"570","NCT04474249","Follow-up of Critical COVID-19 Patients","FUP-COVID","Recruiting","No Results Available","COVID19|ARDS|AKI|Circulatory Failure|Coagulation Disorder|Inflammatory Response","","Mortality|Renal recovery|Respiratory recovery|Working capacity|Quality of life score|Cognitive recovery|Frailty|Activities of Daily Life|Anxiety|Depression|Neurological recovery","Uppsala University|Uppsala University Hospital","All","18 Years and older","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPM-2020-02697","2020-06-25T00:00:00","2022-12-01T00:00:00","2022-12-01T00:00:00","2020-07-16T00:00:00","","2020-07-20T00:00:00","Uppsala University Hospital, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT04474249"
"571","NCT04347876","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","","Recruiting","No Results Available","COVID-19|BCG Vaccination","Diagnostic Test: Tuberculin test","Pneumonia severity index|Need for ICU admission|COVID -19 test conversion|Mortality","Assiut University","All","12 Years to 80 Years","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AssiutU12","2020-04-11T00:00:00","2020-06-16T00:00:00","2020-06-30T00:00:00","2020-04-15T00:00:00","","2020-04-15T00:00:00","AssiutU, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04347876"
"572","NCT04378777","Immunophenotyping Assessment in a COVID-19 Cohort","IMPACC","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 |SARS-CoV-2","Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments","Mortality Rate Among COVID-19 Patients|Proportion of Patients with COVID-19 who Require Intensive Care Unit -Level Care, Mechanical Ventilatory Support , and/or Extracorporeal Membrane Oxygenation  Over Time to Day 28|Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28|Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction  Over Time to Day 28|Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12|Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28|Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28|Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28|Proportion of Patients with COVID-19 with Requirement for New  Supplemental Oxygen Over Time to Day 28|Requirement for Extracorporeal Membrane Oxygenation  in COVID-19 Patients with COVID-19 Over Time to Day 28|Mechanistic: Immune Cell Frequencies and Activation Status  in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12|Mechanistic: Gene Expression  in Blood|Mechanistic: Gene Expression  in Respiratory Epithelium|Mechanistic: Gene Expression  in Plasma Protein|Mechanistic: Gene expression  in Metabolic Profiling|Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology","National Institute of Allergy and Infectious Diseases |Benaroya Research Institute|Boston Children's Hospital","All","18 Years and older","","2000","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DAIT-COVID-19-002","2020-05-01T00:00:00","2020-12-01T00:00:00","2021-12-01T00:00:00","2020-05-07T00:00:00","","2020-07-14T00:00:00","University of Arizona  College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center, Tucson, Arizona, United States|University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Baylor College of Medicine: Department of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04378777"
"573","NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2  in Colombia","","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit |Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19  without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection","Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva","All","18 Years and older","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","76968","2020-05-11T00:00:00","2020-10-11T00:00:00","2020-10-31T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia","","https://ClinicalTrials.gov/show/NCT04359095"
"574","NCT04492358","Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center","","Not yet recruiting","No Results Available","Covid19","Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of care","Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19|Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|Percentage of patients who stop medication due to adverse events.|Severity of symptoms by COVID-19 in the two treatment arms","Maria Joyera Rodríguez|Fundacion Clinic per a la Recerca Biomedica","All","65 Years and older","Phase 2|Phase 3","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-002462-14","2020-09-01T00:00:00","2021-10-01T00:00:00","2021-10-01T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","","","https://ClinicalTrials.gov/show/NCT04492358"
"575","NCT04447131","Effect of COVID-19 on Platelet Aggregation","","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: venipuncture in peripheral vein","Platelet aggregation analyzed by Multiplate-ADP|Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.|Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.|Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Platelet aggregation versus time  of total hospitalization and in the ICU|Reticulated platelet fraction versus time  of total hospitalization and in the ICU|Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years and older","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SDC 5089/20/118","2020-04-29T00:00:00","2020-07-30T00:00:00","2020-12-30T00:00:00","2020-06-25T00:00:00","","2020-06-25T00:00:00","Instituto do Coracao , Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT04447131"
"576","NCT04344977","Collection of Anti-SARS-CoV-2 Immune Plasma","NIAID","Recruiting","No Results Available","Coronavirus Disease 2019","","Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma","National Institute of Allergy and Infectious Diseases |National Institutes of Health Clinical Center","All","18 Years to 70 Years","","1500","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","200081|20-I-0081","2020-06-01T00:00:00","2024-07-01T00:00:00","2025-04-01T00:00:00","2020-04-14T00:00:00","","2020-08-04T00:00:00","Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT04344977"
"577","NCT04252274","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","DC-COVID-19","Recruiting","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Darunavir and Cobicistat","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","DC-COVID-19","2020-01-30T00:00:00","2020-08-31T00:00:00","2020-12-31T00:00:00","2020-02-05T00:00:00","","2020-04-13T00:00:00","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT04252274"
"578","NCT04355234","Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","COVIPREG","Not yet recruiting","No Results Available","Pregnancy","Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples","Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman|Consequences of SARS-CoV-2 infection in pregnant women and their newborns : Pregnancy outcome, maternal or neonatal complications|Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy|Assessment of susceptibility to infection during the 3 trimesters of pregnancy|Evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.|Assessment of the rate of SARS-CoV-2 infection in pregnant women the risk factors for the disease.|Assessment of the rate of SARS-CoV-2 infection in newborns and the risk factors for the disease.","Assistance Publique - Hôpitaux de Paris","Female","18 Years and older","Not Applicable","2200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Screening","APHP 200448","2020-04-24T00:00:00","2021-08-31T00:00:00","2021-08-31T00:00:00","2020-04-21T00:00:00","","2020-04-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04355234"
"579","NCT04407390","Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly","NR-COVID19","Recruiting","No Results Available","COVID","Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo","Hypoxic respiratory failure|Mortality|Sepsis|Circulatory failure|Days in hospital|NAD levels","University of Copenhagen|Bispebjerg Hospital|Elysium Health","All","70 Years and older","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","H-20026601","2020-06-01T00:00:00","2021-05-01T00:00:00","2022-05-01T00:00:00","2020-05-29T00:00:00","","2020-06-02T00:00:00","Bispebjerg Hospital, Copenhagen NV, Denmark","","https://ClinicalTrials.gov/show/NCT04407390"
"580","NCT04408456","Efficacy of Hydroxychloroquine  as Post Exposure Prophylaxis  for Prevention of COVID-19","PEP-CQ","Completed","No Results Available","CoVID-19","Drug: HCQ|Other: Standard therapy","Incidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction","Postgraduate Institute of Medical Education and Research","All","18 Years and older","Phase 3","325","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","IEC-04/2020-1624","2020-03-01T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-05-29T00:00:00","","2020-08-04T00:00:00","Post Graduate Institute of Medical Education and Research , Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India","","https://ClinicalTrials.gov/show/NCT04408456"
"581","NCT04433364","COPE - COVID-19 in Pregnancy and Early Childhood","COPE","Recruiting","No Results Available","Sars-CoV2|Covid-19|Pregnancy Complications|Pregnancy Preterm|Pregnancy in Diabetic|Neonatal Infection","Other: biological samples, questionnaires and interviews","Biobank with linkage to registers|Experiences of pregnancy during a pandemic","Sahlgrenska University Hospital, Sweden","Female","18 Years and older","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-02848 0604","2020-06-02T00:00:00","2021-06-02T00:00:00","2041-06-02T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Falu Hospital, Falun, Dalarna, Sweden|Halmstad lasarett, Halmstad, Halland, Sweden|Varbergs sjukhus, Varberg, Halland, Sweden|Helsingborgs lasarett, Helsingborg, Skåne, Sweden|Skåne Universitetssjukhus, Lund, Skåne, Sweden|Eskiltuna hospital, Eskilstuna, Södermanland, Sweden|Boras hospital, Boras, VGR, Sweden|Sahlgrenska Univeristy Hospital, Gothenburg, VGR, Sweden|Ryhovs sjukhus, Jönköping, Sweden|Kalmar Lasarett, Kalmar, Sweden|Karlstad lasarett, Karlstad, Sweden|Kristiandstad länssjukhus, Kristianstad, Sweden|Skaraborgs sjukhus Skövde, Skövde, Sweden|BB Stockholm, Stockholm, Sweden|Danderyd, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital- Huddinge, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Södertälje, Stockholm, Sweden|Sundsvall, Sundsvall, Sweden|Umeå University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Västerås, Västerås, Sweden|Ystad, Ystad, Sweden|Örebro University Hospital, Örebro, Sweden|Linköping University Hospital, Linköping, Östergötland, Sweden|Vrinnevisjukhuset, Norrköping, Östergötland, Sweden","","https://ClinicalTrials.gov/show/NCT04433364"
"582","NCT04503525","Nutritional Assessment of Hospitalized Patients With COVID-19","DenutCOVID","Recruiting","No Results Available","SARS-CoV|Nutrition Disorders","Other: Nutritional assessment","Nutritional status of COVID infected patients|Correlation between the nutritional status and the supplemental oxygen requirement|Correlation between the nutritional status and the prognostic after hospitalization","Lille Catholic University","All","18 Years and older","","50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RC-P00100","2020-05-25T00:00:00","2021-05-25T00:00:00","2021-06-30T00:00:00","2020-08-07T00:00:00","","2020-08-07T00:00:00","Saint-Vincent Hospital, Lille, Haut-de-France, France","","https://ClinicalTrials.gov/show/NCT04503525"
"583","NCT04493294","Low Dose Whole Lung Radiotherapy for Older Patients With COVID-19 Pneumonitis","","Not yet recruiting","No Results Available","COVID-19 Pneumonitis","Radiation: Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis","Mortality rate|Duration of hospitalization|Time to recovery|Oxygen saturation rate|Patient inflammatory status","International Geriatric Radiotherapy Group|Brigitta G. Baumert","All","65 Years and older","Phase 1|Phase 2","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","IGRG01","2020-11-01T00:00:00","2021-12-01T00:00:00","2021-12-01T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","","","https://ClinicalTrials.gov/show/NCT04493294"
"584","NCT04392427","New Antiviral Drugs for Treatment of COVID-19","","Not yet recruiting","No Results Available","COVID|Drug Effect","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","negative test result for COVID-19","Mansoura University","All","12 Years and older","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single |Primary Purpose: Treatment","20.05.69","2020-05-01T00:00:00","2022-05-01T00:00:00","2022-05-01T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","Mansoura University, Mansoura, Select A State Or Province, Egypt","","https://ClinicalTrials.gov/show/NCT04392427"
"585","NCT04341415","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","SOS-COVID19","Recruiting","No Results Available","Covid19|SARS-CoV Infection","Procedure: Auricular neuromodulation|Procedure: Control","Comparison of the percentage of clinically improved inpatients between D0 and D14","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CRN_2020_8","2020-04-09T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-10T00:00:00","","2020-05-13T00:00:00","Fondation Adolphe de Rothschild, Paris, France","","https://ClinicalTrials.gov/show/NCT04341415"
"586","NCT04371692","Prevalence of COVID-19 Infection Among HCW in a French University Hospital","EXPOCOVIA","Not yet recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care Worker","University Hospital, Lille|Fondation Sante Roquette","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_35|2020-A00951-38","2020-04-01T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04371692"
"587","NCT04515108","Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies","","Completed","No Results Available","Pregnancy, Infections in|Covid19","Other: Clinical assessment","complete blood count parameters .|APGAR score|maternal and newborn length|maternal and newborn weight|body temperature","Ankara City Hospital Bilkent","Female","18 Years to 42 Years","","108","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","E1-20-672","2020-03-10T00:00:00","2020-08-05T00:00:00","2020-08-10T00:00:00","2020-08-17T00:00:00","","2020-08-17T00:00:00","Ankara City Hospital, Ankara, Turkey","","https://ClinicalTrials.gov/show/NCT04515108"
"588","NCT04456413","Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","","Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma|Other: Best Supportive Care","Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.","Hackensack Meridian Health","All","18 Years and older","Phase 2","306","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Treatment","Pro2020-0542","2020-07-01T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-02T00:00:00","","2020-07-02T00:00:00","Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT04456413"
"589","NCT04477213","Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.","","Not yet recruiting","No Results Available","COVID19|Healthcare Workers","","Rate of COVID-19 in healthcare workers |clinical severity of infection in HCWs","NMC Specialty Hospital","All","18 Years to 70 Years","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NMCHCW-COVID","2020-08-01T00:00:00","2020-08-31T00:00:00","2020-09-20T00:00:00","2020-07-20T00:00:00","","2020-07-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04477213"
"590","NCT04438694","Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection","CP IN COVID19","Recruiting","No Results Available","COVID19","Drug: Convalescent Plasma","Duration of hospitalization/Recovery status","Cairo University","All","21 Years to 70 Years","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","N39-2020","2020-06-01T00:00:00","2021-05-31T00:00:00","2021-12-31T00:00:00","2020-06-19T00:00:00","","2020-06-19T00:00:00","Cairo University Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04438694"
"591","NCT04493307","The Evaluation of Hemostasis in Hospitalized COVID-19 Patients","TARGET-COVID","Recruiting","No Results Available","COVID-19","Diagnostic Test: Phlebotomy","Frequency of Hypercoagulability as measured by thromboelastography measured by TEG and platelet aggregation.|Frequency of High Platelet Reactivity |Frequency of thrombo-inflammatory syndrome|Correlation between TEG6s parameters and clinical outcomes|Correlation between HPR and clinical outcomes|Determine response to anticoagulation therapy|Determine level of platelet aggregation|Determine platelet thrombi and fibrin rich platelet thrombus Area Under the Curve","LifeBridge Health|Haemonetics Corporation|Inflammatory Markers Laboratory|Chronolog Corporation|Precision Biologics, Inc","All","3 Years and older","","100","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","1602903","2020-06-30T00:00:00","2020-09-01T00:00:00","2021-06-01T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Sinai Center for Thrombosis Research, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04493307"
"592","NCT04405973","Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO","","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Extracorporeal Membrane Oxygenation|ARDS","Device: vv-ECMO","overall survival|duration of ECMO treatment|duration of ventilation treatment|duration of initiation of ECMO treatment to ICU discharge","Dr. Alexander Supady|University Hospital Freiburg","All","18 Years to 100 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EK-FR 329/20","2020-05-19T00:00:00","2020-06-30T00:00:00","2020-08-31T00:00:00","2020-05-28T00:00:00","","2020-06-01T00:00:00","University Clinic Freiburg, Freiburg, Germany","","https://ClinicalTrials.gov/show/NCT04405973"
"593","NCT04429620","Prospective Assay for SARS-CoV-2  Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method","IIF","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Immunfluorescence","Sensitivity of the method by SARS-CoV2 ELISA compared|Detectability of the antibodies IgA type against SARS-CoV2 virus","Szeged University|Bilogical Research Centre, Szeged","All","18 Years and older","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","SARS-CoV-2-IIF-002","2020-05-30T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-06-12T00:00:00","","2020-06-25T00:00:00","University of Szeged, Albert Szent-Györgyi Health Center, Szeged, Hungary","","https://ClinicalTrials.gov/show/NCT04429620"
"594","NCT04408209","Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection","","Recruiting","No Results Available","COVID-19 Infection","Procedure: Convalescent Plasma","Survival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease","National and Kapodistrian University of Athens|Hellenic Society of Hematology","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","245-14-4-20","2020-04-23T00:00:00","2020-06-30T00:00:00","2021-09-15T00:00:00","2020-05-29T00:00:00","","2020-06-02T00:00:00","""Evangelismos"" General Hospital, Athens, Attiki, Greece|""Agios Savas"" Oncology Hospital, Athens, Attiki, Greece|""Alexandra"" General Hospital, Athens, Attiki, Greece|""Sotiria"" General Hospital, Athens, Attiki, Greece|Attikon"" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece","","https://ClinicalTrials.gov/show/NCT04408209"
"595","NCT04510454","Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19","ONCOVID-21","Not yet recruiting","No Results Available","Cancer|COVID","Diagnostic Test: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR","To determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection|To determine the agreements between nasopharyngeal samples and oropharyngeal samples|To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays|To assess the 28-day mortality rate|To determine potential predictive factors of death among patients' characteristics|To evaluate the over risk of death of patients COVID+ versus COVID-","Centre Leon Berard","All","18 Years and older","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","ONCOVID-21 - ET20-118","2020-09-01T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04510454"
"596","NCT04327531","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","","Completed","No Results Available","COVID-19|Physician-Patient Relations","Behavioral: turkish physicians","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Kanuni Sultan Suleyman Training and Research Hospital","All","25 Years to 55 Years","","200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","turkishcovid19","2020-03-26T00:00:00","2020-05-22T00:00:00","2020-05-28T00:00:00","2020-03-31T00:00:00","","2020-06-05T00:00:00","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04327531"
"597","NCT04422444","Post Intensive Care Syndrome in COVID19 Patients","PICS-COVID19","Recruiting","No Results Available","COVID19|Post Intensive Care Unit Syndrome","Diagnostic Test: Questionnaires","Change from baseline Short Form 12 Health Survey  at 12 month|Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months|Change from baseline Perceived Deficits Questionnaire  at 12 months|Change from baseline Hospital Anxiety and Depression Scale  at 12 months|Change from baseline Davidson Trauma Scale  at 12 months","Corporacion Parc Tauli","All","18 Years to 90 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/577","2020-06-01T00:00:00","2021-05-01T00:00:00","2022-06-01T00:00:00","2020-06-09T00:00:00","","2020-06-12T00:00:00","Corporació Parc Taulí, Sabadell, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04422444"
"598","NCT04366180","Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers","","Recruiting","No Results Available","Covid-19","Dietary Supplement: Probiotic|Dietary Supplement: Control","Incidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 ºC|Days with cough|Days with fatigue|Medical treatment","Biosearch S.A.","All","20 Years and older","Not Applicable","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","P054","2020-04-24T00:00:00","2020-06-01T00:00:00","2020-10-01T00:00:00","2020-04-28T00:00:00","","2020-04-30T00:00:00","Raquel Rodriguez Blanque, Granada, Spain","","https://ClinicalTrials.gov/show/NCT04366180"
"599","NCT04376658","Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19","","Not yet recruiting","No Results Available","Quality of Life|Long-term Outcomes|Coronavirus Infection","Other: COVID-19","One-year utility score of health-related quality of life|Incidence of all-cause mortality|Incidence of rehospitalizations|Percentage of return to work or study|Score of Instrumental Activities of Daily Living|Score of dyspnea|Percentage of long-term ventilatory support need|Symptoms of anxiety and depression|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months|Score of self-rated health","Hospital Moinhos de Vento|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital do Coracao|Hospital Alemão Oswaldo Cruz|Beneficência Portuguesa de São Paulo|Brazilian Clinical Research Institute|Brazilian Research In Intensive Care Network","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Coalition COVID-19: Long-term","2020-06-15T00:00:00","2021-09-15T00:00:00","2021-09-15T00:00:00","2020-05-06T00:00:00","","2020-05-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04376658"
"600","NCT04329507","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry","","Not yet recruiting","No Results Available","COVID-19|Respiratory Disease","Diagnostic Test: Breath test","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","NHS Lothian","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282014","2020-03-25T00:00:00","2020-03-25T00:00:00","2020-03-25T00:00:00","2020-04-01T00:00:00","","2020-04-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04329507"
"601","NCT04330586","A Trial of Ciclesonide in Adults With Mild COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication |Viral load area-under-the-curve  reduction versus control|Time to clinical improvement |Proportion of clinical failure","Korea University Guro Hospital","All","18 Years to 80 Years","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","KUMC-COVID-19","2020-04-01T00:00:00","2020-06-30T00:00:00","2020-09-30T00:00:00","2020-04-01T00:00:00","","2020-04-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04330586"
"602","NCT04433013","A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Lianhua Qingwen|Drug: Placebo","Proportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30","Nanyang Technological University|Ministry of Health, Singapore","All","21 Years and older","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","IRB-2020-05-029","2020-07-01T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-06-16T00:00:00","","2020-06-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04433013"
"603","NCT04391127","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection","","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","2020-A-09","2020-05-04T00:00:00","2020-08-30T00:00:00","2020-09-30T00:00:00","2020-05-18T00:00:00","","2020-06-12T00:00:00","Jose Manuel Arreola Guerra, Aguascalientes, Mexico","","https://ClinicalTrials.gov/show/NCT04391127"
"604","NCT04353596","Stopping ACE-inhibitors in COVID-19","ACEI-COVID","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: ACE inhibitor, angiotensin receptor blocker","Combination of maximum Sequential Organ Failure Assessment  Score and death|Composite of admission to an intensive care unit , the use of mechanical ventilation, or all-cause death|Maximum and median maximum Sequential Organ Failure Assessment  Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein , interleukin 6 , D-Dimer, IL-6, hochsensitives Troponin , NT-pro-brain natriuretic peptide |Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential","Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum für Herz-Kreislauf-Forschung","All","18 Years and older","Phase 4","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","EudraCT 2020-001206-35","2020-04-15T00:00:00","2021-05-15T00:00:00","2022-05-15T00:00:00","2020-04-20T00:00:00","","2020-06-11T00:00:00","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany","","https://ClinicalTrials.gov/show/NCT04353596"
"605","NCT04474067","COVID-19 - Cytokine Storm","","Recruiting","No Results Available","COVID-19","Other: No intervention","Clinical Outcomes of Patients with COVID-19 using the National Early Warning Score 2  system|Clinical Outcomes of Patients with COVID-19 using the new NIH Patient Classification of severity of illness|Mortality|Cytokine/Chemokine/Hematopoietic Growth Factors/ Complement and Other Immune Modulators in Patients with COVID-19","Hadassah Medical Organization|Barzilai Medical Center|The Chaim Sheba Medical Center","All","18 Years and older","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DM002","2020-06-28T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-07-16T00:00:00","","2020-08-13T00:00:00","Hadassah Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT04474067"
"606","NCT04366141","COVID-19  Intubation Barrier Box","","Recruiting","No Results Available","COVID-19","Device: COVID-19 barrier box","Time to tracheal intubation |First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier Box","University of British Columbia","All","18 Years and older","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","H20-01270","2020-05-01T00:00:00","2021-01-01T00:00:00","2021-01-01T00:00:00","2020-04-28T00:00:00","","2020-05-28T00:00:00","Providence Health Care, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT04366141"
"607","NCT04379466","Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19","CovRep","Recruiting","No Results Available","COVID-19","","A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcome","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200544|2020-A01245-34","2020-05-05T00:00:00","2020-10-11T00:00:00","2021-04-01T00:00:00","2020-05-07T00:00:00","","2020-08-18T00:00:00","Hôpital Pitie Salpetrère, Paris, France","","https://ClinicalTrials.gov/show/NCT04379466"
"608","NCT04389489","Postpartum Sexual Function in Pregnant Women With COVID-19","","Recruiting","No Results Available","COVID-19|Dyspareunia|Postpartum Period","","Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years","","140","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","MTalmacCarol","2020-05-14T00:00:00","2020-08-01T00:00:00","2020-08-03T00:00:00","2020-05-15T00:00:00","","2020-06-11T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey","","https://ClinicalTrials.gov/show/NCT04389489"
"609","NCT04376853","CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch","CoronaWatch","Recruiting","No Results Available","COVID-19","Device: Apple Watch Series 5","Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models","University Hospital Heidelberg|The German Heart Foundation|Klaus Tschira Stiftung|Freunde und Förderer der Kardiologie Heidelberg","All","18 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CoronaWatch","2020-04-15T00:00:00","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT04376853"
"610","NCT04359849","Sequencing and Tracking of Phylogeny in COVID-19 Study","STOP COVID 19","Recruiting","No Results Available","Coronavirus Infection","","To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples|To develop a phylogenetic map of the SARS-CoV-2 virus","Portsmouth Hospitals NHS Trust|University of Portsmouth","All","7 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PHT/2020/34","2020-05-01T00:00:00","2022-05-01T00:00:00","2022-09-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT04359849"
"611","NCT04318314","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","Recruiting","No Results Available","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Seroconversion to SARS-CoV-2 positivity","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","All","18 Years and older","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130852","2020-03-18T00:00:00","2020-12-31T00:00:00","2021-12-31T00:00:00","2020-03-23T00:00:00","","2020-05-21T00:00:00","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04318314"
"612","NCT04379479","Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19","FUTURE-T","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral","Change in the score of the ""Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19""|Clinical deterioration|Duration of the clinical status","National Polytechnic Institute, Mexico","All","18 Years and older","Phase 2","562","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IC-20-001|SH-001-2020","2020-05-01T00:00:00","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-05-07T00:00:00","","2020-05-07T00:00:00","Escuela Nacional de Ciencias Biológicas, Instituto Politecnico Nacional, Mexico City, Mexico","","https://ClinicalTrials.gov/show/NCT04379479"
"613","NCT04381338","Rehabilitation for People With COVID-19 in ICU","COVID_REHAB","Not yet recruiting","No Results Available","Corona Virus Disease 19 |COVID|Acute Lung Injury/Acute Respiratory Distress Syndrome |Critical Illness","Other: Pulmonary and Motor Rehabilitation","Length of ICU stay|Length of hospital stay","University of Padova|Prof. S Masiero, University of Padova, Italy|Dr. A. Venturin, General Hosipital, Padova, Italy|Dr. I. Tiberio, General Hospital, Padova, Italy|Dr. D. Zampieri, University of Padova, Italy|Dr.ssa M Cattelan, University of Padova, Italy|Prof. P. Zanatta, University Hosiptal, Verona, Italy|Dr.ssa C. Carollo, General Hospital, Padova, Italy|Prof. E. Polati, University Hospital, Verona, Italy|Prof. K. Donadello, University Hospital, Verona, Italy","All","18 Years and older","Not Applicable","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","UPadova_1","2020-05-10T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-05-08T00:00:00","","2020-05-08T00:00:00","Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italy","","https://ClinicalTrials.gov/show/NCT04381338"
"614","NCT04345510","Testing for COVID-19 Infection in Asymptomatic Persons","","Not yet recruiting","No Results Available","COVID-19 Infection","","COVID-19 infection","German Cancer Research Center","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19-1.0-DKFZ","2020-04-20T00:00:00","2020-05-31T00:00:00","2020-12-31T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","","","https://ClinicalTrials.gov/show/NCT04345510"
"615","NCT04469153","Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19","","Recruiting","No Results Available","the Prognostic Value of Ferritin|Glycosylated Ferritin in SARS-CoV-2 Infection in Hospitalized COVID-19 Patients","Other: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests","assessment of the prognostic value of ferritin in sars-cov2 positiv patients","Hospices Civils de Lyon","All","18 Years and older","","57","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020_FerriGly COVID","2020-06-29T00:00:00","2020-09-01T00:00:00","2020-12-31T00:00:00","2020-07-13T00:00:00","","2020-07-13T00:00:00","hopital de la Croix Rousse, Lyon 4, Rhone Alpes, France","","https://ClinicalTrials.gov/show/NCT04469153"
"616","NCT04414098","Ruxolitinib in the Treatment of Covid-19","","Not yet recruiting","No Results Available","COVID-19","Drug: INC424 / Ruxolitinib","Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib","Marcelo Iastrebner|Novartis|Clinica Zabala","All","18 Years and older","Phase 2","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","CZabala","2020-06-01T00:00:00","2020-08-15T00:00:00","2020-09-15T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04414098"
"617","NCT04393974","COVID-19 and Cancer Patients","OnCovid","Recruiting","No Results Available","Cancer|Sars-CoV2","","Describe presenting characteristics and severity or SARS-CoV-2 infection in patients with cancer|Assessing what factors are involved in prognosis of cancer patients with COVID-19","Imperial College London","All","18 Years and older","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","282140","2020-03-24T00:00:00","2022-03-24T00:00:00","2022-03-24T00:00:00","2020-05-19T00:00:00","","2020-05-21T00:00:00","Imperial College Healthcare NHS Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04393974"
"618","NCT04449042","The PAWS-COVID-19  Registry","","Recruiting","No Results Available","Airway Management|COVID19","Procedure: airway management during sedation or general anesthesia","airway complications|airway device|PPE|First pass success|induction techniques|failed intubation|complication risk factors","Boston Children's Hospital|Children's Hospital of Philadelphia|Children's Hospital Colorado|Istituto Giannina Gaslini|The Hospital for Sick Children|Perth Children's Hospital of Western Austrailia|Lurie Children's Hospital of Chicago","All","up to 18 Years","","15000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00035427","2020-04-01T00:00:00","2025-12-01T00:00:00","2025-12-01T00:00:00","2020-06-26T00:00:00","","2020-06-26T00:00:00","Boston Children's Hopsital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04449042"
"619","NCT04397822","COVID-19: Study of INFLAmmasome and PLAtelets Functions","CO-QUETTES","Recruiting","No Results Available","COVID-19","Biological: Blood samples","Activation of platelet NLRP3 inflammasome","University Hospital, Toulouse","All","18 Years and older","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0142","2020-04-16T00:00:00","2020-10-01T00:00:00","2021-04-01T00:00:00","2020-05-21T00:00:00","","2020-05-21T00:00:00","CHU Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04397822"
"620","NCT04377464","COVID-19 - Quality of Life After Infection","","Not yet recruiting","No Results Available","COVID-19|Quality of Life","Other: SF12, EQ-5D-5L and work status standardized quantitative assessments","Six-month SF-12v2 Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2|One-month EQ-5D-5L Scores|Three-month SF-12v2 Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work Status","Chinese University of Hong Kong","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NTEC-2020-0227","2020-05-05T00:00:00","2021-04-30T00:00:00","2022-04-30T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04377464"
"621","NCT04499391","COVID-19 Project ECHO in Nursing Homes","","Not yet recruiting","No Results Available","Covid19","Other: Project ECHO","Infection rate|Hospitalization|Death","Milton S. Hershey Medical Center","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","PCORI Nursing Homes","2020-08-01T00:00:00","2022-07-01T00:00:00","2022-07-01T00:00:00","2020-08-05T00:00:00","","2020-08-05T00:00:00","","","https://ClinicalTrials.gov/show/NCT04499391"
"622","NCT04381845","Immunity and Infections in the Psychiatric Population","COVIDIMMUNOPSY","Not yet recruiting","No Results Available","COVID|Psychiatric Disorders","Diagnostic Test: COVID19 immunization testing","Number of COVID-positive patients","Assistance Publique - Hôpitaux de Paris|Institut National de la Sante Et de la Recherche Medicale, France","All","18 Years and older","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","APHP200553","2020-05-10T00:00:00","2020-06-10T00:00:00","2020-06-25T00:00:00","2020-05-11T00:00:00","","2020-05-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04381845"
"623","NCT04492904","Singapore COVID-19 Chemosensory Tracking  Study","","Recruiting","No Results Available","Covid19","Other: Home-use Test and Follow-up Questionnaire","Taste and smell acuity|Experienced symptoms, changes in appetite and food-related quality of life","Clinical Nutrition Research Centre, Singapore|National University Hospital, Singapore","All","21 Years to 70 Years","","5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","2020/00810","2020-07-23T00:00:00","2021-03-31T00:00:00","2021-03-31T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Clinical Nutrition Research Centre, Singapore, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT04492904"
"624","NCT04356534","Convalescent Plasma Trial in COVID -19 Patients","","Completed","No Results Available","SARS-CoV 2|COVID-19","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate","Royal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Royal Medical Services, Military Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali","All","21 Years and older","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","BDF/R&REC/2020-423","2020-04-19T00:00:00","2020-06-15T00:00:00","2020-07-09T00:00:00","2020-04-22T00:00:00","","2020-07-28T00:00:00","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain","","https://ClinicalTrials.gov/show/NCT04356534"
"625","NCT04312243","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","Recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Massachusetts General Hospital","All","18 Years to 99 Years","Phase 2","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","NOpreCOVID-19","2020-04-07T00:00:00","2021-04-07T00:00:00","2022-04-07T00:00:00","2020-03-18T00:00:00","","2020-06-16T00:00:00","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04312243"
"626","NCT04355624","Kidney Involvement in COVID-19 Disease","COVKID","Recruiting","No Results Available","COVID|Kidney Injury","","Kidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3","Centre Hospitalier Universitaire de Nice","All","18 Years and older","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid02","2020-04-15T00:00:00","2020-04-30T00:00:00","2020-07-30T00:00:00","2020-04-21T00:00:00","","2020-05-13T00:00:00","Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France","","https://ClinicalTrials.gov/show/NCT04355624"
"627","NCT04367857","ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers","","Recruiting","No Results Available","Covid-19|Coronavirus Infection|Coronavirus","Other: COVID-19 Serology|Behavioral: Health Care Worker Survey","Proportion seropositive","Columbia University","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAS9998","2020-04-18T00:00:00","2021-10-01T00:00:00","2021-10-01T00:00:00","2020-04-29T00:00:00","","2020-04-30T00:00:00","NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04367857"
"628","NCT04381819","Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19","","Recruiting","No Results Available","SARS Virus|Severe Acute Respiratory Syndrome","Diagnostic Test: SARS-CoV-2 PCR","Death|Recovery from COVID-19|Progression to ICU care or ventilation|Clearance of SARS-CoV-2 from respiratory specimen|Immune response to COVID-19","Oslo University Hospital|University Hospital, Akershus|Vestre Viken Hospital Trust|Østfold Hospital Trust|Haukeland University Hospital|University Hospital of North Norway|St. Olavs Hospital","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-04072","2020-03-02T00:00:00","2022-02-28T00:00:00","2023-12-31T00:00:00","2020-05-11T00:00:00","","2020-05-11T00:00:00","Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|Østfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway","","https://ClinicalTrials.gov/show/NCT04381819"
"629","NCT04359615","Favipiravir in Hospitalized COVID-19 Patients","FIC","Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Hydroxychloroquine","Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry  Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","Favipiravir in COVID-19","2020-04-20T00:00:00","2020-05-03T00:00:00","2020-05-05T00:00:00","2020-04-24T00:00:00","","2020-04-28T00:00:00","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04359615"
"630","NCT04345536","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","CovidRegOUH","Recruiting","No Results Available","COVID-19","","Mortality|Severe disease","Oslo University Hospital","All","Child, Adult, Older Adult","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidRegOUH","2020-03-15T00:00:00","2021-01-01T00:00:00","2021-05-01T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT04345536"
"631","NCT04462393","Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19","","Completed","No Results Available","COVID-19|Critical Illness","Other: Admission to ICU for COVID-19","30-day mortality|ICU mortality","Linkoeping University|Region Östergötland","All","18 Years and older","","1563","Other","Observational","Observational Model: Cohort|Time Perspective: Other","SweCOVID","2020-03-06T00:00:00","2020-05-06T00:00:00","2020-05-06T00:00:00","2020-07-08T00:00:00","","2020-07-09T00:00:00","Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland, Linköping, Östergötland, Sweden","","https://ClinicalTrials.gov/show/NCT04462393"
"632","NCT04438837","Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease  Among Health-Care Workers","","Not yet recruiting","No Results Available","Coronavirus Disease 2019 |Post-Exposure Prophylaxis","Drug: Hydroxychloroquine","Clinical COVID-19|Confirmed COVID-19|Time to virological recovery|Time to symptoms onset|Development of pneumonia|Development of severe disease|Need for hospitalization or ICU|Adverse events|Mortality|Time to de-isolation","Rambam Health Care Campus","All","18 Years and older","Not Applicable","582","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","0193-20-RMB CTIL","2020-07-01T00:00:00","2022-06-01T00:00:00","2022-06-01T00:00:00","2020-06-19T00:00:00","","2020-07-23T00:00:00","Rambam Health Care Campus, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT04438837"
"633","NCT04380766","Covid-19 Pandemic and Pancreatic Surgery in Italy","PanCOVID","Completed","No Results Available","Pancreatic Cancer","Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer","Changes in pancreatic cancer management during the COVID-19 pandemic","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older","","730","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","FPGemelliIRCCS","2019-01-01T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-05-08T00:00:00","","2020-08-03T00:00:00","Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italy","","https://ClinicalTrials.gov/show/NCT04380766"
"634","NCT04371510","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","PredictCovid-D","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: blood sample","Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation","Centre Hospitalier Universitaire de Nice","All","18 Years to 85 Years","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","20-PP-08","2020-04-22T00:00:00","2020-10-22T00:00:00","2021-02-22T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","CHU de nice, Nice, Alpes-Maritimes, France","","https://ClinicalTrials.gov/show/NCT04371510"
"635","NCT04426084","Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study","","Active, not recruiting","No Results Available","COVID-19","Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins","Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT|ECMO |ICU Mortality","Karolinska Institutet","All","18 Years and older","","22784","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","4","2020-03-01T00:00:00","2020-05-11T00:00:00","2022-12-31T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Södersjukhuset, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT04426084"
"636","NCT04359316","Azithromycin in Hospitalized COVID-19 Patients","AIC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","Azithromycin in COVID-19","2020-04-20T00:00:00","2020-05-03T00:00:00","2020-05-05T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04359316"
"637","NCT04407169","Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease","CRITICoVid","Not yet recruiting","No Results Available","COVID","Other: no intervention","Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measured","Central Hospital, Nancy, France","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020PI081","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","","","https://ClinicalTrials.gov/show/NCT04407169"
"638","NCT04508712","Long-term Outcomes in Patients With COVID-19","","Not yet recruiting","No Results Available","COVID-19","","Physical functions|Respiratory function|Cognitive function|Depression status|Sensory functions|Heart function","RenJi Hospital","All","18 Years and older","","900","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID-19 Prognosis","2020-08-10T00:00:00","2021-08-31T00:00:00","2021-08-31T00:00:00","2020-08-11T00:00:00","","2020-08-11T00:00:00","Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, China","","https://ClinicalTrials.gov/show/NCT04508712"
"639","NCT04460183","A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care  Compared to SOC Alone in Hospitalized Participants With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care","Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14|Change in room air oxygen saturation  from baseline over time|Change in National Early Warning Score  2 symptom score from baseline over time|Change from baseline on the modified WHO ordinal scale at each visit up to Day 28|Time to improvement to a lower level  of modified WHO ordinal scale|Time to progression to a higher level  of modified WHO ordinal scale|Number of participants with adverse events and serious adverse events","Thirty Respiratory Limited","All","18 Years and older","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RESP301-002","2020-07-06T00:00:00","2021-01-27T00:00:00","2021-04-23T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04460183"
"640","NCT04354519","The United Kingdom Multiple Sclerosis Register Covid-19 Substudy","UKMSRCV19","Recruiting","No Results Available","Multiple Sclerosis|COVID-19","","Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D","Swansea University","All","18 Years and older","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16SW0194","2020-03-14T00:00:00","2021-07-14T00:00:00","2022-07-14T00:00:00","2020-04-21T00:00:00","","2020-06-22T00:00:00","Swansea Univeristy, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04354519"
"641","NCT04349228","Assessment of the Efficacy and Safety of  as a Prophylaxis for COVID19 for Health Professionals","COVID_2Pro","Recruiting","No Results Available","COVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare Worker","Drug: Hydroxychloroquine |Drug: Placebo oral tablet","Symptomatic COVID infection rate","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","All","18 Years to 65 Years","Phase 3","530","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","ECC2020-03","2020-04-28T00:00:00","2020-07-15T00:00:00","2020-07-15T00:00:00","2020-04-16T00:00:00","","2020-05-06T00:00:00","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia","","https://ClinicalTrials.gov/show/NCT04349228"
"642","NCT04366245","Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","","Recruiting","No Results Available","SARS-CoV 2","Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection","Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale .|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement  in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients requiring treatment.|Efficacy: Duration of hospitalization |Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","PC/COVID-19","2020-04-23T00:00:00","2021-12-01T00:00:00","2021-12-01T00:00:00","2020-04-28T00:00:00","","2020-06-11T00:00:00","Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jimenez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT04366245"
"643","NCT04340479","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","","Not yet recruiting","No Results Available","COVID|Trauma|Ultrasound","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients","University of Colorado, Denver","All","Child, Adult, Older Adult","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0751","2020-06-01T00:00:00","2022-05-01T00:00:00","2022-05-01T00:00:00","2020-04-09T00:00:00","","2020-06-04T00:00:00","Children's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT04340479"
"644","NCT04377672","Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2","","Recruiting","No Results Available","Corona Virus Infection","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection","Johns Hopkins University","All","1 Month to 18 Years","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","IRB00247557","2020-05-28T00:00:00","2021-05-28T00:00:00","2022-05-28T00:00:00","2020-05-06T00:00:00","","2020-06-02T00:00:00","Johns Hopkins Hospitals, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04377672"
"645","NCT04490486","Umbilical Cord Tissue  Derived Mesenchymal Stem Cells  Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Corona Virus Infection","Biological: UCMSCs|Other: Placebo","Percent of participants with treatment related Serious Adverse Events |Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms","Joshua M Hare|University of Miami","All","18 Years and older","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","20200575","2020-08-01T00:00:00","2024-06-01T00:00:00","2024-06-01T00:00:00","2020-07-29T00:00:00","","2020-07-29T00:00:00","University of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT04490486"
"646","NCT04402814","IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.","","Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Clungene rapid test cassette","IgG/IgM antibodies","Fadi Haddad, M.D.|Sharp HealthCare","All","18 Years and older","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IgG/IgM COVID19|2005801","2020-05-05T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-05-27T00:00:00","","2020-07-27T00:00:00","Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT04402814"
"647","NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","Ath/ct101/22/3","2020-03-28T00:00:00","2020-05-28T00:00:00","2020-06-28T00:00:00","2020-03-31T00:00:00","","2020-04-02T00:00:00","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan","","https://ClinicalTrials.gov/show/NCT04328272"
"648","NCT04334928","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection  in Healthcare Personnel","EPICOS","Recruiting","No Results Available","Coronavirus Infection","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Number of confirmed symptomatic infections of SARS-CoV-2 |Severity of disease in confirmed infected participants of SARS-CoV-2 |Duration of symptoms in confirmed infected participants of SARS-CoV-2  measured in days","Plan Nacional sobre el Sida |Effice Servicios Para la Investigacion S.L.","All","18 Years to 70 Years","Phase 3","4000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","PrEP COVID-19","2020-04-15T00:00:00","2020-06-30T00:00:00","2020-07-31T00:00:00","2020-04-06T00:00:00","","2020-04-28T00:00:00","Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Deu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital Severo Ochoa, Leganes, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Medico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jimenez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain","","https://ClinicalTrials.gov/show/NCT04334928"
"649","NCT04365231","Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","HASCOPT","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit","Hospital St. Joseph, Marseille, France","Female","18 Years and older","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","HASCOPT2020","2020-04-01T00:00:00","2020-06-01T00:00:00","2021-01-01T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","Hopital Saint Joseph, Marseille, Paca, France","","https://ClinicalTrials.gov/show/NCT04365231"
"650","NCT04346355","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients","","Terminated","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein  and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RCT-TCZ-COVID-19|2020-001386-37","2020-03-31T00:00:00","2020-06-06T00:00:00","2020-06-06T00:00:00","2020-04-15T00:00:00","","2020-06-22T00:00:00","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy","","https://ClinicalTrials.gov/show/NCT04346355"
"651","NCT04446065","Protection of Health Workers Against COVID-19","HERD","Not yet recruiting","No Results Available","COVID-19|SARS-CoV2","Drug: Previfenon®|Drug: Placebo","Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR|Rate of positive cases for IgM and IgG anti-SARS-CoV-2|Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test|Hospitalization due to any acute respiratory infection|Event of upper and lower airway respiratory infection","MELISA Institute Genomics & Proteomics Research SpA|Universidad Austral","All","25 Years and older","Phase 2|Phase 3","524","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","MEL109042020","2020-07-30T00:00:00","2020-10-30T00:00:00","2020-11-30T00:00:00","2020-06-24T00:00:00","","2020-06-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04446065"
"652","NCT04381988","A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy","","Recruiting","No Results Available","COVID-19|Cancer","Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy","cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older","Phase 2","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","20-176","2020-05-07T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-05-11T00:00:00","","2020-05-13T00:00:00","Memoral Sloan Kettering Basking Ridge , Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth , Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen , Montvale, New Jersey, United States|Memorial Sloan Kettering Commack , Commack, New York, United States|Memoral Sloan Kettering Westchester , Harrison, New York, United States|Memorial Sloan Kettering Cancer Center , New York, New York, United States|Memorial Sloan Kettering Nassau , Uniondale, New York, United States","","https://ClinicalTrials.gov/show/NCT04381988"
"653","NCT04407156","Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom","","Not yet recruiting","No Results Available","COVID|AKI","Other: acute kidney injury","Incidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patients","University Hospitals of Derby and Burton NHS Foundation Trust","All","18 Years to 110 Years","","350","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","UHDB/2020/050","2020-06-01T00:00:00","2021-05-21T00:00:00","2021-05-21T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT04407156"
"654","NCT04459455","Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","","Not yet recruiting","No Results Available","Anxiety","Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI","Change in Anxiety Control Questionnaire  from Baseline to Immediately Post-Intervention|Change in Generalized Anxiety Disorder-7  from Baseline to 2-week follow-up|Change in Activity Social Distancing Intentions - 3 item version  from Baseline to immediately post-intervention|COVID-19 Related Questions|Inventory of Depression and Anxiety Symptoms |Self Hate Scale |Comprehension Questions|Everyday Discrimination Scale-Short version|Perceived Changes in generalized anxiety symptoms|Activity Hand Washing Intentions - 3 item version","Stony Brook University","All","18 Years and older","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","IRB2020-00204","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-08-01T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04459455"
"655","NCT04334252","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","","Recruiting","No Results Available","COVID 19","Other: Questionnaire","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Jessa Hospital","All","18 Years and older","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JessaH_COVID19_prescreening","2020-04-17T00:00:00","2020-12-20T00:00:00","2020-12-20T00:00:00","2020-04-06T00:00:00","","2020-05-19T00:00:00","Jessa hospital, Hasselt, Belgium","","https://ClinicalTrials.gov/show/NCT04334252"
"656","NCT04359537","Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","CHEER","Recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo","COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events","Shaheed Zulfiqar Ali Bhutto Medical University","All","18 Years to 60 Years","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","F.1-1/2015/ERB/SZABMU/549","2020-05-01T00:00:00","2020-08-25T00:00:00","2020-09-25T00:00:00","2020-04-24T00:00:00","","2020-05-19T00:00:00","Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan","","https://ClinicalTrials.gov/show/NCT04359537"
"657","NCT04362267","Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital","PRECOVIA","Recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection","University Hospital, Lille|Fondation Sante Roquette","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020_34|2020-A00950-39","2020-06-15T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-04-24T00:00:00","","2020-08-06T00:00:00","Hôpital Claude Huriez, CHU, Lille, France","","https://ClinicalTrials.gov/show/NCT04362267"
"658","NCT04366778","Thrombosis and Covid-19","COVBIO","Recruiting","No Results Available","Thrombosis|Covid-19|SARS-CoV 2","Diagnostic Test: TEM-tPA","Coagulability|Venous thrombotic event  or arterial thrombosis","Hospices Civils de Lyon","All","18 Years and older","","325","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0401 - COVBIO|ID-RCB","2020-05-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-29T00:00:00","","2020-06-17T00:00:00","Hôpital Louis Pradel, Bron, France","","https://ClinicalTrials.gov/show/NCT04366778"
"659","NCT04354389","DAS181 for STOP COVID-19","","Withdrawn","No Results Available","COVID-19","Drug: DAS181|Drug: Placebo","Percent of subjects return to room air |Percent of subjects who have recovered|Improved COVID-19 Clinical Classification|Return To Room Air |Percent of subjects who achieve clinical stability|SARS-CoV-2 RNA undetectable|Clinical Deterioration|Percent of subjects discharged|Death","Ansun Biopharma, Inc.","All","18 Years and older","Phase 2|Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple |Primary Purpose: Treatment","DAS181-2-08|2020-003192-17","2020-07-25T00:00:00","2020-09-30T00:00:00","2020-11-30T00:00:00","2020-04-21T00:00:00","","2020-08-11T00:00:00","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy","","https://ClinicalTrials.gov/show/NCT04354389"
"660","NCT04292327","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","2019-nCoV","Active, not recruiting","No Results Available","Pneumonia Caused by Human Coronavirus","","Mortality|The time interval of Nucleic acid detection become negative","Fujian Provincial Hospital","All","18 Years to 75 Years","","400","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","KY-2020-24.01","2020-01-01T00:00:00","2020-04-30T00:00:00","2020-07-31T00:00:00","2020-03-03T00:00:00","","2020-03-03T00:00:00","Fujian Provincial Hospital, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT04292327"
"661","NCT04416464","Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19","","Not yet recruiting","No Results Available","Quality of Life|Long-term Outcomes|Coronavirus Infection|Morality|Rehospitalization","Other: COVID-19 Pneumonia","Health-related quality of life.|Length of stay at the ICU.|Incidence of all-cause mortality|Rehospitalization.|Percentage of long-term ventilatory support need.|Percentage of renal replacement therapy need.|Symptoms of anxiety and depression.|Score of functional independence.|Score of cognitive function.|Percentage of major cardiac events.|Score of Chronic obstructive pulmonary disease |Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months.|Score of self-rated health.","Universidade do Porto|Centro Hospitalar De São João, E.P.E.|Centro Hospitalar do Porto|Universidade do Algarve|Centro Hospitalar Lisboa Ocidental","All","18 Years and older","","230","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QoL_ICU_COVID","2020-06-15T00:00:00","2022-07-31T00:00:00","2022-10-01T00:00:00","2020-06-04T00:00:00","","2020-06-17T00:00:00","Centro Hospitalar Universitário do Algarve, Faro, Algarve, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário de São João, Porto, Portugal|Centro Hospitalar Universitário do Porto - Hospital de Santo António, Porto, Portugal","","https://ClinicalTrials.gov/show/NCT04416464"
"662","NCT04463264","Efficacy and Safety Study of Nitazoxanide  in the Treatment of Patients With SARS-CoV-2 Virus Infection","","Recruiting","No Results Available","COVID-19","Drug: Nitazoxanide|Drug: Placebo","Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.|Comparative decrease of the viral load|Clinical improvement|Pneumonia patients meeting severity criteria.|Number of days with fever","Laboratorios Roemmers S.A.I.C.F.","All","18 Years to 59 Years","Phase 2|Phase 3","135","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","NTZ-COVID ARG1","2020-06-26T00:00:00","2020-09-15T00:00:00","2020-10-26T00:00:00","2020-07-09T00:00:00","","2020-07-24T00:00:00","Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina","","https://ClinicalTrials.gov/show/NCT04463264"
"663","NCT04331106","Survey of the Anxiety Associated With the COVID-19 Pandemic","CORA","Recruiting","No Results Available","Anxiety Related to the COVID-19 Pandemic","Diagnostic Test: Online Questionnaire","Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms","Charite University, Berlin, Germany","All","18 Years and older","","7500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA1/071/20","2020-03-27T00:00:00","2020-09-01T00:00:00","2021-04-01T00:00:00","2020-04-02T00:00:00","","2020-07-13T00:00:00","Charite-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT04331106"
"664","NCT04324489","DAS181 for Severe COVID-19: Compassionate Use","","Completed","No Results Available","COVID-19","Drug: DAS181","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","All","18 Years to 70 Years","Not Applicable","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","DAS181-SARS-CoV-2","2020-03-06T00:00:00","2020-04-16T00:00:00","2020-04-30T00:00:00","2020-03-27T00:00:00","","2020-05-05T00:00:00","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04324489"
"665","NCT04473053","Rapid Experimental Medicine for COVID-19","DEFINE","Recruiting","No Results Available","COVID-19","Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard care","The safety of the candidate therapies in COVID-19 patients by measuring physiological changes in the circulatory and respiratory system.|The safety of the candidate therapies in COVID-19 patients by recording the number of treatment related adverse events.|Measuring the PK of the proposed trial treatments in COVID-19 patients.|Measure a change in the expression of key coagulation biomarkers in the blood of COVID-19 patients during and after treatment period.|Measure a change in the expression of key cytokines in the blood of COVID-19 patients during and after treatment period.|To evaluate the improvement or deteroriation of patients in each treatment arm.|To evaluate the number of oxygen-free days.|To evaluate incidence of any form of new ventilation use.|To evaluate ventilator-free days|Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration |To evaluate SARS-CoV-2 viral load.|To evaluate time to discharge|To evaluate the use of renal dialysis or haemofiltration for each treatment arm.","University of Edinburgh|University of Oxford","All","16 Years and older","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","AC20063","2020-07-03T00:00:00","2021-07-03T00:00:00","2021-12-03T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","NHS Lothian, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT04473053"
"666","NCT04357444","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","LILIADE-COVID","Not yet recruiting","No Results Available","COVID 19","Drug: 1: ILT101|Drug: 2: Placebo Comparator","The PaO2/FiO2 ratio at D11|Changes in Tregs between Baseline and Day 7 |Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time  from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 |Use of antibiotics for respiratory  infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff  after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.","Assistance Publique - Hôpitaux de Paris|Iltoo Pharma","All","18 Years and older","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","APHP200406|2020-001571-32","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-04-22T00:00:00","","2020-06-09T00:00:00","Service Anesthesie Reanimation - Groupe Hospitalier Pitie-Salpêtrière, Paris, France","","https://ClinicalTrials.gov/show/NCT04357444"
"667","NCT04429724","Health Professional Exposure Assessment to Covid-19","SERODRON","Recruiting","No Results Available","COVID-19","Diagnostic Test: Diagnostic test Covid-19","Number of contaminated personnel|Number of symptomatic staff by occupational category and service|Number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies","Tourcoing Hospital","All","18 Years and older","Not Applicable","6000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","RIPH_2020_8","2020-07-06T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-06-12T00:00:00","","2020-07-20T00:00:00","CH Roubaix, Roubaix, France|CH Tourcoing, Tourcoing, France|CH Wasquehal, Wasquehal, France|CH Wattrelos, Wattrelos, France","","https://ClinicalTrials.gov/show/NCT04429724"
"668","NCT04331600","Chloroquine as Antiviral Treatment in Coronavirus Infection 2020","","Recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","Wroclaw Medical University","All","18 Years and older","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","WROCLAW CORONA STUDY 2020","2020-04-16T00:00:00","2020-09-30T00:00:00","2020-12-31T00:00:00","2020-04-02T00:00:00","","2020-05-22T00:00:00","Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland","","https://ClinicalTrials.gov/show/NCT04331600"
"669","NCT04355533","Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19","PED-COVID","Not yet recruiting","No Results Available","COVID-19 Infection","Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Seroconversion against SARS-CoV2 in children of the Parisian area|Protective immunity|Measure of Ab antiN and Ab anti-S1|Neutralization activity|Positive qPCR|correlation between different Ab and qPCR and neutralization activity|correlation of the NGBiotech rapid test with the classical serological result|correlation of the NGBiotech rapid test with qPCR results|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|correlation of LIPS, the NGBiotech rapid test with the classical serological result|Presence of COVID-19 Symptom|seroconversion against SARS-CoV2 in parents of the Parisian area|Intra-family correlation of serological results|Measure of Ab antiN and Ab anti-S1 and neutralization activity|correlation between different Ab and qPCR","Assistance Publique - Hôpitaux de Paris|Institut National de la Sante Et de la Recherche Medicale, France|NG Biotech|Commissariat a l'energie atomique et aux energies alternatives|Institut Pasteur","All","up to 17 Years","Not Applicable","1920","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","APHP200467|2020-A00999-30","2020-06-01T00:00:00","2020-06-01T00:00:00","2021-09-01T00:00:00","2020-04-21T00:00:00","","2020-05-20T00:00:00","Hôpital necker Enfants-Malades, ¨Paris, France","","https://ClinicalTrials.gov/show/NCT04355533"
"670","NCT04433910","A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","CAPSID","Recruiting","No Results Available","COVID-19","Drug: Convalesscent Plasma","Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, |Case fatality rate|Length of hospital stay Length of hospital stay |Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR |Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions","Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","All","18 Years to 75 Years","Phase 2","106","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Treatment","CAPSID2020-DRK-BSD|2020-001310-38","2020-06-01T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-06-16T00:00:00","","2020-06-23T00:00:00","University Hospital Ulm, Ulm, Baden-Württmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany","","https://ClinicalTrials.gov/show/NCT04433910"
"671","NCT04389710","Convalescent Plasma for the Treatment of COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel  measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein  in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time  in patients after receiving convalescent plasma|Changes in partial thromboplastin time  in patients after receiving convalescent plasma","Thomas Jefferson University","All","18 Years and older","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20D.379","2020-04-15T00:00:00","2021-04-14T00:00:00","2021-04-14T00:00:00","2020-05-15T00:00:00","","2020-06-25T00:00:00","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04389710"
"672","NCT04422613","Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia","PULCO-19","Recruiting","No Results Available","Pneumonia, Viral","Diagnostic Test: pulmonary anomalies 4 months after documented COVID-19 pneumonia","Alteration of the DLCO|Mechanism of the alteration of gas exchanges|Measurement on lung volumes|mechanism of the alteration of gas exchanges by chest scan|mechanism of the alteration of gas exchanges by scintigraphy|Respiratory symptom|Bronchial or ventilatory anomalies|Persistent respiratory anomalies","University Hospital, Toulouse","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","RC31/20/0181","2020-05-28T00:00:00","2021-05-01T00:00:00","2022-05-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","University Hospital of Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04422613"
"673","NCT04427501","A Study of LY3819253  in Participants With Mild to Moderate COVID-19 Illness","BLAZE-1","Recruiting","No Results Available","COVID-19","Drug: LY3819253|Drug: Placebo","Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2  Viral Load|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Pharmacokinetics : Mean Concentration of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room  Visit, or Death","Eli Lilly and Company|AbCellera Biologics Inc.","All","18 Years and older","Phase 2","400","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double |Primary Purpose: Treatment","17947|J2W-MC-PYAB","2020-06-17T00:00:00","2020-11-05T00:00:00","2020-11-05T00:00:00","2020-06-11T00:00:00","","2020-08-18T00:00:00","Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Banner Univ Med Ctr Tucson, Tucson, Arizona, United States|Smart Cures Clin Research, Anaheim, California, United States|VCT-Covina, Covina, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University of CA, Irvine, Orange, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|iACT Health, Columbus, Georgia, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|CAR d/b/a CT of SWLA, LLC, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Central Texas Clinical Rch, Austin, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States","","https://ClinicalTrials.gov/show/NCT04427501"
"674","NCT04344288","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","CORTI-Covid","Recruiting","No Results Available","Viral Pneumonia Human Coronavirus|COVID-19","Drug: Prednisone|Other: Control group","Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths","Hospices Civils de Lyon","All","18 Years and older","Phase 2","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","69HCL20_0321|2020-001553-48","2020-04-21T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-04-14T00:00:00","","2020-06-11T00:00:00","Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Benite, France|Centre hospitalier Lyon Sud, Pierre-Benite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Medipôle, Villeurbanne, France|Clinique des Portes du Sud, Venissieux, France|CH Annecy-Genevois, Épagny, France","","https://ClinicalTrials.gov/show/NCT04344288"
"675","NCT04345406","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","","Not yet recruiting","No Results Available","COVID","Drug: ACEIs|Drug: Conventional treatment","number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ACEIS COVID 19","2020-04-15T00:00:00","2029-12-01T00:00:00","2029-12-01T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","Tanta University, Tanta, Egypt","","https://ClinicalTrials.gov/show/NCT04345406"
"676","NCT04320017","Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19","JOCOVID","Recruiting","No Results Available","COVID-19|Myocardial Injury|Myocarditis","Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes|Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival","Groupe Hospitalier Pitie-Salpetriere","All","16 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIC1421-20-05","2020-03-20T00:00:00","2020-05-20T00:00:00","2020-05-20T00:00:00","2020-03-24T00:00:00","","2020-04-22T00:00:00","Clinical Investigation Center Pitie-Salpêtrière, Paris, France","","https://ClinicalTrials.gov/show/NCT04320017"
"677","NCT04379336","BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","","Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Bacille Calmette-Guerin |Other: Placebo Comparator","Incidence of HCWs hospitalized due to COVID-19 per arm|Incidence of SARS-CoV-2 infection per arm|Incidence of upper respiratory tract infections per arm|Days of unplanned absenteeism due to COVID-19 or any reason per arm|Incidence of hospitalization for any reason per arm|Incidence of intensive care unit admission per arm|Incidence of death per arm|Prevalence of latent TB infection|Incidence of active TB per arm|Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm|Incidence of treatment related adverse events","TASK Applied Science","All","18 Years and older","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","TASK-008 BCG-CORONA","2020-05-04T00:00:00","2021-04-28T00:00:00","2021-04-28T00:00:00","2020-05-07T00:00:00","","2020-05-07T00:00:00","TASK Foundation, Cape Town, Western Cape, South Africa","","https://ClinicalTrials.gov/show/NCT04379336"
"678","NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection  in Exposed Healthcare Workers","COVIDAXIS","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers |Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","All","18 Years and older","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","20PH061|2020-001188-96","2020-04-14T00:00:00","2020-11-30T00:00:00","2020-11-30T00:00:00","2020-03-31T00:00:00","","2020-06-23T00:00:00","CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France","","https://ClinicalTrials.gov/show/NCT04328285"
"679","NCT04337918","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","NOCOVID","Recruiting","No Results Available","Corona Virus Infection","Drug: NORS","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2","Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life Science","All","19 Years and older","Phase 2","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","COVID-CTP-01","2020-05-08T00:00:00","2020-08-31T00:00:00","2020-09-30T00:00:00","2020-04-08T00:00:00","","2020-06-25T00:00:00","BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche Quebec, Quebec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borromee, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT04337918"
"680","NCT04498286","COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients","COMS-19","Recruiting","No Results Available","Multiple Sclerosis","Diagnostic Test: Testing of SARS-CoV-2 antibodies","The correlation of COVID-19 disease course with MS immunomodulatory treatment","Zoe van Kempen|VU University Medical Center","All","18 Years and older","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL74243.029.20","2020-08-06T00:00:00","2021-11-01T00:00:00","2021-12-01T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","VU medical center, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT04498286"
"681","NCT04431856","CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment","Co-PARENT","Recruiting","No Results Available","Anxiety|Depression|Traumatic Stress Disorder","Behavioral: Unified Protocol for COVID-19 Parenting Stress |Behavioral: SHG","Measure of Anxiety as assessed by the OASIS|Measure of Depression as assessed by the ODSIS|Measure of PTSD as assessed by the PCL-5|Measure of Parenting Overprotection/Overcontrol as assessed by the S-EMBU|Measure of Parenting Rejection as assessed by the S-EMBU|Measure of Parenting Emotional Warmth as assessed by the S-EMBU|Measure of Parent Accommodation for Child Anxiety as assessed by the FASA","University of Miami","All","18 Years and older","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","20200484","2020-05-15T00:00:00","2020-11-07T00:00:00","2020-11-07T00:00:00","2020-06-16T00:00:00","","2020-07-08T00:00:00","University of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT04431856"
"682","NCT04359810","Plasma Therapy of COVID-19 in Critically Ill Patients","","Recruiting","No Results Available","SARS-CoV Infection","Biological: Convalescent Plasma |Biological: Non-convalescent Plasma","Time to Improvement|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital 28-day Mortality Rate","Max R. O'Donnell|New York Blood Center|Columbia University","All","18 Years and older","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","AAAS9924","2020-04-21T00:00:00","2020-12-01T00:00:00","2021-04-01T00:00:00","2020-04-24T00:00:00","","2020-04-30T00:00:00","Columbia University Irving Medical Center/NYP, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04359810"
"683","NCT04344015","COVID-19 Plasma Collection","","Recruiting","No Results Available","COVID-19","Other: Plasma Donation","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Thomas Jefferson University","All","18 Years and older","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","20D.346","2020-04-13T00:00:00","2021-04-12T00:00:00","2021-04-12T00:00:00","2020-04-14T00:00:00","","2020-05-11T00:00:00","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04344015"
"684","NCT04377763","Developement and Evaluation of Serological Assays for COVID-19","SEROCOV","Not yet recruiting","No Results Available","COVID-19","","Sensibility and specificity|Delay between the first symptoms and the positive serological result","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20MWI-SEROCOV","2020-05-01T00:00:00","2020-10-01T00:00:00","2020-10-01T00:00:00","2020-05-06T00:00:00","","2020-05-08T00:00:00","Laboratory of microbiology of hospital hygiene, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France","","https://ClinicalTrials.gov/show/NCT04377763"
"685","NCT04367064","To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare","SCOPe","Recruiting","No Results Available","COVID","","we will compare the clinical outcome of the COVID 19 patients with their age and gender|we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital","Max Healthcare Insititute Limited","All","18 Years to 75 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SCOPe/MHC/Covid-19/2020","2020-04-25T00:00:00","2020-11-25T00:00:00","2020-12-25T00:00:00","2020-04-29T00:00:00","","2020-07-14T00:00:00","Max Super Speciality hospital, Saket , New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04367064"
"686","NCT04478539","Extracorporeal Blood Purification as a Treatment Modality for COVID-19","","Recruiting","No Results Available","Covid19","Device: Extracorporeal blood purification using the oXiris®  hemofilter","Changes in cytokine levels of Interleukin  6, IL-8 and Tumor Necrosis Factor-α |Changes in inflammatory markers; C-Reactive Protein  |Changes in thrombocyte counts |Changes in the coagulation marker Fibrinogen |ICU length of stay after admission |Changes in Neutrophil-to-Lymphocyte Ratio|Changes in the coagulation marker D-Dimers |Changes in the Activation Clotting Time .","Zan Mitrev Clinic","All","18 Years and older","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","EBPZ.357","2020-06-01T00:00:00","2021-06-01T00:00:00","2021-07-01T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","Zan Mitrev Clinic, Skopje, North Macedonia","","https://ClinicalTrials.gov/show/NCT04478539"
"687","NCT04357574","Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19","CORONA-SHIELD","Enrolling by invitation","No Results Available","COVID-19|Cancer","Other: Telehealth","Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19|Number of missed telehealth clinical evaluation visits during COVID-19|Number of unplanned emergency department visits or hospital admissions during COVID-19|Number of acute care visits with listed reason as anemia, nutrition , diarrhea, emesis, infectious , nausea, neutropenia, pain category during COVID-19","Duke University","All","18 Years and older","","1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00105266","2020-04-14T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-04-22T00:00:00","","2020-04-22T00:00:00","Duke Cancer Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04357574"
"688","NCT04501796","A Trial of NT-I7 in COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo","Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.","NeoImmuneTech","All","18 Years to 75 Years","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple |Primary Purpose: Treatment","NIT-116","2020-08-01T00:00:00","2021-10-01T00:00:00","2021-12-01T00:00:00","2020-08-06T00:00:00","","2020-08-06T00:00:00","Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT04501796"
"689","NCT04422509","Lanadelumab for Treatment of COVID-19 Disease","COVID_LAN","Not yet recruiting","No Results Available","COVID-19","Biological: lanadelumab|Other: regular care","oxygen|adverse events","Radboud University|Takeda","All","16 Years and older","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","UMCN-AKF20.04","2020-08-03T00:00:00","2021-08-03T00:00:00","2021-08-03T00:00:00","2020-06-09T00:00:00","","2020-07-24T00:00:00","Jereoen Bosch hospital, 's-Hertogenbosch, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Tergooi ziekenhuizen, Blaricum, Netherlands|Amphia hospital, Breda, Netherlands|Haga hospital, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Elisabeth-Tweesteden ziekenhuis, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala klinieken, Zwolle, Netherlands","","https://ClinicalTrials.gov/show/NCT04422509"
"690","NCT04513210","Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection","","Not yet recruiting","No Results Available","Covid19","","Relation of changes in ultrasound and progression to respiratory failure|Impact of ultrasonographic pneumonia signs on the day of admission on severity of COVID-19 infection|Sensitivity of ultrasonographic pneumonia signs in detecting respiratory failure|Sensitivity of ultrasound in detecting interstitial changes in the lungs|Impact change in severity of ultrasonographic pneumonia signs on severity of COVID-19 infection","Jagiellonian University","All","18 Years and older","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","JagiellonianU67","2020-11-01T00:00:00","2021-10-30T00:00:00","2022-02-28T00:00:00","2020-08-14T00:00:00","","2020-08-18T00:00:00","Jagiellonian University Medical College, Department of Neurology, Kraków, Poland","","https://ClinicalTrials.gov/show/NCT04513210"
"691","NCT04339686","Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.","","Recruiting","No Results Available","The Gold Standard for Current SARS CoV2 Detection is RT-PCR","Diagnostic Test: Thoracic CT Scan","Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation .","Poitiers University Hospital","All","18 Years to 100 Years","","56000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","POWER-COVID_CT","2020-04-20T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-04-09T00:00:00","","2020-04-28T00:00:00","Chu de Poitiers, Poitiers, France","","https://ClinicalTrials.gov/show/NCT04339686"
"692","NCT04368988","Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS  Nanoparticle Vaccine With/Without Matrix-M Adjuvant","","Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 rS|Other: Matrix-M Adjuvant|Other: NSS Saline Placebo","Subjects with solicited AEs - Phase 1|Safety Laboratory Values  - Phase 1|Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen - Phase 1","Novavax","All","18 Years to 59 Years","Phase 1","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","2019nCoV-101","2020-05-25T00:00:00","2020-12-31T00:00:00","2021-07-31T00:00:00","2020-04-30T00:00:00","","2020-05-27T00:00:00","Investigational Research Site 1, Herston, Queensland, Australia|Investigational Research Site 2, Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT04368988"
"693","NCT04446429","Anti-Androgen Treatment for COVID-19","","Recruiting","No Results Available","COVID-19|SARS-CoV2|Androgenetic Alopecia|Prostate Cancer|Benign Prostatic Hyperplasia|SARS","Drug: Dutasteride|Drug: Ivermectin|Drug: Azithromycin|Drug: Proxalutamide","COVID-19 hospitalization|COVID-19 Ordinal Outcomes Scale|Symptoms severity of COVID-19","Applied Biology, Inc.","Male","50 Years and older","Not Applicable","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","AB-DRUG-SARS-004","2020-07-02T00:00:00","2020-12-31T00:00:00","2021-01-31T00:00:00","2020-06-24T00:00:00","","2020-07-29T00:00:00","Corpometria Institute, Brasilia, Brazil","","https://ClinicalTrials.gov/show/NCT04446429"
"694","NCT04340544","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","COMIHY","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 |All-cause mortality within 28 days","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years","Phase 3","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","COMIHY","2020-04-22T00:00:00","2021-11-30T00:00:00","2022-09-30T00:00:00","2020-04-09T00:00:00","","2020-05-11T00:00:00","Institute for Tropical Medicine, Tübingen, Germany","","https://ClinicalTrials.gov/show/NCT04340544"
"695","NCT04318015","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients","PHYDRA","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years and older","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","ProfilaxisCOVID","2020-04-14T00:00:00","2020-12-31T00:00:00","2021-03-31T00:00:00","2020-03-23T00:00:00","","2020-04-17T00:00:00","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico","","https://ClinicalTrials.gov/show/NCT04318015"
"696","NCT04389567","Famotidine Outpatient COVID-19 Treatment Study","","Completed","No Results Available","COVID-19","Drug: Famotidine","Symptomatic improvement|Peripheral blood oxygen saturation","Northwell Health|Cold Spring Harbor Laboratory","All","18 Years and older","","10","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","1605914-1","2020-05-12T00:00:00","2020-05-25T00:00:00","2020-05-25T00:00:00","2020-05-15T00:00:00","","2020-06-04T00:00:00","Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States","","https://ClinicalTrials.gov/show/NCT04389567"
"697","NCT04487665","Oral Manifestations of Coronavirus Disease 2019 :a Multicentre Study","","Not yet recruiting","No Results Available","Covid19","","oral ulcer|hyposalivation","Cairo University","All","18 Years to 40 Years","","50","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","8791","2020-09-15T00:00:00","2020-11-15T00:00:00","2020-12-15T00:00:00","2020-07-27T00:00:00","","2020-07-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04487665"
"698","NCT04393558","Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms","","Recruiting","No Results Available","COVID-19|Healthy Control","Device: ADAM Sensor","Body temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.","Shirley Ryan AbilityLab","All","18 Years to 95 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU00212522","2020-04-20T00:00:00","2022-12-31T00:00:00","2022-12-31T00:00:00","2020-05-19T00:00:00","","2020-05-21T00:00:00","Shirley Ryan AbilityLab, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04393558"
"699","NCT04466462","Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel","","Completed","No Results Available","SARS-CoV-2 Infection","","Number of participants with past SARS-CoV-2 infection|Number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for COVID-19 infection|Number of infections in health personnel based on the degree of exposure to patients infected with COVID-19.|Number of infected participants who are active smokers and/or have chronic lung disease and/ or have history of hypertension.Relationship of degree of exposure to participants infected with SARS-CoV-2 admitted to the hospital.Professional category.|Number of participants infected with SARS-CoV-2 that presented symptoms and their grade. Number of participants infected with SARS-CoV-2 who required hospitalization. Number of participants infected with SARS-CoV-2 who received treatment.|Number of family members infected from each participant with SARS-CoV-2 infection","Fundacio Lluita Contra la SIDA","All","18 Years and older","","1000","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Other","COVID-Hosp","2020-05-26T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-07-10T00:00:00","","2020-07-10T00:00:00","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04466462"
"700","NCT04469179","Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV2","Biological: SAB-185|Other: Normal Saline","Number of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Assesment of the PD of SAB-185 administered intravenously|Immune response elicited by SAB-185|Concentration of subject anti-SAB-185 antibodies elicited by SAB-185|Incidence of SARS-CoV-2 in oropharyngeal  or nasopharyngeal  swab specimens|Level of SARS-CoV-2 in oropharyngeal  or nasopharyngeal  swab specimens","SAb Biotherapeutics, Inc.|Biomedical Advanced Research and Development Authority|Joint Program Executive Office  Chemical, Biological, Radiological, and Nuclear Defense  Enabling Biotechnologies","All","18 Years to 60 Years","Phase 1","21","Industry|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple |Primary Purpose: Treatment","SAB-185-102","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-07-13T00:00:00","","2020-07-13T00:00:00","","","https://ClinicalTrials.gov/show/NCT04469179"
"701","NCT04460703","COVID-19 Vaccine Messaging, Part 1","","Completed","No Results Available","Vaccination|COVID-19","Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message","Intention to get COVID-19 vaccine|Vaccine confidence scale|Persuade others item|Fear of those who have not been vaccinated|Social judgment of those who do not vaccinate","Yale University","All","18 Years and older","Not Applicable","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","2000027983","2020-07-03T00:00:00","2020-07-08T00:00:00","2020-07-08T00:00:00","2020-07-07T00:00:00","","2020-07-21T00:00:00","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT04460703"
"702","NCT04423770","COVID-19 Related Health and Infection Control Practices Among Dentists","","Active, not recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: No intervention","COVID-19 probable or confirmed case|Anxiety|Depression|Dental practice infection control efforts|Dentists' use of personal protective equipment","American Dental Association","All","18 Years and older","","4000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","20-08","2020-06-08T00:00:00","2021-06-08T00:00:00","2021-06-08T00:00:00","2020-06-09T00:00:00","","2020-07-08T00:00:00","American Dental Association, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04423770"
"703","NCT04371640","Sirolimus in COVID-19 Phase 1","SirCO-1","Recruiting","No Results Available","SARS-CoV-2|Covid-19","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events","Walter K. Kraft|Thomas Jefferson University","All","18 Years to 65 Years","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","15680","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-05-01T00:00:00","","2020-05-07T00:00:00","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04371640"
"704","NCT04312997","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","","Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","PUL-042-502","2020-06-16T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-03-18T00:00:00","","2020-06-19T00:00:00","University of California Irvine, Orange, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04312997"
"705","NCT04354597","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","MOPHYDA","Not yet recruiting","No Results Available","COVID-19","Drug: HCQ & AZ","Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate","King Hussein Cancer Center","All","25 Years to 70 Years","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","20 KHCC 67","2020-05-01T00:00:00","2020-08-15T00:00:00","2020-10-15T00:00:00","2020-04-21T00:00:00","","2020-05-05T00:00:00","King Hussein Cancer Center, Amman, Jordan","","https://ClinicalTrials.gov/show/NCT04354597"
"706","NCT04406493","Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique","","Recruiting","No Results Available","ARDS|COVID","Diagnostic Test: Lung impedance technique","Correlation between impudence deterioration to clinical conditions and hospitalization period","Hillel Yaffe Medical Center","All","18 Years to 95 Years","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","0059-20-HYMC","2020-04-28T00:00:00","2021-04-28T00:00:00","2021-04-28T00:00:00","2020-05-28T00:00:00","","2020-05-28T00:00:00","Hillel Yaffe MC,, Hadera, Israel","","https://ClinicalTrials.gov/show/NCT04406493"
"707","NCT04392089","Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS","NIRS-COV","Recruiting","No Results Available","COVID-19|Respiratory Failure","Device: Masimo, LidCO","Changes in cerebral oxygenation  during cardiovascular and pulmonary optimization|Changes in peripheral oxygen saturation  during cardiovascular and pulmonary optimization|Changes in systolic arterial pressure  during cardiovascular and pulmonary optimization|Changes in diastolic arterial pressure  during cardiovascular and pulmonary optimization|Changes in mean arterial pressure  during cardiovascular and pulmonary optimization|Changes in heart rate  during cardiovascular and pulmonary optimization|Changes in stroke volume  during cardiovascular and pulmonary optimization|Changes in cardiac output  during cardiovascular and pulmonary optimization|Changes in systemic vascular resistance  during cardiovascular and pulmonary optimization|Changes in peripheral perfussion index  during cardiovascular and pulmonary optimization|Changes in pH during cardiovascular and pulmonary optimization|Changes in PaO2 during cardiovascular and pulmonary optimization|Changes in PaCO2 during cardiovascular and pulmonary optimization|Changes in arterial saturation  during cardiovascular and pulmonary optimization|Changes in PvO2 during cardiovascular and pulmonary optimization|Changes in PvCO2 during cardiovascular and pulmonary optimization|Changes in mixed venous saturation  during cardiovascular and pulmonary optimization|Changes in lacatate during cardiovascular and pulmonary optimization|Changes in hemoglobine concentration  during cardiovascular and pulmonary optimization|Changes in muscular oxygenation  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and peripheral oxygen saturation  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and systemic arterial pressure  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and diastolic arterial pressure  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and mean arterial pressure  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and stroke volume  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and heart rate  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and cardiac output  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and systemic vascular resistance  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and peripheral perfussion index  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and pH during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and PaO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and PaCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and arterial saturation  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and PvO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and PvCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and mixed venous saturation  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and lactate during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and hemoglobine concentration  during cardiovascular and pulmonary optimization|Association between cerebral oxygenation  and muscular oxygenation  during cardiovascular and pulmonary optimization","Hvidovre University Hospital","All","18 Years and older","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20027818","2020-05-01T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","Hvidovre Hospital, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT04392089"
"708","NCT04365101","Natural Killer Cell  Infusions in Adults With COVID-19","CYNK001COVID","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2|Pneumonia|Pneumonia, Viral|Lung Diseases|Respiratory Tract Disease|Respiratory Tract Infections|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Virus Disease|Immunologic Disease|ARDS|Immunologic Factors|Physiological Effects of Drugs|Antiviral Agents|Anti-infective Agents|Analgesics|Antimetabolites, Antineoplastic","Biological: CYNK-001","Phase 1: Frequency and Severity of Adverse Events |Phase 1: Rate of clearance of SARS-CoV-2|Phase 1: Rate of clinical improvement|Phase 2: Time to Clearance of SARS-CoV-2|Phase 2: Time to Clinical Improvement by NEWS2 Score|Rate of Clearance of SARS-CoV-2|Phase 2: Frequency and Severity of Adverse Events |Overall Clinical Benefit by time to medical discharge|Overall Clinical Benefit by hospital utilization|Overall Clinical Benefit by measuring mortality rate|Impact of CYNK-001 on sequential organ failure assessment  score|Time to Pulmonary Clearance|Supplemental oxygen-free days|Proportion of subjects requiring ventilation","Celularity Incorporated|IDRI|Lung Biotechnology PBC|California Institute for Regenerative Medicine","All","18 Years and older","Phase 1|Phase 2","86","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","CYNK-001-COVID-19","2020-05-13T00:00:00","2020-11-30T00:00:00","2021-11-30T00:00:00","2020-04-28T00:00:00","","2020-08-12T00:00:00","UC Irvine, Irvine, California, United States|UC Davis Medical Center, Sacramento, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Atlantic Health, Morristown, New Jersey, United States|Atlantic Health, Summit, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States","","https://ClinicalTrials.gov/show/NCT04365101"
"709","NCT04422626","Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19  Patients With Respiratory Failure","CYTOAID","Not yet recruiting","No Results Available","SARS-CoV-2|COVID-19","","Change in the partial pressure of oxygen/fraction of inspired oxygen  ratio after CytoSorb therapy|Change in inflammatory biomarker levels during treatment|change in organ function|length of stay in ICU|length of hospital stay|Duration of mechanical ventilation|Duration of vasopressor therapy|Duration of renal replacement therapy|Occurrence of critical illness polyneuropathy and/or myopathy|need for extracorporeal membrane oxygenation |cost calculation|device-related adverse and serious adverse events|In-hospital mortality","University of Pecs","All","18 Years and older","","42","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20802-5/2020/EÜIG","2020-07-01T00:00:00","2022-07-01T00:00:00","2022-12-01T00:00:00","2020-06-09T00:00:00","","2020-06-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04422626"
"710","NCT04384380","Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19","","Completed","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]","Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, Taiwan","All","20 Years to 79 Years","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","TYGH109014","2020-04-01T00:00:00","2020-05-31T00:00:00","2020-05-31T00:00:00","2020-05-12T00:00:00","","2020-08-04T00:00:00","Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04384380"
"711","NCT04348396","Clinical and Biological Predictors of COVID-19 Disease in Older Patients","","Not yet recruiting","No Results Available","COVID-19","","Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs","Istituto Nazionale di Ricovero e Cura per Anziani","All","65 Years and older","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","INRCA_01_2020","2020-04-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-04-16T00:00:00","","2020-04-16T00:00:00","IRCCS INRCA Hospital, Ancona, Italy","","https://ClinicalTrials.gov/show/NCT04348396"
"712","NCT04456036","Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care","RECOVER-19","Not yet recruiting","No Results Available","COVID-19","","Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment  assessment, at 3, 6 and 12 months|Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale  at 3, 6 and 12 months|Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up|Change in global ADL disability on modified Barthel Index , from the enrolment , at 3, 6 12 months follow-up|Change in walking capacity on Functional Ambulation Category , from the enrolment  assessment, at 3, 6 12 months follow-up|Change in cognitive abilities on the Montreal Cognitive Assessment  from the enrollment  assessment, at 3, 6 12 months follow-up|Change in patient-reported pain on Numerical Rating Scale from the enrollment  assessment, at 3, 6 12 months follow-up|Change in swallow abilities on Dysphagia Outcome Severity Scale  from the first functional assessment in acute care, at 3, 6 12 months follow-up|Change in endurance on 6-Minutes Walking Test  from the enrolment  assessment, at 3, 6 12 months follow-up|Change in mood status on Beck Depression Inventory  from the enrolment  assessment, at 3, 6 and 12 month follow-up","Università Politecnica delle Marche|Maria Gabriella Ceravolo|Michela Coccia|Lauredana Ercolani|Elisa Andrenelli|Lucia Pepa|Rossella Cima|Michela Aringolo","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NeuroRehabAN_Covid_2020","2020-07-01T00:00:00","2020-12-31T00:00:00","2021-06-30T00:00:00","2020-07-02T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04456036"
"713","NCT04365530","Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City","COVIDGHPSJCite","Recruiting","No Results Available","COVID","","Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2","Groupe Hospitalier Paris Saint Joseph","All","Child, Adult, Older Adult","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Cohorte COVID GHPSJ CiteH","2020-04-01T00:00:00","2022-04-01T00:00:00","2022-12-31T00:00:00","2020-04-28T00:00:00","","2020-04-29T00:00:00","Hôpital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Hôpital Bellan, Paris, France","","https://ClinicalTrials.gov/show/NCT04365530"
"714","NCT04408391","Brain MRI Imaging in Patients With SARS-Cov2  Infection With or Without Anosmia","ANOSIRM","Withdrawn","No Results Available","Covid-19|Anosmia","Other: Brain MRI scan","Brain regional homogeneity between COVID-19 patients with and without anosmia|Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia|Fractional anisotropy between COVID-19 patients with and without anosmia|Mean diffusivity between COVID-19 patients with and without anosmia|Radial diffusivity between COVID-19 patients with and without anosmia|Self-assessed olfactory and gustatory test|Ability to detect odor|Ability to taste a pinch of sugar|Presence of thrombotic and hemorrhagic lesions|Presence of lesions with hyperintensity|Projection network analysis of all patients|Blinded independent component analysis of all patients|default mode network analysis of all patients|executive control network analysis of all patients","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIMAO/2020-01/BL-001","2020-05-20T00:00:00","2020-07-06T00:00:00","2020-07-06T00:00:00","2020-05-29T00:00:00","","2020-08-05T00:00:00","CHU de Nimes, Nîmes, France","","https://ClinicalTrials.gov/show/NCT04408391"
"715","NCT04396067","Combination With Inhibitor of Neutrophil Elastase  and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines","Antibodies","Not yet recruiting","No Results Available","COVID -19","Drug: Aerosolized 13 cis retinoic acid|Drug: Aerosolized All trans retinoic acid|Other: Placebo","lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days","Kafrelsheikh University|Damietta University","All","18 Years to 70 Years","Phase 2","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID-19","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-05-20T00:00:00","","2020-06-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04396067"
"716","NCT04395976","Ayurveda as Prophylaxis for Suspected COVID-19 Patients","","Not yet recruiting","No Results Available","Covid-19","Other: Ayurveda","Clinical confirmation of Covid-19","British Ayurvedic Medical Council|All Party Parliamentary Group - Indian Traditional Sciences|University of Warwick","All","18 Years and older","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","BAMC01","2020-06-10T00:00:00","2020-09-10T00:00:00","2020-10-01T00:00:00","2020-05-20T00:00:00","","2020-05-20T00:00:00","British Ayurvedic Medical Council, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04395976"
"717","NCT04364594","COVID-19 Search in Conjunctival Cells","COVID-T","Completed","No Results Available","COVID 19|Pulmonary Disease","Diagnostic Test: conjunctival swab","Conjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalities","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","0013008/20","2020-03-26T00:00:00","2020-04-24T00:00:00","2020-05-30T00:00:00","2020-04-28T00:00:00","","2020-07-23T00:00:00","Maria Cristina Savastano, Roma, Italy","","https://ClinicalTrials.gov/show/NCT04364594"
"718","NCT04373200","Human Ab Response & immunoMONItoring of COVID-19 Patients","HARMONICOV","Recruiting","No Results Available","SARS-CoV-2 Coronavirus|Acute Respiratory Distress Syndrome","Biological: Blood samples collection|Other: Saliva collection","Number of increased immune population|Number of decreased immune population|Number of statically different phenotypes compared to control patients|Gain or loss of functional phenotypic markers between D1 and D14|Gain or loss of functional phenotypic markers between between acute and mild infections|Gain or loss of functional phenotypic markers between D1 and month 4|Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor  repertoires during ARDS linked to COVID-19|Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies|Characterization of a new set of human antibodies from patients who have recovered of COVID-19","Rennes University Hospital","All","18 Years and older","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","35RC20_9795_HARMONICOV|2020-A01100-39","2020-05-25T00:00:00","2020-11-25T00:00:00","2020-11-25T00:00:00","2020-05-04T00:00:00","","2020-05-28T00:00:00","CHU Rennes, Rennes, France","","https://ClinicalTrials.gov/show/NCT04373200"
"719","NCT04502667","Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19","COVID-19","Recruiting","No Results Available","Covid19|Vitamin D|Children, Only","Drug: Cholecalciferol","INTERLEUKINS  |FERRITIN |DIMER-D|Vitamin D","Coordinación de Investigación en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez|Hospital General de Mexico Dr. Eduardo Liceaga","All","1 Month to 17 Years","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","R-2020-3603-020","2020-07-15T00:00:00","2021-02-01T00:00:00","2021-04-01T00:00:00","2020-08-06T00:00:00","","2020-08-06T00:00:00","Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico","","https://ClinicalTrials.gov/show/NCT04502667"
"720","NCT04401410","Anti-SARS Cov-2 T Cell Infusions for COVID 19","BAT IT","Not yet recruiting","No Results Available","SARS-CoV 2|Viral Infection|COVID 19","Biological: Partially HLA-matched Virus Specific T cells","Safety of administering partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.|Efficacy of anti-COVID19 of administering banked partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients.","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|AlloVir","All","18 Years and older","Phase 1","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","H-47739 BAT IT","2020-07-30T00:00:00","2021-08-15T00:00:00","2021-08-15T00:00:00","2020-05-26T00:00:00","","2020-05-26T00:00:00","Houston Methodist Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04401410"
"721","NCT04395664","Arrhythmias in Patients With COVID-19","ACOVID","Recruiting","No Results Available","COVID-19","Device: C3+ Holter Monitor","In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis","Herlev and Gentofte Hospital","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20021500","2020-04-16T00:00:00","2020-08-01T00:00:00","2021-04-01T00:00:00","2020-05-20T00:00:00","","2020-05-20T00:00:00","Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark","","https://ClinicalTrials.gov/show/NCT04395664"
"722","NCT04303507","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease  in the Healthcare Setting","COPCOV","Recruiting","No Results Available","COVID19|Coronavirus|Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","University of Oxford","All","16 Years and older","Not Applicable","40000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","VIR20001","2020-04-29T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-03-11T00:00:00","","2020-07-15T00:00:00","Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT04303507"
"723","NCT04389554","D-dimer Levels in Pregnant With COVID-19","","Completed","No Results Available","COVID-19|D-dimer","Other: Blood D-dimer assay","Compare D-dimer values of COVID-19 patients and healthy pregnant women","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MTalmac","2020-05-14T00:00:00","2020-05-28T00:00:00","2020-05-29T00:00:00","2020-05-15T00:00:00","","2020-06-01T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey","","https://ClinicalTrials.gov/show/NCT04389554"
"724","NCT04453670","Neuropathology in Adults Intensive Care Unit Patients With COVID 19","","Completed","No Results Available","COVID 19","Procedure: autopsy","detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues|quantification of inflammation, necrosis and hemorrhage in different brain areas","University of Versailles","All","18 Years and older","","7","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Obs2020","2020-03-10T00:00:00","2020-05-11T00:00:00","2020-05-15T00:00:00","2020-07-01T00:00:00","","2020-07-01T00:00:00","Hôpital Raymond Poincare, Garches, France","","https://ClinicalTrials.gov/show/NCT04453670"
"725","NCT04445597","Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19","","Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Sampling of tissue","Prevalence of SARS-CoV-2 in the sampled tissue","Universitaire Ziekenhuizen Leuven|Max-Planck-Institute for Neurological Research","All","up to 70 Years","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Basic Science","S64042","2020-05-07T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-06-24T00:00:00","","2020-06-24T00:00:00","UZ Leuven, Leuven, Vlaams-Brabant, Belgium","","https://ClinicalTrials.gov/show/NCT04445597"
"726","NCT04407143","Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection","SOLID","Recruiting","No Results Available","Lung Cancer|COVID|Corona Virus Infection","Diagnostic Test: IgG test","Description of the characteristics of patients","Fundación GECP","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GECP 20/04_SOLID","2020-04-15T00:00:00","2020-06-15T00:00:00","2020-09-15T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Torrejón, Torrejón, Madrid, Spain|Hospital Universitario Son Llàtzer, Palma De Mallorca, Mallorca, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital La Esperanza, A Coruña, Spain|Hospital Universitario de Ferrol, A Coruña, Spain|Hospital Virgen de los Lirios, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Puerto Real, Cadiz, Spain|Hospital General La Mancha Centro, Ciudad Real, Spain|Hospital Universitario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario de Vinalopó, Elche, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital universitari Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Clínica Universidad de Navarra, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario de Móstoles, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Madrid, Spain|Hospital General Universitario de Málaga, Málaga, Spain|Hospital Costa del Sol, Málaga, Spain|Complejo Hospitalario Universitario de Ourense Santa María Nai, Ourense, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital de Manises, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Lluís Alcanyís, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Río Ortega, Valladolid, Spain|Complejo Hospitalario Zamora, Zamora, Spain","","https://ClinicalTrials.gov/show/NCT04407143"
"727","NCT04357457","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia","AIRVM-COVID","Not yet recruiting","No Results Available","Covid 19|Hypoxemic Respiratory Failure","Drug: Almitrine|Drug: Placebo","Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment","Assistance Publique - Hôpitaux de Paris|Centre Hospitalier de Chartres","All","18 Years to 75 Years","Phase 3","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","APHP200461|2020-001909-22","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-22T00:00:00","","2020-05-13T00:00:00","Hospital Pitie-Salpêtrière, Paris, France","","https://ClinicalTrials.gov/show/NCT04357457"
"728","NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days |Ventilator-free days at 28 days |ICU-free days at 28 days |Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","1051355","2020-03-30T00:00:00","2020-12-31T00:00:00","2021-12-31T00:00:00","2020-04-01T00:00:00","","2020-06-02T00:00:00","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT04329832"
"729","NCT04384900","Accelerated Prone Position Ventilation of Patients With COVID-19","PROVENT-COVID","Recruiting","No Results Available","COVID-19","Procedure: Prone position ventilation","Days alive without respiratory life support  at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support .|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4  pressure wounds.|28-days all-cause mortality.","Nordsjaellands Hospital","All","18 Years and older","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","H-20027361","2020-05-11T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-05-12T00:00:00","","2020-05-14T00:00:00","Nordsjællands Hospital, Hillerød, Region Hovedstanden, Denmark","","https://ClinicalTrials.gov/show/NCT04384900"
"730","NCT04341922","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","","Active, not recruiting","No Results Available","Dysfunctional Worry","Behavioral: Internet-delivered cognitive behavior therapy  for dysfunctional worry related to the Covid-19 pandemic","• Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 |Montgomery Åsberg Depression Rating Scale - Self report |Adapted Covid-19 version of the Work and Social Adjustment Scale |Insomnia Severity Index |Adapted Swedish version of the CoRonavIruS Health Impact Survey |Intolerance of uncertainty Scale |Patient Satisfaction Questionnaire |Adverse events","Karolinska Institutet","All","16 Years and older","Not Applicable","670","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Treatment","2020-01719","2020-05-09T00:00:00","2020-09-10T00:00:00","2021-09-10T00:00:00","2020-04-10T00:00:00","","2020-07-01T00:00:00","Karolinska Institutet, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT04341922"
"731","NCT04428801","Autologous Adipose-derived Stem Cells  for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Biological: autologous adipose-derived stem cells","Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens  collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein   from the baseline|Change of D-dimer  from the baseline|Change of Procalcitonin /L from the baseline|Change of pro-type B natriuretic peptide   from the baseline|Change of Bilirubin  from the baseline|Change of Creatinine  from the baseline|Change in blood test values for cytokine panels  from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens  collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.","Celltex Therapeutics Corporation","All","18 Years and older","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CTX0020-003","2020-08-01T00:00:00","2021-08-31T00:00:00","2021-10-30T00:00:00","2020-06-11T00:00:00","","2020-07-14T00:00:00","","","https://ClinicalTrials.gov/show/NCT04428801"
"732","NCT04410562","Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy","COVID-Preg","Recruiting","No Results Available","Pregnancy Related|COVID|Covid-19","Drug: Hydroxychloroquine|Drug: Placebo","Number of PCR confirmed cases among pregnant women|Incidence of COVID-19 disease during pregnancy|Incidence of COVID-19-related admissions|Incidence of all-cause admissions|Incidence of all-cause outpatient attendances|Mean duration of symptoms-signs of COVID-19|Frequency and severity of adverse events|Incidence of preeclampsia|Incidence of gestational diabetes|Incidence of SARS-CoV-2 infections during pregnancy|Prevalence of intrauterine growth restriction|Maternal mortality rate|Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.|Proportion of neonates with clinical signs/symptoms of COVID-19|Prevalence of low birth weight |Prevalence of preterm birth |Prevalence of embryo and foetal losses |Frequency of congenital malformations|Proportion of adverse perinatal outcome|Neonatal morbidity|Neonatal mortality rate","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|University Hospital of Torrejon|Fundación de investigación HM","Female","Child, Adult, Older Adult","Phase 3","714","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","2020-001587-29","2020-05-13T00:00:00","2021-05-13T00:00:00","2021-08-01T00:00:00","2020-06-01T00:00:00","","2020-06-01T00:00:00","Hospital Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Clínic Maternity, Barcelona, Catalunya, Spain|University hospital of Torrejón, Madrid, Spain|HM Puerta del Sur, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04410562"
"733","NCT04401046","COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder","COVID-TRAUMA","Recruiting","No Results Available","Cancer","Other: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later","Score of the Impact of Event Scale Revisited scale|Factors associated with post-traumatic stress disorder|Measure of the patient's anxiety|proportion of patients perceiving poorer management of their cancer care since the start of the COVID-19 epidemic.|proportion of patients perceiving the implementation of all necessary measures to reduce the risk of exposure to COVID-19|proportion of patients stating that remote consultation is as useful as a face-to-face consultation|proportion of patients with access to a clinical psychology consultation |Score on the cancer recurrence scale","Institut Paoli-Calmettes","All","18 Years and older","Not Applicable","4000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Health Services Research","COVID-TRAUMA-IPC 2020-026","2020-05-20T00:00:00","2020-10-30T00:00:00","2020-10-30T00:00:00","2020-05-26T00:00:00","","2020-07-28T00:00:00","Institut Paoli-Calmettes, Marseille, France","","https://ClinicalTrials.gov/show/NCT04401046"
"734","NCT04509999","Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection","","Not yet recruiting","No Results Available","COVID-19","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo","Proportion x 100 = percent of patients with improved COVID-19 symptoms","University of Florida","Male","18 Years to 99 Years","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IRB202001669-A|OCR38162","2020-09-01T00:00:00","2022-09-01T00:00:00","2022-09-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04509999"
"735","NCT04365439","Convalescent Plasma for COVID-19","","Not yet recruiting","No Results Available","Blood Plasma Therapy|COVID","Biological: Blood plasma","Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration |Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse events","Enos Bernasconi|Ente Ospedaliero Cantonale, Bellinzona","All","18 Years to 75 Years","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","2020-00895","2020-04-27T00:00:00","2020-05-30T00:00:00","2020-06-30T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04365439"
"736","NCT04323514","Use of Ascorbic Acid in Patients With COVID 19","","Recruiting","No Results Available","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","University of Palermo","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","3143","2020-03-13T00:00:00","2021-03-13T00:00:00","2021-03-13T00:00:00","2020-03-26T00:00:00","","2020-03-26T00:00:00","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04323514"
"737","NCT04323878","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Not yet recruiting","No Results Available","Early CPAP Ventilation in COVID-19 Patients","","Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years and older","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EC-COVID-PCS-Fenice","2020-04-06T00:00:00","2020-10-05T00:00:00","2020-11-09T00:00:00","2020-03-27T00:00:00","","2020-03-31T00:00:00","","","https://ClinicalTrials.gov/show/NCT04323878"
"738","NCT04481685","A Trial of Aclaris Therapeutics, Inc. -450 in Patients With Moderate-severe Novel Coronavirus Disease 2019","","Recruiting","No Results Available","Covid19","Drug: ATI-450|Drug: Placebo","Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events |Percentage of serious adverse events |Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome |Change in serum cytokine Interleukin -6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor","University of Kansas Medical Center","All","18 Years and older","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IIT-2020-ATI-450-COVID-19","2020-07-20T00:00:00","2021-07-01T00:00:00","2022-07-01T00:00:00","2020-07-22T00:00:00","","2020-08-07T00:00:00","The University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT04481685"
"739","NCT04498065","MYocardial DOmmages Related to COVID-19","DOMY COVID","Active, not recruiting","No Results Available","Covid19|Non Ischemic Myocardial Injury|Myocardial Infarction|Myocarditis|Troponin Elevation","Biological: Biological data|Other: Clinical data","characterize the myocardial damage associated with CoV-2 SARS infection","Centre Hospitalier Universitaire Dijon","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COTTIN AOIc 2020","2020-03-01T00:00:00","2020-07-01T00:00:00","2021-07-01T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","Chu Dijon Bourgogne, Dijon, France","","https://ClinicalTrials.gov/show/NCT04498065"
"740","NCT04386850","Oral 25-hydroxyvitamin D3 and COVID-19","","Recruiting","No Results Available","COVID 19","Drug: Oral 25-Hydroxyvitamin D3","COVID-19  infection|Severity of COVID-19  infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen |Serum levels of the parathyroid hormone","Tehran University of Medical Sciences|Boston University","All","18 Years to 75 Years","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","IRCT2020-0401046909N2|IRCT20200401046909N1","2020-04-14T00:00:00","2020-11-15T00:00:00","2021-03-15T00:00:00","2020-05-13T00:00:00","","2020-06-12T00:00:00","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04386850"
"741","NCT04382495","The Impact of COVID-19 Pandemic on Cancer Care","","Recruiting","No Results Available","Cancer","Other: survey","patients' and survivors' perspective of their cancer care during COVID-19 pandemic","El Zaitoun Specialized Hospital|Ain Shams University","All","18 Years and older","","200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Cancer Care during Covid-19","2020-06-15T00:00:00","2020-08-15T00:00:00","2020-08-31T00:00:00","2020-05-11T00:00:00","","2020-07-23T00:00:00","EgyBrit Medical Centre, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04382495"
"742","NCT04459312","National Covid-19 Surveillance Physicians","NAT-COV-SURV","Recruiting","No Results Available","Antibody COVID-19","Diagnostic Test: Antibody test","Presence of antibodies against SARS-COV2","Heinrich-Heine University, Duesseldorf|Dr. Wetzchewald","All","18 Years to 99 Years","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_2","2020-06-01T00:00:00","2020-07-10T00:00:00","2020-09-30T00:00:00","2020-07-07T00:00:00","","2020-07-08T00:00:00","University Hospital Duesseldorf, Dept. of Anesthesiology, Duesseldorf, Germany","","https://ClinicalTrials.gov/show/NCT04459312"
"743","NCT04331665","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","","Not yet recruiting","No Results Available","COVID-19|Pneumonia","Drug: Ruxolitinib","Proportion of patients with COVID-19 pneumonia who become critically ill |Number of adverse events|All cause mortality rate|Average duration of hospital stay","University Health Network, Toronto","All","12 Years and older","Not Applicable","64","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","U-DEPLOY: RUX-COVID|20-5315","2020-04-20T00:00:00","2020-10-30T00:00:00","2021-01-31T00:00:00","2020-04-02T00:00:00","","2020-04-13T00:00:00","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04331665"
"744","NCT04414904","Determining the Reproductive Health of Men Post-COVID-19 Infection","","Not yet recruiting","No Results Available","Infertility, Male|Testosterone Deficiency","Other: Exposure: Covid-19 infection","Semen parameters|Sperm Parameters|Hormones measurement|Seminal Reactive oxygen species|Sperm DNA fragmentation rate","Imperial College London","Male","18 Years to 50 Years","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20HH5998","2020-06-10T00:00:00","2021-05-14T00:00:00","2021-05-14T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","Channa Jayasena, London, Outside U.S./Canada, United Kingdom","","https://ClinicalTrials.gov/show/NCT04414904"
"745","NCT04320732","Risk Factors for Community- and Workplace Transmission of COVID-19","","Recruiting","No Results Available","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Rate of COVID-19 infection","Oslo University Hospital|Age Labs AS","All","18 Years and older","","250000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REK-124170","2020-03-27T00:00:00","2022-03-27T00:00:00","2030-03-20T00:00:00","2020-03-25T00:00:00","","2020-06-25T00:00:00","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT04320732"
"746","NCT04370015","Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.","","Not yet recruiting","No Results Available","SARS-CoV-2|Healthcare Workers","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period|Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR|Clinical disease severity in confirmed SARS-CoV-2 participants|Incidence of any acute respiratory infection","Services Institute of Medical Sciences, Pakistan","All","18 Years to 60 Years","Not Applicable","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","16082019","2020-05-15T00:00:00","2020-06-30T00:00:00","2020-10-15T00:00:00","2020-04-30T00:00:00","","2020-05-06T00:00:00","","","https://ClinicalTrials.gov/show/NCT04370015"
"747","NCT04350671","Interferon Beta 1a in Hospitalized COVID-19 Patients","IB1aIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","50 Years and older","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","Interferon Beta 1a in COVID-19","2020-04-15T00:00:00","2020-04-20T00:00:00","2020-04-24T00:00:00","2020-04-17T00:00:00","","2020-04-20T00:00:00","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04350671"
"748","NCT04382586","Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants","","Recruiting","No Results Available","COVID-19 Pulmonary Complications|COVID-19","Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo","Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale","BeiGene","All","18 Years and older","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","BGB-3111-219","2020-07-06T00:00:00","2021-04-01T00:00:00","2021-04-01T00:00:00","2020-05-11T00:00:00","","2020-08-07T00:00:00","Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04382586"
"749","NCT04405102","COVID-19 Ozanimod Intervention Study","COZI","Not yet recruiting","No Results Available","COVID-19","Drug: Ozanimod|Other: Standard of care","The mean oxygen flow required to maintain the oxygen saturation  target at 92%|Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|Rate of non invasive ventilation  / high flow nasal therapy  use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission/length of stay/mortality|Severity index measurement","François Lellouche|Celgene|Bristol-Myers Squibb|Laval University","All","18 Years to 75 Years","Phase 2","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2021-3474","2020-07-06T00:00:00","2022-01-06T00:00:00","2022-07-06T00:00:00","2020-05-28T00:00:00","","2020-05-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04405102"
"750","NCT04501783","Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","","Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Standard of care |Drug: standard concomitant therapy","Time to clinical improvement|Time to viral clearance|Rate of clinical improvement at separate time points|Rate of viral clearance at separate time points|Time to body temperature normalization|Rate of resolution of lung changes on CT|Rate of adverse drug reactions  and serious ADR|Rate of severe ADR|Rate therapy termination due to ADR","R-Pharm","All","18 Years to 60 Years","Phase 3","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","TL-FVP-t-01","2020-05-20T00:00:00","2020-07-29T00:00:00","2020-08-01T00:00:00","2020-08-06T00:00:00","","2020-08-06T00:00:00","Medical center LLC ""Neuroprofi"", Korolev, Russian Federation|Federal budgetary institution of science ""Central Research Institute of Epidemiology"" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation|Medical centers JSC ""Medsi Group of Companies"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital №57 of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""Infectious Diseases Clinical Hospital №1 of the Moscow City Healthcare Department"", Moscow, Russian Federation|Medical center LLC ""Medical Center Eco-safety"", Saint Petersburg, Russian Federation|St. Petersburg State Budgetary Healthcare Institution ""City Hospital No. 40 of the Kurortny District"", Saint Petersburg, Russian Federation|Budgetary healthcare institution of the Voronezh region ""Voronezh Regional Clinical Hospital No. 1"", Voronezh, Russian Federation|State Budgetary Healthcare Institution of the Moscow Region ""Zhukovskaya City Clinical Hospital""., Zhukovskiy, Russian Federation","","https://ClinicalTrials.gov/show/NCT04501783"
"751","NCT04482621","Decitabine for Coronavirus  Pneumonia- Acute Respiratory Distress Syndrome  Treatment: DART Trial","DART","Recruiting","No Results Available","COVID-19","Drug: Decitabine|Other: Placebo Saline","Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time  to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction  negativity|Percentage of patients with National Early Warning Score 2 of 3 or more","Johns Hopkins University","All","18 Years and older","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IRB00247544","2020-08-31T00:00:00","2021-01-01T00:00:00","2021-07-01T00:00:00","2020-07-22T00:00:00","","2020-08-18T00:00:00","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04482621"
"752","NCT04382651","Study of Efficacy and Safety of MAS825 in Patients With COVID-19","MAS-COVID","Recruiting","No Results Available","COVID-19 Pneumonia, Impaired Respiratory Function","Drug: MAS825|Drug: Matching placebo","APACHE II severity of disease score on Day 15 or on day of discharge |Serum C-reactive protein |Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CMAS825F12201","2020-06-11T00:00:00","2020-10-02T00:00:00","2021-01-26T00:00:00","2020-05-11T00:00:00","","2020-08-14T00:00:00","Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04382651"
"753","NCT04408235","High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy","COVID-19 HD","Not yet recruiting","No Results Available","COVID|Pneumonia, Viral|Coagulation Disorder","Drug: Enoxaparin","Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:|Any of the following events occurring within the hospital stay|Mortality at 30 days","Azienda Ospedaliero-Universitaria di Modena","All","18 Years to 80 Years","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","EudraCT N°: 2020-001972-13","2020-06-01T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","Azienda Ospedaliero-Universitaria, Modena, Italy","","https://ClinicalTrials.gov/show/NCT04408235"
"754","NCT04401033","Increased Risk of SARS-CoronaVirus-2  Infection Associated With Endoscopy","DECORE","Completed","No Results Available","SARS-CoV 2|COVID","Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound","SARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCW","Hospital del Río Hortega","All","18 Years and older","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","003","2020-05-11T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-05-26T00:00:00","","2020-07-28T00:00:00","Hospital Rio Hortega, Valladolid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04401033/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04401033"
"755","NCT04476888","Convalescent Plasma Treatment in COVID-19","COLLATE","Recruiting","No Results Available","Covid19","Biological: Convalescent Plasma |Other: Drugs and supportive care","Decrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findings","Aga Khan University","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CON000000000880","2020-04-26T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-07-20T00:00:00","","2020-07-22T00:00:00","Aga Khan University Hospital, Karachi, Sind, Pakistan","","https://ClinicalTrials.gov/show/NCT04476888"
"756","NCT04371107","Proactive Care of Ambulatory COVID19 Patients","AMBU-COVID","Not yet recruiting","No Results Available","Covid19|Azithromycin|Ambulatory","Other: consultation|Drug: Azithromycin","Length of symptom duration  with azithromycin treatment","Centre Hospitalier Universitaire, Amiens","All","18 Years and older","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","PI2020_843_0039","2020-04-29T00:00:00","2020-06-01T00:00:00","2020-07-01T00:00:00","2020-05-01T00:00:00","","2020-05-06T00:00:00","CHU Amiens, Amiens, France","","https://ClinicalTrials.gov/show/NCT04371107"
"757","NCT04415086","Treatment of Patients With COVID-19 With Convalescent Plasma","COOPCOVID-19","Recruiting","No Results Available","COVID-19","Biological: convalescent plasma","Time elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodies","University of Sao Paulo General Hospital|Ministerio da Ciência, Tecnologia, Inovações e Comunicações|Faculty of Medicine of Ribeirão Preto |Hospital de Clínicas, Faculdade de Medicina Universidade Estadual de Campinas|Hospital Sirio-Libanes|Hospital Israelita Albert Einstein","All","18 Years and older","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COOP-COVID-19-MCTIC","2020-06-01T00:00:00","2022-04-20T00:00:00","2022-05-22T00:00:00","2020-06-04T00:00:00","","2020-06-09T00:00:00","University of Sao Paulo - General Hospital, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT04415086"
"758","NCT04352491","An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease","","Completed","No Results Available","COVID 19","Other: No intervention","Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease |Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease |Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease |Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score","Institute of Liver and Biliary Sciences, India","All","18 Years to 75 Years","","347","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ILBS-COVID-03","2020-04-24T00:00:00","2020-05-31T00:00:00","2020-05-31T00:00:00","2020-04-20T00:00:00","","2020-06-17T00:00:00","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04352491"
"759","NCT04478019","SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding","SHIELD","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse","Number of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimen","University of Wisconsin, Madison","All","18 Years and older","Early Phase 1","94","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Prevention","2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020","2020-07-07T00:00:00","2021-04-30T00:00:00","2021-04-30T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","University of Wisconsin-Madison, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04478019"
"760","NCT04331509","COVID-19 Symptom Tracker","","Recruiting","No Results Available","COVID-19","Other: No Intervention","Physical health symptoms|Lack of physical health symptoms|Fever","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","All","18 Years and older","","10000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Symptom tracker","2020-03-23T00:00:00","2022-03-23T00:00:00","2022-03-23T00:00:00","2020-04-02T00:00:00","","2020-04-07T00:00:00","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04331509"
"761","NCT04488562","Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands","HOMECOMIN'","Recruiting","No Results Available","COVID-19|Pulmonary Fibrosis","","VAS|Temperature|Oxygen measurements|Forced Vital Capacity  home spirometry in %|Forced Vital Capacity  home spirometry in L|Forced Vital Capacity  hospital spirometry in %|Forced Vital Capacity  hospital spirometry in L|Adherence to weekly home spirometry|EQ5D|FAS|GRoC|ABC tool|Correlation between FVC, HRCT patterns, symptoms and quality of life|Predictors for the course of recovery of COVID-19 infection after hospital admission|Satisfaction of patients and caregivers with the use of a home monitoring system","Erasmus Medical Center|Leiden University Medical Center|VU University Medical Center|Dutch Society of Physicians for Pulmonology and Tuberculosis","All","18 Years and older","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MEC-2020-0318","2020-05-08T00:00:00","2021-12-01T00:00:00","2021-12-31T00:00:00","2020-07-28T00:00:00","","2020-07-28T00:00:00","Amsterdam University Center - location VUmc, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC, Rotterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT04488562"
"762","NCT04343248","Trial to Evaluate the Efficacy and Safety of Nitazoxanide  for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities","","Recruiting","No Results Available","COVID-19|Viral Respiratory Illnesses","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI","Romark Laboratories L.C.","All","65 Years to 120 Years","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","RM08-3006","2020-05-12T00:00:00","2020-08-31T00:00:00","2020-08-31T00:00:00","2020-04-13T00:00:00","","2020-06-04T00:00:00","The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04343248"
"763","NCT04473118","Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients","BADS-PTSD","Recruiting","No Results Available","COVID-19","Other: Survey","To reflect the effect of COVID-19 on the burnout, anxiety, depression and stress levels of healthcare professionals during the COVID-19 crisis|To reflect the effect of COVID-19 on the post-trauma stress disorder levels of healthcare professionals following the COVID-19 crisis","Hamad Medical Corporation","All","18 Years and older","","25000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MRC-05-017","2020-07-11T00:00:00","2020-09-01T00:00:00","2021-06-01T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Hamad Medical Corporation, Doha, Qatar","","https://ClinicalTrials.gov/show/NCT04473118"
"764","NCT04425317","Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients","COVID_OFF","Not yet recruiting","No Results Available","Infertility|COVID|IVF","Diagnostic Test: Blood sample","Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium|Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium","CRG UZ Brussel","Female","up to 45 Years","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","COVIDOFF001","2020-06-15T00:00:00","2021-06-15T00:00:00","2021-06-15T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04425317"
"765","NCT04361500","Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter","COSA","Recruiting","No Results Available","COVID-19","Device: Seraph 100","Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse events","Hannover Medical School|Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick","All","18 Years to 99 Years","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COSA-8998","2020-04-15T00:00:00","2020-10-01T00:00:00","2021-10-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germany","","https://ClinicalTrials.gov/show/NCT04361500"
"766","NCT04439045","Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2  Infection Rate and Severity","COBRA","Recruiting","No Results Available","SARS-CoV-2 Infection","Biological: VPM1002|Other: Placebo","COVID-19 infection|Incidence of hospitalization for COVID-19|Incidence of ICU admission for COVID-19|Incidence of ARDS|Mechanical ventilation for COVID-19|Secondary infection in COVID-19|COVID-19-related Mortality|Incidence of DVT","University Health Network, Toronto|Serum Institute of India Pvt. Ltd.|Max Planck Institute for Infection Biology|Verity Pharmaceuticals","All","18 Years and older","Phase 3","3626","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","20-5413","2020-06-24T00:00:00","2021-04-01T00:00:00","2021-07-01T00:00:00","2020-06-19T00:00:00","","2020-08-14T00:00:00","University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04439045"
"767","NCT04386083","Neurologic Manifestations of COVID-19","CORONA","Recruiting","No Results Available","Coronavirus Disease 2019","","Mortality |Respiratory failure |Duration of ventilator dependence |Intensive care unit  admission","University of the Philippines|Asian Hospital and Medical Center, Muntinlupa City, Philippines|Baguio General Hospital and Medical Center, Baguio City, Philippines|Cagayan Valley Medical Center, Tuguegarao City, Philippines|Capitol Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan City, Philippines|Chong Hua Hospital, Cebu City, Philippines|De La Salle University Medical Center|East Avenue Medical Center, Philippines|Jose B. Lingad Memorial Regional Hospital, San Fernando, Pampanga, Philippines|Jose R. Reyes Memorial Medical Center|Lung Center of the Philippines|Manila Doctors Hospital, Philippines|Manila Medical Center, Philippines|Makati Medical Center|New Era General Hospital, Philippines|Quirino Memorial Medical Center, Philippines|Ospital ng Makati, Philippines|Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines|Philippine Heart Center|Research Institute for Tropical Medicine, Philippines|San Juan De Dios Educational Foundation Inc. - Hospital, Philippines|San Lazaro Hospital, Philippines|Southern Isabela Medical Center, Philippines|St. Luke's Medical Center, Philippines|St Lukes Medical Center, Bonifacio Global City, Philippines|Southern Philippines Medical Center|The Medical City, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Inc, Philippines|University of Santo Tomas Hospital, Philippines|Veterans Memorial Medical Center, Philippines|Jose N. Rodriguez Memorial Hospital, Caloocan City|Zamboanga City Medical Center, Zamboanga City|Western Visayas Medical Center, Iloilo City|Northern Mindanao Medical Center, Cagayan de Oro City|Vicente Sotto Memorial Medical Center, Cebu City|Perpetual Succor Hospital, Cebu City","All","19 Years and older","","1342","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RGAO-2020-0348","2020-06-10T00:00:00","2020-12-01T00:00:00","2021-03-01T00:00:00","2020-05-13T00:00:00","","2020-07-28T00:00:00","Philippine General Hospital - University of the Philippines Manila, Manila, Philippines","","https://ClinicalTrials.gov/show/NCT04386083"
"768","NCT04448145","Determinants of SARS-COV2  Persistence After Convalescence","","Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV 2","","Duration of SARS-CoV-2 viral persistence in naso/oropharyngeal samples|Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples|Duration of SARS-CoV-2 viral persistence in semen samples|Duration of SARS-CoV-2 viral persistence in breast milk samples|Prevalence of cell immune responses|Duration of COVID-19 Symptoms|Prevalence of post-viral sequelae|Prevalence of SARS-CoV-2 persistence and bacterial/viral community structures","Columbia University","All","7 Years and older","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAS9722","2020-03-26T00:00:00","2021-03-01T00:00:00","2021-03-01T00:00:00","2020-06-25T00:00:00","","2020-06-25T00:00:00","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04448145"
"769","NCT04423692","Knowledge About Covid-19 Infection in Pregnant Women","","Recruiting","No Results Available","Viral Infection","Other: labs","The number of pregnant women who have knowledge about covid-19","Aljazeera Hospital","Female","18 Years to 42 Years","","30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Knowledge about covid 19","2020-06-01T00:00:00","2020-08-15T00:00:00","2020-08-20T00:00:00","2020-06-09T00:00:00","","2020-07-21T00:00:00","Aljazeera hospital, Giza, Egypt","","https://ClinicalTrials.gov/show/NCT04423692"
"770","NCT04360707","Solid Organ Transplant Recipients With SARS-CoV-2 French Registry","TX-COVID","Recruiting","No Results Available","SARS-CoV-2","","Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients","University Hospital, Strasbourg, France","All","1 Year and older","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","7766","2020-04-08T00:00:00","2021-04-08T00:00:00","2021-04-08T00:00:00","2020-04-24T00:00:00","","2020-05-05T00:00:00","Service de Nephrologie et Transplantation, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04360707"
"771","NCT04470609","Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years","","Enrolling by invitation","No Results Available","COVID-19","Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Placebo on a 0- and 28-day schedule","Adverse reactions/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIb|Serious adverse events|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Level of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Level of IgG antibodies against SARS-CoV-2 Phase IIb","Chinese Academy of Medical Sciences|West China Second University Hospital|Yunnan Center for Disease Control and Prevention","All","60 Years and older","Phase 1|Phase 2","471","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","20200402","2020-07-10T00:00:00","2020-11-01T00:00:00","2021-11-01T00:00:00","2020-07-14T00:00:00","","2020-07-14T00:00:00","West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT04470609"
"772","NCT04459533","Sparing in Neuromuscular Blockade in COVID 19 ICU","TOF-COVID","Completed","No Results Available","Neuromuscular Blockade|Human Characteristics|Complication of Medical Care|Intensive Care Unit Acquired Weakness","Device: TOF protocol","NMB agents consumption","Hospices Civils de Lyon","All","18 Years and older","","250","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2020_TOF-COVID","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Department of Anesthesiology and Intensive Care Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France","","https://ClinicalTrials.gov/show/NCT04459533"
"773","NCT04338672","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","","Recruiting","No Results Available","Emergency Service, Hospital|General Surgery","Other: COVID-19 Pandemic","Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits  of surgical patients depending on the presentation and the co morbidity","Sheba Medical Center","All","18 Years and older","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SMC-20-7078-YZ-CTIL","2020-04-05T00:00:00","2021-04-01T00:00:00","2022-04-01T00:00:00","2020-04-08T00:00:00","","2020-04-21T00:00:00","Sheba Medical Center, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT04338672"
"774","NCT04472078","Seroprevalence of Coronavirus Disease 2019  Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina","","Active, not recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: Serological Assay or IgG for SARS-CoV-2","to establish the seroprevalence of SARS-CoV-2","Hospital Italiano de Buenos Aires|Hospital de Niños R. Gutierrez de Buenos Aires|Salud Comunitaria Ministerio de Salud GCBA","All","14 Years and older","","873","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","1831","2020-06-10T00:00:00","2020-06-26T00:00:00","2020-07-18T00:00:00","2020-07-15T00:00:00","","2020-07-15T00:00:00","Hospital de Niños Ricardo Gutierrez, Buenos Aires, Caba, Argentina","","https://ClinicalTrials.gov/show/NCT04472078"
"775","NCT04374565","Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","","Recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia","Drug: High-Titer Anti-SARS-CoV-2  Convalescent Plasma","Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation |Hospital length of stay |ICU LOS|Grade 3 or 4 Adverse Events","University of Virginia","All","18 Years and older","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","200114","2020-05-05T00:00:00","2021-04-05T00:00:00","2021-04-05T00:00:00","2020-05-05T00:00:00","","2020-06-09T00:00:00","University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT04374565"
"776","NCT04410263","Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches","MICRO-COV","Recruiting","No Results Available","Corona Virus Infection|ARDS|Coinfection","Diagnostic Test: Sampling","Change of pro-inflammatory response over the ICU stay as a causative for primary endothelial dysfunction|Time-to-event ""pulmonary bacterial superinfection or death""|Positive bacteria and/ or SARS-CoV-2 cultures on handheld devices used in clinical routine and correlation to the adherence to disinfection protocols|Life Quality after COVID-19 Infection","University of Zurich","All","18 Years and older","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00646","2020-04-09T00:00:00","2023-12-30T00:00:00","2023-12-31T00:00:00","2020-06-01T00:00:00","","2020-06-01T00:00:00","University Hospital Zurich, Zürich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT04410263"
"777","NCT04406038","Study of the Spread of COVID-19 in Saint Petersburg, Russia","","Active, not recruiting","No Results Available","COVID19","","Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamics","European University at St. Petersburg","All","18 Years and older","","1038","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDRU-001","2020-05-27T00:00:00","2020-10-28T00:00:00","2020-10-28T00:00:00","2020-05-28T00:00:00","","2020-08-18T00:00:00","Clinic ""Scandinavia"", Saint Petersburg, Russian Federation","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04406038/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04406038"
"778","NCT04344600","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2  Infection","PROTECT","Recruiting","No Results Available","Sars-CoV2","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Proportion of participants with no evidence of SARS-CoV-2 infection|Time  to no detection of SARS-CoV-2 in two upper respiratory samples","Johns Hopkins University|Eiger BioPharmaceuticals","All","18 Years to 80 Years","Phase 2","164","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","IRB00248163","2020-05-29T00:00:00","2021-06-01T00:00:00","2021-12-01T00:00:00","2020-04-14T00:00:00","","2020-06-02T00:00:00","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT04344600"
"779","NCT04472585","Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients","SINZ-COVID-PK","Recruiting","No Results Available","Coronavirus Infection|COVID|Sars-CoV2","Drug: Nigella Sativa / Black Cumin|Drug: Ivermectin Injectable Solution|Other: Placebo|Drug: Zinc","qRT-PCR|Severity of symptoms","Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute","All","18 Years and older","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","SZMC/IRB/Internal/215/2020","2020-07-14T00:00:00","2020-09-15T00:00:00","2020-09-30T00:00:00","2020-07-15T00:00:00","","2020-07-15T00:00:00","Shaikh Zayed Hospital, Lahore, Punjab, Pakistan","","https://ClinicalTrials.gov/show/NCT04472585"
"780","NCT04351646","Diagnostics of COVID-19/DARTS","","Not yet recruiting","No Results Available","COVID-19","","Antibody titres to SARS-CoV-2","St George's, University of London","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020.0075","2020-04-15T00:00:00","2022-04-15T00:00:00","2022-04-15T00:00:00","2020-04-17T00:00:00","","2020-04-17T00:00:00","St. Georges Hospital Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04351646"
"781","NCT04383587","Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers","","Enrolling by invitation","No Results Available","SARS-CoV 2|COVID-19","Other: Serologic testing","Prevalence of COVID19 Antibody Positivity|Ability to predict immune status/antibody positivity","Mayo Clinic","All","18 Years and older","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Health Services Research","20-004054","2020-05-06T00:00:00","2020-07-01T00:00:00","2020-07-31T00:00:00","2020-05-12T00:00:00","","2020-07-02T00:00:00","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT04383587"
"782","NCT04361344","Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection","MARNEVO-Covid","Recruiting","No Results Available","COVID-19 Infection|Encephalitis","Biological: blood samples","Change of neurodegeneration markers level","Centre Hospitalier de PAU","All","18 Years and older","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","CHPAU2020/02","2020-05-19T00:00:00","2021-01-19T00:00:00","2021-01-19T00:00:00","2020-04-24T00:00:00","","2020-05-21T00:00:00","CH de Pau, Pau, France","","https://ClinicalTrials.gov/show/NCT04361344"
"783","NCT04414267","Bacillus Calmette-guerin Vaccination to Prevent COVID-19","ACTIVATEII","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection|Coronary Heart Disease|Chronic Obstructive Pulmonary Disease","Biological: BCG vaccine|Biological: Placebo","Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5|Prevalence of IgG/IgM against SARS-CoV-2|Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19.|The impact of new cardiovascular events between the two study groups|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters  between the two sub-study groups in Visit 5|Differences in cardiac ultrasound at visit 5 between the two sub-study groups|Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups","Hellenic Institute for the Study of Sepsis","All","50 Years and older","Phase 4","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","Activate II|2020-002448-21","2020-05-26T00:00:00","2021-05-25T00:00:00","2021-05-25T00:00:00","2020-06-04T00:00:00","","2020-07-14T00:00:00","General Hospital of Argolida - Nafplion Unit, Náfplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Therapeutics, Alexandra General Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, General Hospital of Karditsa, Kardítsa, Greece|General Hospital of Korinthos, Kórinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolemaḯda, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece|General Hospital of Imathia - Veria Unit, Veria, Greece","","https://ClinicalTrials.gov/show/NCT04414267"
"784","NCT04508985","The McGill RAAS-COVID-19 Randomized Controlled Trial","RAAS-COVID","Not yet recruiting","No Results Available","COVID-19|Cardiovascular Diseases","Other: Temporarily holding the RAAS inhibitor [intervention]|Other: RAAS inhibitor [continued standard of care]","Global rank score","McGill University Health Centre/Research Institute of the McGill University Health Centre|Jewish General Hospital |Montreal General Hospital |Universite de Lorraine, Centre d'Investigation Clinique- Plurithematique Inserm CIC-P 1433","All","18 Years and older","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","MP-37-2021-6614","2020-08-01T00:00:00","2021-01-01T00:00:00","2021-09-01T00:00:00","2020-08-11T00:00:00","","2020-08-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04508985"
"785","NCT04314232","Mechanisms for Covid-19 Disease Complications","COVID MECH","Recruiting","No Results Available","COVID|Coronavirus Infection","","Number of participants with ICU admission or death|Number of participants with ICU admission|Number of participants with death from all causes|Total duration of ICU stay|Total duration of hospital stay","University Hospital, Akershus","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","117589","2020-03-18T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-03-19T00:00:00","","2020-06-26T00:00:00","Akershus University Hospital, Lørenskog, Norway","","https://ClinicalTrials.gov/show/NCT04314232"
"786","NCT04510038","Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury","COLHEART-19","Not yet recruiting","No Results Available","Covid19|Myocardial Injury","Drug: Colchicine|Other: Covid-19 Standard of Care","All Cause Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time to Deterioration|Adverse Events|Troponin|Delta|BNP|Changes in C Reactive Protein|LOS|Re-Hospitalization|Changes in D Dimer","Miami Cardiac and Vascular Institute|University of California, Los Angeles","All","18 Years to 100 Years","Phase 2|Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","152247","2020-09-01T00:00:00","2021-09-01T00:00:00","2022-01-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04510038"
"787","NCT04499300","Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age","","Recruiting","No Results Available","Covid19","Other: Data collection from medical files","Demographic data|Comorbidities|Cumulative Illness Rating Scale-Geriatric |Treatments|Signs and symptoms|Fever|Hypoxemia|Tachycardia|Hypotension|Gasometry|Infectious data|Blood count|Ionogram|Liver function|Coagulation|Renal function|Albumin|CRP|Fibrinogen|D-dimers at hospital admission or first recorded|NTproBNP|CK|Troponin|Ferritin|Procalcitonin|Biology - highest rate|Biology - lowest rate|Percentage of pulmonary involvement on chest CT scan|Number of pulmonary lobes affected|Type of lesions|Need for oxygenotherapy|Means of ventilation|Treatment received|Length of ICU Stay|Status at hospital exit|Mortality","Murielle Surquin|Brugmann University Hospital","All","90 Years and older","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHUB-COVID-19-90+","2020-06-09T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-08-05T00:00:00","","2020-08-07T00:00:00","CHU Brugmann, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT04499300"
"788","NCT04311697","Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure","COVID-AIV","Recruiting","No Results Available","Critical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome |Corona Virus Infection|Acute Lung Injury","Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","NeuroRx, Inc.|Lavin Consulting, LLC|International Business Machines","All","18 Years to 100 Years","Phase 2","144","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","COVID-AIV","2020-05-15T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-03-17T00:00:00","","2020-07-28T00:00:00","University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|Rambam Health Care Campus, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT04311697"
"789","NCT04343261","Convalescent Plasma in the Treatment of COVID 19","","Enrolling by invitation","No Results Available","SARS-CoV-2|COVID|Coronavirus","Biological: Convalescent Plasma","Mortality|Viral Load|Serum Antibody Titers","Saint Francis Care","All","18 Years to 90 Years","Phase 2","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","SFH-20-23","2020-04-10T00:00:00","2020-12-01T00:00:00","2021-04-01T00:00:00","2020-04-13T00:00:00","","2020-06-17T00:00:00","Trinity Health Of New England, Hartford, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT04343261"
"790","NCT04500626","Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients","","Not yet recruiting","No Results Available","Covid19","Drug: Oxygen","7-level COVID Ordinal Outcome Scale|Length of hospital stay|Days with oxygen supplementation|Daily oxygen flow values required to obtain saturation values ≥90%,|ICU admission|ICU length of stay|Days on invasive mechanical ventilation or high flow oxygenation|Major arterial and venous thrombotic events|Sleep quality|Fatigue|Mortality|Incidence of any adverse events related to HBOT","Ottawa Hospital Research Institute|Climate Foundation","All","18 Years and older","Phase 2|Phase 3","234","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","OHRI-HBOT-001","2020-08-01T00:00:00","2022-08-01T00:00:00","2022-08-01T00:00:00","2020-08-05T00:00:00","","2020-08-12T00:00:00","The Ottawa Hospital, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT04500626"
"791","NCT04452669","VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation","VPCOVID","Not yet recruiting","No Results Available","COVID-19","Drug: VentaProst","Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes","Aerogen Pharma Limited|Ohio State University","All","18 Years and older","Phase 2","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","APC-VPCOV-CLN-001","2020-08-15T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-06-30T00:00:00","","2020-07-31T00:00:00","Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT04452669"
"792","NCT04447144","Nutritional Habits, and Coronavirus Disease 2019  Outcome","","Recruiting","No Results Available","Covid19|Chronic Inflammation|Non-Communicable Chronic Diseases","","Western versus Mediterranean diet in COVID-19 outcome|Gut- Lung axis in COVID-19|Protective role of minerals and vitamins in COVID-19 patients|non-communicable diseases and COVID-19","Cairo University","All","18 Years to 80 Years","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1003","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-09-01T00:00:00","2020-06-25T00:00:00","","2020-06-30T00:00:00","Faculty of Medicine Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04447144"
"793","NCT04366024","A Novel Nomogram to Predict Severity of COVID-19","","Recruiting","No Results Available","COVID-19 Disease|Nomogram Model","Other: other","the consistency of predicted severe rate and observed severe rate of COVID-19 patients|Duration of severe illness","Xinqiao Hospital of Chongqing","All","18 Years and older","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","XQonc-016","2020-01-17T00:00:00","2020-08-30T00:00:00","2021-12-31T00:00:00","2020-04-28T00:00:00","","2020-07-14T00:00:00","Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT04366024"
"794","NCT04411680","Study of Sargramostim in Patients With COVID-19","iLeukPulm","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Sargramostim|Drug: Standard of care","Change in oxygenation parameter of PO2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions","Partner Therapeutics, Inc.","All","18 Years and older","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","PTX-001-002","2020-06-01T00:00:00","2020-10-01T00:00:00","2021-01-01T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","","","https://ClinicalTrials.gov/show/NCT04411680"
"795","NCT04326036","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","GARM-COVID19","Enrolling by invitation","No Results Available","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction |Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme |Drug: Sterile Normal Saline for Intravenous Use","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Healeon Medical Inc|Robert W. Alexander, MD","All","18 Years to 90 Years","Early Phase 1","10","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","GARM COVID19","2020-03-25T00:00:00","2021-11-01T00:00:00","2021-12-31T00:00:00","2020-03-30T00:00:00","","2020-03-31T00:00:00","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States","","https://ClinicalTrials.gov/show/NCT04326036"
"796","NCT04328129","Household Transmission Investigation Study for COVID-19 in French Guiana","EPI-COVID-19","Recruiting","No Results Available","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","Procedure: Human biological samples","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andree Rosemon de Cayenne","All","Child, Adult, Older Adult","Not Applicable","450","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Screening","2020-009","2020-03-23T00:00:00","2022-03-23T00:00:00","2022-03-23T00:00:00","2020-03-31T00:00:00","","2020-05-18T00:00:00","Centre Hospitalier Andree Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana","","https://ClinicalTrials.gov/show/NCT04328129"
"797","NCT04462627","Reduction of COVID 19 Transmission to Health Care Professionals","","Recruiting","No Results Available","COVID 19","Diagnostic Test: Blood group determination|Diagnostic Test: Antibody titration|Dietary Supplement: Probiotic","Anti-A antibody concentration|Anti-B antibody concentration|Blood group","Hanane EL KENZ|Brugmann University Hospital","All","18 Years and older","Not Applicable","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","CHUB-BDS-COVID19","2020-04-14T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-07-08T00:00:00","","2020-07-08T00:00:00","CHU Brugmann, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT04462627"
"798","NCT04394208","Silymarin in COVID-19 Pneumonia","SCOPE","Recruiting","No Results Available","COVID-19|Viral Pneumonia Human Coronavirus","Drug: Silymarin|Drug: Placebo","Time to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse events","Cairo University","All","18 Years and older","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CairoU COVID-19 Study Group","2020-08-16T00:00:00","2021-01-30T00:00:00","2021-02-28T00:00:00","2020-05-19T00:00:00","","2020-08-18T00:00:00","Cairo University, Giza, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04394208"
"799","NCT04367870","COVID-19 Detection Test in Oncology","EVIDENCE","Recruiting","No Results Available","Oncology","","To evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.|To estimate the prevalence of patients immunized to the SARS-CoV-2 virus in an oncology population over the whole study duration and within one-month periods.|To estimate the discordance rate between local immunoassay and a centralized ELISA in patients with a positive immunoassay, whatever the immunoassay.|To identify patients with very low risk of recurrence of COVID-19 within 6 months following a positive immunoassay result.|To characterize the evolution over time of the serologic response against SARS-CoV-2 .","UNICANCER","All","18 Years and older","","2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UC-TRA-2002|2020-A01002-37","2020-05-23T00:00:00","2020-08-01T00:00:00","2021-05-01T00:00:00","2020-04-29T00:00:00","","2020-06-04T00:00:00","Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Universitaire Pitie Salpêtrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France","","https://ClinicalTrials.gov/show/NCT04367870"
"800","NCT04484545","Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection","","Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: Prognostic score","mortality","Glasgow Royal Infirmary","All","18 Years to 100 Years","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IRAS 282807","2020-04-01T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","Glasgow Royal Infirmary, Glasgow, United Kingdom","","https://ClinicalTrials.gov/show/NCT04484545"
"801","NCT04457570","Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer","ONCOVID-AURA","Recruiting","No Results Available","COVID, Cancer","Other: mortality","mortality for SARS-CoV-2 infection","Hospices Civils de Lyon","All","18 Years and older","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","69HCL20_0509","2020-06-15T00:00:00","2020-12-15T00:00:00","2021-02-15T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","Centre de lutte contre le Cancer JEAN PERRIN, Clermont-Ferrand, France|Centre Hospitalier Uniersitaire de Clermont-Ferrand, Clermont-Ferrand, France|Centre Leon Berard, Lyon, France|Institut de Cancerologie de la Loire Lucien Neurwirth, Saint-Priest-en-Jarez, France|Centre Hospitalier Universitaire de St Etienne, Saint-Étienne, France","","https://ClinicalTrials.gov/show/NCT04457570"
"802","NCT04354766","COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","ANTI-COV-2","Recruiting","No Results Available","COVID","Other: Blood sample","Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.","Hospices Civils de Lyon|Eurobio Scientific","All","18 Years and older","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0340|2020-A01038-31","2020-04-29T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-21T00:00:00","","2020-05-04T00:00:00","Hôpital de la Croix-Rousse, Lyon, France","","https://ClinicalTrials.gov/show/NCT04354766"
"803","NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","Active, not recruiting","No Results Available","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute","All","18 Years and older","Phase 3","479","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","PETAL 05 Orchid","2020-04-02T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-03T00:00:00","","2020-06-23T00:00:00","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT04332991"
"804","NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","","Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","COVID-19","2020-03-16T00:00:00","2020-06-30T00:00:00","2020-09-30T00:00:00","2020-03-18T00:00:00","","2020-03-18T00:00:00","Stem Cells Arabia, Amman, Jordan","","https://ClinicalTrials.gov/show/NCT04313322"
"805","NCT04345315","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 , COVID-19 Causative Agent.","CORSA","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing  analysis|Other: serum chemistry analysis","epidemiology|Immunoglobulin G  and Immunoglobulin M  antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL Romagna","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRSTB113","2020-03-27T00:00:00","2021-03-01T00:00:00","2022-03-01T00:00:00","2020-04-14T00:00:00","","2020-04-15T00:00:00","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy","","https://ClinicalTrials.gov/show/NCT04345315"
"806","NCT04510441","Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms","AI-COV-19","Recruiting","No Results Available","Coronavirus","Other: Nil intervention","Accuracy of machine learning to be able to predict outcome of coronavirus  infection|Accuracy of machine learning to be able to predict prognosis of coronavirus  infection|Accuracy of machine learning to be able to predict cardiac involvement of coronavirus  infection|Accuracy of machine learning vs human assessment to diagnose coronavirus  infection","Imperial College London|Imperial College Healthcare NHS Trust|Chelsea and Westminster Hospital NHS Foundation Trust|LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST","All","18 Years and older","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20HH5967","2020-05-26T00:00:00","2022-05-01T00:00:00","2022-05-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","London North West University Healthcare NHS Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Imperial College London , London, United Kingdom|St Mary's Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04510441/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04510441"
"807","NCT04472572","Expanded Access to Convalescent Plasma for Treatment of COVID-19","","Temporarily not available","No Results Available","COVID-19","Biological: Convalescent Plasma","","Hackensack Meridian Health","All","18 Years and older","","","Other","Expanded Access:Treatment IND/Protocol","","Pro2020-0663","","","","2020-07-15T00:00:00","","2020-07-15T00:00:00","Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT04472572"
"808","NCT04347408","Seroprevalence of SARS-Cov-2 Antibodies in Children","","Recruiting","No Results Available","COVID|Corona Virus Infection","Diagnostic Test: Covid-19 Antibody testing","Immunoglobulins  to SARS-Cov2 in plasma","Queen's University, Belfast|Belfast Health and Social Care Trust","All","2 Years to 15 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282617","2020-05-06T00:00:00","2020-12-13T00:00:00","2020-12-13T00:00:00","2020-04-15T00:00:00","","2020-06-16T00:00:00","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT04347408"
"809","NCT04497987","A Study of LY3819253  in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","BLAZE-2","Recruiting","No Results Available","COVID-19|SARS-CoV2","Drug: LY3819253|Drug: Placebo","Percentage of Participants with SARS-CoV-2 Infection|Percentage of Participants with Moderate or Worse Severity COVID-19|Percentage of Participants with Mild or Worse Severity COVID-19|Percentage of Participants Who are Hospitalized due to COVID-19|Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19","Eli Lilly and Company|National Institute of Allergy and Infectious Diseases |AbCellera Biologics Inc.","All","18 Years and older","Phase 3","2400","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","18063|J2X-MC-PYAD|CoVPN #3501","2020-08-02T00:00:00","2021-03-08T00:00:00","2021-06-29T00:00:00","2020-08-04T00:00:00","","2020-08-17T00:00:00","Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Proj Wish Univ of IL CDM, IDS, Chicago, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|Univ of Penn PS of Med IDD, Philadelphia, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT04497987"
"810","NCT04434131","Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples","University of New Mexico","All","18 Years and older","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","20-227","2020-04-28T00:00:00","2021-04-28T00:00:00","2025-04-28T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04434131"
"811","NCT04431466","A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19","IFORS","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Ivermectin|Other: Standard treatment for COVID-19","Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Viral load variation in the nasopharyngeal swab.|Variation of serum lymphocyte counts.|Variation of serum AST/ALT values.|Variation of serum D-dimer values.|Variation of serum CPK values.|Variation of serum LDH values.|Time to clinical improvement","Universidade Federal de Sao Carlos","All","18 Years and older","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","IFORS","2020-07-01T00:00:00","2020-12-01T00:00:00","2021-07-01T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Hospital Univeristário da Universidade Federal de São Carlos , São Carlos, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT04431466"
"812","NCT04371835","COHIVE: Coronavirus  Outcomes in HIV Evaluation in Resource Limited Settings","","Not yet recruiting","No Results Available","HIV-infection/Aids|Coronavirus Infection","","Clinical features of symptomatic COVID-19 in people living with HIV |Clinical outcomes of symptomatic COVID-19 in PLWH|Seroprevalence of COVID-19 in all parent study participants","Kirby Institute|University of Witwatersrand, South Africa|University of Liverpool|Universite Montpellier|UNITAID","All","18 Years and older","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-04-COHIVE","2020-05-15T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04371835"
"813","NCT04374591","Sodium Bicarbonate for Treatment of COVID-19 Pneumonia:A Preliminary Prospective Controlled Crossover Study","","Active, not recruiting","No Results Available","Pneumonia|Covid19","Drug: Sodium Bicarbonate","Time to clinical recovery|Pulmonary recovery status","Mansoura University","All","18 Years and older","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None |Primary Purpose: Treatment","Sodium Bicarbonate COVID-19","2020-07-01T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-05-05T00:00:00","","2020-07-23T00:00:00","Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt","","https://ClinicalTrials.gov/show/NCT04374591"
"814","NCT04408014","Seroepidemiological Study of SARS-CoV-2  Infection in Population Subgroups in the State of São Paulo","","Not yet recruiting","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: Serological test|Diagnostic Test: Nasopharyngeal Swab|Diagnostic Test: Oropharyngeal Swab","Prevalence of antibodies against SARS-CoV-2 through serological testing|Frequency of participants with a positive RT-PCR test result for SARS-CoV-2","Butantan Institute","All","6 Months to 100 Years","","18901","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19-Epi-01","2020-06-01T00:00:00","2020-07-15T00:00:00","2020-07-30T00:00:00","2020-05-29T00:00:00","","2020-05-29T00:00:00","","","https://ClinicalTrials.gov/show/NCT04408014"
"815","NCT04331171","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","Recruiting","No Results Available","COVID-19","Device: Web application users","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Generale de l'Offre de Soins","All","18 Years and older","","3000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WP-2020-02","2020-03-17T00:00:00","2020-03-31T00:00:00","2020-07-31T00:00:00","2020-04-02T00:00:00","","2020-04-17T00:00:00","All French Emergency services, Le Mans, France","","https://ClinicalTrials.gov/show/NCT04331171"
"816","NCT04473261","Efficacy of Iodine Complex Against COVID-19 Patients","I-COVID-PK","Recruiting","No Results Available","Covid19|SARS-CoV-2|Corona Virus Infection","Drug: Iodine Complex|Drug: Placebo","qRT-PCR|Severity of Symptoms","Sohaib Ashraf|MTI Medical Private Limited, Pakistan|Sheikh Zayed Federal Postgraduate Medical Institute","All","18 Years and older","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","SZMC/IRB/Internal/216/2020","2020-07-14T00:00:00","2020-09-15T00:00:00","2020-09-30T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","Shaikh Zayed Hospital, Lahore, Pakistan","","https://ClinicalTrials.gov/show/NCT04473261"
"817","NCT04353284","Camostat Mesylate in COVID-19 Outpatients","","Active, not recruiting","No Results Available","COVID-19","Drug: Camostat Mesilate|Other: Placebo","Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature","Yale University","All","18 Years and older","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","2000027971","2020-06-19T00:00:00","2021-05-31T00:00:00","2021-05-31T00:00:00","2020-04-20T00:00:00","","2020-07-28T00:00:00","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT04353284"
"818","NCT04371289","Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up","CARDICoVRISK","Not yet recruiting","No Results Available","COVID-19|Cardiovascular Risk Factor","","Predictive modeling of in-hospital outcome|Clinical, pathophysiological and molecular mechanisms|Short -Term Sequelae","Istituto Auxologico Italiano","All","18 Years and older","","5500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CE_2020_03_26_02","2020-04-01T00:00:00","2020-07-10T00:00:00","2020-09-10T00:00:00","2020-05-01T00:00:00","","2020-05-01T00:00:00","Istituto Auxologico Italiano, Milan, Italy","","https://ClinicalTrials.gov/show/NCT04371289"
"819","NCT04375124","Treatment of Angiotensin Peptide  for COVID-19","","Recruiting","No Results Available","COVID-19","Biological: Biological/Vaccine: Angiotensin peptide  derived plasma","mortality","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","KSSEAH--0059","2020-04-25T00:00:00","2020-08-31T00:00:00","2020-09-30T00:00:00","2020-05-05T00:00:00","","2020-05-15T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04375124"
"820","NCT04410510","P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19","","Not yet recruiting","No Results Available","COVID|Coronavirus Infection|SARS-CoV 2|COVID19","Drug: P2Et |Other: Placebo","Evaluate the efficacy of P2Et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of COVID-19|Efficacy of P2Et in reducing the time to clinically significant improvement in patients with clinical suspicion or confirmed case of COVID-19|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 14 days of treatment|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 28 days of treatment|Efficacy of P2Et in reducing the proportion of hospitalized patients with clinical suspicion or confirmed case of COVID-19 who require admission to the ICU due to worsening clinical symptoms.|Efficacy of P2Et in reducing the proportion of patients with clinical suspicion or confirmed case of COVID-19 who die from the disease.|Incidence of Treatment-Emergent Adverse Events  of the P2Et in patients with COVID-19","Hospital Universitario San Ignacio|Pontificia Universidad Javeriana","All","18 Years and older","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Supportive Care","CS002-COVID19","2020-08-01T00:00:00","2020-12-01T00:00:00","2021-06-01T00:00:00","2020-06-01T00:00:00","","2020-07-31T00:00:00","","","https://ClinicalTrials.gov/show/NCT04410510"
"821","NCT04377815","Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste","FORECAST","Recruiting","No Results Available","COVID-19|Anosmia","Other: General Public cohort","Percentage of people reporting changes in smell/taste|mortality rate|Percentage of people with change in smell/taste before other symptoms|proportion of other COVID-19 linked symptoms in people with smell and/or taste change|Percentage of people with persistent changes in smell and/or taste|Percentage of hospitalisation|co-morbidities association|prevalence of changes in smell/taste|clinical outcomes","University College, London","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","132311|20/HRA/1879","2020-04-23T00:00:00","2020-08-30T00:00:00","2020-12-23T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04377815"
"822","NCT04479124","The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul","","Completed","No Results Available","Trauma|Covid19","Diagnostic Test: COVID-19 PCR","trauma admissions","Kanuni Sultan Suleyman Training and Research Hospital","All","up to 50 Years","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KSSTHR-TPED","2020-03-10T00:00:00","2020-06-30T00:00:00","2020-07-14T00:00:00","2020-07-21T00:00:00","","2020-07-21T00:00:00","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey","","https://ClinicalTrials.gov/show/NCT04479124"
"823","NCT04386044","Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients","","Not yet recruiting","No Results Available","COVID-19|Vitamin D Deficiency","","COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19","Tameside General Hospital","All","18 Years and older","","1000","Other","Observational","Observational Model: Other|Time Perspective: Other","TGH1234","2020-06-01T00:00:00","2020-12-31T00:00:00","2021-06-01T00:00:00","2020-05-13T00:00:00","","2020-05-13T00:00:00","Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT04386044"
"824","NCT04386668","Let It Out  and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic","LIO-C","Active, not recruiting","No Results Available","COVID19","Other: Let It Out -C|Other: Neutral writing control","Kessler Psychological Distress Scale |Perceived Stress Scale |Pittsburgh Sleep Quality Index |Self-compassion scale |UCLA Loneliness Scale |Uptake of existing mental health services |Mood and meaning|Acceptability","University College, London","All","18 Years and older","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Other","15281/003","2020-05-26T00:00:00","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-05-13T00:00:00","","2020-07-15T00:00:00","University College London, London, Kent, United Kingdom","","https://ClinicalTrials.gov/show/NCT04386668"
"825","NCT04481360","Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital","","Not yet recruiting","No Results Available","Coronavirus","Device: CT of the chest","Clinical evaluation","Assiut University","All","18 Years to 99 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Presentation of COVID19 in AUH","2020-08-01T00:00:00","2021-08-01T00:00:00","2021-09-01T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","","","https://ClinicalTrials.gov/show/NCT04481360"
"826","NCT04445233","COVID-19 Household Transmission Study","CO-HOST","Recruiting","No Results Available","COVID-19","","Secondary household infection rate|Secondary household infection rate - risk factors|Sensitivity of self-collected nasal swabs","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","All","1 Year and older","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0982|550KR242023","2020-04-29T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-06-24T00:00:00","","2020-06-24T00:00:00","University of North Carolina Health Care, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04445233"
"827","NCT04473365","Rapid Diagnostic Profiling of SARS-CoV-2","Profile-Cov","Recruiting","No Results Available","SARS-CoV-2|COVID-19","","Proportion of patients identified as Covid-19 by and monitoring virus clearance with COVID-19 using algorithm of RDTs.|Proportion of non-Covid-19 cases identified as negative by antibody assay","Mekelle University|Ethiopian Public Health Institute|Liverpool School of Tropical Medicine|Academisch Medisch Centrum - Universiteit van Amsterdam","All","Child, Adult, Older Adult","","186","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIA2020EF-2905","2020-07-20T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-07-16T00:00:00","","2020-08-11T00:00:00","Mekelle University College of Health Sciences, Mekelle, Ethiopia","","https://ClinicalTrials.gov/show/NCT04473365"
"828","NCT04394429","Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation","TubeObs-Covid","Recruiting","No Results Available","Sars-CoV2","","Analysis of risk factors for intubation tube obstruction","University Hospital, Strasbourg, France","All","18 Years and older","","184","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7803","2020-04-24T00:00:00","2020-06-24T00:00:00","2020-06-24T00:00:00","2020-05-19T00:00:00","","2020-05-19T00:00:00","Service d'Anesthesie-Reanimation - Nouvel Hôpital Civil, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04394429"
"829","NCT04516811","Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19","","Not yet recruiting","No Results Available","Coronavirus Disease 2019|Severe Acute Respiratory Syndrome Coronavirus 2","Biological: COVID-19 convalescent plasma  plus standard of care |Biological: Standard of care  plus placebo","Clinical Improvement|Adverse Events of special interest|Serious Adverse Events|Survival|Invasive mechanical ventilation|Disease severity|Time to outcomes of interest|Length of stay meausures|SARS-CoV PCR|Inflammatory markers|Radiography|Fever & Hypoxia|patients with HIV infection and other comorbidities|Timing of IP & Efficacy Outcome|Neutralising Ab|SARS CoV Antibody titre","South African National Blood Service","All","18 Years and older","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","PROTECT-Patient trial","2020-09-03T00:00:00","2021-12-30T00:00:00","2022-07-31T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","","","https://ClinicalTrials.gov/show/NCT04516811"
"830","NCT04350684","Umifenovir in Hospitalized COVID-19 Patients","UAIIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","Umifenovir in COVID-19","2020-04-15T00:00:00","2020-04-22T00:00:00","2020-04-24T00:00:00","2020-04-17T00:00:00","","2020-04-20T00:00:00","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04350684"
"831","NCT04487639","Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?","FERTICOVID","Recruiting","No Results Available","Sperm Preservation in Oncological Patients|Fertility|Cryopreservation","Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics","Detection of SARS-CoV-2 in sperm during fertility preservation procedures by RT-qPCR|To correlate the presence of SARS-CoV-2 in the seminal fluid and the spermatozoa fractions of the same ejaculate|To determine if the presence of this virus in sperm is associated with its presence in nasal swabs|To determine if the presence of this virus in sperm is associated with COVID symptoms|To determine if the presence of this virus in sperm is associated with specific serological profiles|To determine if the presence of this virus in sperm is associated with particular oncological pathologies/treatments|To determine if the presence of this virus in sperm could impair its quality","University Hospital, Clermont-Ferrand|Agence de La Biomedecine","Male","18 Years to 60 Years","Not Applicable","250","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","RNI 2020 BRUGNON|2020-A01409-30","2020-07-10T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-07-27T00:00:00","","2020-07-27T00:00:00","AP-Hôpitaux de Paris - Hôpital Jean Verdier - Service de Biologie de la reproduction, Bondy, France|AP-Hôpitaux de Paris - Hôpital Antoine Beclere - Service de Biologie de la reproduction et AMP DPI CECOS, Clamart, France|CHU de Clermont-Ferrand - Laboratoire de Virologie, Clermont-Ferrand, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon - Laboratoire de Biologie de la Reproduction-CECOS, Dijon, France|CHU de Grenoble - Laboratoire d'Aide à la Procreation CECOS, Grenoble, France|Hospices Civils de Lyon - Service AMP-CECOS, Lyon, France|Hôpital de la Conception - AP-Hôpitaux de Marseille - Service AMP-CECOS, Marseille, France|CHU de Nancy - Laboratoire de biologie de la reproduction - CECOS, Nancy, France|AP-Hôpitaux de Paris - Hôpital Tenon - Service de Biologie de la reproduction - CECOS, Paris, France|AP-Hôpitaux de Paris - Hôpital Cochin - Service d'Histologie-Embryologie-Biologie de la reproduction, Paris, France|Centre Hospitalier intercommunal  de Poissy Saint Germain en Laye, Poissy, France|CHU de Reims - Service de Biologie de la Reproduction - CECOS Champagne-Ardenne de Reims, Reims, France|CHU de Rouen Normandie - Service Biologie de la Reproduction-CECOS, Rouen, France|CHU de Strasbourg - Service de Biologie de la reproduction, Strasbourg, France|CHU de Toulouse - CECOS Midi-Pyrenees, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04487639"
"832","NCT04422873","The Impact of COVID-19 on Dialysis Users","","Recruiting","No Results Available","End Stage Renal Disease|Sars-CoV2","","Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours|Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK","University of Portsmouth|Portsmouth Hospitals NHS Trust|University of Reading","All","18 Years and older","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","004","2020-06-03T00:00:00","2020-09-03T00:00:00","2020-09-03T00:00:00","2020-06-09T00:00:00","","2020-07-21T00:00:00","School of Sport, Health and Exercise Science, Portsmouth, Outside The United States Or Canada, United Kingdom","","https://ClinicalTrials.gov/show/NCT04422873"
"833","NCT04395807","Helmet CPAP Versus HFNC in COVID-19","COVID HELMET","Recruiting","No Results Available","COVID|Acute Hypoxemic Respiratory Failure","Device: Helmet CPAP|Device: HFNC","Ventilator-Free Days |SpO2/FiO2-ratio|Patient comfort|Frequency of endotracheal intubation|Frequency of carbon dioxide rebreathing|Days alive within","Lund University|Region Skane","All","18 Years and older","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","COVID HELMET","2020-06-03T00:00:00","2020-12-31T00:00:00","2021-05-01T00:00:00","2020-05-20T00:00:00","","2020-06-05T00:00:00","Helsingborg's Hospital, Helsingborg, Region Skane, Sweden","","https://ClinicalTrials.gov/show/NCT04395807"
"834","NCT04517136","Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions","COVID-TRUST","Not yet recruiting","No Results Available","Covid19|SARS-CoV Infection|Burnout, Caregiver|Burnout, Professional","Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Device: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation","Professional burnout|Mindfulness level|Perceived stress level following the emotional stimulation|Parasympathetic flexibility evolution during emotional recall|Sympathetic tone at rest|Corticotropic activation at rest|Mood disorders |Post-traumatic stress disorder|Sleep quality","Direction Centrale du Service de Sante des Armees","All","18 Years to 60 Years","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-28","2020-09-01T00:00:00","2021-02-01T00:00:00","2021-02-01T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","Groupement Hospitalier Regional de Mulhouse Sud Alsace, Mulhouse, France","","https://ClinicalTrials.gov/show/NCT04517136"
"835","NCT04343690","COPING With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Behavioral: Crisis management coaching","Change in stress level as measured by survey|Change wellness as measured by survey","Duke University","All","18 Years and older","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","Pro00105319","2020-04-13T00:00:00","2020-06-30T00:00:00","2020-06-30T00:00:00","2020-04-13T00:00:00","","2020-04-13T00:00:00","Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT04343690"
"836","NCT04418284","Online Learning of Veterinary Anatomy During COVID-19 Pandemic","","Recruiting","No Results Available","COVID-19","Other: survey","Measure the students' interest in studying anatomy on-line.|Assess the easiness of using technology during studying anatomy online|Assess the student satisfaction regarding the provided study materials","South Valley University","All","17 Years to 35 Years","","400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2-2020","2020-06-05T00:00:00","2020-07-05T00:00:00","2020-07-05T00:00:00","2020-06-05T00:00:00","","2020-07-07T00:00:00","South Valley University, Qinā, Egypt","","https://ClinicalTrials.gov/show/NCT04418284"
"837","NCT04387955","Analysis of Chilblains pROfile During coVID-19 Epidemic","ACROVID","Not yet recruiting","No Results Available","COVID-19|Chilblains","Diagnostic Test: Biological Sample Collection","Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.|Study of the SARS-CoV-2 virological profile of patients presenting chilblains during a COVID-19 epidemic.|Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status .|Comparison of the capillaroscopic profiles of patients with chilblains according to their SARS-CoV-2 virological status .|Comparison of the TCPO2 profiles of patients with chilblains according to their SARS-CoV-2 virological status .|Comparison of the toe or Finger Pressure Index profiles of patients with chilblains according to their SARS-CoV-2 virological status .|Comparison of histo-pathological profiles of chilblains according to their SARS-CoV-2 virological status of patients with the disease .|Comparison of the gene expression profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the immunostaining profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the ELISA assays profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.","Poitiers University Hospital","All","12 Years and older","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Diagnostic","ACROVID","2020-05-01T00:00:00","2021-05-01T00:00:00","2021-06-01T00:00:00","2020-05-14T00:00:00","","2020-05-14T00:00:00","","","https://ClinicalTrials.gov/show/NCT04387955"
"838","NCT04346264","CoVid-19 - Infection and Antibody Formation in the Viennese Population","","Enrolling by invitation","No Results Available","Virus Diseases|COVID-19","Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Prevalence of SARS-CoV-2 antibody titres|Prevalence of SARS-CoV-2 antibody titres after 3 Months","Ludwig Boltzmann Institute for Lung Health","All","6 Years to 85 Years","","5500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LEAD CoVid-19","2020-04-27T00:00:00","2020-06-01T00:00:00","2020-09-30T00:00:00","2020-04-15T00:00:00","","2020-04-16T00:00:00","The LEAD Study Center, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT04346264"
"839","NCT04335123","Study of Open Label Losartan in COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay |30-day mortality rate|Hospital length of stay |Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity  or adjunctive therapy use |Incidence  of extracorporeal membrane oxygenation use|Incidence  of renal replacement therapy use|Intolerance of high dose  losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","STUDY00145514","2020-03-25T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-04-06T00:00:00","","2020-04-24T00:00:00","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT04335123"
"840","NCT04346056","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Explore","Recruiting","No Results Available","Coronavirus Disease |COVID-19","","Exploring the presence of COVID-19","Ain Shams University","All","1 Year to 80 Years","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FMASU P17a/ 2020","2020-04-14T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-04-15T00:00:00","","2020-04-20T00:00:00","Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","","https://ClinicalTrials.gov/show/NCT04346056"
"841","NCT04397614","Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients","","Recruiting","No Results Available","Sars-CoV2|Covid-19","Other: mHealth Assessments","Percentage of ecological momentary assessments completed|Percentage of satisfied mHealth app users|Proportion of manifestation of severe disease|Proportion of treatment-related toxicity|Proportion of hospitalization|Proportion of COVID-19 related mortality","University of Oklahoma","All","18 Years and older","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Mobile Health","2020-07-01T00:00:00","2021-12-01T00:00:00","2021-12-01T00:00:00","2020-05-21T00:00:00","","2020-08-03T00:00:00","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT04397614"
"842","NCT04356417","Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse","TRAPSAH","Not yet recruiting","No Results Available","AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection","Other: - Synthetic anti-malarial drugs","Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death","Assistance Publique - Hôpitaux de Paris|GIS EPI-PHARE","All","18 Years and older","","6000000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200412","2020-04-01T00:00:00","2020-06-01T00:00:00","2020-06-01T00:00:00","2020-04-22T00:00:00","","2020-04-22T00:00:00","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Creteil, France","","https://ClinicalTrials.gov/show/NCT04356417"
"843","NCT04413955","Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Device: Seraph®-100 Microbind® Affinity Blood Filter","Rate of known, expected, or unanticipated adverse device effects|Change in cardiovascular hemodynamic stability|Change in cardiovascular hemodynamic support|Change in pulmonary/respiratory status|Change in laboratory measures of cytokine reactions and/or viral sepsis: IL-6|Change in laboratory measures of cytokine reactions and/or viral sepsis: CRP|Change in laboratory measures of cytokine reactions and/or viral sepsis: Ferritin|Change in laboratory measures of cytokine reactions and/or viral sepsis: D-Dimer|Change in laboratory measures of cytokine reactions and/or viral sepsis: ALC","Children's Hospital Medical Center, Cincinnati|ExThera Medical Corporation","All","18 Years and older","","100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","001-Seraph®-100 for SARS-CoV-2","2020-05-31T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","","","https://ClinicalTrials.gov/show/NCT04413955"
"844","NCT04347382","Honey & Nigella Sativa Trial Against COVID-19","HNS-COVID-PK","Recruiting","No Results Available","Coronavirus Infection|Sars-CoV2","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Days required to get a positive COVID-19 PCR to negative|HRCT/ X-ray findings of disease progression|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Oxygen Saturation at room air|Incidence of viral myocarditis|Incidence of Acute respiratory Distress Syndrome","Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute","All","18 Years and older","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","SZMC/IRB/Internal/0026/2020|IRB/2020/658/SIMS","2020-04-30T00:00:00","2020-08-25T00:00:00","2020-08-30T00:00:00","2020-04-15T00:00:00","","2020-06-09T00:00:00","Kingedward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan|Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan","","https://ClinicalTrials.gov/show/NCT04347382"
"845","NCT04359914","Neurocognitive Impairment in Patients With COVID-19","NCoV","Recruiting","No Results Available","Critical Illness|COVID-19|Central Nervous System Injury|Delirium|Encephalopathy","","Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19|Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19|Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19|Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge|Length of hospital stay in patients with COVID-19 compared to patients without COVID-19|90-day survival in patients with COVID-19 compared to patients without COVID-19","University of Rostock|Ludwig-Maximilians - University of Munich|University College, London","All","Child, Adult, Older Adult","","80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-BRAIN","2020-04-15T00:00:00","2020-12-31T00:00:00","2021-04-01T00:00:00","2020-04-24T00:00:00","","2020-04-24T00:00:00","Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Vorpommern, Germany","","https://ClinicalTrials.gov/show/NCT04359914"
"846","NCT04442191","Convalescent Plasma as a Possible Treatment for COVID-19","","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma|Biological: Placebo","Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit |Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein |Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase |Ferritin|D-Dimer|White Blood Cell  Count","University of Illinois at Chicago","All","40 Years and older","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","2020-0441","2020-05-05T00:00:00","2021-05-05T00:00:00","2021-05-05T00:00:00","2020-06-22T00:00:00","","2020-06-22T00:00:00","University of Illinois at Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT04442191"
"847","NCT04511949","COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease","FAMICOV","Recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: COVID-19 IgG / IgM rapid test","Measure of the proportion of contact persons who have developed anti-SARS-CoV-2 antibodies  within the same household of a subject who had a COVID-19 disease assessed by a rapid diagnostic-oriented test","Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","All","3 Years and older","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Other","CREPATS 012","2020-07-12T00:00:00","2020-09-30T00:00:00","2020-11-30T00:00:00","2020-08-13T00:00:00","","2020-08-17T00:00:00","Christine KATLAMA, Paris, Ile De France, France","","https://ClinicalTrials.gov/show/NCT04511949"
"848","NCT04411459","Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome","","Recruiting","No Results Available","COVID-19|Mechanical Ventilation|Quality of Life|Radiologic Increased Density of Lung|Sedation|Complication of Treatment","Other: Invasive mechanical ventilation","Duration of mechanical ventilation and 28 days ventilator free days|ICU Mortality|30 days survival after ICU discharge|90 days survival after ICU discharge|Quality of life at 90 days after ICU discharge measured with 15D instrument|Radiologic aspects - structured description of CT and RX data","Azienda Usl di Bologna|Lorenzo Gamberini","All","18 Years and older","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","273/2020/OSS/AUSLBO","2020-02-01T00:00:00","2020-06-30T00:00:00","2020-10-30T00:00:00","2020-06-02T00:00:00","","2020-07-28T00:00:00","Ospedale Santa Maria Annunziata - Anestesia e Rianimazione, Bagno A Ripoli, FI, Italy|A.O. SS. Antonio, Biagio e Cesare Arrigo - Anestesia e Rianimazione, Alessandria, Italy|Anestesia e Rianimazione - Ospedale Civile di Baggiovara, Baggiovara, Italy|Anestesia e Rianimazione - Ospedale di Bentivoglio, Bentivoglio, Italy|Azienda Unità Sanitaria Locale, Bologna, Italy|Anestesia e Rianimazione - Ospedale Bellaria, Bologna, Italy|Anestesia e Rianimazione - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia intensiva dei trapianti addominali e chirurgia epatobiliare - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia Intensiva Polivalente - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Ospedale SS. Trinità - Anestesia e Rianimazione, Borgomanero, Italy|Anestesia e Rianimazione - Ospedale M. Bufalini, Cesena, Italy|Anestesia e Rianimazione - Ospedale degli Infermi, Faenza, Italy|Anestesia e Rianimazione Universitaria - Arcispedale Sant'Anna Ferrara, Ferrara, Italy|Anestesia e Rianimazione - Ospedale Morgagni - Pierantoni, Forlì, Italy|Anestesia e Rianimazione - Ospedale di Imola S.Maria della Scaletta, Imola, Italy|Ospedale Santo Stefano - Anestesia e Rianimazione, Prato, Italy|Anestesia e Rianimazione - Ospedale S. Maria delle Croci, Ravenna, Italy|Anestesia e Rianimazione - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Anestesia e Rianimazione - Ospedale di Riccione, Riccione, Italy|Anestesia e Rianimazione - Ospedale Infermi, Rimini, Italy","","https://ClinicalTrials.gov/show/NCT04411459"
"849","NCT04474236","Lung Ultrasound for COVID-19 Initial Triage and Monitoring","QUICK","Recruiting","No Results Available","COVID-19|Acute Respiratory Failure|Triage|Lung Ultrasound|CT Scan","Other: thoracic lung ultrasound","Area Under the Curve  of a predictive model built on LUS and clinical  data|Area Under the Curve  of a predictive model built on CT scan and clinical  data|mortality","University Hospital, Toulouse","All","17 Years and older","","148","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0182|2020-A01445-34","2020-05-27T00:00:00","2021-02-27T00:00:00","2021-03-27T00:00:00","2020-07-16T00:00:00","","2020-07-16T00:00:00","University Hospital Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04474236"
"850","NCT04429828","COVID-19 Psychological Wellbeing for Healthcare Students","PoWerS","Not yet recruiting","No Results Available","Psychological Wellbeing","Other: COVID-19 e-package: Psychological wellbeing for healthcare workers","Qualitative Interviews with Healthcare Students|Warwick-Edinburgh Mental Wellbeing Scale|Single Item Measure of Global Job Stressfulness |Single Item Global Job Satisfaction Measure |Single Item Measure of Presenteeism |Single Item Measure of Turnover intentions|Work Engagement","University of Nottingham","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Supportive Care","PoWerS_June2020","2020-06-13T00:00:00","2020-09-30T00:00:00","2020-12-30T00:00:00","2020-06-12T00:00:00","","2020-06-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04429828"
"851","NCT04401098","Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak","","Recruiting","No Results Available","COVID 19","","awareness of Egyptian population","Damanhour University","All","Child, Adult, Older Adult","","700","Other","Observational","Observational Model: Other|Time Perspective: Prospective","covid 19","2020-05-02T00:00:00","2020-10-01T00:00:00","2021-04-01T00:00:00","2020-05-26T00:00:00","","2020-05-26T00:00:00","Damanhour University, Damanhūr, Beheira, Egypt","","https://ClinicalTrials.gov/show/NCT04401098"
"852","NCT04370262","Multi-site Adaptive Trials for COVID-19","","Recruiting","No Results Available","COVID-19","Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo","Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity","Northwell Health","All","18 Years and older","Phase 3","942","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","20-0268","2020-04-07T00:00:00","2020-09-07T00:00:00","2021-04-07T00:00:00","2020-04-30T00:00:00","","2020-06-16T00:00:00","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States","","https://ClinicalTrials.gov/show/NCT04370262"
"853","NCT04358380","Liver Injury in Patients With COVID-19","","Enrolling by invitation","No Results Available","Liver Injury","Other: Liver injury","Liver injury in patients with COVID-19|Prognostic factors associated with death|Clinical characteristics of patients who developed liver injury","Austral University, Argentina","All","17 Years and older","","320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIE N° P 20-011","2020-04-15T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-04-24T00:00:00","","2020-07-21T00:00:00","Universidad Austral, Pilar, Buenos Aires, Argentina","","https://ClinicalTrials.gov/show/NCT04358380"
"854","NCT04343092","Efficacy of Ivermectin as Add on Therapy in COVID19 Patients","","Completed","No Results Available","COVID 19","Drug: Ivermectin","Number of cured patients|Mean time to cure of the covid 19 patients","University of Baghdad","All","18 Years and older","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","PRO20040001","2020-04-18T00:00:00","2020-05-31T00:00:00","2020-06-01T00:00:00","2020-04-13T00:00:00","","2020-06-05T00:00:00","General Directorate of Medical City, Bagdad, Baghdad, Iraq","","https://ClinicalTrials.gov/show/NCT04343092"
"855","NCT04500418","Charite Trial of Cenicriviroc  Treatment for COVID-19 Patients","","Not yet recruiting","No Results Available","Covid19","Drug: Cenicriviroc |Drug: Placebo","Subject´s Responder status |Evaluation of change in clinical condition based on the 7-point ordinal scale|Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status|Hospital resource utilization comparison","Charite University, Berlin, Germany|Allergan","All","18 Years and older","Phase 2","183","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","CVC for COVID-19|2020-001493-29","2020-08-10T00:00:00","2021-09-30T00:00:00","2021-09-30T00:00:00","2020-08-05T00:00:00","","2020-08-07T00:00:00","Medical Department of Hepatology and Gastroenterology, Charite University Medicine, Campus Virchow Klinikum  and Campus Charite Mitte , Berlin, Germany","","https://ClinicalTrials.gov/show/NCT04500418"
"856","NCT04498936","Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19","","Recruiting","No Results Available","COVID","Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide","Change of PCR from positive to negative|Clinical improvement|Adverse events","Assiut University|Helwan University","All","12 Years to 65 Years","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID-19 treatment","2020-07-15T00:00:00","2020-10-30T00:00:00","2020-12-30T00:00:00","2020-08-05T00:00:00","","2020-08-05T00:00:00","15th May Hospital, Helwan, Cairo, Egypt|Assiut University Hospital, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04498936"
"857","NCT04482205","Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures","","Completed","No Results Available","Economic Burden","","the effect of Covid -19 on the total costs of inpatient care|drop in the collective revenue generated in covid era","Aga Khan University","All","Child, Adult, Older Adult","","840","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","akupde","2020-03-16T00:00:00","2020-05-31T00:00:00","2020-05-31T00:00:00","2020-07-22T00:00:00","","2020-07-22T00:00:00","Aga Khan University Hospital, Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT04482205"
"858","NCT04405999","Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease","","Recruiting","No Results Available","Increased Risk of SARS-CoV-2 Infection","Drug: Bromhexine Hydrochloride","Polymerase chain reaction |Time to symptoms|Time to positive PCR|Number of cases|Case severity|Drug tolerance","Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","All","18 Years and older","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","05-20-02-С","2020-05-14T00:00:00","2020-06-20T00:00:00","2020-09-30T00:00:00","2020-05-28T00:00:00","","2020-05-28T00:00:00","Almazov National Medical Research Centre, Saint Petersburg, Russian Federation","","https://ClinicalTrials.gov/show/NCT04405999"
"859","NCT04351919","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19","COVID+PA","Not yet recruiting","No Results Available","Patients With COVID19","Drug: Hydroxychloroquine|Drug: Azithromycin","improvment or healing of clinical signs|Evolution of clinical signs","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years","Phase 4","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","ECC2020-04","2020-05-05T00:00:00","2020-07-15T00:00:00","2020-07-15T00:00:00","2020-04-17T00:00:00","","2020-05-05T00:00:00","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia","","https://ClinicalTrials.gov/show/NCT04351919"
"860","NCT04346212","Oropharyngeal Dysphagia in Patients With COVID-19","","Recruiting","No Results Available","Oropharyngeal Dysphagia|COVID-19|Sars-CoV2|Nutrition","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test","Prevalence of oropharyngeal dysphagia|Swallowing screening|Swallowing status.|Nutritonal status of study patient's.|Needs of compensatory treatments in those patients with oropharyngeal dysphagia .|Needs of compensatory treatments in those patients with oropharyngeal dysphagia .|Clinical complications at 6 months follow up from patient's medical history .|Clinical complications at 6 months follow up from patient's medical history .|Clinical complications at 6 months follow up from patient's medical history .|Clinical complications at 6 months follow up from patient's medical history .|Clinical complications at 6 months follow up from patient's medical history .|Clinical complications at 6 months follow up from patient's medical history .","Hospital de Mataró|Centro Investigación Biomedica en Red de Enfermedades Hepáticas Digestivas","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID_OD","2020-04-14T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-04-15T00:00:00","","2020-04-22T00:00:00","Consorci Sanitari del Maresme , Mataró, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT04346212"
"861","NCT04441710","Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus","CoVid3S","Not yet recruiting","No Results Available","COVID","Other: Questionnaire","Establishment of a reliable prediction model for the effectiveness of virus control","Hospices Civils de Lyon","All","Child, Adult, Older Adult","","2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0395","2020-07-01T00:00:00","2022-01-01T00:00:00","2022-01-01T00:00:00","2020-06-22T00:00:00","","2020-06-22T00:00:00","CHU de Grenoble - Hôpital Nord, La Tronche, France|Hôpital de la Croix Rousse, Lyon, France|Hôpital Henry Gabrielle, Saint-Genis-Laval, France|CHU de Saint Etienne, Saint-Étienne, France","","https://ClinicalTrials.gov/show/NCT04441710"
"862","NCT04512079","FREEDOM COVID-19 Anticoagulation Strategy","FREEDOM COVID","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Enoxaparin|Drug: Apixaban","Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism","Valentin Fuster|Icahn School of Medicine at Mount Sinai","All","18 Years and older","Phase 4","3600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","GCO 20-2115","2020-09-01T00:00:00","2021-03-01T00:00:00","2021-06-01T00:00:00","2020-08-13T00:00:00","","2020-08-14T00:00:00","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04512079"
"863","NCT04388410","Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","EPCOvid-1","Not yet recruiting","No Results Available","COVID-19","Biological: convalescent plasma","Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Hospital San Jose Tec de Monterrey|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Cardiologia Ignacio Chavez|Hospital General Dr. Manuel Gea González|Instituto Nacional de Cancerologia, Columbia|Hospital Regional de Alta Especialidad del Bajio","All","18 Years and older","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","3380","2020-06-01T00:00:00","2020-10-31T00:00:00","2020-12-31T00:00:00","2020-05-14T00:00:00","","2020-05-15T00:00:00","","","https://ClinicalTrials.gov/show/NCT04388410"
"864","NCT04406389","Anticoagulation in Critically Ill Patients With COVID-19","IMPACT","Recruiting","No Results Available","COVID-19","Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban","30-day mortality|Length of Intensive Care Unit  Stay in Days|Number of documented venous thromboembolism , arterial thrombosis  and microthrombosis events|Number of major and clinically relevant non-major bleeding events","Weill Medical College of Cornell University","All","18 Years and older","Phase 4","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","20-04021936","2020-08-01T00:00:00","2020-12-01T00:00:00","2021-06-01T00:00:00","2020-05-28T00:00:00","","2020-08-07T00:00:00","Weill Cornell Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04406389"
"865","NCT04368260","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic","","Recruiting","No Results Available","COVID19","Device: Control swab|Device: Prototype swab","Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result","University of Virginia","All","up to 99 Years","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Other","HSR200127","2020-04-24T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT04368260"
"866","NCT04460547","Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","","Not yet recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A","Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.","Qassim University","All","1 Year and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COAHS","2020-07-25T00:00:00","2020-08-15T00:00:00","2020-09-20T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04460547"
"867","NCT04445272","Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia","","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction  virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function","Fundacion SEIMC-GESIDA|Roche Pharma AG|Dynamic Science S.L.","All","18 Years and older","Phase 2","500","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","BREATH-19","2020-05-22T00:00:00","2020-08-22T00:00:00","2020-08-22T00:00:00","2020-06-24T00:00:00","","2020-06-24T00:00:00","Hospital Universitario de Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central Asturias, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de Deu de Manresa, Manresa, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario Marques Valdecilla, Santander, Cantabria, Spain|Hospital Público General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, Cádiz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clínic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro Alcántara, Cáceres, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario Clínico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","","https://ClinicalTrials.gov/show/NCT04445272"
"868","NCT04390191","Early CPAP in COVID-19 Confirmed or Suspected Patients","PAP-COVID","Recruiting","No Results Available","COVID-19|COVID|Coronavirus","Device: Continuous Positive Airway Pressure","Efficacy Endpoint composite score|Time to ICU admission|Time to Intubation and mechanical ventilation|14 day and 28 day mortality|Conversion rate of COVID household members in CPAP vs control|Clinical COPD Questionnaire |Percentage of patients electing to continue CPAP for greater than 72 hours|Degree of improvement in oxygen saturation|Time to hospital admission or ED","Icahn School of Medicine at Mount Sinai|Itamar Medical LTD|Community Surgical Supply of Toms River, Inc|Philips Healthcare","All","18 Years and older","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","GCO 20-0900","2020-05-07T00:00:00","2021-04-01T00:00:00","2021-05-01T00:00:00","2020-05-15T00:00:00","","2020-05-15T00:00:00","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04390191"
"869","NCT04469647","COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH","","Enrolling by invitation","No Results Available","COVID 19","Diagnostic Test: Serology Test","Seroconversion status|The proportion of asymptomatic infections among staff who have seroconverted|The durability of COVID 19 seroconversion in asymptomatic healthcare workers at JHAH|Identification of risk factors for COVID 19 seroconversion in asymptomatic healthcare workers","Johns Hopkins Aramco Healthcare","All","18 Years and older","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB20-09","2020-07-19T00:00:00","2021-01-15T00:00:00","2021-06-15T00:00:00","2020-07-14T00:00:00","","2020-07-29T00:00:00","Johns Hopkins Aramco Healthcare, Dhahran, Eastern, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04469647"
"870","NCT04449081","Knowledge, Attitude and Practice of Dental Students About COVID-19","","Completed","No Results Available","Acute Respiratory Distress Syndrome|Corona Virus Infection|Acute Lung Injury|Fever|Myalgia|Cough|Dyspnea|Septic Shock|Bleeding","Behavioral: Knowledge, Attitude, Practice, Awareness, Preference","Knowledge, Attitude, Practice of dental students towards COVID-19|Awareness level about Infection control to prevent COVID-19 transmission in clinics|Preference towards online learning.","Melaka Manipal Medical College","All","18 Years to 30 Years","","215","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","MelakaMMC","2020-04-25T00:00:00","2020-06-10T00:00:00","2020-06-20T00:00:00","2020-06-26T00:00:00","","2020-06-26T00:00:00","Faculty of Dentistry, Melaka-Manipal Medical College, Melaka Tengah, Melaka, Malaysia","","https://ClinicalTrials.gov/show/NCT04449081"
"871","NCT04346186","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","","Not yet recruiting","No Results Available","COVID","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2","Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test","Herlev Hospital|Nordsjaellands Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark|Mental Health Services in the Capital Region, Denmark|University Hospital Bispebjerg and Frederiksberg","All","Child, Adult, Older Adult","","30000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RegHCOVIDScreening","2020-04-15T00:00:00","2020-10-01T00:00:00","2021-08-01T00:00:00","2020-04-15T00:00:00","","2020-04-15T00:00:00","Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, København NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center København, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Børne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Psykiatrisk Center Nordsjælland, Hillerød, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rønne, Denmark|Psykiatrisk Center Bornholm, Rønne, Denmark","","https://ClinicalTrials.gov/show/NCT04346186"
"872","NCT04328454","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","","Recruiting","No Results Available","Coronavirus","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","All","18 Years and older","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HBCBH-IEC-2020-101","2020-01-30T00:00:00","2020-04-02T00:00:00","2020-04-15T00:00:00","2020-03-31T00:00:00","","2020-03-31T00:00:00","Shanghai 10th People's Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT04328454"
"873","NCT04429867","Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease","","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy","WellStar Health System","All","18 Years and older","Phase 4","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","1604885","2020-05-07T00:00:00","2020-12-07T00:00:00","2020-12-07T00:00:00","2020-06-12T00:00:00","","2020-06-16T00:00:00","Wellstar Kennestone Hospital, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT04429867"
"874","NCT04511819","Losmapimod Safety and Efficacy in COVID-19","LOSVID","Recruiting","No Results Available","COVID-19","Drug: Losmapimod oral tablet|Drug: Placebo oral tablet","Day 28 Mortality|Clinical Status Assessment|Respiratory Failure Assessment|Treatment Survival|Treatment-Emergent Adverse Events","Fulcrum Therapeutics","All","50 Years and older","Phase 3","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","FIS-001-2020","2020-08-01T00:00:00","2020-11-01T00:00:00","2020-11-01T00:00:00","2020-08-13T00:00:00","","2020-08-18T00:00:00","University of California Irvine - Irvine Medical Center, Irvine, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Irmandade de Santa Casa de Misericordia de Porto Alegre, Centro Histórico, Porto Alegre - RS, Brazil|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|JM Research Cuernavaca, Cuernavaca, Morelos, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada, S.C., Culiacán, Sinaloa, Mexico","","https://ClinicalTrials.gov/show/NCT04511819"
"875","NCT04444310","Antibody Responses in Contacts of COVID-19 Patients","","Active, not recruiting","No Results Available","COVID-19","","Measure level of Abs in asymptomatic close contacts of COVID 19 patients.","Assiut University","All","18 Years to 80 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Assiut13","2020-06-15T00:00:00","2020-06-18T00:00:00","2020-09-30T00:00:00","2020-06-23T00:00:00","","2020-06-23T00:00:00","AssiutU, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04444310"
"876","NCT04328961","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis","","Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS |SARS-CoV-2","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Polymerase chain reaction  confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years","Phase 2|Phase 3","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","STUDY00009750|INV-016204","2020-03-31T00:00:00","2020-09-30T00:00:00","2020-10-31T00:00:00","2020-04-01T00:00:00","","2020-08-11T00:00:00","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT04328961"
"877","NCT04357535","Prognosis of Coronavirus Disease 2019  Patients Receiving Receiving Antihypertensives","","Completed","No Results Available","COVID-19","Drug: Angiotensin-Converting Enzyme Inhibitors  and Angiotensin II Receptor Blockers","Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria","Hakeam Abdulaziz Hakeam|Buraidah Central Hospital|King Khalid University Hospital|Princess Nourah Bint Abdulrahman University|King Faisal Specialist Hospital & Research Center","All","18 Years and older","","314","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2210061","2020-05-10T00:00:00","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-04-22T00:00:00","","2020-08-04T00:00:00","King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04357535"
"878","NCT04385251","International SARS-CoV-2  Infection Observational Study","ICOS","Recruiting","No Results Available","COVID|COVID19|SARS-CoV 2|Dyspnea","Other: Data Collection","Time to Hospitalization|Time to Expiration|Rate of Death at 7 Days|Rate of Death at 14 Days|Rate of Death at 28 Days|Rate of Hospitalization at 7 Days|Rate of Hospitalization at 14 Days|Rate of Hospitalization at 28 Days|Participant Health at 7 Days|Participant Health at 14 Days|Participant Health at 28 Days|Modified Borg Dyspnea Scale at 7 Days|Modified Borg Dyspnea Scale at 14 Days|Modified Borg Dyspnea Scale at 28 Days","University of Minnesota|National Institutes of Health |National Institute of Allergy and Infectious Diseases","All","18 Years and older","","10000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICOS|75N91019D00024","2020-06-18T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-05-12T00:00:00","","2020-08-17T00:00:00","Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT04385251"
"879","NCT04426253","Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","","Active, not recruiting","No Results Available","COVID-19|Sars-CoV2","","Identification of genetic factors determining the course of the disease in case of COVID-19","Szeged University","All","18 Years and older","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID19_HUNGEN_001","2020-06-05T00:00:00","2020-12-31T00:00:00","2021-07-31T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","University of Pecs 1st Department of Internal Medicine Intensive Care Unit, Pecs, Hungary|University of Pecs First Department of Internal Medicine, Pecs, Hungary|University of Pecs Infection Department of the Coronavirus Center, Pecs, Hungary|University of Pecs Institute of Laboratory Medicine, Pecs, Hungary|University of Pecs Szentágotahi Research Centre, Pecs, Hungary|University of Pecs Szentágothai Research Centre Genomics and Bioinformatics Core Facility, Pecs, Hungary|University of Szeged Szentágothai Research Centre Virology Research Group, Pecs, Hungary|University of Szeged Department of Anaesthesiology And Inthensive Therapy, Szeged, Hungary|University of Szeged Department of Dermatology and Allergology, Szeged, Hungary|University of Szeged Department of Medical Biology, Szeged, Hungary|University of Szeged Department of Paediatrics, Szeged, Hungary|University of Szeged First Department of Medicine, Szeged, Hungary|University of Szeged Institute of Clinical Microbiology, Szeged, Hungary|University of Szeged Institute of Medical Microbiology and Immunobiology, Szeged, Hungary","","https://ClinicalTrials.gov/show/NCT04426253"
"880","NCT04353154","The RAPID COVID TRIAGE Algorithm","","Not yet recruiting","No Results Available","COVID","Diagnostic Test: Spartan Cube Point-of Care Covid-19 test","Sensitivity","Ottawa Heart Institute Research Corporation","All","18 Years and older","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200228-01H","2020-04-15T00:00:00","2020-08-31T00:00:00","2021-02-28T00:00:00","2020-04-20T00:00:00","","2020-04-20T00:00:00","","","https://ClinicalTrials.gov/show/NCT04353154"
"881","NCT04483635","Preventing COVID-19 With High-dose Vitamin D Supplements","PROTECT","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Placebo|Dietary Supplement: Vitamin D","Change in incidence of laboratory-confirmed COVID-19 infection|Distribution of disease severity|Duration of COVID-19 positivity|Number of participants with COVID-19 positive IgG serology|Number of workday absences due to COVID-19 suspected/confirmed infection|Number of workday absences for any reason|Changes in adverse health events","St. Justine's Hospital|Canadian Institutes of Health Research |Laboratoire RIVA","All","18 Years to 69 Years","Phase 3","2414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","MP-21-2021-3044","2020-09-01T00:00:00","2021-04-01T00:00:00","2021-06-30T00:00:00","2020-07-23T00:00:00","","2020-07-23T00:00:00","CHUM, Montreal, Quebec, Canada|CHU Sainte-Justine , Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT04483635"
"882","NCT04452643","Efficacy of BACMUNE  in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel","Bacmune","Not yet recruiting","No Results Available","Covid19","Biological: BACMUNE |Other: Placebo","Incidence of subjects with COVID-19|Severity of COVID-19|Seroconversion to SARS-CoV-2|Subjects with symptoms|Hospital admission due to COVID-19|Admission to an intensive care unit due to COVID-19|Elapsed time until hospitalization|Elapsed time until admission into an care unit for COVID-19|Elapsed time until death not related to COVID-19","Inmunotek S.L.|BioClever 2005 S.L.","All","18 Years to 65 Years","Phase 3","3312","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Prevention","MV130-SLG-037","2020-07-01T00:00:00","2021-11-01T00:00:00","2021-12-01T00:00:00","2020-06-30T00:00:00","","2020-07-02T00:00:00","Instituto Nacional de Enfermedades Respiratorias , Ciudad de Mexico, Mexico|Hospital General de Pachuca, Pachuca de Soto, Mexico|Hospital de Ciudad Valles, San Luis Potosí, Mexico","","https://ClinicalTrials.gov/show/NCT04452643"
"883","NCT04256395","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","COVID-19","Completed","No Results Available","Susceptibility to Viral and Mycobacterial Infection","Other: mobile internet survey on self-test","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","All","Child, Adult, Older Adult","","102456","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RWS-BTCH-002","2020-02-01T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-02-05T00:00:00","","2020-07-07T00:00:00","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT04256395"
"884","NCT04384250","Genetic Basis of COVID-19 Infection","","Recruiting","No Results Available","Genetic Basis of COVID-19 Infection","Diagnostic Test: Whole Exome Sequencing","Mutations leading to increase susceptibility to SARS-COV-2 infection","Mansoura University","All","up to 50 Years","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RP:20.05.70","2020-05-10T00:00:00","2020-08-31T00:00:00","2021-05-01T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Mansoura University, Mansoura, Dakahlyia, Egypt","","https://ClinicalTrials.gov/show/NCT04384250"
"885","NCT04378595","Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin","","Recruiting","No Results Available","Food Insecurity","Other: During COVID-19 Pandemic|Other: After COVID-19 Pandemic","Food Insecurity Score","University of Texas at Austin","All","18 Years to 100 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-004-0019","2020-04-10T00:00:00","2020-12-30T00:00:00","2021-07-30T00:00:00","2020-05-07T00:00:00","","2020-05-08T00:00:00","Dell Medical School, Austin, Texas, United States|CommUnity Care Clinic - Southeast Health and Wellness Clinic, Austin, Texas, United States|CommUnity Care Clinic - Rundberg, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT04378595"
"886","NCT04475211","LILLE COVID RESEARCH NETWORK","LICORNE","Not yet recruiting","No Results Available","Sars-CoV2","","Number of patients ""confirmed cases"" of SARS-CoV-2 infection who died at D28 of inclusion|Correlation between Infection characteristics of patients at inclusion and all predictors for Covid-19|Correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for Covid-19|Positivity for Covid-19 patients performed and all predictors for Covid-19|Correlation between hospitalisation and all predictors for Covid-19|Correlation between risk factors measured at D0 for severe CoV-2 SARS infection and all predictors for Covid-19|Correlation between overall survival at Day 28 and all predictors for Covid-19|Cumulative incidence of at least one complication related to COVID 19|Cumulative incidence of the thrombosis complication related to COVID 19|All type of co-infections|Alteration of microbiota|Biobanking for further analyses such as SARS-CoV2 studies","University Hospital, Lille","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020_54|2020-A01514-35","2020-07-01T00:00:00","2022-07-01T00:00:00","2022-07-01T00:00:00","2020-07-17T00:00:00","","2020-07-17T00:00:00","","","https://ClinicalTrials.gov/show/NCT04475211"
"887","NCT04353180","Assessment the Activity Value of Isotretinoin  in the Treatment of COVID-19","Isotretinoin","Not yet recruiting","No Results Available","COVID19","Drug: Drug Isotretinoin  capsules+standard treatment|Drug: Isotretinoin +standard treatment|Drug: Standard treatment","lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap|Angiotensin 1-7  changes over time|Angiotensin 1-5  changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme  changes over time|Frequency of adverse events and severe adverse events|Angiotensin II  changes over time|Sequential organ failure assessment score over time|Transe membrane protease ,serine II  changes over time|Testosterone levels changes over time|Dihydrotestosterone levels changes over time|Cholesterol levels changes over time|Thrombin time","Kafrelsheikh University","All","18 Years to 80 Years","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Proposed by Mahmoud Elkazzaz","2020-07-01T00:00:00","2020-08-01T00:00:00","2020-11-01T00:00:00","2020-04-20T00:00:00","","2020-07-07T00:00:00","Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04353180"
"888","NCT04348448","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","","Not yet recruiting","No Results Available","COVID-19","Drug: Canakinumab 150 MG/ML [Ilaris]","intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event","AUSL Romagna Rimini","All","18 Years to 100 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CANASCOV","2020-04-01T00:00:00","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-04-16T00:00:00","","2020-04-16T00:00:00","","","https://ClinicalTrials.gov/show/NCT04348448"
"889","NCT04442087","Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP","FamilyPEDCOVID","Not yet recruiting","No Results Available","SARS-CoV2","Biological: Serology SARS-CoV2|Behavioral: Data collection","Seroprevalence of antibodies anti- SARS Cov2 in children of Hospital workers|Number of Asymptomatic Children with a positive seroloy|Number of severely symptomatic Children with a positive serology|Prevalence of different clinical symptoms in children with a positive serology|Serological result of each member of the family|Number of spouses of hospital workers with a positive serology|Number of Asymptomatic spouses of hospital workers with a positive serology|Number of severely symptomatic spouses of hospital workers with a positive serology","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Basic Science","APHP200627|2020-A01480-39","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-09-01T00:00:00","2020-06-22T00:00:00","","2020-06-22T00:00:00","Centre d'investigation clinique  Necker Cochin in Necker Children's Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT04442087"
"890","NCT04460651","PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial","PREPARE-IT","Not yet recruiting","No Results Available","COVID19","Drug: Icosapent ethyl |Drug: Placebo","Percentage of SARS-CoV-2 positive subjects|Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.|Highest mean WHO score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit|Total cholesterol, LDL, HDL, triglycerides  at baseline and at day 60|Ultrasensitive C-reactive Protein  at baseline and at day 60|Difference in hospital length of stay between groups|Difference in duration of mechanical ventilation in both groups|Rate of hospital admissions due to SARS  in patients who were negative for SARS CoV-2 upon admission|Mean highest WHO descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients  without serum evidence / PCR detecting SARS-CoV-2 infection|Rate of total events, non-fatal myocardial infarction or non-fatal stroke or death , up to day 60","Estudios Clínicos Latino America|Amarin Pharma Inc.","All","18 Years and older","Phase 3","1500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","PREPARE-IT. Version 1.2","2020-07-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-07-07T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04460651"
"891","NCT04370119","Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers","SeCo","Recruiting","No Results Available","SARS-Cov-2","Diagnostic Test: Nasal swab|Diagnostic Test: Serum testing","Number of people with detectable antibodies to SARS-COV2|Number of people with detectable SARS-COV2 nucleic acid","University Medicine Greifswald|Friedrich Loefler Institute for Animal Health|EUROIMMUN AG","All","18 Years and older","","4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BB 068/20","2020-04-27T00:00:00","2021-05-01T00:00:00","2025-05-01T00:00:00","2020-04-30T00:00:00","","2020-04-30T00:00:00","Greifswald University Medicine, Greifswald, Germany","","https://ClinicalTrials.gov/show/NCT04370119"
"892","NCT04426344","Core Warming of COVID-19 Patients","","Not yet recruiting","No Results Available","COVID 19","Device: ensoETM device","Viral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilation","Washington University School of Medicine","All","18 Years and older","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","202005150","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-06-11T00:00:00","","2020-07-22T00:00:00","Barnes-Jewish Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT04426344"
"893","NCT04425252","Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19","CRISIS","Recruiting","No Results Available","COVID-19","Drug: Brequinar|Other: Standard of Care","Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration","Clear Creek Bio, Inc.","All","18 Years and older","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CCB-CRISIS-01","2020-06-25T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-06-11T00:00:00","","2020-08-04T00:00:00","Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|Temple University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04425252"
"894","NCT04421534","Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Lactoferrin","Time to clinical improvement|Rate of virological cure","Cairo University","All","18 Years to 65 Years","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CUKA-001","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","","","https://ClinicalTrials.gov/show/NCT04421534"
"895","NCT04443270","Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients","","Not yet recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate","Negative Polymerase Chain Reaction assay at day 0|Polymerase Chain Reaction assay at day 60|Clinical improvement related to COVID-19|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic|COVID-19 symptomatic onset rate","CMN ""20 de Noviembre""","All","18 Years to 59 Years","Phase 1","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","01","2020-07-27T00:00:00","2020-10-31T00:00:00","2021-01-31T00:00:00","2020-06-23T00:00:00","","2020-07-14T00:00:00","Centro Medico Nacional ""20 de Noviembre"", Mexico City, Benito Juárez, Mexico","","https://ClinicalTrials.gov/show/NCT04443270"
"896","NCT04409522","Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients","","Recruiting","No Results Available","COVID-19","Drug: Melatonin|Drug: The usual treatment","Melatonin|Inflammatory cytokines|C-reactive protein |Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route","Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University","All","16 Years to 100 Years","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IR.BMSU.REC.1399.039","2020-05-12T00:00:00","2020-06-05T00:00:00","2020-09-25T00:00:00","2020-06-01T00:00:00","","2020-06-01T00:00:00","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04409522"
"897","NCT04439084","COVID-19 in Patients With Chronic Liver Diseases","COLD","Enrolling by invitation","No Results Available","COVID-19|Chronic Liver Disease","Other: Prospective Chart Review","All-cause mortality|Liver-related mortality|Overall survival|Number of patients with hepatic decompensation|Number of patients requiring hospitalization|Duration of hospitalization|Length of intensive care unit  stay|Number of participants requiring mechanical ventilation","Stanford University","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","55819","2020-03-06T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-06-19T00:00:00","","2020-07-27T00:00:00","University of Arizona,, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|UCSF Fresno, Fresno, California, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Georgetown University, Washington, District of Columbia, United States|VA Medical Center, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Oschner Medical Center, Baton Rouge, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Hennepin County Medical Center , Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04439084"
"898","NCT04392141","Colchicine Plus Phenolic Monoterpenes to Treat COVID-19","","Recruiting","No Results Available","COVID-19","Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions","Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|lymphocyte count|serum lactate dehydrogenase|serum Interleukin-6|erythrocyte sedimentation rate","Kermanshah University of Medical Sciences","All","10 Years and older","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","1399.062","2020-04-01T00:00:00","2020-06-01T00:00:00","2020-10-01T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04392141"
"899","NCT04492943","To Observe Whether Isoflurane Can Treat COVID-19 Patients","","Recruiting","No Results Available","COVID-19","","Survival Outcome|COVID-19 Testing Methods|COVID-19 Clearance","Massachusetts General Hospital","All","18 Years and older","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020P001048","2020-04-20T00:00:00","2020-07-20T00:00:00","2020-07-20T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04492943"
"900","NCT04323332","Traditional Chinese Medicine for Severe COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay |Duration  of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement |The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","up to 85 Years","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020XLA015-1","2020-03-01T00:00:00","2020-03-01T00:00:00","2020-04-01T00:00:00","2020-03-26T00:00:00","","2020-03-26T00:00:00","Hao Li, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT04323332"
"901","NCT04487119","Hematology and Clinical Picture in Pediatric COVID-19 Infection","","Recruiting","No Results Available","Covid19","","hematological findings|clinical presentations","Benha University","All","up to 18 Years","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC 6-7-2020","2020-08-12T00:00:00","2020-08-19T00:00:00","2020-08-22T00:00:00","2020-07-27T00:00:00","","2020-08-14T00:00:00","Benha Faculty of Medicine, Banhā, Qalubia, Egypt","","https://ClinicalTrials.gov/show/NCT04487119"
"902","NCT04372017","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection","","Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.","Sanford Health","All","18 Years and older","Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","PEPCOH","2020-05-14T00:00:00","2020-06-04T00:00:00","2021-06-04T00:00:00","2020-05-01T00:00:00","","2020-06-09T00:00:00","Sanford Health, Sioux Falls, South Dakota, United States","","https://ClinicalTrials.gov/show/NCT04372017"
"903","NCT04485338","Chest Radiography in COVID-19 Patients","","Not yet recruiting","No Results Available","Covid19","","The prognostic capacity of the Radiographic Assessment of Lung Edema  score of the first CXR under invasive ventilation in patients with severe COVID-19.|The prognostic capacity of changes in the RALE score of consecutive CXRs under invasive ventilation in patients with severe COVID-19|Number of ventilator-free day and alive at day 28","Academisch Medisch Centrum - Universiteit van Amsterdam |University of Bari Aldo Moro|Mahidol University|Universitair Ziekenhuis Brussel|Chonburi Hospital","All","18 Years and older","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RALE-COVID","2020-08-01T00:00:00","2020-12-31T00:00:00","2021-03-01T00:00:00","2020-07-24T00:00:00","","2020-07-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04485338"
"904","NCT04364763","A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals","","Recruiting","No Results Available","COVID-19","Drug: RBT-9 |Drug: 0.9% sodium chloride","Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization  Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Oxygen saturation /fraction of inspired oxygen  ratio|Fever incidence|Acute kidney injury  incidence|New or worsening congestive heart failure |Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit  status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status","Renibus Therapeutics, Inc.","All","18 Years and older","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","REN-005","2020-07-20T00:00:00","2021-06-30T00:00:00","2021-12-31T00:00:00","2020-04-28T00:00:00","","2020-07-21T00:00:00","Fort Worth, TX, Fort Worth, Texas, United States","","https://ClinicalTrials.gov/show/NCT04364763"
"905","NCT04337541","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","","Completed","No Results Available","COVID-19","Other: Surgical facial mask","The primary endpoint is the difference in SARS-CoV-2 infection between the two groups after 1 months and is a combined endpoint consisting of primary outcome components 1, 2 and/or 3:|Positive oropharyngeal/nasal swab ;","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","All","18 Years and older","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","2020-04-02","2020-04-02T00:00:00","2020-06-02T00:00:00","2020-06-02T00:00:00","2020-04-07T00:00:00","","2020-08-03T00:00:00","Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT04337541"
"906","NCT04328493","The Vietnam Chloroquine Treatment on COVID-19","VICO","Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|fever clearance time|Ordinal outcome scale|Development of ARDS","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","All","18 Years and older","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","COVID","2020-04-07T00:00:00","2021-04-01T00:00:00","2022-04-01T00:00:00","2020-03-31T00:00:00","","2020-05-29T00:00:00","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","","https://ClinicalTrials.gov/show/NCT04328493"
"907","NCT04363385","Collection of Biological Samples With Clinical Characterization of Covid-19 Patients","","Recruiting","No Results Available","Covid-19","Biological: Biological test","Phenotype/genotype correlation research modulating the severity of Covid-19 disease|Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease|Phenotype/biomarker correlation research modulating the severity of Covid-19 disease|Development of clinical-biological scores in the severity of Covid-19 disease|Development of predictive imaging scores in the severity of Covid-19 disease|Identification of pathophysiological pathways to susceptibility to Covid-19 disease|Identification of genetic markers for treatment response|Identification of transcriptomic markers for treatment response|Identification of proteomic for treatment response","Centre Hospitalier Intercommunal Creteil","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","COVIGENET","2020-05-31T00:00:00","2021-05-31T00:00:00","2021-05-31T00:00:00","2020-04-27T00:00:00","","2020-07-24T00:00:00","Centre hospitalier intercommunal de Creteil, Creteil, France","","https://ClinicalTrials.gov/show/NCT04363385"
"908","NCT04509713","Canine COVID-19 Detection","","Recruiting","No Results Available","Covid19","Behavioral: Collection of odour samples","Sensitivity and specificity precision of dogs to detect people with COVID-19 by their odour.|Identification of the volatile profile that is specific to asymptomatic or mild symptomatic participants with SARS-CoV-2 compared with uninfected individuals.","ARCTEC|Durham University|Cardiff University|Medical Detection Dogs","All","16 Years and older","","16250","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Other","LSH1285","2020-07-02T00:00:00","2020-09-30T00:00:00","2020-10-31T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","ARCTEC, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04509713"
"909","NCT04348305","Hydrocortisone for COVID-19 and Severe Hypoxia","COVID STEROID","Active, not recruiting","No Results Available","Covid-19|Hypoxia","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year","Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital","All","18 Years and older","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","RH-ITA-008|2020-001395-15","2020-04-17T00:00:00","2021-03-30T00:00:00","2021-12-30T00:00:00","2020-04-16T00:00:00","","2020-06-24T00:00:00","Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Køge Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark","","https://ClinicalTrials.gov/show/NCT04348305"
"910","NCT04330599","Longitudinal Population-based Observational Study of COVID-19 in the UK Population","COVIDENCE UK","Not yet recruiting","No Results Available","COVID-19","","Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of the COVID-19 pandemic and the societal response on participants' financial status|Incidence of COVID-19 on participant's physical health|Impact of COVID-19 on participants' mental health|Impact of COVID-19 on physical health of offspring born to participants during follow-up","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine|University of Edinburgh|Swansea University|Queen's University, Belfast|Barts Charity","All","16 Years and older","","12000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDENCE UK","2020-05-05T00:00:00","2025-04-01T00:00:00","2025-04-01T00:00:00","2020-04-01T00:00:00","","2020-04-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04330599"
"911","NCT04433039","COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising","","Completed","No Results Available","COVID","","COVID19 versus H1N1; radiological comparative study","Alexandria University","All","4 Years to 80 Years","","130","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","IRB , SN","2020-05-22T00:00:00","2020-06-12T00:00:00","2020-06-14T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Faculty of Medicine, University of Alexandria, Alexandria, Egypt","","https://ClinicalTrials.gov/show/NCT04433039"
"912","NCT04466371","Perceptions of Undergraduate Students and Teaching Staff on Online Teaching","","Not yet recruiting","No Results Available","Covid19","Other: Questionnaire","Satisfaction with online learning|Knowledge about COVID-19 crisis|Perception of COVID-19 crisis","Misr International University","All","18 Years and older","","9209","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","PUB 1114005","2020-10-15T00:00:00","2021-01-01T00:00:00","2021-11-01T00:00:00","2020-07-10T00:00:00","","2020-07-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04466371"
"913","NCT04412369","Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury","MIIC-MI","Not yet recruiting","No Results Available","COVID19|Cardiovascular Diseases","Diagnostic Test: Non-invasive cardiac imaging","Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.|Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging|Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|British Heart Foundation|Wellcome Trust","All","18 Years to 99 Years","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A09565","2020-06-01T00:00:00","2021-06-01T00:00:00","2021-06-01T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","Cambridge Univeristy Hospitals NHS Foundation Trust, Cambridge, United Kingdom","","https://ClinicalTrials.gov/show/NCT04412369"
"914","NCT04346446","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","","Completed","No Results Available","COVID","Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma","Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.","Institute of Liver and Biliary Sciences, India","All","18 Years and older","Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","ILBS-COVID-02","2020-04-20T00:00:00","2020-05-30T00:00:00","2020-05-30T00:00:00","2020-04-15T00:00:00","","2020-06-12T00:00:00","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","","https://ClinicalTrials.gov/show/NCT04346446"
"915","NCT04339426","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","","Recruiting","No Results Available","Covid19","Drug: Atovaquone/Azithromycin","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","HonorHealth Research Institute","All","18 Years to 95 Years","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","HRI-COVID-19-Anti-Malarial-001","2020-04-20T00:00:00","2020-10-01T00:00:00","2021-04-01T00:00:00","2020-04-09T00:00:00","","2020-06-09T00:00:00","HonorHealth, Scottsdale, Arizona, United States","","https://ClinicalTrials.gov/show/NCT04339426"
"916","NCT04410328","Aggrenox To Treat Acute Covid-19","ATTAC-19","Not yet recruiting","No Results Available","Covid19","Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care","Covid  Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale","Rutgers, The State University of New Jersey|Boehringer Ingelheim","All","19 Years and older","Phase 3","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Pro2020001399","2020-07-28T00:00:00","2020-12-15T00:00:00","2021-12-15T00:00:00","2020-06-01T00:00:00","","2020-07-07T00:00:00","","","https://ClinicalTrials.gov/show/NCT04410328"
"917","NCT04468139","The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19","","Recruiting","No Results Available","Covid-19","Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C","days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19","Ministry of Health, Saudi Arabia","All","18 Years and older","Phase 4","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-95M","2020-06-20T00:00:00","2020-07-20T00:00:00","2020-07-30T00:00:00","2020-07-13T00:00:00","","2020-07-13T00:00:00","Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04468139"
"918","NCT04372602","Duvelisib to Combat COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0","Washington University School of Medicine|Verastem, Inc.","All","18 Years and older","Phase 2","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple |Primary Purpose: Treatment","202007009","2020-09-30T00:00:00","2021-10-31T00:00:00","2022-03-31T00:00:00","2020-05-04T00:00:00","","2020-07-28T00:00:00","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT04372602"
"919","NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","","Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells |Other: Intravenous saline injection","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing |Utooth Biological Technology Co., Ltd. Hubei","All","18 Years to 65 Years","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","2020-04-06T00:00:00","2020-12-31T00:00:00","2021-03-31T00:00:00","2020-04-07T00:00:00","","2020-04-07T00:00:00","Renmin Hospital of Wuhan University , Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04336254"
"920","NCT04488588","Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt","","Completed","No Results Available","Covid19|Coronavirus Disease|SARS-CoV-2","Other: Kaplan Meier analysis","number of co-morbidities in hospitalized patients with COVID-19|causes of ICU admission","Assiut University","All","36 Years to 63 Years","","1064","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AssiutU17","2020-03-15T00:00:00","2020-05-01T00:00:00","2020-07-01T00:00:00","2020-07-28T00:00:00","","2020-07-28T00:00:00","AssiutU, Assiut, Egypt|Aliae Mohamed-Hussein, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04488588"
"921","NCT04409834","Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","COVID-PACT","Recruiting","No Results Available","COVID-19|Venous Thromboembolism|Arterial Thrombosis","Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution","Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events","The TIMI Study Group","All","18 Years and older","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None |Primary Purpose: Prevention","CCCTN/TIMI COVID-PACT","2020-08-05T00:00:00","2021-05-01T00:00:00","2021-05-01T00:00:00","2020-06-01T00:00:00","","2020-08-18T00:00:00","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04409834"
"922","NCT04368065","Registry to Study Factors That May Impact COVID-19 Occurrence and Severity","","Recruiting","No Results Available","COVID-19","","COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization","Iqvia Pty Ltd","All","18 Years and older","","100000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IQVIA_COVIDREGISTRY_2020","2020-04-02T00:00:00","2021-12-31T00:00:00","2022-06-01T00:00:00","2020-04-29T00:00:00","","2020-04-29T00:00:00","IQVIA, Cambridge, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04368065"
"923","NCT04344080","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","CYTOCOV-19","Recruiting","No Results Available","COVID-19","Device: CytoSorb-Therapy","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6  level|Change of plasma Interleukin-10  level|Change of plasma Procalcitonin  level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 90 Years","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","CYTOCOV-19|U1111-1250-2078|DRKS00021199","2020-04-01T00:00:00","2020-12-01T00:00:00","2021-02-01T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","University Medical Center Hamburg-Eppendorf, Hamburg, Germany","","https://ClinicalTrials.gov/show/NCT04344080"
"924","NCT04373759","Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs","ACICOVID","Recruiting","No Results Available","Sars-CoV2|Covid-19","Other: Cardiopulmonary resuscitation|Other: Modified Rankin score","Incidence of unexpected cardiac arrest|Charlson score|Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest|Etiology retained to explain cardiac arrest occurrence|Modified Rankin score  at ICU discharge, at hospital discharge and at 3 months","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-CHITS-004","2020-05-02T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-05-04T00:00:00","","2020-08-10T00:00:00","CHU Felix Guyon, Saint-Denis, La Reunion, France|CHU Amiens Picardie, Amiens, France|CH Angoulème, Angoulême, France|CH Argenteuil, Argenteuil, France|CH Bethune, Beuvry, France|CHU Ambroise Pare AP-HP, Boulogne-Billancourt, France|CH Brive, Brive-la-Gaillarde, France|CHU Caen, Caen, France|Hôpital Prive St Martin, Caen, France|CH Cahors, Cahors, France|CHU Antoine Beclère AP-HP, Clamart, France|CH Louis Mourier AP-HP, Colombes, France|CHU Henri Mondor AP-HP, Creteil, France|CHU Dijon, Dijon, France|CH de la Dracenie, Draguignan, France|CHI Frejus St Raphael, Frejus, France|Grand Hôpital de l'Est Francilien, Jossigny, France|CH La Rochelle, La Rochelle, France|CHU Grenoble-Alpes, La Tronche, France|CH Versailles, Le Chesnay, France|CHU Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH Lens, Lens, France|CHRU Roger Salengro, Lille, France|CH Sambre Avesnois, Maubeuge, France|CHU Meaux, Meaux, France|Groupe Hospitalier Sud Ile de France, Melun, France|CHU Montpellier, Montpellier, France|CHR Orleans, Orleans, France|CHU Lariboisière AP-HP, Paris, France|CHU Saint Louis AP-HP, Paris, France|CHU St Antoine, Paris, France|Groupe Hospitalier Saint Joseph, Paris, France|CHU Necker Enfants Malades, Paris, France|Groupe Hospitalier Diaconesse Croix Saint-Simon, Paris, France|Hôpital Prive Claude Galien, Quincy-sous-Senart, France|CHU Rouen, Rouen, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Hôpital Nord Franche Comte, Trevenans, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France|CHU Martinique - Fort de France, Fort-de-France, Martinique","","https://ClinicalTrials.gov/show/NCT04373759"
"925","NCT04342182","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease","ConCoVid-19","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer  <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function","Erasmus Medical Center|Sanquin Plasma Products BV","All","18 Years and older","Phase 2|Phase 3","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","NL73489.078.20","2020-04-08T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-10T00:00:00","","2020-05-18T00:00:00","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands","","https://ClinicalTrials.gov/show/NCT04342182"
"926","NCT04395859","Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections  of Anti-angiogenic Agents","COVIDIV","Recruiting","No Results Available","Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion","Procedure: Questionnaire|Other: Data collection up to 1 year","Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MMT_2020_15","2020-05-27T00:00:00","2021-12-01T00:00:00","2021-12-01T00:00:00","2020-05-20T00:00:00","","2020-06-23T00:00:00","Centre Pôle Vision du val d'Ouest, Ecully, France|Fondation Adolphe de Rothschild, Paris, France|Hôpital Lariboisière, Paris, France|Centre ophtalmologique Maison Rouge, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04395859"
"927","NCT04357834","WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","WAVE","Not yet recruiting","No Results Available","COVID|COVID 19|SARS-CoV 2","Other: Equipment with smartwatch throughout hospital stay on the general ward","Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve .|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve .|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline  to ICU admission|Change of heart rate variability from baseline  to ICU admission|Change of skin temperature from baseline  to ICU admission|Change of blood oxygen saturation from baseline  to ICU admission|Change of respiration rate from baseline  to ICU admission|Change of physical activity from baseline  to ICU admission|Change of stress level from baseline  to ICU admission|Change of sleep pattern from baseline  to ICU admission|Change of steps per day from baseline  to ICU admission|Change of systolic blood pressure from baseline  to ICU admission|Change of diastolic blood pressure from baseline  to ICU admission|Change of body temperature from baseline  to ICU admission|Change of oxygen partial pressure  from baseline  to ICU admission|Change of CO2 partial pressure  from baseline  to ICU admission|Change of blood pH from baseline  to ICU admission|Change of bicarbonate from baseline  to ICU admission|Change of base excess from baseline  to ICU admission|Change of oxygen flow rate from baseline  to ICU admission","University Hospital Inselspital, Berne|ETH Zurich","All","18 Years to 120 Years","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","WAVE","2020-05-01T00:00:00","2020-07-31T00:00:00","2020-07-31T00:00:00","2020-04-22T00:00:00","","2020-04-24T00:00:00","Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland","","https://ClinicalTrials.gov/show/NCT04357834"
"928","NCT04427865","Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: prophylactic lactoferrin daily","Incidence of SARS-CoV-2|Severity of disease in confirmed infected participants","Cairo University","All","18 Years to 65 Years","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","CUKA-002","2020-07-01T00:00:00","2020-09-01T00:00:00","2020-11-01T00:00:00","2020-06-11T00:00:00","","2020-06-16T00:00:00","","","https://ClinicalTrials.gov/show/NCT04427865"
"929","NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","","Active, not recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent change in C-reactive protein  levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement  in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement  in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2  of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit |Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation |Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia |Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia |Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase  level|Aspartate aminotransferase  level","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older","Phase 2|Phase 3","1912","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","6R88-COV-2040","2020-03-18T00:00:00","2020-07-24T00:00:00","2020-08-31T00:00:00","2020-03-19T00:00:00","","2020-08-11T00:00:00","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","","https://ClinicalTrials.gov/show/NCT04315298"
"930","NCT04477668","Helmet Non-Invasive Ventilation for COVID-19 Patients","Helmet-COVID","Not yet recruiting","No Results Available","COVID-19|Acute Hypoxemic Respiratory Failure","Device: Helmet non-invasive ventilation","28-day all-cause mortality|Requirement for endotracheal intubation within 28 days|ICU mortality|Hospital mortality|ICU free days at day 28|Ventilator free days at day 28|Renal replacement therapy free days at day 28|Vasopressor free days at day 28|Skin pressure ulcers|Tolerance of helmet |180-day mortality|180-day 5-level EQ-5D version","King Abdullah International Medical Research Center","All","14 Years and older","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RC20/306/R","2020-07-01T00:00:00","2021-12-01T00:00:00","2022-01-01T00:00:00","2020-07-20T00:00:00","","2020-07-20T00:00:00","Intensive Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT04477668"
"931","NCT04516915","IMU-838 and Oseltamivir in the Treatment of COVID-19","IONIC","Recruiting","No Results Available","Covid 19","Drug: IMU-838|Drug: Oseltamivir","To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir  vs. Oseltamivir alone in adult subjects with COVID-19|To evaluate safety  and tolerability  of IMU 838 + Oseltamivir vs. Oseltamivir alone in adult subjects with COVID-19.|To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale |To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO|To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit  stay|To assess the effects of IONIC Intervention vs. Oseltamivir on the time from treatment initiation to death","University Hospitals Coventry and Warwickshire NHS Trust|Immunic AG|University of Warwick|MODEPHARMA","All","18 Years to 90 Years","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RA486120","2020-06-15T00:00:00","2021-05-01T00:00:00","2021-07-01T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom","","https://ClinicalTrials.gov/show/NCT04516915"
"932","NCT04425538","A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 .","","Recruiting","No Results Available","COVID-19","Drug: Infliximab","Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections","Tufts Medical Center|National Institutes of Health","All","18 Years and older","Phase 2","17","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","STUDY00000564","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-12-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","Tufts Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT04425538"
"933","NCT04363060","Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit","AziA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate","Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion","Nantes University Hospital","All","18 Years to 99 Years","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","RC20_0168","2020-04-30T00:00:00","2020-07-30T00:00:00","2020-07-30T00:00:00","2020-04-27T00:00:00","","2020-04-29T00:00:00","Chu Angers, Angers, France|CHD Vendee, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France","","https://ClinicalTrials.gov/show/NCT04363060"
"934","NCT04377477","COVID-19 Pneumonitis Low Dose Lung Radiotherapy","COLOR-19","Recruiting","No Results Available","COVID-19","Radiation: Single fraction whole lung radiotherapy","Lenght of hospital stay |Number of Intensive Care Unit admissions|Variation of the Brescia COVID-19 Respiratory Severity Scale after treatment|Occurence of CTCAE 5.0 adverse events|Variation of the chest X-ray radiological findings according to Brixia scoring system","Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","All","50 Years and older","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","NP 4097","2020-05-10T00:00:00","2021-08-10T00:00:00","2022-08-30T00:00:00","2020-05-06T00:00:00","","2020-07-22T00:00:00","Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy","","https://ClinicalTrials.gov/show/NCT04377477"
"935","NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2  Infection","","Recruiting","No Results Available","COVID-19","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm","All","18 Years to 100 Years","Phase 2|Phase 3","372","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","CL04041078","2020-04-23T00:00:00","2020-10-15T00:00:00","2020-11-15T00:00:00","2020-05-08T00:00:00","","2020-05-08T00:00:00","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation , Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation","","https://ClinicalTrials.gov/show/NCT04380519"
"936","NCT04424771","Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia","","Completed","No Results Available","COVID|Post Traumatic Stress Disorder","Behavioral: Maslach Burnout Inventory","Number of patients with diagnosis of PTSD.","Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia","All","18 Years to 70 Years","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PTSD-COVID-19","2020-03-01T00:00:00","2020-06-30T00:00:00","2020-07-01T00:00:00","2020-06-11T00:00:00","","2020-07-27T00:00:00","Ospedale Perrino Asl Brindisi, Brindisi, Italy|Piazza della Vittoria 14 Studio medico - Ginecologia e Ostetricia, Genoa, Italy","","https://ClinicalTrials.gov/show/NCT04424771"
"937","NCT04345848","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","COVID-HEP","Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Enoxaparin","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration","University Hospital, Geneva","All","18 Years and older","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Treatment","2020-00794","2020-04-28T00:00:00","2020-11-30T00:00:00","2020-11-30T00:00:00","2020-04-15T00:00:00","","2020-04-30T00:00:00","Geneva University Hospitals, Geneva, Switzerland","","https://ClinicalTrials.gov/show/NCT04345848"
"938","NCT04365634","A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.","","Completed","No Results Available","COVID-19","","Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes","Tongji Hospital","All","Child, Adult, Older Adult","","306","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","TJ20200202","2020-02-02T00:00:00","2020-03-15T00:00:00","2020-04-01T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","Tongji Hospital, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT04365634"
"939","NCT04446169","COVID-19  in Urine and Semen","","Recruiting","No Results Available","SARS-CoV 2|Sexual Function and Fertility Disorders|Urinary Function Disorders|Urine|Semen","Diagnostic Test: SARS-CoV 2 RNA PCR Urine|Diagnostic Test: SARS-CoV 2 RNA PCR Semen|Diagnostic Test: Semen Qualitative Analysis|Diagnostic Test: IIEF-5 questionnaire|Diagnostic Test: Male Sexual Health Questionnaire |Diagnostic Test: IPSS questionnaire|Diagnostic Test: SECRET questionnaire|Diagnostic Test: Interleukin assessment in semen","SARS-CoV 2 presence in semen|SARS-CoV 2 presence in urine|Inflammation in Semen|Semen quantitative and qualitative analysis|Erectile Function|Sexual Habits|Urinary function|Sexual and Ejaculatory Function","University of Florence|Azienda Ospedaliero-Universitaria Careggi","Male","18 Years to 80 Years","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17104_oss/2020","2020-06-27T00:00:00","2020-09-01T00:00:00","2020-09-02T00:00:00","2020-06-24T00:00:00","","2020-08-14T00:00:00","AOU Careggi, Florence, Tuscany, Italy","","https://ClinicalTrials.gov/show/NCT04446169"
"940","NCT04509752","Dysphagia Management During COVID-19 Pandemic","","Not yet recruiting","No Results Available","Dysphagia|Covid19","Other: Survey","Online survey","Hacettepe University","All","25 Years to 60 Years","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Dysphagia during COVID-19","2020-08-20T00:00:00","2020-11-15T00:00:00","2020-11-30T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","Hacetttepe University, Ankara, Turkey","","https://ClinicalTrials.gov/show/NCT04509752"
"941","NCT04365699","Cardiovascular Effects of COVID-19","","Recruiting","No Results Available","COVID-19","Drug: AT-001","Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization","NYU Langone Health","All","18 Years and older","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-00416","2020-04-08T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-04-28T00:00:00","","2020-04-28T00:00:00","NYU Langone Health, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04365699"
"942","NCT04341207","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","ONCOVID","Recruiting","No Results Available","Cancer & COVID 19","Drug: Hydroxychloroquine|Drug: Azithromycin","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-001250-21|2020/3078","2020-04-03T00:00:00","2022-04-01T00:00:00","2022-04-01T00:00:00","2020-04-10T00:00:00","","2020-04-10T00:00:00","Gustave Roussy, Villejuif, Val De Marne, France","","https://ClinicalTrials.gov/show/NCT04341207"
"943","NCT04418609","Neuro-COVID-19: Neurological Complications of COVID-19","Neuro-COVID","Recruiting","No Results Available","Neurologic Complication","Other: further processing of health data","Prevalence of neurological complications|Prevalence and outcome of severe neurological complications|Impact of neurological complications|Characteristic patterns in cerebral imaging and electroencephalography , as well as cerebrospinal fluid |Brain for pathological changes and histopathological findings .","Emanuela Keller|University of Zurich","All","18 Years and older","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Neuro-COVID-19","2020-05-01T00:00:00","2022-04-30T00:00:00","2022-05-30T00:00:00","2020-06-05T00:00:00","","2020-06-05T00:00:00","University Hospital Zurich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT04418609"
"944","NCT04344379","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","PREP-COVID","Suspended","No Results Available","SARS-CoV-2 Infection","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events","Assistance Publique - Hôpitaux de Paris","All","18 Years and older","Phase 3","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Prevention","APHP200386|2020-001273-73","2020-04-17T00:00:00","2020-06-30T00:00:00","2020-07-15T00:00:00","2020-04-14T00:00:00","","2020-06-12T00:00:00","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitie-Salpetrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital europeen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France","","https://ClinicalTrials.gov/show/NCT04344379"
"945","NCT04498325","Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2","","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody","Safe and tolerable dose of NT-I7 |Percent change in absolute lymphocyte count |Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status","Washington University School of Medicine|NeoImmune Tech","All","18 Years and older","Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple |Primary Purpose: Treatment","06-29-20-Campian","2020-09-30T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-08-04T00:00:00","","2020-08-07T00:00:00","Saint Louis University Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT04498325"
"946","NCT04392531","Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19","","Recruiting","No Results Available","COVID19 Infection","Drug: Cyclosporine|Drug: Standard treatment","Severity Category|Mortality Rate|Number of Days in hospital|Number of days in ICU beds|Fio2 Needs|Adverse events rate|Change in CRP|Change in ferritin|Change in LDH|Change in CPK|Change in D Dimer|Change in IL-6|Change in KL-6|Change in Viral Load|Change specific antibodies","Instituto de Investigación Sanitaria de la Fundación Jimenez Díaz","All","18 Years to 75 Years","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","FJD-COVID19-20-01","2020-04-16T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-05-19T00:00:00","","2020-05-19T00:00:00","Complejo Hospitalario Universitario La Coruña, La Coruña, Galicia, Spain|Hospital Quiron La Coruña, La Coruña, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04392531"
"947","NCT04352946","HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","HERO","Not yet recruiting","No Results Available","Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet","Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost","GeoSentinel Foundation","All","18 Years and older","Phase 3","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","GFICOVID-19-1","2020-04-24T00:00:00","2020-06-24T00:00:00","2020-08-24T00:00:00","2020-04-20T00:00:00","","2020-04-22T00:00:00","The New York Center for Travel and Tropical Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT04352946"
"948","NCT04354441","Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","HyPreC","Withdrawn","No Results Available","COVID-19|SARS-CoV-2|Pregnant Women|Hydroxychloroquine","Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet","COVID-19-related hospital admissions|Symptoms related to COVID-19 infection|Adverse Events|Maternal outcomes|Newborn outcomes","Sir Mortimer B. Davis - Jewish General Hospital","Female","18 Years to 50 Years","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","1, March 30, 2020","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-05-01T00:00:00","2020-04-21T00:00:00","","2020-06-25T00:00:00","","","https://ClinicalTrials.gov/show/NCT04354441"
"949","NCT04510194","MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19","","Not yet recruiting","No Results Available","Covid19|SARS-CoV Infection","Drug: Metformin|Drug: Placebo","Rate of Death due to COVID-19|Rate of Hospitalization due to COVID-19|Rate of Emergency Department Utilization|Rate of Urgent Care Utilization|Incidence of Possible COVID-19 Symptoms|Incidence of all-cause study medicine discontinuation|Disease Severity Rating|Dyspnea Assessment |Global Health Survey |Seroconversion of SARS-Cov2 Antibodies OR SARS-Cov2 PCR Positivity","University of Minnesota","All","50 Years to 85 Years","Phase 2|Phase 3","1522","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Treatment","Metformin","2020-09-01T00:00:00","2021-09-01T00:00:00","2021-09-01T00:00:00","2020-08-12T00:00:00","","2020-08-12T00:00:00","","","https://ClinicalTrials.gov/show/NCT04510194"
"950","NCT04434144","A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh","","Completed","No Results Available","Ivermectin|Hydroxychloroquine|COVID19","Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin","Number of participants with ""treatment success"" determine by a negative RT PCR for COVID19.|Number of participants with ""adverse effects"" determined by the existence of the pharmacological side effects of the particular drug during treatment.","Upazila Health & Family Planning Officer's  Office, Chakoria, Cox's Bazar","All","16 Years to 80 Years","","116","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","10000918","2020-05-02T00:00:00","2020-06-05T00:00:00","2020-06-05T00:00:00","2020-06-16T00:00:00","","2020-06-16T00:00:00","Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh","","https://ClinicalTrials.gov/show/NCT04434144"
"951","NCT04492267","Inflammatory Bowel Disease  and Covid-19 Infection","MICI-Covid-19","Recruiting","No Results Available","Inflammatory Bowel Disease","","Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients","University Hospital, Strasbourg, France","All","18 Years and older","","700","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7930","2020-07-07T00:00:00","2021-01-07T00:00:00","2021-01-07T00:00:00","2020-07-30T00:00:00","","2020-07-30T00:00:00","Service Hepato-Gastroenterologie et Assistance Nutritive Hôpitaux Univesitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04492267"
"952","NCT04344197","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","","Enrolling by invitation","No Results Available","Surgery|COVID|Asymptomatic Patient|Covid-19|Preventive Measures","Other: global survey","overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.","University of Rome Tor Vergata","All","Child, Adult, Older Adult","","1200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","s-covid survey","2020-04-02T00:00:00","2020-04-08T00:00:00","2020-04-15T00:00:00","2020-04-14T00:00:00","","2020-04-14T00:00:00","Tor Vergata Hospital, Rome, Italy","","https://ClinicalTrials.gov/show/NCT04344197"
"953","NCT04422678","The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia","","Not yet recruiting","No Results Available","COVID-19","Drug: Imatinib Mesylate|Drug: Standard of Care","Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib","Alexandria University|Science, Technology & Innovation Funding Authority , Egypt","All","18 Years and older","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Alex CCM 2020/5","2020-06-01T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-06-09T00:00:00","","2020-06-09T00:00:00","","","https://ClinicalTrials.gov/show/NCT04422678"
"954","NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","Recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Imperial College London","All","18 Years to 85 Years","Not Applicable","3170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","20HH5868","2020-04-03T00:00:00","2021-03-30T00:00:00","2021-03-30T00:00:00","2020-04-03T00:00:00","","2020-04-09T00:00:00","Charing Cross Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT04333407"
"955","NCT04344327","Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF","CCF","Completed","No Results Available","Infection Viral|Infection, Hospital|COVID","","Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form","French Cardiology Society|Institut National de la Sante Et de la Recherche Medicale, France","All","18 Years and older","","2878","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02","2020-04-10T00:00:00","2020-04-21T00:00:00","2020-04-21T00:00:00","2020-04-14T00:00:00","","2020-04-28T00:00:00","CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Frejus / Saint-Raphael, Frejus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orleans, Orleans, France|Bichat , Paris, France|Georges Pompidou European Hospital , Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vandœuvre-lès-Nancy, France","","https://ClinicalTrials.gov/show/NCT04344327"
"956","NCT04346628","Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19","","Enrolling by invitation","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment","Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir","Stanford University","All","18 Years and older","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","56032","2020-07-12T00:00:00","2021-07-01T00:00:00","2021-07-01T00:00:00","2020-04-15T00:00:00","","2020-07-27T00:00:00","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT04346628"
"957","NCT04384926","Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis","CovidSurg-Can","Recruiting","No Results Available","COVID-19|Coronavirus|Cancer|Surgery","Procedure: Elective Cancer Surgery","30-day postoperative COVID-19 infection rate|30-day postoperative mortality rate|Postoperative critical care utilisation rate in high-risk cancer surgery patients.|Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery|Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery","University of Birmingham","All","18 Years and older","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CSC-20200324","2020-03-30T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-05-12T00:00:00","","2020-05-12T00:00:00","Hospital del Henares, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT04384926"
"958","NCT04397328","COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic fever >37.8, dry cough, or shortness of breath  respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery .","Lawson Health Research Institute","All","40 Years and older","Phase 3","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","9881","2020-05-19T00:00:00","2021-04-30T00:00:00","2021-04-30T00:00:00","2020-05-21T00:00:00","","2020-05-21T00:00:00","","","https://ClinicalTrials.gov/show/NCT04397328"
"959","NCT04385108","Predictive Immune Biomarkers for COVID-19 Pathogenesis","COVIDBioToul","Recruiting","No Results Available","COVID-19","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Immune signature|Dosage of cytokines and chemokines in plasma samples|Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity","University Hospital, Toulouse","All","18 Years and older","Not Applicable","170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Basic Science","RC31/20/0162","2020-03-04T00:00:00","2021-12-31T00:00:00","2021-12-31T00:00:00","2020-05-12T00:00:00","","2020-07-31T00:00:00","Purpan University Hospital, Toulouse, France","","https://ClinicalTrials.gov/show/NCT04385108"
"960","NCT04336904","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","","Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Other: Placebo","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","All","18 Years to 75 Years","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","HS216C17-PHASE III","2020-03-25T00:00:00","2020-07-01T00:00:00","2020-07-01T00:00:00","2020-04-07T00:00:00","","2020-04-08T00:00:00","Asst Fatebenefratelli Sacco, Milano, Italy","","https://ClinicalTrials.gov/show/NCT04336904"
"961","NCT04517188","Halodine Nasal Antiseptic in Patients With COVID-19","","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP","Nasopharyngeal SARS-CoV-2 Viral Load","Halodine LLC","All","18 Years and older","Phase 4","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Prevention","HDN-N02-COV24A","2020-09-01T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-08-18T00:00:00","","2020-08-18T00:00:00","","","https://ClinicalTrials.gov/show/NCT04517188"
"962","NCT04454372","Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019","","Not yet recruiting","No Results Available","COVID-19","Other: demographic and clinical data obtained from hospital's electronic medical record.","Outcome 30 days after ICU admission","Hospital Sao Domingos","All","1 Year and older","","187","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","covid-19 ICU","2020-07-15T00:00:00","2020-09-20T00:00:00","2020-11-30T00:00:00","2020-07-01T00:00:00","","2020-07-02T00:00:00","","","https://ClinicalTrials.gov/show/NCT04454372"
"963","NCT04377308","Fluoxetine to Reduce Intubation and Death After COVID19 Infection","","Recruiting","No Results Available","COVID-19|Cytokine Storm","Drug: Fluoxetine","Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale","University of Toledo Health Science Campus","All","18 Years and older","Phase 4","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","FRIDA COVID19","2020-05-01T00:00:00","2021-04-20T00:00:00","2021-10-20T00:00:00","2020-05-06T00:00:00","","2020-05-06T00:00:00","University of Toledo, Toledo, Ohio, United States","","https://ClinicalTrials.gov/show/NCT04377308"
"964","NCT04327570","In-depth Immunological Investigation of COVID-19.","COntAGIouS","Recruiting","No Results Available","Coronavirus Infections","Other: Patient sampling","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","Universitaire Ziekenhuizen Leuven","All","18 Years and older","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COntAGIouS","2020-03-27T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-03-31T00:00:00","","2020-05-29T00:00:00","UZ Leuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT04327570"
"965","NCT04413747","Yoga Pranayama Adjuvant to Treat Burden COVID-19","YOCO","Not yet recruiting","No Results Available","Coronavirus Infection|Cytokine Storm|Mental Disorder","Behavioral: morning Yoga-based breathing support|Behavioral: pre_lunch Yoga-based breathing support|Behavioral: pre_dinner Yoga-based breathing support","Mortality|Mortality-suicide|Incidence of hospitalization for respiratory failure of COVID-19's Patients-|Incidence of al home professional psychiatric-psychological interventions for mental disorder.|Incidence of mental disorder: Beck Depression Inventory-Second Edition .|Incidence od spleep disorder:Pittsburgh Sleep Quality Index .","Health Ricerca e Sviluppo S.R.L.|Swami Vivekananda Yoga Anusandhana Samsthana, Bangaluru , India|Yoga Experience Association,Cervia , Italy|EJTN GEIE, Brussellese, Belgium|Casa di Riposo e Ambulatorio Giardino St Lucia, Massa Lomabarda  Italy|Halnet Srl, Faenza , Italy","All","18 Years to 75 Years","Not Applicable","1000","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Supportive Care","2020_COVID-19_YOGA","2020-08-15T00:00:00","2021-06-01T00:00:00","2021-09-30T00:00:00","2020-06-04T00:00:00","","2020-08-07T00:00:00","Ambulatorio Telemedicina Giardino St Lucia, Massa Lombarda, Ravenna, Italy","","https://ClinicalTrials.gov/show/NCT04413747"
"966","NCT04462120","IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study","","Active, not recruiting","No Results Available","Covid-19","","Measure level of polymorphisms of interleukin -12 receptor B1  and TNF- α alpha on COVID-19 related severe acute respiratory syndrome .","Assiut University","All","18 Years to 80 Years","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AssiutU15","2020-06-16T00:00:00","2020-06-18T00:00:00","2020-07-30T00:00:00","2020-07-08T00:00:00","","2020-07-08T00:00:00","AssiutU, Assiut, Egypt|Assiut University Hospitals, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT04462120"
"967","NCT04512300","Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic","","Completed","No Results Available","Dental Treatment During Covid -19","","Assessment of parental attitude toward children dental visit during Coronavirus crisis","Cairo University","All","Child, Adult, Older Adult","","267","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Covid -19 and dental visit","2020-06-15T00:00:00","2020-06-25T00:00:00","2020-06-25T00:00:00","2020-08-13T00:00:00","","2020-08-13T00:00:00","faculty of dentistry, Cairo university , Egypt, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT04512300"
"968","NCT04426279","Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants","CORhum","Not yet recruiting","No Results Available","Sars-CoV2|Rheumatoid Arthritis|Rheumatic Diseases","Other: questionnaire assesment","the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave  among patients with IRC under IS.|Diagnosis of Covid-19 either confirmed by diagnostic test , or by a physician, or by serology.|The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave  and the six-month period preceding it .|The number of patients who maintained, modified, or discontinued their treatment.","University Hospital, Lille","All","18 Years and older","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EQ2020_04|2020-A01650-39","2020-08-01T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-06-11T00:00:00","","2020-06-11T00:00:00","","","https://ClinicalTrials.gov/show/NCT04426279"
"969","NCT04475991","Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults","COMVIVIR","Not yet recruiting","No Results Available","COVID-19","Drug: Maraviroc + Currently used therapy|Procedure: Curently used therapy for COVID-19 non-critical patients|Drug: Favipiravir + Currently used therapy|Drug: Maraviroc+Favipiravir+CT","Patients free of mechanical ventilation or death|Time of clinical improvement|Rate of change in phosphorilated CCR5|Rate of change in peripheral blood levels of proinflammatory cytokines and chemokynes|Change in the trafficking and activation pattern of peripheral leukocytes","Hospital General de Mexico Dr. Eduardo Liceaga|CCINSHAE. Secretaría de Salud. Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Centro de Investigación en. Enfermedades Infecciosas, Mexico","All","18 Years to 70 Years","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","DI/20/407/04/38","2020-08-01T00:00:00","2020-12-01T00:00:00","2021-01-01T00:00:00","2020-07-17T00:00:00","","2020-08-07T00:00:00","Hospital General de Mexico ""Dr. Eduardo Liceaga"", Mexico City, Cdmx, Mexico","","https://ClinicalTrials.gov/show/NCT04475991"
"970","NCT04470739","Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?","","Recruiting","No Results Available","Covid19|Thymic Hypoplasia","Diagnostic Test: chest x-ray","Cardiothymic index|Immune profile","Kanuni Sultan Suleyman Training and Research Hospital","All","up to 7 Hours","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Diagnostic","KSSEAH--CT","2020-05-30T00:00:00","2020-09-30T00:00:00","2020-10-30T00:00:00","2020-07-14T00:00:00","","2020-07-14T00:00:00","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04470739"
"971","NCT04456556","Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease","","Completed","No Results Available","Endophthalmitis and Orbital Cellulitis","","Combined Endophthalmitis and Orbital Cellulitis in patients with Novel Coronavirus Disease","Minia University","All","Child, Adult, Older Adult","","5","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ocular infection in covid19","2020-04-27T00:00:00","2020-06-20T00:00:00","2020-06-30T00:00:00","2020-07-02T00:00:00","","2020-07-02T00:00:00","Minia university Hospital, Minya, Minia, Egypt","","https://ClinicalTrials.gov/show/NCT04456556"
"972","NCT04385121","Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection","Familles-COVID","Recruiting","No Results Available","Covid-19|Stress Disorders, Post-Traumatic|Anxiety|Depression","Other: Questionnary","Existence of a post-intensive care syndrome-family  and IES-R  questionnaires))","University Hospital, Strasbourg, France","All","18 Years and older","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7761","2020-04-16T00:00:00","2020-04-16T00:00:00","2021-03-01T00:00:00","2020-05-12T00:00:00","","2020-07-21T00:00:00","Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04385121"
"973","NCT04412252","Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy","","Withdrawn","No Results Available","COVID-19","Drug: Tofacitinib|Other: Placebo","Clinical status using ordinal scale|Status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation |Status of discharged or not requiring supplemental oxygen|Mortality","Pfizer","All","18 Years to 99 Years","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","A3921377","2020-07-06T00:00:00","2020-09-16T00:00:00","2020-10-18T00:00:00","2020-06-02T00:00:00","","2020-07-31T00:00:00","Hartford Hospital , Hartford, Connecticut, United States|University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT04412252"
"974","NCT04391400","The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines","","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: nasal pharyngeal  swab samples|Diagnostic Test: peripheral blood draw","Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines","Invivoscribe, Inc.","All","Child, Adult, Older Adult","","500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IVS-000-002","2020-06-01T00:00:00","2021-06-30T00:00:00","2021-06-30T00:00:00","2020-05-18T00:00:00","","2020-05-18T00:00:00","","","https://ClinicalTrials.gov/show/NCT04391400"
"975","NCT04371354","Outcomes of Covid-19 Protective Measures in Endoscopy","","Recruiting","No Results Available","Covid-19 Disease|Endoscopy Unit","","Rate of new Covid infection of patients and staff members|Covid disease prevalence in the patients referred to endoscopy|Categorization by clinical triage and Covid Test|Influence of the fype of endoscopy procedure and staff protective equipment","Fundacion Miguel Servet","All","18 Years and older","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2020-COCHE","2020-04-27T00:00:00","2020-06-14T00:00:00","2020-07-27T00:00:00","2020-05-01T00:00:00","","2020-06-19T00:00:00","Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain","","https://ClinicalTrials.gov/show/NCT04371354"
"976","NCT04411511","COVID-19, Obesity and Lifestyle in Children","COLC","Recruiting","No Results Available","Covid-19|Obesity, Childhood|Lifestyle|Lifestyle, Healthy|Overweight, Childhood|Children, Only|Family","Other: Exposure to the Dutch measures due to the Covid-19 pandemic.","Change in weight child|Change in weight parents|Eating behaviour|Symptoms|Day structure|Physical activity|Screentime|Online possibilities|Quality of life in children|Parenting practices","Maastricht University Medical Center","All","4 Years to 17 Years","","4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-1330","2020-05-06T00:00:00","2020-11-06T00:00:00","2021-05-06T00:00:00","2020-06-02T00:00:00","","2020-06-02T00:00:00","Maastricht University Medical Center, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT04411511"
"977","NCT04414410","Echocardiography in Critically-ill Patients With COVID-19 Pneumonia","ECHO-COVID","Enrolling by invitation","No Results Available","COVID|Sars-CoV2","","Incidence of Left ventricular systolic dysfunction|Incidence of RV failure|Incidence of Vasoplegia|Incidence of Hypovolemia|Relation between plateau pressure and RV failure|Relation between tidal volume and RV failure|Relation between PaO2 and RV failure|Relation between PaCO2 and RV failure|Relation between PEEP and RV failure","Hospital Ambroise Pare Paris","All","Child, Adult, Older Adult","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RedCap19","2020-05-12T00:00:00","2020-09-30T00:00:00","2020-09-30T00:00:00","2020-06-04T00:00:00","","2020-06-04T00:00:00","University Hospital Ambroise Pare, Boulogne-Billancourt, Hauts De Seine, France","","https://ClinicalTrials.gov/show/NCT04414410"
"978","NCT04347954","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers","","Recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test","Stanford University","All","18 Years and older","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","IRB-56134","2020-06-11T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-04-15T00:00:00","","2020-06-18T00:00:00","Stanford Health Care, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT04347954"
"979","NCT04324866","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 75 Years","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Gisondi 4","2020-04-01T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-03-27T00:00:00","","2020-03-27T00:00:00","","","https://ClinicalTrials.gov/show/NCT04324866"
"980","NCT04456010","COVID-19 in ART: Perception and Experience","COVAPEX","Recruiting","No Results Available","COVID19|Fertility Issues|ART","Other: Questionnaire","Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation|Risk assessment|Patients'expectations regarding the management of an abrupt closure of the fertility center","University Hospital, Montpellier","All","18 Years to 60 Years","","600","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RECHMPL20_0351","2020-06-01T00:00:00","2020-07-30T00:00:00","2020-07-30T00:00:00","2020-07-02T00:00:00","","2020-07-02T00:00:00","Uhmontpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT04456010"
"981","NCT04335188","COVID-19 Registry Rhineland-Palatinate","","Recruiting","No Results Available","COVID","Other: Prospective oberservational registry","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","All","Child, Adult, Older Adult","","4000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19 Registry","2020-04-06T00:00:00","2021-07-31T00:00:00","2021-09-30T00:00:00","2020-04-06T00:00:00","","2020-04-08T00:00:00","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany","","https://ClinicalTrials.gov/show/NCT04335188"
"982","NCT04343768","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","COVIFERON","Completed","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization","Shahid Beheshti University of Medical Sciences","All","18 Years and older","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","Different Interferons in COVID","2020-04-09T00:00:00","2020-04-27T00:00:00","2020-04-27T00:00:00","2020-04-13T00:00:00","","2020-05-05T00:00:00","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT04343768"
"983","NCT04432922","Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection","","Not yet recruiting","No Results Available","COVID19","Other: Hospitalized Patients for COVID-19 Infection","To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients","Centre Hospitalier Intercommunal Creteil","All","18 Years and older","","15","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ISOCOV","2020-09-01T00:00:00","2020-09-15T00:00:00","2020-09-15T00:00:00","2020-06-16T00:00:00","","2020-07-29T00:00:00","Centre hospitalier intercommunal de Villeneuve St Georges, Villeneuve St Georges, France","","https://ClinicalTrials.gov/show/NCT04432922"
"984","NCT04442165","Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique","AfriCoVER","Not yet recruiting","No Results Available","COVID-19","","COVID-19 disease incidence rate |COVID-19 related hospitalization rate due to SARS-CoV-2|Case  fatality risk  due to SARS-CoV-2|Proportion asymptomatic infections, by age group|SARS-CoV-2 infection annual attack rate |SARS-CoV-2 infection fatality risk|Infection fatality of SARS-CoV-2 infection.|Serial interval number of SARS-CoV-2 infection|Reproduction number of SARS-CoV-2 infection|Correlation between anti-coronavirus  antibody titers and reinfection|Antibody titers against SARS-CoV-2 over time","Institute of Tropical Medicine, Belgium|EDCTP|Instituto Nacional de Saude, Mozambique|Institut de Recherche pour le Developpement|UMC Utrecht","All","Child, Adult, Older Adult","","15393","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AfriCoVER","2020-07-15T00:00:00","2021-07-14T00:00:00","2021-07-14T00:00:00","2020-06-22T00:00:00","","2020-06-24T00:00:00","","","https://ClinicalTrials.gov/show/NCT04442165"
"985","NCT04497948","Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Acalabrutinib","Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h|Acalabrutinib and ACP-5862 plasma PK parameter: AUClast|Acalabrutinib and ACP-5862 plasma PK parameter: Cmax|Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention|Proportion of participants alive and free of respiratory failure at Days 14 and 28|Percent change from baseline in CRP at Days 3, 5, 7, 14, 28|Time to improvement- clinical improvement of ≥ 2 pointson a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for dischargewhichever comes first,by Day 28","AstraZeneca|Acerta Pharma B.V.","All","18 Years and older","Phase 1","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","D822FC00005","2020-07-31T00:00:00","2020-09-28T00:00:00","2020-09-28T00:00:00","2020-08-04T00:00:00","","2020-08-04T00:00:00","Research Site, Baltimore, Maryland, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04497948"
"986","NCT04355767","Convalescent Plasma in Outpatients With COVID-19","C3PO","Enrolling by invitation","No Results Available","Covid19","Biological: Convalescent Plasma|Biological: Saline","Number of patients with disease progression|Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization|Time to disease progression|Number of Hospital-free days during the 30 days following randomization|All-cause mortality","Stanford University|National Heart, Lung, and Blood Institute |Strategies to Innovate EmeRgENcy Care Clinical Trials Network  - Network","All","18 Years and older","Phase 3","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double |Primary Purpose: Treatment","C3PO","2020-07-31T00:00:00","2022-12-01T00:00:00","2022-12-01T00:00:00","2020-04-21T00:00:00","","2020-08-06T00:00:00","Stanford University, Stanford, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT04355767"
"987","NCT04379544","Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19","CLUSCO","Recruiting","No Results Available","Coronavirus|Respiratory Failure","Other: Observation only","Patient requires invasive mechanical ventilation and suffers from acute respiratory failure.|Patient is discharged|Patient is hospitalized, but does not require mechanical ventilation through the duration of hospital stay.|Lung ultrasound findings|Cardiac ultrasound findings","University of Pennsylvania","All","18 Years and older","","105","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","843008","2020-04-23T00:00:00","2020-12-01T00:00:00","2020-12-01T00:00:00","2020-05-07T00:00:00","","2020-05-11T00:00:00","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04379544"
"988","NCT04382391","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIORII","Recruiting","No Results Available","COVID|Corona Virus Infection|Respiratory Failure|Respiratory Distress Syndrome, Adult|ARDS, Human|SARS","Device: gammaCore® Sapphire |Other: Standard of care therapies","change in initiation of mechanical ventilation in patients with CoViD-19 compared to the control group.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation","Allegheny Singer Research Institute |ElectroCore INC","All","18 Years and older","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Treatment","2020-132-AGH","2020-05-08T00:00:00","2020-09-01T00:00:00","2020-12-30T00:00:00","2020-05-11T00:00:00","","2020-05-13T00:00:00","AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT04382391"
"989","NCT04409327","Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes","","Recruiting","No Results Available","COVID19","Drug: RTB101|Drug: Placebo","The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die|The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection|Mortality rate in subjects who develop laboratory-confirmed COVID19|Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2|Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19|Safety and tolerability will be assessed by report of AE/SAEs","Restorbio Inc.","All","65 Years and older","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple |Primary Purpose: Prevention","RTB101-210","2020-07-11T00:00:00","2020-09-01T00:00:00","2020-10-01T00:00:00","2020-06-01T00:00:00","","2020-07-31T00:00:00","Nursing Home, Middletown, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT04409327"
"990","NCT04443803","Characterizing the Perioperative Epidemiology of SARS-CoV-2  Spread for Quality Improvement of Perioperative Infection Control Program","","Not yet recruiting","No Results Available","COVID-19","","Perioperative transmission of SARS-CoV-2","Randy Loftus|University of Iowa","All","18 Years to 120 Years","","9","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","202005391","2020-07-01T00:00:00","2020-08-31T00:00:00","2020-08-31T00:00:00","2020-06-23T00:00:00","","2020-06-23T00:00:00","","","https://ClinicalTrials.gov/show/NCT04443803"
"991","NCT04448418","The Impact of COVID-19 Outbreak on Trans-population's Health in Italy","","Active, not recruiting","No Results Available","Transgender Persons|Coronavirus|Coronavirus Infection|COVID|COVID-19","Other: web based survey","Assessment of the specific health need of the transpopulation during the COVID-19 pandemic in Italy|Assessment of risk factors for COVID-19 infection in the traspopulation|Evaluation of the satisfaction of this population with telemedicine for hormonal treatment monitoring|Evaluation of the psychological wellbeing of the trans-population during COVID-19 outbreak in Italy|Evaluation of the psychological and physical wellbeing of the trans-population during COVID-19 outbreak in Italy","Unita Complessa di Ostetricia e Ginecologia","All","18 Years to 100 Years","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","TRANSCOVID-19","2020-05-20T00:00:00","2020-06-20T00:00:00","2020-11-20T00:00:00","2020-06-25T00:00:00","","2020-08-11T00:00:00","1Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences , University of Bologna, Bologna, Italy","","https://ClinicalTrials.gov/show/NCT04448418"
"992","NCT04452422","Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology","VT-Covid-19","Recruiting","No Results Available","Deep Venous Thrombosis","","Number of cumulated deep venous thrombosis among the hospitalization","University Hospital, Strasbourg, France","All","18 Years and older","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7908","2020-06-23T00:00:00","2020-09-23T00:00:00","2020-09-23T00:00:00","2020-06-30T00:00:00","","2020-06-30T00:00:00","Service Unite Neurovasculaire, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT04452422"
"993","NCT04330144","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2","","Not yet recruiting","No Results Available","Contact Person From COVID-19 Confirmed Patient","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others","The rate of COVID-19","Gangnam Severance Hospital","All","18 Years to 99 Years","Phase 3","2486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single |Primary Purpose: Prevention","3-2020-0036","2020-04-01T00:00:00","2021-03-30T00:00:00","2022-03-30T00:00:00","2020-04-01T00:00:00","","2020-04-01T00:00:00","","","https://ClinicalTrials.gov/show/NCT04330144"
"994","NCT04375670","COVID19-FOIE National Observatory","","Recruiting","No Results Available","Liver Diseases|COVID19","","Mortality rate related to Covid-19 in patients with a chronic liver disease|mortality rate according the stage of fibrosis and the cirrhotic status|mortality related to Covid-19 according an history of hepatocellular carcinoma, an immunosuppressive treatment and this type the etiology-ies of liver disease at the infection and comorbidities.|Incidence of liver complications","Assistance Publique - Hôpitaux de Paris|Association Française pour l'Etude du Foie","All","18 Years to 80 Years","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRB00006477","2020-05-11T00:00:00","2020-12-31T00:00:00","2020-12-31T00:00:00","2020-05-05T00:00:00","","2020-05-21T00:00:00","Ganne, Bondy, France","","https://ClinicalTrials.gov/show/NCT04375670"
"995","NCT04340232","Safety and Efficacy of Baricitinib for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events |Phase 2: Cumulative incidence of serious adverse events |Phase 2: Changes in white blood cell count  through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time  through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count  through End of Study |Phase 2: Changes in hemoglobin through End of Study |Phase 2: Changes in platelets through End of Study |Phase 2: Changes in creatinine through End of Study |Phase 2: Changes in glucose through End of Study |Phase 2: Changes in prothrombin time  though End of Study |Phase 2: Changes in total bilirubin through End of Study |Phase 2: Changes in ALT through End of Study |Phase 2: Changes in AST through End of Study |Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score |Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score |Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events |Phase 3: Cumulative incidence of serious adverse events |Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count  through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time  through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count  through End of Study |Phase 3: Changes in hemoglobin through End of Study |Phase 3: Changes in platelets through End of Study |Phase 3: Changes in creatinine through End of Study |Phase 3: Changes in glucose through End of Study |Phase 3: Changes in prothrombin time  though End of Study |Phase 3: Changes in total bilirubin through End of Study |Phase 3: Changes in ALT through End of Study |Phase 3: Changes in AST through End of Study","University of Colorado, Denver","All","18 Years to 89 Years","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-0738","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-10-01T00:00:00","2020-04-09T00:00:00","","2020-05-06T00:00:00","University of Colorado, Denver, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT04340232"
"996","NCT04348071","Safety and Efficacy of Ruxolitinib for COVID-19","","Not yet recruiting","No Results Available","COVID-19","Drug: Ruxolitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events |Phase 2: Cumulative incidence of serious adverse events |Phase 2: Changes in white blood cell count  through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time  through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count  through End of Study |Phase 2: Changes in hemoglobin through End of Study |Phase 2: Changes in platelets through End of Study |Phase 2: Changes in creatinine through End of Study |Phase 2: Changes in glucose through End of Study |Phase 2: Changes in prothrombin time  though End of Study |Phase 2: Changes in total bilirubin through End of Study |Phase 2: Changes in ALT through End of Study |Phase 2: Changes in AST through End of Study |Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score |Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score |Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events |Phase 3: Cumulative incidence of serious adverse events |Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count  through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time  through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count  through End of Study |Phase 3: Changes in hemoglobin through End of Study |Phase 3: Changes in platelets through End of Study |Phase 3: Changes in creatinine through End of Study |Phase 3: Changes in glucose through End of Study |Phase 3: Changes in prothrombin time  though End of Study |Phase 3: Changes in total bilirubin through End of Study |Phase 3: Changes in ALT through End of Study |Phase 3: Changes in AST through End of Study","University of Colorado, Denver","All","18 Years to 89 Years","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None |Primary Purpose: Treatment","20-0869","2020-06-01T00:00:00","2020-08-01T00:00:00","2020-10-01T00:00:00","2020-04-15T00:00:00","","2020-05-06T00:00:00","","","https://ClinicalTrials.gov/show/NCT04348071"
"997","NCT04487873","COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic","","Not yet recruiting","No Results Available","Covid19|Bronchiectasis","","COVID-19 Phobia|Qol|Health anxiety|Physical activity|Quality of sleep","Hacettepe University","All","18 Years to 60 Years","","28","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GO 20/602","2020-07-23T00:00:00","2020-10-01T00:00:00","2020-12-01T00:00:00","2020-07-27T00:00:00","","2020-07-28T00:00:00","","","https://ClinicalTrials.gov/show/NCT04487873"
"998","NCT04360122","Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19","","Not yet recruiting","No Results Available","Coronavirus Disease","Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine","Decrease the incidence of COVID-19 infection or its severity","Ain Shams University","All","18 Years and older","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None |Primary Purpose: Prevention","FMASU P20a/ 2020","2020-05-20T00:00:00","2020-11-01T00:00:00","2020-12-01T00:00:00","2020-04-24T00:00:00","","2020-05-05T00:00:00","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","","https://ClinicalTrials.gov/show/NCT04360122"
"999","NCT04363346","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia","","Recruiting","No Results Available","COVID-19","Drug: FT516","Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge","Masonic Cancer Center, University of Minnesota","All","18 Years to 76 Years","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None |Primary Purpose: Treatment","IDIM-2020-28708|2020LS083","2020-05-14T00:00:00","2022-01-01T00:00:00","2022-01-01T00:00:00","2020-04-27T00:00:00","","2020-05-18T00:00:00","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT04363346"
"1000","NCT04495907","COVID-19 Progression in End-Stage Kidney Disease","COPE","Recruiting","No Results Available","SARS-CoV-2 Infection |SARS-CoV-2 Infection","","SARS-CoV-2 IgG|Anti-SARS-CoV-2 IgG","Davita Clinical Research","All","18 Years to 80 Years","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","20-M-0047-00","2020-08-06T00:00:00","2020-12-01T00:00:00","2021-03-01T00:00:00","2020-08-03T00:00:00","","2020-08-17T00:00:00","DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT04495907"
"1001","NCT04410939","COVID-19 PCR Test Results in Asymptomatic Pregnants","","Completed","No Results Available","COVID-19|Asymptomatic Pregnant","Diagnostic Test: Reverse transcription polymerase chain reaction","Rate of positive COVID-19 cases in asymptomatic pregnant women","Istanbul Medipol University Hospital","Female","Child, Adult, Older Adult","","179","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","Gpolat1","2020-04-10T00:00:00","2020-05-20T00:00:00","2020-05-21T00:00:00","2020-06-01T00:00:00","","2020-06-01T00:00:00","Istanbul Medipol University, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT04410939"
